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Abstract of Thesis 
 
Natural killer (NK) cells are a distinct population of lymphocytes with powerful 
cytotoxic effects against virus infected cells and transformed cells, without the need for 
prior sensitisation. They play an important role in innate immunity, providing a first line 
of defence against invading pathogens and also play a part in initiating and influencing 
adaptive immunity. There are two major subsets of NK cells; CD56bright and 
CD56dim. The CD56dim subset are more proficient killers, whereas the CD56bight 
subset are more adept at producing cytokines. In the peripheral blood, the majority of 
NK cells are CD56dim. However, previous work has shown the converse to be true in 
the synovial fluid of joints that are inflamed in patients with rheumatoid arthritis and at 
other sites of peripheral inflammation including that involving pleural and peritoneal 
cavities; here ~90% of the NK cells are of the CD56bright phenotype. These synovial 
CD56bright NK cells can engage with CD14+ monocytes in a reciprocal activatory 
fashion, possibly contributing to the inflammatory state. The enrichment of CD56bright 
NK cells at sites of inflammation could reflect either preferential recruitment to the site 
of inflammation or local differentiation of the CD56dim to the CD56bright subset. 
 
This thesis addresses the mode of accumulation of CD56bright NK cells at sites of 
inflammation using an in vitro model. Trafficking of NK cells from the periphery to the 
site of inflammation involves transmigration across vascular endothelium, a process that 
has been shown to alter the phenotype and function of cells. This study provides novel 
evidence that the interaction of NK cells with endothelium results in the activation of 
NK cells and modifies the NK cell phenotype including the expression of certain 
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adhesion molecules. Work presented in this study suggests that migration does not 
increase the functional capacities of NK cells but may to some degree maintain the 
capacity of NK cells to express interferon-γ and to degranulate. Furthermore, this thesis 
extends previous findings by examining the consequence of migration on NK cell 
interactions with macrophages and dendritic cells. The final results chapter in this study 
describes a population of CD56 negative CD16 expressing cells that share some 
characteristics with NK cells. This potentially novel subset of NK cells and has been 
described in several studies as being a dysfunctional. This thesis aims to provide data on 
the phenotype of these cells and to compare this with that of conventional NK cell 
subsets.
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Chapter 1 
 
Introduction 
 
1.1 Natural Killer Cell Biology 
 
1.1.1 The Discovery of NK cells 
 
In the early 1970’s scientists attempted to explain some unusual results when studying 
the cytotoxic effects of lymphocytes against target cells.  They were surprised to find a 
considerable quantity of spontaneous killing of tumour cell lines without prior 
immunisation (Baldwin RW et al (1973) Int J Cancer 12: 73-83, Hellstrom I and 
Helstrom KE (1974) Cancer 34 (suppl. 8), O’Toole C et al (1994) J Exp Med 139: 457-
466). In these experiments, cells taken from healthy donors, non-immunised animals 
and cancer patients displayed comparable levels of cytotoxicity to cells from immunised 
animals (Tagasugi M et al (1973) Cancer Res 33: 2898-2902). Adding to this, efficient 
killing of target cells that were infected with viruses in the absence of immunisation 
meant that these ‘artefacts’ could no longer be ignored (Labowskie R et al (1974) J 
Infect Dis 129: 233-239, Rola-Plezczynski M et al (1975) JI 115: 239-242). The 
accidental discovery of these cells that appeared to have a ‘natural’ ability to kill non-
self cells without needing to be activated led to the name natural killer cell (Kiessling et 
al (1975) Eur JI 5: 112-117). 
 
1.1.2 The Importance of NK Cells 
 
Seminal studies carried out by Kiessling and Wigzell began to turn the tide of opinion 
about what was initially thought to be a relatively unimportant group of cells. Their 
studies demonstrated that natural killer (NK) cell activity was directly proportional to 
the resistance to tumour growth in mouse models (Kiessling and Wigzell, 1979). The 
first report of an NK cell deficiency in a clinical setting highlighted how crucial these 
cells are in anti-viral immunity. A patient with uncontrolled and serious  herpes viral 
infections was able to control other types of viral infections such as influenza. 
Immunological assessment of this patient showed a complete NK cell deficiency (Biron 
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et al., 1989). Another clinical report published by Joncas and colleagues described a 
father and daughter with chronic active Epstein Barr virus infection. The daughter had 
defective NK cell cytotoxicity. However, the father showed slow improvement over the 
15 years from diagnosis and this was attributed to rising NK cell cytotoxicity (Joncas et 
al., 1989). In addition to their role in anti-viral immunity, many studies of human 
cancers have shown the importance of NK cells in tumour regression with examples of 
NK cell deficiency having direct consequences such as the recurrence of cervical 
carcinoma that was observed by the Ballas group (Ballas et al., 1990). Furthermore, 
experimental mouse models demonstrated the importance of NK cells in protection 
against bacterial infections including Listeria monocytogenes (Wherry et al., 1991) and 
parasitic infections such as malaria (Doolan and Hoffman, 1999) and Leishmania 
(Laskay et al., 1993). Throughout the years, a picture of the broad range of protection 
that NK cells can provide has emerged along with the ever growing list of functions 
which enable the NK cell to carry out their task. This cell is no longer cast aside in 
analyses, but is now known to be a crucial player in innate immunity and an important 
link to the adaptive immune reaction.  
  
1.1.3 The Life Cycle of the NK Cell 
 
NK cells are defined as CD3 negative (-) CD19- large granular lymphocytes and are 
divided into two main subsets based on expression levels of CD56 and CD16. The 
CD56bright subset expresses high levels of CD56 and does not express CD16 whereas 
the CD56dim subset expresses low levels of CD56 and is positive for CD16. In 
peripheral blood, approximately 90% of NK cells are of the CD56dim subset and 10% 
are of the CD56bright subset (Cooper et al., 2001a). NK cells derive from CD34+ 
hematopoietic precursors in bone marrow and share a common lymphoid progenitor 
with thymocytes and B cells.  
 
At the beginning of their life cycle, NK cells differentiate from haematopoietic cells and 
it is known that IL-15 is a crucial component at this early stage (Fehniger and Caligiuri, 
2001). This cytokine, which in part signals through the IL-2 receptor  chain, can 
stimulate differentiation haematopoietic cells into NK cells in the absence of any other 
cytokines in vitro (Mrozek et al., 1996). Furthermore, mice lacking this receptor or IL-
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15 itself have severe NK cell deficiencies (Suzuki et al., 1997; Kennedy et al., 2000) 
making evident the necessity for IL-15 in the initial part of NK cell differentiation. NK 
cell expression of the IL-2 receptor β chain is maintained throughout the development 
of the cell until full functional maturation is reached (Williams et al., 1997) and growth 
factors such as flt3 ligand can increase the frequency of NK cell precursors by up-
regulating the expression of the IL-15 receptor complex which includes the IL-2 
receptor  chain (Yu et al., 1998). Although human and mouse NK cells differ, data are 
in agreement that functional maturity is a late stage of NK cell development and in 
humans this occurs after the acquisition of CD56. Subsequently, there is a systematic 
acquisition of NK cell receptors starting with CD161 and NKp46, followed by CD94 
and finally the KIRs and CD16 (reviewed in (Colucci et al., 2003; Yokoyama et al., 
2004). 
Hematopoietic precursors and indeed mature NK cells are found at many different 
anatomical sites in adult humans including the bone marrow, thymus, liver, spleen, 
omentum and lymph nodes (Godin and Cumano, 2002). However, the location of NK 
cell development is a matter of debate. The bone marrow can provide cytokines that are 
important in NK cell development and bone marrow stromal cells are known to be 
crucial for the full development of NK cell precursors. In fact bone marrow ablation in 
mice using -oestradiol or radio-isotope treatment leaves NK cells with deficiencies in 
natural killing (Seaman et al., 1979). The general consensus is that the bone marrow is 
the site of NK cell differentiation at least to the stage of commitment to a NK cell 
precursor. Lymph nodes have been nominated as a possible site for further NK cell 
development (Freud et al., 2006) with the thought that cells which reside at this 
anatomical location, namely stimulated dendritic cells (Mattei et al., 2001) and CD14+ 
monocytes that have been stimulated with LPS or IFN- (Carson et al., 1995) are able to 
provide the crucial NK cell survival factor IL-15. However, both subsets of NK cells 
cannot be produced in the absence of bone marrow stroma, and Yu et al. have shown 
that only cells resembling the CD56bright subset can be made under these conditions 
(Yu et al., 1998). Perhaps then the bone marrow is the site of development for the 
CD56dim NK cells and the lymph node is the site of development for the CD56bright 
subset. The observation that 90% of lymph node NK cells are CD56bright certainly 
supports this theory (Fehniger et al., 2003). It is possible however, that lymphoid 
CD56bright NK cells represent a distinct lineage from peripheral blood CD56bright NK 
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cells such as that seen with uterine NK cells (Koopman et al., 2003) and it is also 
feasible that CD56bright NK cells are trafficking through lymphoid tissues rather than 
being developing from precursors here.  
 
As aforementioned, NK cell precursors are also found in the thymus, spleen and liver. 
However, the latter two organs appear not to be important in NK cell development in 
adults (Colucci et al., 2003). Bi-potential NK/T cell precursors are produced in the liver 
in early fetal life (Phillips et al., 1992; Jaleco et al., 1997) but at birth the anatomical site 
switches to the bone marrow where NK precursors and not bi-potential NK/T cell 
precursors are made.  
 
1.1.4 The development of NK cell subsets 
 
The two subsets of NK cells differ not only in the expression levels of CD56 and CD16 
but also in their expression of many other molecules, as discussed in section 1.1.11, and 
in their functions. Lanier and colleagues revealed that the CD56dim subset is more 
cytotoxic (Lanier et al., 1986) and that the CD56bright subset is more capable of 
proliferating and producing cytokines (Robertson et al., 1993; Cooper et al., 2001c). 
The above discussion on the lifecycle of the NK cell touched on the developmental 
relationship between the two subsets of NK cells, with suggestions that both derive 
from a common precursor and differentiate at different anatomical sites, and an 
alternative hypothesis that lymphoid CD56bright NK cells represent a distinct lineage 
from peripheral blood CD56bright NK cells. These are not the only two possible 
hypothesis; four theories on the developmental relationship between the subsets have 
been proposed and are depicted in Figure 1 and described thereafter. 
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Figure 1. The developmental relationship between the NK cell subsets. (i)The two 
subsets derive from one precursor and differentiate in sequence. The CD56bright subset 
is an intermediate and the CD56dim subset is the terminally differentiated NK cell. (ii) 
The two subsets derive from one precursor and differentiate in sequence. The CD56dim 
subset is an intermediate and the CD56bright subset is the terminally differentiated NK 
cell. (iii) NK cell subsets derive from one precursor with early divergence of the 
differentiation pathway; discrete factors drive their differentiation into two fully mature 
sub-populations. (iv) NK cell subsets derive from two discrete precursors. 
 
(i) The two subsets derive from one precursor and differentiate in sequence. The 
CD56bright subset is an intermediate and the CD56dim subset is the terminally 
differentiated NK cell. 
CD56dim     CD56brightPrecursor 
Precursor CD56dim     CD56bright 
(i) 
(ii) 
(iv) 
(iii) Precursor
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There are several studies supporting this first theory, each providing a different piece of 
the puzzle. Firstly, Mrozek et al. noticed that the treatment of hematopoietic precursor 
cells with IL-15 in vitro induces the development of cells that are CD56bright and 
abundantly express cytokines, but do not express other antigens that are specific to the 
CD56bright subset and are also similar to the CD56dim subset in that they possess 
cytotoxic properties (Mrozek et al., 1996). In view of this CD56bright population 
having both CD56bright and CD56dim features, the authors suggest that these cells are 
an intermediate population, and that the CD56dim subset is the terminally differentiated 
NK cell. In support of this theory, the CD56dim subset has a lower proliferative 
capacity than the CD56bright subset, a feature often associated with a more mature 
status (Nagler et al., 1989). In addition, CD56dim NK cells have shorter telomeres 
implying that these cells are further along in the differentiation pathway (Ouyang et al., 
2007). This research forms the basis of the hypothesis that CD56dim NK cells are the 
terminally differentiated subset and the CD56bright subset acts as a precursor.  
Furthermore, Romagnani et al. have reported the presence of mature KIR+ CD56dim 
NK cells in the efferent lymph (Romagnani et al., 2007). However, as mentioned in the 
previous subchapter, the majority of lymph node NK cells are CD56bright. Therefore, it 
could be postulated that CD56dim differentiation occurs downstream from this lymph 
node pool (Caligiuri, 2008). A convincing study has proposed that the differentiation of 
CD56bright into CD56dim NK cells results from contact with peripheral fibroblasts 
(Chan et al., 2007) providing an alternative location for the last stage in this 
hypothetical process. However, the fact that CD56bright NK cells produce cytokines in 
abundance, an attribute associated with maturity, does not seem to support the view that 
CD56bright NK cells are intermediates. 
(ii) The two subsets derive from one precursor and differentiate in sequence. The 
CD56dim subset is an intermediate and the CD56bright subset is the terminally 
differentiated NK cell. 
There is very little evidence for the CD56dim subset acting as a precursor for 
CD56bright NK cells. One study carried out by Loza and Perussia proposed that 
CD56bright NK cells are terminally differentiated and are not precursors for the 
CD56dim subset. Their experiments show that co-culture of CD56dim NK cells with 
IL-12 can induce the expression of all the markers which are constitutively expressed by 
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CD56bright NK cells. Once this differentiation step has taken place, the re-expression 
of CD16 by stimulation with either IL-2 or IL-15 is not possible, and implies that the 
CD56bright subset is fully mature and cannot revert back to the CD56dim phenotype 
(Loza and Perussia, 2004). 
(iii) NK cell subsets derive from one precursor with early divergence of the 
differentiation pathway; discrete factors drive their differentiation into two fully mature 
sub-populations. 
 
For NK cell subsets to derive from one precursor and for their differentiation not to be 
in sequence, the differentiation pathway must diverge at an early stage. At the point of 
divergence, distinct factors that drive the differentiation of the two subsets are required. 
For this theory to be verified, these factors need to be identified. 
Parrish-Novak et al. proposed IL-21 as a candidate cytokine for differentiation of NK 
cell precursors to CD56dim NK cells. In combination with IL-15, IL-21 was reported to 
produce CD56+CD16+ cells from hematopoietic precursor cells. Although these cells 
are positive for CD16, an antigen that is associated with the CD56dim subset, whether 
these cells have other attributes that would define them as a CD56dim NK cell is yet to 
be determined (Parrish-Novak et al., 2000). In a separate report on siblings with 
transporter associated with antigen processing (TAP) deficiency, Zimmer et al. 
proposed that MHC class I expression is required for the development of CD56dim NK 
cells. The patients had almost no MHC class I molecules, possessed large populations of 
CD56bright NK cells, and their CD56dim NK expressed abnormally low levels of 
CD16 (Zimmer et al., 1998). This could suggest that normal expression of MHC class I 
is required for the full development of CD56dim NK cells.  
These two reports propose IL-21 and MHC class I molecules as factors required for the 
differentiation of precursors into CD56dim NK cells. It is feasible that these factors 
could be driving the differentiation of (i) a precursor to CD56dim NK cells or (ii) 
CD56bright to CD56dim NK cells. This is not addressed by either paper. Further 
experiments using pure hematopoietic cells and testing for the presence of CD56bright 
NK cells are required to test the possibility that CD56bright NK cells are acting as 
precursors. 
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(iv) NK cell subsets derive from two discrete precursors 
It is possible that NK cell subsets have discrete precursors. In favour of this argument, a 
recent study identified a novel hematopoietic precursor: CD34dimCD45RA+7high from 
which CD56bright but not CD56dim NK cells can derive (Freud et al., 2005). Other 
studies have successfully generated CD56dim NK cells from hematopoietic precursors. 
However, they cannot be considered as evidence that CD56dim NK cells can derive 
directly from a precursor as the possibility that CD56bright NK cells are intermediates 
was not eliminated (Zimmer et al., 1998; Parrish-Novak et al., 2000). A separate 
precursor for CD56dim NK cells has never been reported, but the possibility that one 
doesn’t exist is far from proven. 
 
1.1.5 NK Cell Recognition 
 
NK cells recognise target cells without the need for prior sensitisation (Herberman and 
Ortaldo, 1981). NK cells develop normally in scid mice (Hackett et al., 1986) and mice 
with abnormal RAG-1 or RAG-2 genes (Mombaerts et al., 1992; Shinkai et al., 1992), 
indicating that the generation of NK cell receptors and NK cell development does not 
require gene recombination, bestowing them with the ability to act quickly and 
recognise harmful cells. In order for the NK cell to act this quickly having not 
previously ‘seen’ the adversary requires them to posses receptors that can recognise 
harmful cells but that can also allow them to distinguish between normal ‘self’ cells and 
cells posing a potential threat. Although NK cell receptors are not antigen specific, fine 
control of the response to a harmful cell is achieved by a calculation of the net sum of 
inputs from both activatory and inhibitory receptors. 
 
1.1.6 NK cell inhibitory receptors 
 
How do NK cells distinguish between self and non-self? Recent pioneering studies 
solved this question and have clarified the mechanism allowing NK cells to selectively 
kill virus infected and tumour cells, while sparing normal cells. Ljungren and Kärre 
observed that murine NK cells could lyse lymphoma cells that had lost MHC class I 
expression but not the MHC class I + cells. As a result the ‘missing self’ hypothesis was 
proposed: NK cells kill target cells that have lost or express insufficient MHC class I 
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molecules (Ljunggren and Karre, 1990) implying that MHC class I receptors inhibit NK 
cell function. This safety mechanism prevents auto-reactive NK cells destroying normal 
self tissues, the importance of which was realised once the ligands for NK cell 
activating receptors were detected on healthy self cells.  
 
The recognition of MHC class I by NK cells is not achieved through one universal 
receptor, there are many, each with different specificity for distinct HLA-A, B or C 
molecule alleles (Moretta et al., 1996). Collectively these inhibitory receptors are called 
killer immunoglobulin-like receptors or KIRs. Mature NK cells express at least one 
receptor for self-MHC and co-expression of more than one receptor on a single NK cell 
is rare (Shilling et al., 2002). A detailed description of the inhibitory KIRs is beyond the 
scope of this thesis but is extensively reviewed by Alessandro Moretta (Moretta et al., 
1996). Another NK cell receptor that is involved in the recognition of HLA is CD94-
NKG2A which is specific for HLA-E (Lopez-Botet et al., 1997; Braud et al., 1998). The 
genes encoding HLA and KIRs are variable whereas the genes encoding the CD94 and 
NKG2 family are conserved in humans. Through differential expression of these genes 
NK cells generate diverse repertoires of MHC class I receptors (Uhrberg et al., 1997). 
The clonal distribution of inhibitory KIRs gives the NK cell pool the ability to sense the 
loss of even one allele on harmful cells, providing a very efficient first line of defence 
(Garrido et al., 1997). 
 
The interaction between MHC class I molecules and inhibitory NK cell receptors 
provides a major checkpoint for the activation of an NK cell. However, Zijlstra and 
colleagues found that the even when MHC class I is absent this does not necessarily 
lead to target cell lysis (Zijlstra et al., 1992). Similarly, it has been reported that the 
presence of MHC class I does not always provide a cell with protection against NK cell 
mediated lysis (Routes, 1992). These two pieces of evidence suggest the involvement of 
other receptors in the regulation of NK cell function. As has been discussed, NK cells 
have inhibitory ‘off switches’. It follows there may be corresponding activatory ‘on 
switches’ and so the hunt for NK cell activatory receptors began.  
 
1.1.7 NK cell activatory receptors 
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The first activatory receptors to be identified in humans were found to belong to the 
KIR family. The activatory KIRs are paired with the corresponding inhibitory KIRs and 
bind to the same ligands. It is not clear why NK would express both activatory and 
inhibitory receptors that bind to the same ligand, but it has been suggested that the 
inhibitory receptor binds to HLA with higher affinity (Biassoni et al., 1996).  
 
The recently described Natural Cytotoxicity Receptors (NCRs) have been implicated in 
the activation of NK cell cytotoxicity against tumours. Three NCRs have been 
described: NKp46 (Sivori et al., 1999), NKp44 and NKp30 (Pende et al., 1999). NK 
cells are commonly identified by the expression of CD56. However, NKp46 and NKp30 
are the only molecules that are constitutively and exclusively expressed by NK cells and 
are therefore the most reliable way to identify an NK cell. The expression of NKp44 is 
induced upon NK cell activation, particularly if the NK cell is treated with IL-2 
(Cantoni et al., 1999). The receptors NKp44 and NKp46 have been shown to be capable 
of binding to viral haemagglutinins implying that they may be important for NK cell 
recognition of virally infected cells (Arnon et al., 2001). Furthermore, the surface 
density of the NCRs determines the magnitude of the cytotoxic response from the NK 
cell (Sivori et al., 1999). The ligands for the NCRs are yet to be identified although it is 
thought that they are only expressed by stressed or hyper-proliferative cells hence 
normal tissues would not be susceptible to NK cell killing that is triggered through these 
receptors (Bottino et al., 2005). 
 
A further activatory receptor, NKG2D, is constitutively expressed by NK cells and also 
by δT cells. There are two families of ligands for NKG2D; the first family is the MHC 
class I Chain Related (MIC) peptides, MICA and MICB (Bauer et al., 1999) the 
expression of which is thought to be induced by cellular stress or transformation, and 
these molecules are mostly found on cells of epithelial origin. The second family are the 
human cytomegalovirus UL16 binding proteins (ULBPs) and the expression of these 
molecules is more widespread than the MIC peptides (Sutherland et al., 2001). The 
contribution of NKG2D and the NCRs to the final signal given to the NK cell, to kill or 
not to kill, is not clear. There is some evidence that the targeting of certain tumours 
require co-operation of both types of receptor (Pende et al., 2001). However, there have 
also been some reported instances where the activatory signal from NKG2D alone has 
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been able to override the inhibition from MHC class I expression (Cosman et al., 2001) 
suggesting that NKG2D can independently provide a strong activatory signal. 
CD16 (FcRIII) is the most extensively studied receptor on NK cells. It is the low 
affinity receptor for IgG and directs antibody dependent cellular cytotoxicity of 
opsonised target cells. Ligation of CD16 also mediates NK cell cytokine secretion 
(Perussia et al., 1984) and may also induce highly activated NK cells to undergo Fas 
ligand-induced apoptosis (Ortaldo et al., 1995).  
Another stimulatory molecule, CD69, is expressed on NK cells shortly after activation 
and is commonly used by scientists as a quantitative measure of activation. Ligation of 
this molecule triggers NK cell mediated cytotoxicity (Moretta et al., 1991), NK cell 
proliferation, up-regulation of TNF- producion, and induces the expression of ICAM-1 
and CD25 on NK cells (Borrego et al., 1999). However, a specific ligand for CD69 has 
not yet been identified. CD69 is not exclusively expressed by NK cells, but has a wide 
cellular distribution and has been implicated in the pathogenesis of diseases such as 
rheumatoid arthritis, acquired immunodeficiency syndrome and chronic liver disease 
(Marzio et al., 1999).  
 
1.1.8 NK cell co-receptors 
 
NK cells express co-receptors which act to amplify signalling and require simultaneous 
engagement of another triggering receptor (Biassoni et al., 2001). A number of co-
receptors for NK cell activation have been identified and the list is growing (Lanier, 
1998).  An example is 2B4, belonging to a subfamily of CD2, this co-receptor is 
expressed by all NK cells and a subset of CD8+ T cells. The ligand for 2B4 has been 
identified as CD48 (Nakajima et al., 1999) and this receptor-ligand interaction strongly 
enhances NK cell cytotoxicity (Valiante and Trinchieri, 1993). This particular co-
receptor enhancement is however, restricted to NKp46bright NK cells (Sivori et al., 
2000a). Interestingly, 2B4 has been suggested to play a protective role early in the life 
cycle of an NK cell by preventing the lysis of by-stander bone marrow cells. Early in 
NK cell development, NK cells possess cytolytic molecules but lack safeguarding 
inhibitory receptors. This makes by-stander bone marrow cells particularly vulnerable to 
NK cell killing. However 2B4 is expressed early in NK cell development and Sivori et 
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al. suggest that 2B4 expression prevents lysis of these by-stander cells by transducing 
an inhibitory rather than activatory signal. In the mature NK cell, the downstream 
signalling molecule SAP is crucial for transduction of the activatory signal from 2B4. 
However, SAP transcripts are absent early in NK cell development therefore ligation of 
2B4 sends a strong inhibitory signal (Sivori et al., 2002). In X-linked 
lymphoproliferative disease there are critical mutations in the gene encoding SAP 
(Coffey et al., 1998). As a result, 2B4 only ever transduces inhibitory signals and NK 
cells then fail to kill EBV-infected cells (Parolini et al., 2000) resulting in a mortality 
rate of 70-80% of sufferers who have been exposed to EBV (Seemayer et al., 1995). 
 
A novel activatory receptor, NKp80 is expressed by almost all peripheral blood NK 
cells. Functioning as a co-receptor that enhances NK cell killing, antibody-mediated 
blocking of NKp80 partially inhibits NK cell cytotoxicity with complete inhibition 
achieved by simultaneous blocking of NK cell NCRs including NKp46 (Vitale et al., 
2001).  
 
1.1.9 Toll-Like Receptors on NK cells 
Toll-like receptors (TLRs) are innate receptors that recognise conserved pathogen-
associated molecular patterns (PAMPs). They are important for the detection of 
pathogens, particularly intracellular viruses early in the immune response (Akira and 
Sato, 2003). As NK cells act early in the immune response, it is tempting to speculate 
that they may express TLRs. Indeed, there is mounting evidence to support this theory. 
One of the first pieces of evidence surprisingly came from infection with the parasite 
Leishmania major. Infection stimulated the production of IFN- and TNF- from NK 
cells via the ligation of TLR2 (Becker et al., 2003).  
It has been known for years that NK cells can respond to Poly I:C, a synthetic analogue 
of double stranded RNA, and a known ligand for TLRs.  This circumstantial evidence 
later confirmed that signalling was occurring via a TLR when Schmidt et al. 
demonstrated that TLR3 is expressed by NK cells and accounts for the response to Poly 
I:C (Schmidt et al., 2004).  
Almost all CD56dim NK cells express TLR4. However, this receptor is not expressed 
by the CD56bright subset. One study found that although CD56dim NK cell express 
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TLR4, and therefore should respond to the ligand LPS, co-culture of CD56dim NK with 
LPS failed to elicit a response. Perhaps then the expression of this TLR on NK cells is 
redundant and the authors suggest this could reflect a lack of co-stimulatory molecules 
such as CD14 (O'Connor et al., 2006).  
Studies are emerging that suggest a role for other toll-like receptors in NK cell biology 
including TLR9 (Sivori et al., 2004), TLR7 and TLR8 (Hart et al., 2005). Furthermore, 
it appears that NK cells express almost all of the TLRs however, not all of these 
receptors are functional and it is likely that accessory cells are required to assist NK cell 
activation through these TLRs. 
 
1.1.10 Cytokine mediated regulation of NK cells  
 
Signalling via activatory and inhibitory receptors is not the only input controlling the 
actions of NK cells; cytokines from immune cells, virus infected cells, transformed cells 
and bacteria also contribute to their regulation. A report of all the cytokines that affect 
NK cells is beyond the scope of this thesis but has been comprehensively reviewed by 
Biron and colleagues (Biron et al., 1999) with a selection of the important ones 
described below. 
 
Virus infection triggers monocytes and plasmacytoid dendritic cells to produce the type 
I interferons, IFN- and IFN-. These cytokines have a broad range of immuno-
regulatory functions, spanning both the innate and adaptive immune systems (Vilcek, 
1996) including inducing NK cell cytotoxicity (Biron et al., 1996), proliferation (Biron 
et al., 1984), and cytokine production. However, at high but physiological 
concentrations, IFN-/  suppresses the production of IL-12 which is a potent 
stimulator for the production of IFN- by NK cells. Therefore IFN-/ indirectly curbs 
the production of IFN- by NK cells (Cousens et al., 1997; McRae et al., 1998). 
Regarding IL-12, other cytokines such as TNF, IL-1 and IL-1 can synergise with IL-
12 to stimulate the production of IFN- by NK cells (Tripp et al., 1993; Hunter et al., 
1997). The vital role for IL-15 in NK cell biology has already been described in this 
thesis. It is a NK cell stimulating cytokine that promotes differentiation, maturation and 
boosts proliferation (Puzanov et al., 1996; Warren et al., 1996). Its necessity is 
demonstrated by the fact that IL-15 deficient mice completely lack NK cells (Williams 
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et al., 1998). Murine studies on another NK cell promoting cytokine, IL-18, showed that 
deficiency of this cytokine decreases but not abolishes both NK cell killing and IFN- 
production (Takeda et al., 1998), demonstrating that while IL-18 is important it is not 
essential for correct NK cell functions. 
 
A number of negative regulators of NK cells have been identified including IL-10 and 
TGF-. IL-10 inhibits the induction of IL-12 and therefore inhibits the downstream 
stimulation of NK cells (D'Andrea et al., 1993). TGF- blocks many functions of NK 
cells including NK cell proliferation, production of IFN- and killing (Rook et al., 
1986). It is thought that negative regulators of NK cells act later in the course of viral 
infections to terminate the NK cell response and prevent persistent cytotoxicity and 
tissue damage (Su et al., 1991). 
 
1.1.11 NK Cell Function 
 
NK cell activation is finely controlled by a balance of cytokine stimulation and the net 
sum of signals from activatory and inhibitory receptors. The functional responses of NK 
cells; cytotoxicity, cytokine production and proliferation are rapid as cells do not 
undertake de novo transcription and translation of cytokines and cytotoxic mediators. 
Resting NK cells constitutively express pre-stored transcripts of IFN- allowing quick 
synthesis of this cytokine once the NK cell has been activated (Stetson et al., 2003). 
Lysosomes provide storage of the cytotoxic mediators perforin and granzymes which 
allow for their release within minutes of NK cell activation (Henkart, 1985). The 
functions of NK cells are described in more detail below. 
 
1.1.12 NK cell cytotoxicity 
 
NK cells can kill target cells using 3 main pathways 
 
1. The granule exocytosis pathway 
 
Granule exocytosis is the major mechanism by which NK cells kill target cells. NK cells 
possess granules which store the powerful degradative proteins perforin and granzymes. 
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Perforin integrates into the membrane of the target cell and disrupts its integrity 
allowing entry of the granzymes (Krahenbuhl and Tschopp, 1991). Five granzymes 
have been described in humans (Smyth and Trapani, 1995). These proteases are 
required for the triggering of apoptotic cell death which they achieve either indirectly by 
the activation of caspases, directly by fragmentation of the target cell DNA (Heusel et 
al., 1994), or by causing damaging  DNA ‘nicks’ (Beresford et al., 1999; Fan et al., 
2003). There is also evidence for perforin independent uptake of granzymes into target 
cells (Trapani et al., 1996), in particular the mannose-6-posphate receptor has been 
shown to mediate the uptake of Granzyme-B by receptor-mediated endocytosis (Motyka 
et al., 2000). Although a perforin independent pathway exists, a number of studies have 
shown this molecule to be vital for NK cytotoxicity (Kagi et al., 1994) particularly in 
suppression of tumour initiation and metastasis (van den Broek et al., 1995; Street et al., 
2004). Furthermore, deficiency of a single granzyme has little effect (Ebnet et al., 
1995), but if more than one of the granzymes is missing, NK cell cytotoxicity is 
ineffectual. This was demonstrated by Mullbacher et al. who showed that mice lacking 
both Granzyme-A and Granzyme-B were susceptible to ectromelia virus (Mullbacher et 
al., 1999). 
 
2. Receptor mediated cytotoxicity  
 
Davis and colleagues found that NK cells lacking both Granzymes A and B cannot 
cause cellular death by fragmentation of target cell DNA but still have anti-tumour 
effects (Davis et al., 2001). This suggests that NK cells can employ another mechanism 
of killing other than granule exocytosis of perforin molecules and granzymes. One such 
mechanism suggested is receptor mediated cytotoxicity where apoptosis is initiated 
upon engagement of ‘death receptors’ with respective ligands on target cells. Two NK 
cell ‘death receptors’ that have been studied; TNF Related Apoptosis Inducing Ligand 
(TRAIL) and FasL and are described below. 
 
(i) TRAIL 
 
Murine studies have revealed that TRAIL is only constitutively expressed on a subset of 
NK cells found in the liver (Takeda et al., 2001a). However, this molecule is expressed 
by most NK cells upon activation with IL-2, IFNs or IL-15 (Smyth et al., 2001). The 
  Chapter 1 
 33
effect provided by TRAIL is totally dependent on IFN- (Cretney et al., 2002). This 
cytokine can both induce the expression of TRAIL on NK cells and sensitise tumours to 
the cytotoxic effects of TRAIL (Smyth et al., 2003). Two ligands, DR4 and DR5 that 
are capable of transducing apoptotic signals in the target cell have been described 
(Degli-Esposti, 1999). Their interactions with TRAIL have been shown to mediate NK 
cell cytotoxicity of tumour targets that are sensitive to TRAIL (Takeda et al., 2001b). 
 
(ii) FasL 
 
FasL expression on NK cells correlates with the suppression of tumour growth (Bradley 
et al., 1998). Tumour cells do not constitutively express Fas, therefore NK cells take a 
two step approach to overcome this. Firstly, NK cells produce IFN- which induces the 
expression of Fas on tumour cells, they then subsequently use Fas to execute FasL 
mediated cytotoxicity (Screpanti et al., 2001). Once Fas is engaged, it associates with an 
intra-cytoplasmic molecule MORT-1, leading to activation of caspases and apoptosis of 
the target cell (Berglund et al., 2000). 
 
3. Cytotoxicity induced by cytokines from NK cells  
 
An alternative to both granule exocytosis and receptor mediated NK cell killing is the 
induction of target cell apoptosis by factors that are secreted by NK cells. One 
suggested candidate is TNF- which binds to its receptor TNFR-1 on target cells. 
Belonging to the same receptor family as Fas, once TNFR1 is engaged, the receptor 
clusters and results in the induction of caspase dependent apoptosis (Menart et al., 
2000). Other cytokines can effect NK cytotoxicity but with a more indirect approach; 
Hashimoto et al. showed that systemic administration of rIL-18 into mice significantly 
increases the protection against tumour cell lines (Hashimoto et al., 1999) but rather 
than having a direct effect like TNF-α, IL-18 acted to increase the expression of FasL 
on NK cells and subsequently enhanced binding to Fas on tumour cells. 
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1.1.13 NK cell cytokine production 
 
The importance of NK cell derived IFN-γ in anti-viral defence is well established, 
particularly as they are a major source of this cytokine (Biron et al., 1999). The 
production of IFN- by NK cells has been shown to be dependent on IL-12 (Orange and 
Biron, 1996a) indicating that NK cell, DC and macrophage cytokine production are 
closely linked, the latter two cell types being the main producers of IL-12. NK cells can 
also produce TNF-. However, unlike IFN-γ, many other cells also produce this 
cytokine early in an immune response (Orange and Biron, 1996b). 
 
Monocyte derived chemokines (monokines) stimulate the production of an array of NK 
cell derived cytokines including TNF-, IL-10, IL-13, GM-CSF and IFN-. 
Interestingly, the optimal combination of monokines for the expression of each 
individual cytokine by NK cells is different. For example, IL-12 in combination with 
IL-18 causes NK cells to produce optimal quantities of IFN-; whereas IL-15 in 
combination with IL-18 induces optimal GM-CSF production by NK cells (Cooper et 
al., 2001c). The same spectrum of cytokines is produced by a particular NK cell 
whether it is in a resting or active state, although active NK cells will produce greater 
quantities (Perussia, 1996).  
 
NK cells also produce chemokines and arguably one of the most important ones is MIP-
1. The receptor for MIP-1, CCR5, is utilised as a co-receptor in HIV infection and it 
has been shown that MIP-1 competes with HIV at the CCR5 receptor and blocks 
infection (Moore et al., 1997; Oliva et al., 1998). 
 
1.1.14 NK cell proliferation 
 
Mature peripheral blood NK cells undergo low levels of proliferation and have a half 
life of 7-10 days (Prlic et al., 2003). However when the number of NK cells in the body 
is low, proliferation occurs to maintain a stable NK cell pool. Evidence for this is seen 
when splenic NK cells are transferred into RAG-/- x -/- mice. These animals are 
completely devoid of NK cells. The splenic NK cells proliferate and successfully re-
populate the NK cell pool (Ranson et al., 2003). However, NK cells do not proliferate to 
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this degree if the host has a sufficient number of NK cells, suggesting the existence of a 
mechanism controlling the size of the NK cell pool. Studies using cytokine deficient 
mice have found that the presence of IL-15, and to a lesser extent IL-7, are cytokines 
that are required to stimulate NK cell proliferation (Cooper et al., 2002). 
  
Although low levels of proliferation are observed in normal physiology, NK cells 
proliferate rapidly in response to viral infections. Murine studies of MCMV by Dokun 
et al. demonstrated that the first stage of NK cell proliferation in response to the virus is 
non-specific and is stimulated by cytokines released early in infection (Dokun et al., 
2001). The second stage of proliferation is characterised by the selective expansion of 
only NK cells that express Ly49h, a receptor recognising MCMV infected cells. This 
preferential proliferation of a specific subset of NK cells peaked at 4-6 days after the 
initial infection. Furthermore, vaccinia virus infection does not result in a selective 
expansion of Ly49h+ NK cells suggesting that the NK cells that are selected to expand 
are virus specific. The final stage of NK cell proliferation in response to infection is a 
return of NK cell numbers to steady state levels. This process involves apoptosis of 
unnecessary NK cells and results from the withdrawal of stimulating cytokines and the 
emergence of anti-proliferative cytokines. The contraction of NK cell numbers in 
Dokun’s MCMV model occurs at around day 6 post-infection and correlates with the 
initiation of the adaptive immune response. A recent report has suggested CD4+ T cell-
derived IL-21 may be an anti-proliferative cytokine contributing to the resolution of NK 
cell proliferation (Kasaian et al., 2002). 
 
As mentioned, the early proliferative response of NK cells to virus is likely to be 
mediated by IL-15. Viral infections elicit strong IFN-/ responses that can up-regulate 
the expression of IL-15 mRNA in both dendritic cells and macrophages suggesting that 
these cells could be the source of this pro-proliferative cytokine (Mattei et al., 2001). 
However, it is difficult to definitively prove that IL-15 drives NK cell proliferation. This 
is because IL-15 knock-out or blockade of IL-15 signalling results in NK cell death as it 
is an essential cytokine for NK cell survival (Cooper et al., 2002). However, the 
circumstantial evidence for IL-15 being the pro-proliferative cytokine for NK cells is 
strong. 
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1.1.15 NK Cell Heterogeneity 
 
The first description of NK cell subsets was given by Nagler and colleagues in 1989. 
This seminal study not only recognised that NK cells have distinct subsets but also 
identified many of the key functional and phenotypic differences (Nagler et al., 1989). 
The subsets were defined by the surface density of CD16 with CD16bright cells 
comprising 10-15% with CD16dim and CD16negative cells comprising <1% of 
peripheral blood lymphocytes. The subsets are now more commonly known as 
CD56dim and CD56bright respectively. NK cell subsets are similar in that they all 
express CD2, CD7, CD11b, CD38, CD45R, CD18 and the IL-2 receptor. However, they 
have several prominent differences; phenotypically the CD56bright population differ in 
that they express higher levels of CD44, CD11c, CD25 and lower levels of CD57. 
Morphological examination by Nagler and colleagues showed that the CD56bright NK 
cells are mostly agranular, whereas CD56dim NK cells possess granules. Functional 
experiments revealed that the CD56bright population had almost negligible ability to 
kill NK cell sensitive tumour cells, fitting in with their agranular morphology. 
Furthermore, the CD56dim subset showed potent cytotoxicity, which is consistent with 
their granular morphology. However, CD56bright NK cells can achieve a similar level 
of cytotoxicity after treatment with IL-2 (Caligiuri et al., 1990). CD56bright NK cells 
have a greater capacity for cytokine production than the CD56dim subset. In fact, a 
major function of CD56bright NK cells is to provide macrophages and antigen 
presenting cells with early cytokines, in particular IFN-. CD56bright NK cells are a 
source of other cytokines including IL-10, IL-13, TNF- and GM-CSF, with the 
CD56dim subset producing negligible amounts of these cytokines (Fehniger et al., 
1999). In addition to the above described differences, the CD56bright subset has a much 
higher proliferative capacity than the CD56dim subset and proliferates readily in 
response to very low concentrations of IL-2. The findings from this Nagler’s seminal 
paper have been confirmed many times over and form the basis of our knowledge of 
NK cell subsets (for reviews on the subject see (Cooper et al., 2001a; Poli et al., 2009). 
 
NK cell subsets not only differ in phenotype and function but their regulation is also 
unique owing to their differential expression of activatory and inhibitory receptors. 
CD56bright NK cells express little or no KIRs but high levels of CD94-NKG2A 
  Chapter 1 
 37
inhibitory receptors; the opposite is found on the CD56dim subset (Colonna et al., 1997; 
Voss et al., 1998). Regarding activatory receptors, no correlation has been found 
between CD16 and the NCRs (Bauer et al., 1999; Sivori et al., 2000b) although the 
differential expression of CD16 has functional consequences itself as it is a triggering 
receptor for antibody dependent cellular cytotoxicity (ADCC) (Leibson, 1997). 
Therefore CD56dim NK cells, with the higher expression level of CD16, exhibit greater 
levels of ADCC than the CD56bright subset. 
  
Early in the immune response NK cells receive signals from monocytes via monokines 
and the subsets differ in the monokine receptors that they express. For example, the 
CD56bright subset has been found to have higher expression of the IL-18 receptor 
(Kunikata et al., 1998) and the IL-1 receptor than the CD56dim subset (Cooper et al., 
2001b) bestowing the CD56bright subset a greater ability to react to signals from cells 
of the monocyte/macrophage lineage.  
 
Furthermore, Campbell et al. described the two NK cell subsets based on their 
differential expression of chemokine receptors (Campbell et al., 1998; Campbell et al., 
2001). The discovery that the CD56bright subset expresses CCR7, a receptor involved 
in T cell homing to secondary lymphoid organs, hinted towards the possibility that this 
subset may traffic to lymph nodes. Indeed, 90% of NK cells found in the lymph node 
are of the CD56bright subset (Frey et al., 1998). The CD56dim subset lack the 
expression of CCR7 but express high levels of CXCR1 and CX3CR1 and respond to IL-
8 and fractalkine, which are the ligands for these receptors (Campbell et al., 2001). 
 
NK cell subsets also express different adhesion molecules. CD56bright NK cells 
express high levels of L-selectin, the ligand for which, GlyCAM-1, is found on the high 
endothelial venules of lymph nodes (Frey et al., 1998), further supporting the likelihood 
that CD56bright NK cells traffic to secondary lymphoid tissues. Sedlmayr et al. 
compared the NK cell subsets for their expression of a comprehensive list of adhesion 
molecules. They found that the CD56bright subset expressed a higher density of CD2, 
CD11c, CD15s, CD44, CD49e, CD55, CD62L, and HLA-DR, with CD56dim NK cells 
exclusively expressing CD49e (Sedlmayr et al., 1996). Different profiles of adhesion 
molecules strengthen the theory that NK cell subsets have different homing properties 
and therefore different tissue distributions.  
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1.2 Monocyte/Macrophage Biology 
 
Derived from the common lymphoid progenitor, monocytes continuously circulate 
through the blood and tissues and it is within tissue that they differentiate into 
macrophages. Monocytes are defined as being CD115+, CX3CR1+, NKp46-, CD3-, 
CD19-, and CD15- and are divided into three subpopulations depending on expression 
levels of CD14 and CD16 (Passlick et al., 1989; Grage-Griebenow et al., 2000). Both 
monocytes and macrophages are phagocytic however, most infections occur in the 
tissues, therefore macrophages are considered the more important phagocyte of these 
two cells. The phagocytic function of macrophages allows the killing of invading 
pathogens. Macrophages also help to coordinate an immune response by inducing 
inflammation and by activating and recruiting other immune cells. Monocytes are also 
able to differentiate into DCs, and the differentiation pathway they take depends on 
external signals; GM-CSF combined with IL-4 induces differentiation to DCs whereas 
M-CSF stimulates differentiation into macrophages (Randolph et al., 1999; MacDonald 
et al., 2005; Martinez et al., 2006; Strauss-Ayali et al., 2007). Macrophages can be 
activated by pathogen; through the recognition of bacterial LPS via TLR4 (Beutler, 
2000; Beutler and Rietschel, 2003) or can be activated by apoptotic or necrotic cells 
through signalling via scavenger receptors (Peiser et al., 2002). Macrophages can also 
be activated indirectly through cytokine signalling from other cells. There are two type 
of indirect activation; ‘classical’ activation, requiring the production of IFN-γ from TH1 
T cells and NK cells, and IL-12 and IL-18 from antigen presenting cells (Dalton et al., 
1993) and ‘alternative’ activation needing IL-4 and IL-13 most probably sourced from 
TH2 T cells. Classical macrophage activation is associated with resistance to 
intracellular pathogens and alternative activation is more commonly linked with allergy 
and parasitic infection. With regard to their regulation, the activation status of 
macrophages is controlled through the regulatory actions of IL-10, TGF-β, 
Prostaglandin E2, and glucocorticosteroids. The phagocytic action of macrophages is 
aided in many ways; opsonins enhance pathogen engulfment (Barrington et al., 2001; 
Ravetch and Bolland, 2001; Roozendaal and Carroll, 2006), inducible nitric oxide 
synthase (iNOS) allows cytotoxic activity which is assisted by glutathione, cysteine, 
superoxide and hydrogen peroxide (MacMicking et al., 1997; Aderem and Underhill, 
1999). The second function of cells of the monocyte/macrophage lineage is the 
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provision of signals to influence the immune response. These signals include reactive 
oxygen species, complement factors, prostaglandins, nitric oxide, TNF-α, IL-1β, 
CXCL8, IL-6, IL-10 and proteolytic enzymes (Geissmann et al., 2008; Serbina et al., 
2008). It is through these signals that cells of the monocyte/macrophage lineage are able 
to alter the impending adaptive response and also to interact with NK cells, as will be 
described in the subsequent section.  
 
1.2.1 NK Cell Interactions with Cells of the Monocyte/Macrophage Lineage 
 
Both NK cells and macrophages are rapidly recruited and co-localise in the early phase 
of an immune response (Dalbeth and Callan, 2002; Ottaviani et al., 2006). Therefore it 
is perhaps of little surprise that these two cells influence each other. Cells of the 
monocyte/macrophage lineage enlist NK cells by releasing macrophage inflammatory 
protein-1alpha (MIP-1α) which has been shown to be important for NK cell migration 
to sites of inflammation and stimulation of the production of IFN-γ by NK cells 
(Salazar-Mather et al., 2000; Dalbeth et al., 2004). The interaction of monocytes with 
NK cells is not a one-way exchange and NK cells can also affect cells of the 
monocyte/macrophage lineage in a number of ways; of relevance to the current study, 
CD56bright NK cells have been shown to drive the differentiation of monocytes into 
TH1 promoting DCs, a process that is dependent on cell contact and NK cell derived 
GM-CSF and CD154 (Zhang et al., 2007). This study also examined the ability of 
synovial fluid from different arthritidies and found that synovial fluid from rheumatoid 
and psoriatic arthritis but not osteoarthritis could induce monocytes to differentiate into 
DCs in an NK dependent manner, leading to the possibility that CD56bright NK cells 
play a part in the maintenance of TH1-mediated inflammatory conditions. Furthermore, 
NK cell-derived IFN-γ activates macrophages (Diefenbach and Raulet, 2002). NK cells 
can also provide a regulatory function for macrophages by killing any ‘over-stimulated’ 
cells (Nedvetzki et al., 2007; Lunemann et al., 2009). Receptors mediating this crosstalk 
have been postulated in these studies describing the reciprocal activation of monocytes 
and DCs, although only one study has identified a candidate; Welte et al. showed that 
the engagement of NK cell-bound NKp80 to activation-induced C-type lectin (AICL), 
which is exclusively expressed by myeloid cells, stimulated the secretion of cytokines 
from both cell types (Welte et al., 2006).  
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1.3 Dendritic cell biology 
 
The dendritic cell provides the body with a way of surveying for pathogens and 
initiating a quick and appropriate response. Immature dendritic cells reside in peripheral 
tissues and in mucosa. Here, they are continuously sampling the environment and 
checking for any foreign antigens (Steinman, 2003). The recognition of pathogen is 
achieved by Toll-like receptors (Kaisho and Akira, 2003) and signalling through these 
receptors is also essential for the majority of dendritic cell functions including survival 
(Akira, 2003). If a pathogen is recognised, dendritic cells mature and up-regulate the 
expression of MHC molecules and the co-stimulatory molecules CD40, CD80 and 
CD86. Pathogen recognition also triggers the migration of dendritic cells to lymph 
nodes. Here, equipped with co-stimulatory molecules, and presenting the antigen, 
dendritic cells effectively stimulate naïve T cells. 
 
In humans there are two main subsets of dendritic cells; myeloid (mDC) and 
plasmacytoid (pDC). The dendritic cell subsets differ in their ability to respond to TLR 
ligands and also show functional heterogeneity (Liu, 2001). The mDC subset is CD11c+ 
CD1a+ and CD14- and can receive signals through TLR3, TLR4; the ligands for which 
are poly(I:C) and LPS respectively, and also through TLR8 (Kadowaki et al., 2001). 
mDCs respond to such signals by producing the cytokine IL-12. For experimentation 
mDCs can either be isolated from peripheral blood or derived from monocytes in vitro 
by treatment with GM-CSF and IL-4. In vitro derived mDCs are termed monocyte-
derived dendritic cells (mdDC) and these cells have proved to be extremely useful for 
research owing to the fact that so few DCs are found in peripheral blood. However, the 
expression of TLRs can differ between these in vitro derived dendritic cells and those 
occurring naturally in the blood so care must be taken when extrapolating laboratory 
findings to in-vivo biology. The second main subset, pDCs are CD11c- CD45RA+ 
CD123+ and BDCA2+ and produce IFN-α in response to CpG oligodeoxynucleotides 
and viruses through signalling via TLR9 and TLR7 (Jarrossay et al., 2001; Kadowaki et 
al., 2001; Hornung et al., 2002). 
  
The dendritic cell is also involved in the process of achieving T cell tolerance to self. 
This is achieved by thymic dendritic cells that eliminate any potentially reactive T cells 
by inducing their apoptosis (Brocker et al., 1997). The dendritic cells that carry out this 
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process differ from the norm in that they spend their ‘lives’ in the thymus- deriving 
from thymic precursors, developing and dying here (Ardavin et al., 1993).  
 
1.3.1 NK Cell Interactions with Dendritic Cells 
 
It has long been known that NK cell cytotoxicity is enhanced by IFN-α (Trinchieri and 
Santoli, 1978) and since the major source of IFN-α is pDCs, the interaction of NK cells 
with DCs has been inferred for quite some time. Indeed, from quite early in NK cell 
research, pDCs have been shown to be a requirement for NK cell-mediated lysis of 
virus infected cells, in particular cytomegalovirus-infected fibroblast cells 
(Bandyopadhyay et al., 1986). However, it wasn’t until much later that the first report 
was published that demonstrated in vivo the importance of this interaction (Fernandez et 
al., 1999). The field has expanded since this time and many reports have documented 
the nature of signalling between DCs and NK cells. Amongst these reports was the 
confirmation that IFN-α from pDCs enhances NK cell functional activity (Reiter, 1993; 
Orange and Biron, 1996b). Other communications between these two innate cells came 
to light, including the cell contact dependent interaction of the NKG2D ligand; MICA, 
which is expressed by DCs with the NKG2D receptor on NK cells (Jinushi et al., 2003) 
as well as soluble factors such as DC derived IL-12 and IL-18 being able to induce NK 
cell IFN-γ production (Fernandez et al., 2002; Borg et al., 2004). The importance of 
DC-derived soluble factors has also been shown to be dependent on the antigenic 
challenge, for example, DC-derived IL-2 is thought to be more important than IL-12 
and IL-18 in bacterial infection in mice (Granucci et al., 2004). Indeed, in some disease 
states, the interaction of NK cells with DCs is of critical importance; in a murine study 
this cross-talk has been shown to provide IFN-γ dependent immunity to blood-stage 
Plasmodium chabaudi infection (Ing and Stevenson, 2009). Furthermore, the crosstalk 
between NK cells and DCs can manipulate the NK cell response so that the function of 
the NK cells is more effective for a particular stimulus. For example in HCMV 
infection, pDCs deviate the NK cell response towards cytokine production rather than 
killing (Cederarv et al., 2009). 
 
The studies described above tell of DC stimulation of NK cell effector functions. 
However, DCs have also been implicated earlier in NK cell functioning and one study 
has suggested that DCs have a role in priming NK cells. This claim is contrary to the 
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concept that NK cells provide a front line defence ‘without the need for priming’. 
Nevertheless, using an in vivo murine model, Lucas et al. showed a requirement for NK 
cells to some into contact with type I IFN receptor and IL-15 expressing DCs in 
lymphoid tissue with the prerequisite of L-selectin-dependent migration of NK cells to 
the lymphoid tissue (Lucas et al., 2007). These ‘primed’ NK cells require other signals 
to enable the functions of cytotoxicity and IFN-γ production. Lucas’s theory does not 
however take into account the L-selectin negative NK cells, namely the CD56dim 
subset of NK cells, which are still able to become fully functional. Furthering the 
possibility that NK: DC interactions are in fact CD56bright NK: DC interactions, Vitale 
et al. reported that only this subset is responsible for the observed interaction with DCs 
(Vitale et al., 2004). Supporting the priming theory is the observation that NK cells are 
rapidly recruited to lymph nodes of mice immunised with antigen (Martin-Fontecha et 
al., 2004). Here, these NK cells produce IFN-γ raising the possibility that the NK cells 
in lymph nodes could not only be being primed but could also be providing stimulus for 
other cells. 
 
Reciprocally, NK cells can influence DCs by either inducing DC maturation or by 
lysing immature but not mature DCs depending on the state activation of the NK cell 
and also on the ratio of NK cells to DCs (Gerosa et al., 2002; Piccioli et al., 2002). The 
protection of mature DCs from NK cell killing has been attributed to the expression 
levels of MHC class I molecules, in particular HLA-E, (Carbone et al., 1999; Wilson et 
al., 1999) and the balance of signals from NKp30 and CD94-NKG2C receptor 
engagement on the NK cells (Ferlazzo et al., 2002; Della Chiesa et al., 2003). The 
hypothesis behind this selection process, which is also termed DC ‘editing’ is that only 
the DCs that are suitable for T cell priming are chosen, thereby increasing the efficiency 
of the adaptive immune response (Ferlazzo and Munz, 2004). Furthermore, adhesion 
molecules could affect the cross-talk between DCs and NKs. A recent report has 
implicated LFA-1 in this interaction with important consequences as the strength of the 
immune synapse that is formed between these two cells could determine the outcome of 
the response (Poggi et al., 2002). 
 
The complexity of the relationship between NK cells and DCs is furthered by the 
findings that NK cells also express some TLRs (Chalifour et al., 2004; Neves et al., 
2009). One study has shown that NK cells respond to stimulation via these receptors 
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with increased cytokine production and killing (Sivori et al., 2004). Such findings blur 
the boundaries of the definitions of DCs and NK cells (Spits and Lanier, 2007) and 
there have even been suggestions of a hybrid, multitasking interferon-producing killer 
dendritic cell or IKDC (Shortman and Villadangos, 2006). 
 
1.4 NK Cell Regulation of the Acquired Immune Response 
 
The innate and adaptive arms of the immune response, which were once thought to be 
quite distinct, are now known to be much more tightly entwined and the interaction of 
NK cells with DCs is now known to provide part of the bridge that integrates these two 
arms. The first report to indicate that NK cells can regulate the adaptive response of T 
cells was produced as early as 1985 (Shah et al., 1985) and since then, several studies 
have shown more unconventional NK cell functions such the localisation of CD56bright 
NK cells in lymph nodes with the purpose of providing IFN-γ for T cell proliferation 
and polarisation towards a Th1 response (Martin-Fontecha et al., 2004). The marginal 
zones of lymphoid organs, where these CD56bright NK cells can be found, is also a 
location where DCs prime T cells, and the proximity of these cells make it likely that 
CD56bright NK cells can influence one or both of these immune cells (Daniels et al., 
2001). Adding to the evidence that NK cells can influence T cell responses is the 
immune systems ability to react to tumours. Being composed of self-tissue, tumours are 
poorly immunogenic and therefore lack signals to stimulate DCs. However, NK cells 
can react to the tumour in 3 possible ways; 1. Directly kill tumour cells (van den Broek 
et al., 1995), 2. Recognise MHC class I deficient tumours and stimulate DC maturation 
with a subsequent appropriate adaptive T cell response as shown in a report by Mocikat 
et al. (Mocikat et al., 2003), 3. Directly trigger the adaptive response for example Kelly 
et al. showed that NK cells mediated the tumour specific response of both CTLs and 
Th1 T cells with the interaction of CD27 on NK cells and CD70 on the tumour cell line 
providing the link (Kelly et al., 2002). This latter method for dealing with the tumour 
shows a direct NK: T cell interaction without DCs being present. In support of this, a 
substantial number of reports have shown T cells to express ligands for both inhibitory 
and stimulatory NK cell receptors (reviewed by (Raulet, 2004) therefore bestowing the 
T cell with the ability to directly interact with NK cells. 
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1.5 Tissue Inflammation 
 
Descriptions of tissue inflammation can be found in texts dating back from thousands of 
years. Initially described as physical symptoms, an explanation of the underpinning 
physiology was pieced together through breakthroughs such as Metchnikoff’s discovery 
of phagocytes, Ehrlich’s theory of humoral immunity and the appreciation of microbial 
agents as inducers of inflammation by Louis Pasteur. The description of inflammation is 
now complex, with multiple pathways leading to a fine-tuned response suited to the 
trigger. Bacterial, viral and parasitic infections, tissue damage and hypoxia can all act as 
triggers and are sensed  by the sentinel cells; macrophages, mast cells and dendritic cells 
which express TLRs. The response elicited by these cells is appropriate for the trigger; 
viral infections induce the production of IFN-α and IFN-β from the infected cell and 
activate cytotoxic lymphocytes, parasites stimulate mast cells and basophils to release 
histamine and the cytokines IL-4, IL-5 and IL-13 whereas bacterial infections induce 
the pro-inflammatory cytokines TNF, IL-6 and IL-1 as well as CCL2 and CXCL8 
(Reviewed by (Medzhitov) In these early stages of inflammation, the mediators cause 
vasodilation resulting in plasma leakage into the infected tissue. Neutrophils are 
recruited quickly and destroy the pathogen alongside mast cells and macrophages. The 
effects of inflammation are not just confined to cells; a system and body-wide response 
is induced including the production of prostaglandins by endothelium in the brain 
causing changes in the behaviour of the person including fatigue and social withdrawal 
(Pecchi et al., 2009). Sustained neutrophil and mast cell activation causes the 
inflammatory response to evolve into the immune response with the activation of 
antigen presenting cells and lymphocytes. Inappropriate inflammation can be costly in 
terms of causing tissue damage, which itself can be a trigger for further inflammation, 
therefore checkpoints are crucial for preventing a self-propagating pathological 
response (Reviewed by (Nathan, 2002). Many cells involved in an inflammatory 
response have self regulatory mechanisms; for example as neutrophils pass through 
tissues, the tissue makes lipoxins which blocks further neutrophil influx (Levy et al., 
2001). There are also a substantial number of interactions between the immune cells 
themselves that moderate inflammation; two of the major mediators of these are IL-10 
and TGF-β. Cleverly, these mediators are able to selectively shut down part of a cell’s 
inflammatory response rather than the whole cell’s response; IL-10 inhibits the 
expression of only 10-15% of macrophage genes that are targeted by TLR engagement 
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thereby preventing further production of inflammatory mediators by macrophages but 
allowing their involvement in tissue repair and metabolism. The final stages of 
inflammation are recovery and repair and at this stage, macrophages produce more 
serine leucocyte peptidase inhibitor which itself suppresses the release of elastase by 
neutrophils (Grobmyer et al., 2000). Furthermore, this protease inhibitor synergises with 
proepithelin which promotes epithelial growth and repair (Ashcroft et al., 2000). Some 
pro-inflammatory molecules switch to an anti-inflammatory status. For example TNF 
induces the production of IL-12 by macrophages which has an autocrine effect by 
promoting macrophages to secrete IFN-γ. Normally, early on in inflammation, IFN-γ 
would promote pro-inflammatory cytokine production, but at this late stage it in fact 
suppresses it (Hodge-Dufour et al., 1998). An excessive inflammatory response is of 
course, detrimental and dysregulation at any of the stages in inflammation can result in 
a loss of normal function of tissues or organs. Anti-inflammatory therapies are a very 
attractive prospect, although just blocking the pro-inflammatory agents is not without 
consequences; as described above, IFN-γ switches from pro-to anti-inflammatory once 
the infectious agent has been cleared. There are reports of associated tuberculosis 
infections being linked with anti-TNF-α therapies (Keane et al., 2001). 
 
1.6 The role of NK cells in pathological inflammation 
 
There is now a substantial body of correlative evidence pointing towards a role for NK 
cells in inflammatory diseases (Korsgren, 2002; French and Yokoyama, 2004). Indeed, 
other evidence such as a change in the number of NK cells and also the localisation of 
NK cells at the site of disease, make it very likely that these cells play some part in 
inflammatory, autoimmune diseases. It has proven difficult to work out if NK cells are 
contributing to pathology i.e. they are the cause, or if their presence is a secondary 
phenomenon i.e. the increased numbers and localisation is an effect of the disease. The 
NK cells could contribute to either protection from or pathology from a disease 
depending on the cytokine profile. In MS, where NK cells have been shown to 
accumulate in brain lesions, NK cell production of IFN-γ correlates with active disease 
whereas IL-5 production correlates with disease remission (Takahashi et al., 2001). The 
large collection of murine experiments using the animal model of MS; experimental 
autoimmune encephalomyelitis (EAE), could be interpreted as supporting this bi-
potential theory of NK cell involvement in disease progression in MS. Indeed, mice 
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devoid of NK cells and mice with defects in NK cell functions such as those deficient in 
IL-18 production can not be induced to have EAE (Shi et al., 2000). The majority of 
studies have shown NK cells to provide a protective effect (Matsumoto et al., 1998; 
Huang et al., 2006). Conflicting findings could be explained by different experimental 
techniques, particularly in the timing of NK cell depletion or sampling as the NK cells 
could be providing a regulatory role early in the disease but could then be contributing 
to pathology once the inflammation is uncontrolled and the disease is established. These 
questions could be answered by using an in vivo time course, sampling NK cells 
throughout the disease progression and testing their cytokine profile. Genetic 
associations of different KIR haplotypes leading to the susceptibility for particular 
autoimmune diseases have been described; systemic sclerosis and rheumatoid arthritis 
(RA) have been associated with the expression of KIR2DS2, an activatory KIR and the 
absence of the inhibitory KIR2DL2 (Perricone et al., 2008), perhaps leading to more 
‘trigger happy’ NK cells. Indeed, if the synovial fluid of patients with RA is examined, 
a large accumulation of the CD56bright NK cell subset is seen with 90% of the NK 
cells being of this phenotype compared to only 10% in the periphery (Dalbeth and 
Callan, 2002; Pridgeon et al., 2003). It appears that in this setting, the NK cells are 
contributing to inflammation and pathology by engaging with monocytes in a cycle of 
reciprocal activation (Dalbeth et al., 2004). Furthermore, this subset is more adapted to 
produce cytokines, in particular IFN-γ, therefore the inflammatory milieu of the joints 
will be polarised to a TH1 response. The dominance of the CD56bright subset of NK 
cells in inflamed joints could reflect either preferential recruitment from the periphery 
or could reflect differentiation from the CD56dim NK cell subset locally.  
 
1.7 Cell migration to the site of inflammation  
 
For a cell to get to the site of inflammation, it must first traverse the vascular 
endothelium. This process was initially thought of as passive, with the endothelium 
opening up when told to, allowing immune cells to pass through, and closing when 
required. The endothelium is now known to play a much more active role in cell 
migration, from regulating the functions of immune cells to suit the inflammatory 
stimuli (reviewed by (Nourshargh and Marelli-Berg, 2005) to acting as antigen 
presenting cells with the ability to recruit antigen specific T cells (Savage et al., 1995; 
Savinov et al., 2003). The endothelium is also a heterogeneous tissue, with both inter-
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organ variation (Chi et al., 2003; Tomlinson and Topper, 2003) and variation according 
to the inflammatory status of the tissues in which the blood vessel resides. As the latter 
statement suggests, the endothelium can play a role in immune surveillance and this is 
achieved through their display of chemokines and adhesion molecules (Alon et al., 
1994; Hamann et al., 1994; Bargatze et al., 1995; Luscinskas et al., 1995). Their 
connection with immunity means that endothelial cells also have the potential to, and 
sometimes do play a role in immune-mediated disorders. In RA, changes to the vascular 
endothelium occur very early in the disease process and lead to extravsation of plasma, 
migration of monocytes and neutrophils (Middleton et al., 2004). Furthermore, an 
increase in endothelium turnover helps feed the pannus, the invasive synovial 
membrane which degrades cartilage and bone, with fresh oxygen and nutrients (Walsh, 
1999). The post-capillary venules of inflamed rheumatoid synovium display a high 
endothelial venule-like morphology and cells appear to flatten out with therapy (Yanni 
et al., 1993). This morphology is associated with lymphocyte trafficking, and is most 
commonly seen in the lymph nodes, but has also been noted in other inflammatory 
conditions (Girard and Springer, 1995). Interestingly, the endothelium of vessels in the 
synovium have been shown to express peripheral lymph node addressin (PNAd) which 
is a counter ligand for L-selectin (Michie et al., 1993) and the CD56bright subset of NK 
cells expresses L-selectin at levels higher than other lymphocytes or their counter subset 
of NK cells, suggesting that the endothelium is becoming more adapted to attract 
migration of this particular subset of NK cells. Other adhesion molecules are 
particularly up-regulated in rheumatoid arthritis including E-selectin (Szekanecz et al., 
1996) and ICAM-1, the latter molecule has been noted to be expressed more highly on 
endothelial cells that resemble high endothelial venules (Szekanecz et al., 1994; 
Haskard, 1995). The importance of the endothelium in the pathology of rheumatoid 
arthritis is consistent with observations of diminished activation of the endothelium and 
a decrease in the migration of cells into rheumatic joints, seen as a decrease in serum E-
selectin and ICAM-1, of patients that are being treated with the anti-TNF treatment, 
infliximab (Paleolog et al., 1996). 
 
Cell migration through endothelium occurs not only in pathological situations but also 
in the normal physiological events of tissue surveillance and angiogenesis. A general 
description of the events and molecules involved in cell migration is given below 
followed by a description of the specific features of NK cell migration. 
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Transendothelial migration begins with a sequence of cell adhesions. There are 
molecular ‘choices’ at each step providing diversity and specificity. Initially the cell is 
tethered and rolls on the surface of the endothelium. This step is mediated by selectins. 
Chemokines from the endothelial cells then signal to the leukocyte to arrest via 
interactions with integrins. Finally the leukocyte passes through the endothelium by a 
process known as diapedesis.  
 
Step 1: Tethering and rolling. The selectins 
 
Low affinity selectin-ligand interactions capture cells and initiate rolling of the cell on 
the endothelium. The selectin family has 3 members all of which are C-type lectins; L-
selectin (CD62L) is constitutively expressed by most circulating leukocytes and is the 
key receptor at high-endothelial venules in secondary lymphoid tissue. P-selectin 
(CD62P) is expressed by activated platelets and the endothelial cells in response to 
mediators of acute inflammation. P-selectin is preformed and stored in Weibel-Palade 
bodies of endothelial cells and the α granules of platelets enabling rapid expression of 
the molecule.  The expression of E-selectin (CD62E) by the endothelium is regulated by 
cytokines such as IL-1 or TNF-α. It is not pre-formed and therefore requires de-novo 
protein synthesis (Patel et al., 2002). 
 
Selectin ligands  
 
The selectins bind to mucin ligands displaying sialyl-Lewis X like carbohydrate 
epitopes. L-selectin can recognise two mucins; Glycam-1 and CD34 (Lasky, 1992). The 
major ligand for P-selectin is PSGL-1 (Ley and Kansas, 2004) however there seems to 
be some amount of cross-over as in vitro assays have also demonstrated that L-selectin 
can also bind PSGL-1.  The best characterised ligand for E-selectin is Cuntaneous 
Lymphocyte Antigen (CLA) which is expressed by the majority of T cells and as the 
name suggests, the cells that express this selectin ligand are mainly found at sites of 
chronic skin inflammation (Berg et al., 1991).  
 
Step 2: Cytokine signalling 
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Cytokines orchestrate the response by providing directionality through concentration 
gradients. Secondly, cytokine signalling activates integrin expression on leucocytes and 
increases integrin binding affinity for ligands on the endothelium resulting in firm 
adhesion. (Moser et al., 2004). Receptor specificity overlap and variations in the 
patterns of anchoring proteins that display cytokines at the endothelial cell surface 
enable homing of specific cells that are required for the particular pathogen or injury. 
 
Step 3: Arrest of the leukocyte: The integrins. 
 
The binding of cells to integrins is transient but the strength of adhesion can be rapidly 
regulated by the cell through conformational changes. Integrins are arranged in dimers 
with one α and one β subunit. The β2 integrins LFA-1 (αLβ2 or CD11a/CD18) and Mac-
1 (αMβ2 or CD11b/CD18) interact with ICAM-1 and ICAM-2 resulting in firm 
adhesion of the leucocyte on the endothelium (Hogg et al., 2002). The α4 integrins 
include VLA-4 (α4β1 or CD49d/CD29) and LPAM1 (lymphocyte Peyer’s patch 
adhesion molecule or α4β7 or CD49d/CD-) which bind to VCAM-1 in inflamed tissues 
and MadCAM in Peyer’s patches respectively (Ulbrich et al., 2003). LPAM1 mediates 
the binding of mucosal lymphocytes to high endothelial venules directing lymphocytes 
into the intestine. Both α4 integrins have been shown to mediate tethering and firm 
adhesion of lymphocytes to endothelium (Berlin et al., 1995). 
 
Integrin ligands 
 
ICAM-1 and ICAM-2 are endothelial ligands for the β2 integrins. They were initially 
identified by their ability to bind LFA-1 but are now known to also bind Mac-1. 
Engagement of ICAM-1 is thought to be one of the most important receptors for firm 
adhesion of the leukocyte to the endothelium. ICAM-1 is constitutively expressed and at 
inflammatory sites ICAM-1, expression can be up-regulated by cytokines and 
inflammatory cells. ICAM-2 is also constitutively expressed, and is thought to be 
important for lymphocyte recirculation (Springer, 1994). The expression of VCAM, 
another integrin ligand, is inducible on endothelial cells. This ligand binds to VLA-4 
and more weakly to LPAM1 and is mainly involved in cell migration during 
inflammation (Ruegg et al., 1992). MadCAM-1 is a dual purpose ligand binding to both 
the integrin LPAM1 in Peyer’s patches and L-selectin therefore playing important roles 
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in both homing of lymphocytes to the gut and lymphocyte recirculation (Berg et al., 
1993). 
 
Step 4: Diapedesis 
 
The final stage of migration is diapedesis. The leucocyte extends itself via a pseudopod 
and passes through the endothelium and its associated peri-vascular membrane. 
Investigators are agreement that the majority of cells pass between endothelial cells- the 
paracellular route. Some leucocytes have been shown to pass through the body of the 
endothelial cell which is also known as the transcellular route. There is significant 
interest in the mechanism of transcellular migration and importance of this mode of 
diapedesis (Carman and Springer, 2004; Engelhardt and Wolburg, 2004). The first stage 
of diapedesis is a rise in endothelial cell cytosolic free calcium in response to soluble 
cations released by inflammatory cells and possibly by the cross linking of E- or P-
selectin or VCAM-1, and this rise causes the endothelial cell to retract. As the stimulus 
is local to the migrating lymphocyte, this ensures that only endothelial cells local to the 
inflammation retract to allow the passage of the cell to the underlying tissue. To prevent 
the endothelium from becoming pathologically leaky, the junctions between endothelial 
cells are also filled with adhesion molecules (Huang et al., 1988) which include 
PECAM-1 (CD31), members of the junctional adhesion molecule (JAM) family, VE-
Cadherin and the recently described PRV, ESAM and CD99 (Dejana et al., 1995). 
Immune cells must interact with these adhesion molecules in order to successfully pass 
through the endothelium (reviewed in (Muller, 2003) and therefore these molecules 
provide a checkpoint for cell migration. A description of the adhesion molecules 
involved in the final process of migration, diapedesis, is given below. 
 
One of the most important and perhaps best known adhesion molecule found at high 
concentrations between the borders of endothelial cells is PECAM-1 and up to 90% of 
diapedesis is inhibited by blocking PECAM-1. This molecule appears to work along the 
whole border of the endothelial cell as blocking of PECAM-1 can both prevent a cell 
from extending a pseudopod into the intercellular junction (Muller, 2003) and can trap 
cells right down to the level of the basement membrane, just before it reaches the 
underlying tissue (Duncan et al., 1999). 
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CD99 is one of the most recently described molecules involved in leucocyte migration. 
The engagement of this molecule occurs after PECAM-1 and blocking of this molecule 
arrests the migrating cells so that part of the cell remains above the endothelium and 
another part remains between the endothelium and basement membrane. Blocking of 
both CD99 and PECAM-1 halts migration completely and demonstrates the stepwise 
nature of diapedesis (Schenkel et al., 2002). 
 
VE-Cadherin is a rather unique adhesion molecule as its presence blocks rather than 
facilitates cell migration. Its purpose is to maintain the integrity of the blood vessel at 
adherens junctions (Ali et al., 1997) and interactions must dissociate to enable cell 
migration (Shaw et al., 2001). 
 
One member of the JAM family of adhesion molecules; JAM-A, is of varying 
importance in diapedesis and the degree of its involvement appears to depend on the cell 
type and the inflammatory model used. A deficiency of this molecule appears to 
facilitate faster migration of dendritic cells through lymph node endothelium (Cera et 
al., 2004) but hinders neutrophil migration into inflamed peritoneum (Corada et al., 
2005). 
 
Endothelial selective adhesion molecule (ESAM) was quite recently identified as 
having a role in diapedesis. This molecule is selectively expressed by endothelial cells 
and is inducible on platelets (Nasdala et al., 2002) and seems to support  T cell and 
neutrophil migration (Wegmann et al., 2006).  
 
A novel adhesion molecule, PVR, was originally found as the poliovirus receptor. It 
functions on tumour cells as a ligand for the NK surface protein DNA accessory 
molecule-1 (DNAM-1). DNAM-1 is also expressed by other lymphocytes and 
antibodies specific for either PVR or DNAM-1 block monocyte migration at a location 
similar to PECAM-1, above the junctions between endothelial cells (Reymond et al., 
2004).  
 
Diapedesis is a complex process which requires many membrane proteins. Immune 
cells use different adhesion molecules to traverse the endothelium; ICAM-1 and ICAM-
2 are used by neutrophils, monocytes and lymphocytes. CD99 thus far is only known to 
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mediate migration of lymphocytes and its involvement is also dependent on the 
activation state of the lymphocyte, PECAM-1 and ESAM selectively support the 
migration of cells of the myeloid lineage. At each step in the process of transmigration, 
multiple receptors and ligands are involved, each with distinct distributions on different 
immune cells and on the endothelium itself, providing huge diversity and enabling 
selective and specific cell migration (reviewed in (Lasky, 1992). Despite much recent 
progress it is unlikely that all the molecules involved in migration have been identified 
and there are many questions left unanswered making the field of cell migration an 
active and very interesting area of research. Cell migration is a possible process that can 
be exploited for targeting therapies to halt non-resolving inflammation. As most 
inflammatory diseases are tissue or organ specific, this suggests that local, rather than 
universal processes are involved. Identifying both the specific cell subsets that cause or 
worsen non-resolving inflammation, and also the molecules that bring them to the site 
of inflammation would bring us a step closer to more disease specific anti-inflammatory 
therapy. 
 
1.8 NK cell transmigration 
 
The next section will review the current knowledge of the specific features of NK cell 
migration. 
 
1.8.1 The selectins and NK cells 
 
L-selectin is involved in adhesion of leucocytes to the high endothelial venules of 
peripheral lymph nodes. The CD56bright subset of NK cells express L-selectin at levels 
higher than that of all other immune cells giving this subset a selective advantage over 
other NK cells for their migration to the lymph nodes. Activation of NK cells can 
modify the expression of L-selectin; in the presence of  IL-2, IL-15 or TGF- the 
expression levels of L-selectin are decreased on the CD56bright subset with IL-12, IL-
10 and IFN-α increasing the expression levels on both subsets of NK cells (Frey et al., 
1998). NK cells also express selectin ligands including sialyl-Lewis X and PSGL-1 
which shows that NK cells can engage with P- and E-selectin to mediate cell rolling on 
the vascular endothelium (Moore and Thompson, 1992; Pinola et al., 1994). 
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Interestingly, a molecule that that enables binding to L-selectin; PEN5, has been shown 
to be exclusively expressed by the CD56dim subset of NK cells. CLA, like PEN5, is a 
carbohydrate modification of PSGL-1 and NK cells that express CLA do not express 
PEN5. This shows that adhesion molecule expression adds another level of complexity 
to the division of NK cells into subsets, and also provides further evidence that NK cell 
subsets have different homing properties (Andre et al., 2000).  
 
1.8.2 Integrins and NK cells 
 
NK cells express 1, 2 and 7 integrins. Peripheral blood NK cells abundantly express 
41 (CD49d) as the VCAM-1 receptor. Indeed, anti-VCAM-1 antibodies inhibit NK 
cell homing into experimental melanoma metastasis in vivo (Fogler et al., 1996). The 
41-VCAM-1 interaction has been shown to be to be important in the migration of 
NK cells across activated but not resting endothelium (Gismondi et al., 1991). For this 
reason, one can speculate that this interaction may be important in inflammation rather 
than NK cell recirculation. The 4 subunit can also localise with the 7 subunit to form 
MadCAM-1. NK cells can also express MadCAM-1, and this molecule facilitates 
binding to mucosal high endothelial venules (Perez-Villar et al., 1996). If an NK cell 
expresses both 41 and 47 it will only bind efficiently to VCAM-1 therefore the 
regulation of expression of these integrins will determine the recruitment of NK cells to 
certain tissues (Rott et al., 1996). NK cells express all the members of the 2 integrin 
family; CD11a/CD18 which is also known as LFA-1 is known to be crucial for NK cell 
binding to target cells and for NK cell transmigration. Anti-2 integrin and anti-ICAM-
1 antibodies are known to inhibit NK cell adhesion to cultured endothelial cells 
implicating this adhesion pathway is important in NK cell interactions with the 
endothelium (Bianchi et al., 1993; Uksila et al., 1997). Differential expression of 
integrins can be controlled by cytokines allowing recruitment of specific NK cell 
subsets. NK cells also express different integrins over the course of their development 
and maturation. This would allow recruitment of NK cells at an appropriate stage of 
maturation or with a specific effector function to a location where these cells are 
required (Kim et al., 2002).  
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CD44 is widely expressed by many cell types and has been implicated in a number of 
processes including lymphocyte migration, haematopoiesis, metastasis and lymphocyte 
activation (Haynes et al., 1989; Shimizu et al., 1989). It is a major hyaluronate receptor 
and a potent ligand for E- and L-selectin. NK cells constitutively express CD44 and 
expression levels are up-regulated upon treatment with IL-2 (Maenpaa et al., 1993). NK 
cells express CD44 in its inactive form and require the presence of pro-inflammatory 
cytokines such as IL-2 and IL-15 to enable CD44 activation. Engagement of CD44 in 
combination with such cytokines has been shown to increase the production of IFN- by 
NK cells (Sague et al., 2004). Galadrini investigated the biological function of CD44 
and found that its ligation enhances NK cell cytotoxicity (Galandrini et al., 1994). A 
study using in vitro murine bone marrow cultures demonstrated the necessity for CD44 
engagement for the development of immature non-cytotoxic NK into mature cytotoxic 
NK cells (Delfino et al., 1994). It has been suggested that CD44 has a role in NK cell 
migration to mucosal tissues. In agreement with the work by Mäenppää et al., Uksila et 
al. found that NK cells treated with IL-2 displayed a decrease in L-selectin expression 
with a concomitant increase in CD44 and α4 integrins and may facilitate preferential 
recruitment of these cells to mucosal sites (Uksila et al., 1997).  
 
Berman et al. studied the role of PECAM-1 in NK cell transmigration. Ligation of 
PECAM-1 activates NK cell 2 integrins therefore mediating NK cell firm adhesion to 
the endothelium. This group found that when resting endothelial cells were used, anti-
PECAM-1 antibodies caused a 50% decrease in the migration of both NK cell subsets. 
When the endothelium was activated by pre-treatment with IFN-, the transmigration of 
the CD56bright subset was increased by 4 fold but the CD56dim subset by only 1.5 fold 
and the addition of anti-PECAM-1 antibodies caused a 30% decrease in the migration of 
CD56dim but did not affect the migration of CD56bright NK cells in these experiments 
with IFN-γ pre-treated endothelium (Berman et al., 1996). This suggests that PECAM-1 
plays a role in NK cell tissue surveillance and CD56dim NK homing to sites of 
inflammation but may not be important for CD56bright NK cell homing to sites of 
inflammation.  
 
 
 
  Chapter 1 
 55
1.8.3 NK cell subsets and adhesion molecules 
 
The two well known subsets of NK cells: CD56bright and CD56dim have different 
functions and phenotypes. Adhesion molecule expression adds to the segregation of 
these two subsets. As previously described the CD56bright subset express significantly 
more L-selectin than the CD56dim subset giving these cells a selective advantage for 
homing to lymph nodes. Differential adhesion molecule expression gives NK cell 
subsets the ability to home to distinct sites. Recently, another level of complexity has 
been suggested regarding adhesion molecules with NK cells showing differential 
expression depending on the expression of MHC class-I receptors, therefore dividing 
NK cells into further subsets (Morris and Ley, 2004).  
 
Recent publications have suggested that the CD56bright subset of NK cells is more 
immature than CD56dim NK (Poli et al., 2009). This suggestion is partly based on 
trends in adhesion molecule expression levels that are seen in T and B cells; for 
example naïve T cells express high levels of CCR7 and L-selectin which is likely to aid 
homing to lymphoid organs and these molecules are down-regulated upon maturation. 
The authors suggest a similar pattern for NK cells with the high expression levels of L-
selectin on CD56bright NK cells suggesting a more immature status and the CD56dim 
subset, with much lower expression levels of L-selectin, being the fully differentiated 
effector cells. Andre et al. have also suggested that the CD56bright subset of NK cells is 
less mature and came to this conclusion from observations of a down regulation of L-
selectin along with increased PSGL-1 correlating with lower CD56 and higher CD16 
and KIR expression (Andre et al., 2000).  
  
 
1.8.4 Cytokines, Chemokines and NK cells 
 
NK cells can respond to variety of cytokines and chemokines including IL-12, IFN-α/β, 
CCL2, 3, 4, 5, 7, 8, CXCL8 and CX3CL1 and migrate towards them with the aim of 
either homing to sites of inflammation or to lymph nodes. NK cells produce, and also 
react to IFN-γ, TNF-α, GM-CSF, CCL3, CCL4 and CCL5 and as a result, these cells 
can both respond to, and promote inflammation (Robertson, 2002). NK cells can also 
migrate towards IL-8 and fractalkine; Campbell et al. showed distinct profiles for 
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CD56bright and CD56dim NK cells with IL-8 and fractalkine preferentially attracting 
the CD56dim population and the CD56bright subset responding better to CCR7 ligands 
and poorly to MCP-1, MIP-1 and RANTES (Campbell et al., 2001). The expression 
profile of chemokine and cytokine receptors may in part be naturally different between 
NK cell subsets, but can also be modified by cytokines; treatment of NK cells with IL-2 
increases the spectrum of chemokines that they respond to (Inngjerdingen et al., 2001) 
and more recently, it has been shown that IL-18 can selectively induce the expression of 
CCR7 on the CD56dim subset, which accompanied by a decrease in CD16 expression 
levels and an enhanced ability to migrate towards lymph node derived chemokines and 
cytokines (Mailliard et al., 2005).  
 
1.9 The effect of transmigration on immune cell phenotype and function 
 
The molecules employed by both immune cells and the endothelium in the process of 
transmigration have been described in the sections above, and as previously mentioned, 
the endothelium is now known to be an active player in this process, with the potential 
to modify cells to suit the inflammatory stimulus. Migration-induced cell modifications, 
like all biological processes, has the potential cause inappropriate changes to cell 
function and phenotype and the endothelium also has the capacity to recruit 
inappropriate numbers or inappropriate cells to a site of inflammation, and thereby 
contribute to the pathology of inflammatory diseases. This next section will review the 
current state of knowledge about migration-induced changes to the functions and 
phenotypes of immune cells. There are many difficulties with studying migration-
induced changes to cells; it is difficult to differentiate between changes that are 
occurring as a direct result of endothelial cell-immune cell interactions and changes that 
are occurring once cells have come into contact with the inflammatory milieu on the 
other side of the endothelium. Some studies that will be described do successfully work 
out if it is the interplay between the endothelium and the immune cells that cause the 
changes in immune cell function and phenotype, but another perhaps more important 
question still remains; are these changes protective or are they pathological? 
Interpretations can be made; one can assume that a migration-induced increase in the 
production of pro-inflammatory cytokines, for example, could be detrimental in an 
inflammatory disease which results from an immune reaction that is struggling to 
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resolve. However, these assumptions can, and have been on several occasions, be 
proven wrong and whether migration-induced changes are protective or pathological 
often depends on the stage of disease progression. This adds an additional level of 
complexity for investigators; if animal models are being used, a quantitative measure of 
the stage of disease at which the experiment is being carried out, or at which the sample 
is being taken, is therefore required. Furthermore, it is unlikely that in vitro assays could 
answer this question, making findings of migration-induced changes to cells in 
inflammation a difficult subject to transfer from the laboratory to the clinic. 
 
1.9.1 The effect of cell migration in inflammatory joint diseases  
 
Inflammation of the joints of patients with rheumatoid arthritis results in a large 
accumulation of immune cells in the synovial fluid. These cells are recruited from the 
bloodstream and in order to get to the site of inflammation, the cells must traverse the 
vascular endothelium. The process of migration across endothelium is a point of 
interaction which has the potential to induce changes to the migrating cell; one study by 
Bruhl et al. looked at migration-induced changes in the surface expression of CC- and 
CXC-chemokine receptors using paired synovial fluid and peripheral blood samples 
from patients with inflammatory joint diseases (Bruhl et al., 2001). Their research 
showed that synovial fluid T cells had higher CCR5, CCR2 and CXCR4 expression 
levels than their peripheral blood counterparts. The authors suggested that this 
accumulation resulted from selective recruitment of T cells expressing these 
chemokines rather than a phenotypic change resulting from interactions with the 
endothelium. In this study, monocytes from the synovial fluid were also found to 
express higher levels of CCR5 but less CXCR1, CXCR2, CXCR4 and CCR1 when 
compared to monocytes from the peripheral blood and the authors suggest that the 
higher CCR5 expression reflects maturation of the monocytes to macrophages at the site 
of inflammation rather than selective migration. Regarding lower expression levels of 
other chemokine receptors, the authors suggest that receptor engagement during 
transmigration caused their internalisation (Penton-Rol et al., 1998). The Bruhl study 
thereby showed several ways in which migration can change the cells that are recruited 
to the site of inflammation. Another study that looked at the differences between 
synovial fluid and peripheral blood monocytes taken from patients with inflammatory 
arthritidies found a universal three fold increase in selectin ligand expression compared 
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to osteoarthritis, regardless of whether cells were taken from the synovial fluid or from 
the peripheral blood (Koller et al., 1999). The authors of this study suggest that 
preferential recruitment of monocytes that express the selectin ligand sialyl-Lewis X 
had occurred, but that migration through the endothelium had caused a down-regulation 
of this molecule hence explaining the comparable expression levels when comparing 
blood monocytes to synovial fluid monocytes. Another possibility is that soluble 
selectins have bound to the sialyl-Lewis X on the synovial fluid monocytes, therefore 
blocking their detection and masking their presence. The endothelium has also been 
implicated as being able to contribute to T cell activation, with the adhesive interactions 
of ICAM-1 being important and IL-15 further enhancing the activation induced by 
interactions with the endothelium (Sancho et al., 1999). Berg and colleagues also noted 
that interactions of T cell populations with endothelial αLβ2 integrin-CD54 interactions 
appeared to cause the T cells to become hyperresponsive to the antigenic challenge and 
that functional and phenotypic alterations are also induced by the endothelium, with T 
cells becoming more able to migrate further into the tissue and also being more 
activated (Berg et al., 2002). A study by the Callan group analysed NK cells in synovial 
fluid of patients with inflammatory arthritidies, and found quite a dramatic difference in 
their phenotype with 90% being of the CD56bright subset compared to only 10% in the 
peripheral blood (Dalbeth and Callan, 2002). This group went on to further study NK 
cells at sites of inflammation in infectious, reactive or malignant pulmonary disease and 
also in the peritoneal fluid of patients with bacterial peritonitis. Like the synovial fluid 
of inflammatory arthritis, the CD56bright NK cell subset was found to predominate. 
This study also showed that in suitable cytokine environment, CD56bright NK cells are 
able to reciprocally activate cells of the monocyte/macrophage lineage, resulting in 
increased IFN-γ production by the NK cells and TNF-α by the monocyte/macrophages, 
which could propagate further, damaging inflammation (Dalbeth et al., 2004). Their 
work corroborated with Pridgeon et al. who showed that although no difference was 
seen in the proportion of NK cells in the total lymphocyte pool, when NK cells from 
patients with rheumatoid arthritis were compared with NK cells from healthy controls, 
the phenotype of synovial fluid NK cells was quite different. They found that synovial 
fluid NK cells had a higher surface expression of CD56, CD94, CD158a/b and had 
lower perforin levels compared to their peripheral blood counterparts or to blood from 
healthy controls (Pridgeon et al., 2003). 
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1.9.2 The effect of cell migration in lung diseases. 
 
Similar to joint diseases, when patients with allergic lung diseases are exposed to 
antigenic challenge, immune cells cross from the bloodstream through the endothelium 
into the alveoli of the lung. A bronchoalveolar lavage (BAL) sample taken after the 
antigenic challenge would contain immune cells that have migrated across endothelium 
to get into the lung, therefore assessment of these cells would allow a comparison of 
cells post-migration at the site of inflammation with ‘non-migrated’ cells from the 
peripheral blood. One such study by Sedgwick and colleagues found that eosinophils 
from BAL samples taken from allergic patients after antigenic challenge have higher 
expression of the adhesion molecules CD11b/CD18 and also HLA-DR (Sedgwick et al., 
1992). The authors of this study do not comment on the method of accumulation of 
CD11b/CD18high HLA-DRhigh eosinophils, however there are several possible 
explanations; these cells could have been preferentially recruited, their phenotype could 
have been altered as a result of interactions with the vascular endothelium as the cells 
migrated through from the bloodstream, or cell-cell interactions/soluble factors at the 
site of inflammation could have affected their phenotype.  BAL eosinophils in another 
study were found to have higher expression levels of CR-3, p150/95, CD67, CD63 and 
decreased L-selectin compared to their peripheral blood counterparts. This profile 
indicates the BAL eosinophils are activated regarding their capacity for degranulation. 
This study also found that BAL eosinophils had increased CD54 (ICAM-1), CD58 
(LFA-3) and HLA-II, this phenotype would allow more efficient interactions with T 
cells (Mengelers et al., 1994). Mengelers’ study, like the Sedgwick study described 
above, did not investigate the method of enrichment of cells with this phenotype. It is 
likely that all three possible explanations that are listed above could be relevant. 
 
1.10 Possible mechanisms causing changes to cells during migration. 
 
The body of evidence for the involvement of the endothelium in the modification of 
cells that arrive at the site of inflammation is growing, to list all these studies would be 
beyond the scope of this thesis, but the subject has been comprehensively reviewed by 
Nourshargh and Marelli-Berg (Nourshargh and Marelli-Berg, 2005). There are several 
mechanisms that the endothelium can employ to cause changes in the functions and 
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phenotype of migrating immune cells or to recruit a particular to the site of 
inflammation: 
 
(i) Antigen presentation. 
(ii) Transfer of molecules from the membranes of the endothelial cell to the migrating 
immune cell. 
(iii) Engagement with adhesion molecules that are expressed by the endothelium. 
 
Each of these possible mechanisms, along with supporting literature is described in the 
following paragraphs. 
 
1.10.1 Antigen presentation by the endothelium. 
 
Recent and exciting discoveries have begun to emerge suggesting that the endothelium 
can present antigen; Pober and colleagues showed that the endothelium cells can 
process antigen and express MHC class I and II (Pober, 1999) and Heidemann et al. 
noted endothelial cell TLR expression, indicating that these cells have the potential to 
recognise PAMPs and might function as an antigen presenting cells (Heidemann et al., 
2006). For effective antigen presentation and T cell stimulation, co-stimulatory 
molecule expression is required and it is known that endothelial cells do not express 
CD80 and CD86. However, an alternative co-stimulation pathways have been reported 
(Khayyamian et al., 2002) which bestows endothelium with the full capacity to operate 
as antigen presenting cells. Therefore, although the endothelium does not posses T or B 
cell-like qualities, it may be able to influence the adaptive immune system by not only 
presenting antigen to naïve T cells but also by recruiting antigen-specific memory T 
cells to the site of inflammation (Reviewed by (Marelli-Berg and Jarmin, 2004). 
 
1.10.2 Membrane transfer 
 
Another mechanism by which the endothelium can influence the phenotype and 
function of immune cells during migration is through the transfer of components of the 
endothelial cell membrane to the migrating cell. One study has provided evidence that 
dendritic cells could acquire MHC: peptide complexes during transmigration. These 
dendritic cells did not have contact with the antigen prior to interacting with the 
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endothelium and did not process the antigen and the authors suggest that this could be a 
new pathway of antigen presentation to T cells (Herrera et al., 2004). Migrating CD4+ T 
cells have been shown to gain endothelial cell membrane components including an array 
of adhesion molecules which would provide the T-cells with a better ability for further 
migration and allow them to engage more effectively with B cells and macrophages 
(Brezinschek et al., 1999). 
 
1.10.3 Adhesion molecules 
 
The majority of data on the subject of migration induced changes in immune cell 
phenotype and function involve the adhesion molecules present at the junctions between 
endothelial cells. One particular adhesion molecule, PECAM-1, has been studied in 
great detail; In vivo experiments have shown that homophillic PECAM engagement 
between immune cells and endothelial cells up-regulates α6β1 on the transmigrating 
cell. This interaction not only changes the phenotype, but also has functional 
consequences as α6β1 is required for efficient migration across the basal lamina 
(Dangerfield et al., 2002). Luu et al. demonstrated increased velocity of neutrophils 
post-migration through HUVEC monolayers and found this to be dependent on 
engagement with PECAM-1 on the endothelium (Luu et al., 2003). In a study using 
CXCR2 to induce chemotaxis of neutrophils, PECAM-1 was found to increase both the 
velocity and the directionality of neutrophils post-migration (Wu et al., 2005). These 
studies give evidence for migration and more specifically PECAM-1-induced changes 
that support further migration through the extra-vascular tissue. However, these effects 
appear to be stimulus dependent; conflicting evidence has shown neutrophil velocity 
and directionality to be PECAM-1 independent when neutrophils migrate in response to 
a gradient of IL-8 (Duncan et al., 1999). Albelda et al. found that Fcγ-receptor 
dependent phagocytosis and TNF-α release were significantly decreased in 
macrophages from PECAM-1 knockout mice (Albelda et al., 2004). Interestingly, this 
group found that leucocyte migration into lung alveoli was PECAM-1 independent in 
several different types of lung disease. Their experiments suggest that PECAM-1 
engagement during migration is not a pre-requisite for successful migration in all 
situations, but in these experiments its presence acts to preserve effective macrophage 
function. 
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Contact of immune cells with endothelial cells but without full transmigration can also 
cause phenotypic changes; the co-culture of CD4+ T cells with human umbilical vein 
endothelial cells (HUVECs) has been shown to up-regulate the expression of the co-
stimulatory molecules CD80 and CD86 (Denton et al., 1999). These T cells were found 
to provide trans-co-stimulatory signals to other CD4+ T cells. Perhaps this could also be 
the missing link with regard to antigen presentation by the endothelium; the 
endothelium up-regulates the co-stimulatory molecules it lacks and therefore provides 
an alternative co-stimulatory pathway enabling the endothelium to effectively present 
antigen to T cells with the help of trans-presentation of CD80 and CD86 by the CD4+ T 
cells.  
 
The multi-step process of transmigration has been shown to alter the phenotype and 
enhance the cellular function of leucocytes resulting in more efficient progress to the 
site of inflammation and an enhanced response to antigen. In normal immune defence 
these changes are advantageous. However, prolonged or excessive infiltration with 
subsequent inappropriate arming of immune cells can lead to tissue and vessel damage 
resulting in inflammatory diseases. A cause of disease is also a target for therapy and 
research into blocking adhesion molecules has proven a useful tool in treatments. 
Inhibition of IL-1β and TNF-α has potent effects on the expression of adhesion 
molecules (Gonzalez et al., 2009) and corticosteroids, non-steroidal anti-inflammatory 
drug (NSAIDs) and antioxidants are powerful anti-inflammatory agents working by 
blocking intracellular signalling through NF-κB (Pitzalis et al., 2002). The production 
of synthetic antagonists for adhesion molecules has given more opportunities for drug 
targeting. For example, selectin targeting using drugs that mimic the structure of sLex 
have been developed and have shown good results when used in the treatment of 
psoriasis. However, there have been many inconsistent results from clinical trials of 
drugs which block adhesion molecules. This most likely reflects the many alternative 
pathways of cell migration, and the disease and cell specific nature of migration (Harlan 
and Winn, 2002; Ulbrich et al., 2003). Broad spectrum adhesion molecule blocking is 
attractive as an option for the treatment of inflammation. However, to avoid the 
inevitable side-effects of this method and to also treat the inflammatory disease 
effectively, investigators would need to carefully examine the relative contribution the 
endothelium makes to the cell functioning compared to the other factors cells may 
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encounter such as the cytokine milieu. Nevertheless, the future will undoubtedly see 
significant advances in these treatments. 
 
 
1.11 An in vitro model of endothelium 
 
The study of NK cell transmigration is difficult. Many in vivo experiments use mouse 
models and NK and NKT cells are commonly grouped together, which for obvious 
reasons has clouded results, but these experiments do have the advantage of including 
all cytokines, cells and molecules, whether identified or not, that may be involved in 
NK cell migration. In vitro experiments do however, allow the scientist to discriminate 
between NK and NKT cells and boyden chambers or transwell inserts with a monolayer 
of endothelium grown on top are commonly used to emulate cell migration. The 
disadvantage with in vitro models is that it is very difficult, if not impossible to include 
all the cytokines, cells and other molecules that have a role in migration. The knowledge 
of cell migration is not complete enough to copy in the laboratory. However, the 
advantage of in vitro experiments is that they do enable the scientist to dissect particular 
parts of the process and to compare their relative importance in cell migration. 
 
In vitro models of the endothelium have proved an invaluable tool for the study of cell 
migration. Much work has been carried out using endothelium derived from human 
umbilical veins. Primary cells bring experiments closer to in-vivo environment. 
Working with primary cells does however have its pitfalls. Primary cells are senescent 
and endothelial cells have an average life span of 10 passages. Primary cells also tend to 
loose their molecule expression and responsiveness to stimuli the longer they are kept in 
culture. No long term research can be carried out using freshly isolated human 
endothelial cells from one donor. If endothelial cells are used from different donors, 
inter-experiment variation becomes an issue and results can not be easily compared. 
Donor variation is addressed by pooling endothelial cells from several samples. Most 
commercially available HUVEC samples use a minimum of 5 donors in the pool.  
 
An alternative is to use transformed cell lines. When choosing a cell line it is crucial to 
consider the properties of the cell line and to match these to the experiment. Migration 
assays for example, require a cell line to express adhesion molecules. It is inevitable that 
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the cell line will possess tumour traits which deviate further from the in-vivo 
environment. However, it is the exploitation of the tumour trait of immortality that 
eliminates the donor variation. EA.hy 926 cell line endothelial cells are to date one of 
the best characterised and up-regulate ICAM-1, VCAM-1 and E-selectin expression 
when stimulated. These cells are therefore suitable candidates for development of an in 
vitro trans-endothelial cell migration model. 
 
1.12 Aims of thesis 
 
The aim of this study is to sucessfully create an in vitro model of NK cell migration 
across vascular endothelium and to examine any changes in the phenotype and 
functional capacities of NK cells that may arise during the process of cell migration. As 
described in the present chapter, interactions of immune cells with the endothelium 
during inflammation results in important alterations in the numbers of particular subsets 
of immune cells and also modifications to their functions. We predict that the model of 
NK cell migration will corroborate with studies that have shown an accumulation of the 
CD56bright subset of NK cells which is seen in vivo at sites of inflammation. We 
hypothesise that the accumulation of the CD56bright NK cells is due to preferential 
recruitment of this subset and not a result of local differentiation from CD56dim NK 
cells. Experiments in this thesis will exploit tracking dyes to test this hypothesis. 
Previous studies have shown the CD56bright NK cell subset to be paritcularly apt at 
interacting with DCs and macrophages with the cross-talk between these cells 
enhancing inflammation. Experiments in this thesis will test the hypothesis that 
migration through endothelium can influence the cross-talk between NK cells and DCs 
or macrophages. Finally, this thesis will analyse the phenotype of a possible novel 
subset of NK cells that have been described as dysregulated and abnormal and will put 
forward theories as to the role these cells may have in the immune system. 
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Chapter 2 
 
Materials and Methods 
 
2.1 Notes 
 
All culture, subculture, cryopreservation and thawing of cells was carried out in a sterile 
field.  
 
Centrifugations took place at room temperature unless otherwise stated. 
 
Centrifuge models: Eppendorf 5810R and Boeco U-32R 
 
All incubations and cell culture were carried out in a humidified chamber at 37 °C with 
5% CO2 unless otherwise stated. 
 
2.2 Reagents and cells  
 
Plasticware 
 
Tissue culture flasks were from Iwaki, Jencons, UK. 
Falcon tubes, pipettes, tissue culture plates and pipette tips were from VWR, UK. 
Transwell inserts with a pore size of 5 μm were used for transmigration assays and were 
supplied by Corning Costar, Appleton Woods, Birmingham UK. 
 
 
Cells 
 
EA.hy 926 cells are the endothelial cell line EA.hy 926 (donated by F. Marelli-Berg, 
Imperial College London, UK). 
 
K562 are an NK cell sensitive tumour cell line (European Tissue culture Collection). 
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HUVECs are cryopreserved primary human umbilical vein endothelial cells, pooled 
from several donors (Cambrex, UK). 
 
 
Tissue culture media 
  
FCS is fetal calf serum (Sigma Aldrich, UK) 
 
TCM is tissue culture medium.  
 
For K562 cells, TCM consisted of RPMI supplemented with 100 U/ml penicillin, 100 
μg/ml streptomycin, and 35.04 μg/ml L-glutamine (Invitrogen, UK) and 10% FCS 
(Sigma Aldrich, UK) and is called RPMI medium in this thesis.  
 
For the EA.hy 926 cells, TCM consisted of DMEM supplemented with 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 35.04 μg/ml L-glutamine (all Invitrogen, UK) 
and 10% FCS (Sigma Aldrich, UK) and is called DMEM medium in this thesis. 
 
For HUVECs, the TCM used was the BulletKit® (Cambrex, UK). 
 
RPMI wash consists of RPMI supplemented with 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 35.04 μg/ml L-glutamine (all the reagents are from Invitrogen, UK). 
 
 
Buffers 
 
FACS buffer was made with phosphate-buffered saline (PBS, Sigma Aldrich, UK) 
supplemented with 0.1% sodium azide (Sigma Aldrich, UK), 2 mM ethylenediamine 
tetra-acetic acid (EDTA, Sigma Aldrich, UK) and 2% FCS (Sigma Aldrich, UK).  
 
MACS buffer was made with PBS supplemented with 2 mM EDTA and 2% FCS. 
 
FACS FIX was made with PBS supplemented with 4% paraformaldehyde (Sigma 
Aldrich, UK) and 1% FCS. 
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Antibodies 
 
Fluorochrome-conjugated monoclonal antibodies were used to stain for specific markers 
of interest. Below is a table of the antibodies, their fluorochrome conjugates and the 
suppliers, that were used in this study. 
 
Conjugate and supplier Antibody 
Anti- FITC PE PerCP APC APC-Cy7 PE-Cy7 
CCR7  BD      
CD1a Pharm   Pharm   
CD3 BD      
CD4 BD  R&D 
systems 
   
CD8  Pharm     
CD11a BD      
CD11b  Pharm  Pharm BD  
CD11c BD BD  Pharm   
CD14  Pharm     
CD16 BD BD     
CD18 BD      
CD19   BD    
CD20   BD    
CD25  BD     
CD27 Pharm BD     
CD29 Pharm      
CD31 Pharm      
CD40    Pharm   
CD44 Pharm      
CD49d Pharm      
CD54 Pharm      
CD56  BD  BD   
CD62L BD      
CD69 BD      
CD70 Pharm      
CD80 Pharm BD     
CD83 BD Pharm     
CD85 Pharm      
CD86 Pharm Pharm  Pharm   
CD94 BD      
CD107a BD      
CD123  BD     
CD161 BD      
CFSE Invitrogen      
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2B4 Pharm      
Granzyme A BD Pharm     
HLA-DR BD  BD   BioLegend
IFN- BD      
IL-12 Pharm      
IL-13 AbD 
Serotec 
     
KIR Pharm      
lin-1 BD      
NKG2A  R&D 
systems 
    
NKG2C  R&D 
systems 
    
NKG2D Pharm      
NKp30  R&D 
systems 
    
NKp44  R&D 
systems 
    
NKp46  R&D 
systems 
    
Perforin  BD     
TNF- BD      
TRAIL BioLegend      
 
Table 2.1 Antibodies used for flow cytometry 
 
Abbreviations; FITC: Flourescein isothiocyanate, PE: Phycoerythrin, PerCP: Peridinin 
Chlorophyll Protein, APC: Allophycoyanin. BD is an abbreviation for the company 
name Becton Dickinson Biosciences, UK, Pharmingen indicates that the antibody is 
from the Pharmingen division of Becton Dickinson Biosciences, UK. BioLegend 
indicates that the antibody is from BioLegend, Cambridge BioScience, Ltd. UK. AbD 
Serotec is AbD Serotec, Kidlington, Oxford, Invitrogen is Invitrogen, UK, and R&D 
systems is R&D systems, Abingdon, UK. 
 
2.3 Ethics and blood samples 
 
Ethics 
 
Ethical approval for this study was granted by the Riverside Research Ethics 
Committee, Charing Cross Hospital, London (05/Q040/37). The study was registered 
with the Chelsea and Westminster Foundation Trust Research and Development 
Committee (OSMT003). 
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Phlebotomy 
 
Venous blood was collected from consented healthy volunteers on the day of 
experimentation. Blood was drawn into 10ml LiHep BD Vacutainer tubes (Beckton 
Dickinson, UK). 
 
Buffy Coats were obtained from the National Blood Services (Colindale Blood Centre, 
London UK). 
 
2.4 Isolation of cells from human blood samples using lymphoprep and percoll  
 
2.4.1 Isolation of human peripheral blood mononuclear cells 
 
Blood that was obtained from healthy volunteers was diluted 1:1 with RPMI wash in 
sterile 50 ml Falcon tubes. Blood obtained from Buffy Coats was diluted 1:3 in RPMI 
wash. Diluted blood was then layered on to Lymphoprep (Axis-Sheild, Oslo, Norway) 
at a ratio of 1:2 Lymphoprep to diluted blood and centrifuged at 240 x g for 30 minutes 
with no brake applied. Peripheral blood mononuclear cells (PBMCs) were aspirated 
from the Lymphoprep-plasma interface and placed in a fresh sterile 50 ml Falcon tube. 
PBMCs were re-suspended in RPMI wash and centrifuged at 650 x g for 15 minutes. 
The supernatant was discarded and the pellet was re-suspended in RPMI wash for a 
final washing step with centrifugation at 240 x g for 10 minutes. Finally, cells were re-
suspended in 1 ml RPMI wash. A sample of cells was stained with Trypan blue (Sigma 
Aldrich, UK) to exclude any non-viable cells. The sample was then counted using a 
haemocytometer (see cell counting subchapter).  
 
2.4.2 Separation of PBMC into lymphocyte and non-lymphocyte fractions  
 
PBMCs were diluted to a maximum concentration of 30 x 106 PBMCs in 8 ml RPMI 
wash. Cells were then layered onto 4ml of 50% Percoll in a sterile 15 ml Falcon tube 
and centrifuged at 240 x g for 30 minutes with no brake. Both the interface, consisting 
of monocytes and dendritic cells, and the Percoll pellet, comprising an enriched 
lymphocyte fraction, were harvested and re-suspended separately in 20 ml RPMI wash 
in a 50 ml Falcon tube. Cells were then centrifuged at 650 x g for 15 minutes. The 
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supernatant was discarded and the pellet was re-suspended in RPMI wash and 
centrifuged at 240 x g for 10 minutes. Percoll pellet cells were re-suspended in 1 ml 
RPMI wash and counted with a haemocytometer using Trypan blue to exclude any non-
viable cells.  
 
The 50% Percoll was made as follows: 
 
1. A Percoll mix solution was prepared by mixing 15 ml of 10x PBS with 44 ml of 
distilled water. 
2. A 70% Percoll solution was prepared by mixing 14.5 ml of Percoll with 6 ml of 
Percoll mix solution. 
3. A 50% Percoll solution was prepared by mixing 10.7 ml of 70% Percoll solution with 
4.3 ml of Hanks Balanced Salt Solution. 
 
2.5 Counting, freezing and thawing of cells 
 
2.5.1 Counting 
 
Prior to counting cells were thoroughly re-suspended in culture medium using a vortex. 
The volume of medium was noted. Cells were diluted in Trypan Blue (Sigma Aldrich, 
UK), enabling exclusion of any dead cells, to a final volume of 20 μl. The dilution 
factor was noted and was usually 1 in 2, 10, 20 or 40 depending on the estimated 
concentration of cells in the sample. For the migration assay cells were counted in three 
serial dilutions of 1 in 2, 10 and 20 to achieve a very accurate cell count. The 20 μl cell 
sample was then dispensed into a disposable haemocytometer (Biostat, UK) and 
examined under a microscope. Nine squares of the haemocytometer were counted and 
the number of cells in the initial sample was calculated using the following formula: 
 
Number of cells in sample = cell count x dilution factor x volume of medium x 104 
 
 
 
 
 
  Chapter 2 
 71
2.5.2 Freezing of cells 
 
The EA.hy 926 cells, K562 cells, and the HUVECs were stored in a -140 °C freezer or 
in liquid nitrogen until they were required. 
 
For the cryopreservation of the K562 and EA.hy 926 cell lines, and the HUVECs, cells 
were washed in RPMI wash and re-suspended in TCM containing 10% Dimethyl 
sulphoxide (DMSO, Sigma Aldrich, UK) and 10% FCS (Sigma Aldrich, UK). Aliquots 
of 1 ml were pipetted into cryovials (Fisher Scientific, UK). The aliquots were then 
insulated in a Nalgene propanol freezer canister (Jencons, UK, propanol from Sigma 
Aldrich, UK). The freezer canister was placed in a -80 °C freezer overnight and then 
transferred on dry ice to a -140 °C freezer or into liquid nitrogen for long term storage. 
 
2.5.3 Thawing of cells 
 
The process of thawing of cells was carried out rapidly. Cells were transferred from the 
freezer on dry ice and immediately placed in a water bath at 37 °C. Once the sample had 
defrosted, the cells were re-suspended in warm TCM. To remove the DMSO (Sigma 
Aldrich, UK), samples were centrifuged at 240 x g for 5 minutes, the supernatant was 
discarded and the cells were re-suspended in fresh TCM. This was not carried out for 
HUVECs as the process of centrifugation is more damaging than the effects of DMSO 
residue. Instead, thawed HUVECs were immediately transferred into pre-warmed tissue 
culture flasks with TCM.  
 
2.6 Cell culture 
 
2.6.1 Method of cell culture and subculture of the EA.hy 926 endothelial cell line  
 
EA.hy 926 cells were cultured adherently in DMEM medium. Cells were sub-cultured 
once they had reached 70-80% confluence. To subculture the cells, medium in the flask 
was aspirated and the flask was washed twice using 1 ml PBS per 5 cm2 of flask. Cells 
were then incubated with 1 ml Trypsin (Invitrogen, UK) per 5 cm2 of flask for 2 
minutes or until the cells were no longer adherent. To remove any cells that were stuck 
to the flask, the flask was rapped against a hand. Cells were poured into a sterile falcon 
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tube and topped up with fresh TCM. Cells were washed twice in DMEM wash with 
centrifugation at 240 x g for 5 minutes. Cells were then re-suspended in DMEM 
medium and were divided into three fresh tissue culture flasks at a final volume of 2 ml 
per 5 cm2 of flask and incubated until required. 
 
2.6.2 Method of cell culture and subculture of the K562 tumour cell line 
 
K562 cells were cultured in RPMI medium in tissue culture flasks. Cells were sub-
cultured two or three times per week. To subculture, K562 cells were aspirated from the 
flask and centrifuged at 240 x g for 5 minutes. The supernatant was discarded and cells 
were re-suspended in fresh RPMI medium. Cells were then divided between three flasks 
at a final volume of 2 ml per 5 cm2 of flask and incubated until required. 
 
2.6.3 Method of cell culture and subculture of HUVECs 
 
HUVECs were cultured and subcultured as per the manufacturer’s instructions 
(Cambrex, UK). Briefly, HUVECs were cultured adherently in BulletKit (Cambrex, 
UK) in 25cm2 tissue culture flasks. HUVECs were seeded at the density specified in the 
sample analysis that was provided by the manufacturer. HUVECs were subcultured 
once they reached 70-80% confluence. To subculture, the flask was rinsed with 5 ml 
HEPES buffered saline solution (Cambrex, UK) and cells were incubated with 2 ml 
Trypsin (Cambrex, UK) for 2 minutes or until the cells were no longer adherent. To 
remove any HUVECs that remained stuck, the flask was rapped against a hand. 4 ml of 
Trypsin neutralizing solution (Cambrex, UK) was added to neutralize the Trypsin. 
HUVECs were transferred to a sterile 15 ml Falcon tube and the flask was rinsed with a 
final 2 ml of HEPES buffered saline solution. HUVECs were then centrifuged at 220 x 
g for 5 minutes and the supernatant was discarded. HUVECs were re-suspended in fresh 
BulletKit® medium at a concentration of 1 ml of medium for every 5 cm2 surface area 
of flask. HUVECs were re-seeded in 2 or 3 fresh tissue culture flasks at the 
recommended seeding density and incubated until required. 
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2.7 Detection of surface and intracellular molecules by flow cytometry 
 
2.7.1 Surface staining of lymphocytes for analysis by flow cytometry 
 
The analysis of cell surface molecules was carried out by flow cytometry using a 
FACSCalibur flow cytometer (BD Biosciences, UK) and Cell Quest Pro software (BD) 
or WinMDI 2.8 PC software (The Scripps Research Institute, USA). To enable this, 
cells were stained with fluorochrome-conjugated antibodies. Firstly, cells at a maximum 
concentration of 1 x 106 cells/ ml were washed with 1 ml of FACS buffer. Cells were 
then re-suspended in 200 μl FACS buffer and stained for 30 minutes on ice with 2 μl of 
CD16 PE, 10 μl of CD56 APC or 5 μl of all other fluorochrome-conjugated antibody 
preparations. Cells were washed in 1 ml FACS buffer, fixed with 200 μl FACS FIX and 
kept on ice. 
 
2.7.2 Detection of NK cell IFN-, granzymes and perforin by intracellular staining of 
lymphocytes and analysis by flow cytometry 
 
The analysis of the intracellular molecules of interest, IFN-, granzymes and perforin, 
was carried out by flow cytometry using a FACSCalibur flow cytometer and software as 
specified above. Prior to intracellular staining, cells were stained for surface molecules 
with the final fixing step being omitted. Cells were washed in 1 ml FACS buffer, then 
fixed and permeablised using cytofix/cytoperm (BD Biosciences, UK) as per the 
manufacturer’s instructions. Briefly, cells were incubated with cytofix/cytoperm for 20 
minutes in the fridge and subsequently washed twice in 1 ml cytoperm/wash solution 
(BD Biosciences, UK). Cells were then re-suspended in saturating amounts of 
fluorochrome-conjugated antibody and incubated for 30 minutes in the fridge. Finally, 
cells were washed twice in cytoperm/wash solution, re-suspended in 200 μl FACS FIX, 
and kept on ice in the dark. 
 
2.7.3 Gating strategy for the analysis of NK cell subsets by flow cytometry 
 
The analysis of the NK cell subsets was carried out by flow cytometry. In order to 
assess molecules of interest expressed by either CD56bright or CD56dim NK cells, or 
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to quantify the percentage of each subset that make up the total NK cell population, a 
method of gating on each of the NK cell subsets was required. Percoll pellet cells were 
stained with fluorochrome-conjugated antibodies against CD3, CD19, CD16 and CD56 
and were analysed by flow cytometry. Live lymphocytes were gated on (Figure 2.1 A), 
followed by exclusion of cells that expressed CD3 or CD19 (Figure 2.1 B). To visualise 
the NK cell subsets, CD16 was plotted on the X-axis and CD56 on the Y-axis. To gate 
on the CD56bright subset, a region was drawn around cells that were CD56 positive and 
CD16 negative. To gate on the CD56dim subset, a region was drawn around cells that 
were CD56 positive, CD16 positive. Every effort was made to avoid bias, however 
gating in this manner is inevitably subjective. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Gating strategy for the analysis of NK cell subsets by flow cytometry 
Percoll pellet cells from a representative experiment were stained with fluorochrome-
conjugated antibodies against CD3, CD19, CD16 and CD56 and were analysed by flow 
cytometry. Live events were acquired based on cell size (forward scatter, FSC-Height) 
and granularity (side scatter, SSC-Height). Cells were gated on live lymphocytes (A, 
R1), the CD3 and CD19 negative population (B, R2) and CD16 was plotted against 
CD56 to visualise the NK cell subsets (C). CD56bright cells were selected using the 
A B
C 
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definition of CD56 positive and CD16 negative (R3) and CD56dim cells were selected 
using the definition of CD56 positive and CD16 positive (R4). 
 
To enable an analysis of the expression of a particular marker of interest by a population 
of cells to be made, the ‘fluorescence minus one’ approach was adopted. Cells were 
stained with all antibodies except the marker of interest and the quadrant was set with 
98% of the negative population being within its lower left boundaries. The same 
quadrant was then applied to the test sample to determine the percentage of cells that 
express the marker of interest. 
 
2.8 Isolation of NK cells, dendritic cells and monocytes 
 
2.8.1 Isolation of NK cells by negative selection 
 
To isolate NK cells by negative selection, PBMCs were first separated into a 
lymphocyte enriched fraction using Percoll. Two methods of NK cell isolation by 
negative selection were used in this study; both were based on the principle of removing 
the T and B lymphocyte populations identified on the basis of expression CD3 and 
CD19 or CD20 respectively. 
 
2.8.1.1 Negative selection using MACS MicroBeads 
 
Lymphocytes were magnetically labelled for CD3, CD19 and CD20 with MACS 
MicroBeads as per the manufacturer’s instructions (Miltenyi Biotec, Germany). Briefly, 
cells were centrifuged at 300 x g and re-suspended in 80 μl MACS buffer per 107 total 
cells. Cells were magnetically labelled with 20 μl of anti-CD3, anti-CD19 and anti-
CD20 MACS MicroBeads (Miltenyi Biotec, Germany) and incubated for 15 minutes on 
ice. Labelled cells were put onto a pre-washed LD column. After the cell suspension 
had passed through, the column was washed twice with MACS buffer to collect all the 
unlabelled NK cells. For higher purity, NK cells were applied to a second LD column. 
 
2.8.1.2 Negative selection using Dynal® magnetic beads 
 
Lymphocytes were magnetically labelled with anti-CD3 and anti-CD19 Dynal® 
magnetic beads (Invitrogen, UK) as per the manufacturer’s instructions. Briefly, cells 
  Chapter 2 
 76
were incubated with the magnetic beads for 30 minutes at 4 oC. Subsequently, cells were 
placed onto a Dynal MPC® magnet (Invitrogen, UK) and the eluted NK cell rich 
fraction collected.  
 
2.8.2 Isolation of NK cells by positive selection 
 
To isolate NK cells by positive selection, PBMCs were first separated into a 
lymphocyte enriched fraction using Percoll and the lymphocyte populations then 
separated using MACS MicroBeads. An initial step was undertaken to deplete T cells; 
lymphocytes were labelled with anti-CD3 MACS MicroBeads (Miltenyi Biotec, 
Germany) as per the manufacturer’s instructions and as described above. Cells were 
then placed on a pre-washed LD depletion column (Miltenyi Biotec, Germany). The 
CD3 depleted fraction was collected and labelled with anti-CD56 MACS MicroBeads 
and placed on a pre-washed MS selection column (Miltenyi Biotec, Germany) to 
positively select the NK cells. The eluted fraction was discarded and the CD56+ NK 
cells were flushed out of the column by plunging with MACS buffer. The CD56+ NK 
cells were placed on a second MS column to increase the purity of the sample. 
 
2.8.3 Isolation of NK cell subsets by FACS sorting 
 
Lymphocytes were stained with CD16PE, CD56APC, CD3PerCP and CD19PerCP. 
Cells were FACS sorted into CD56bright CD16- and CD56dim CD16+ NK cell subsets. 
FACS sorting was carried out by technicians using the FACS Aria (BD Biosciences, 
UK) at the MRC clinical sciences centre, Hammersmith Hospital, London. 
 
2.8.4 Isolation of dendritic cell populations from peripheral blood 
 
To isolate dendritic cell populations from blood, PBMCs were isolated from buffy coats 
and subsequently separated into lymphocyte and non-lymphocyte fractions using 
Percoll. The Percoll interface was harvested and the dendritic cells were isolated from 
the interface by positive selection using BDCA-1 and BDCA-4 MACS MicroBead kits 
(Miltenyi Biotec, Germany) for myeloid (mDC) and plasmacytoid dendritic cells (pDC) 
respectively. The isolation procedures were carried out as per the manufacturer’s 
instructions and are described in brief below. 
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Firstly, pDCs were isolated using BDCA-4 MACS Microbeads. Percoll interface cells 
were washed and re-suspended in 300 µl of MACS buffer with 100 µl of FcR blocking 
reagent and 100 µl of BDCA-4 MicroBeads per 108 cells. The cells and reagents were 
vortexed to mix thoroughly and incubated for 15 minutes at 4 oC. Cells were then 
washed and put onto a pre-washed LS column (Miltenyi Biotec, Germany). The column 
was washed three times with 500 µl of MACS buffer. The negative fraction was 
collected and stored at 4 oC for the isolation of mDCs. The pDCs were collected by 
removing the column from the magnetic field and plunging with 1 ml of MACS buffer. 
The pDCs were passed through a second MS column to increase cell purity. Isolated 
pDCs were cultured in RPMI medium supplemented with 10 ng/ml of IL-3 (R&D 
Systems, UK) in 96 well plates. A sample of pDCs was taken to assess the purity. The 
pDC sample was stained with anti-CD123, CD11c, HLA-DR and lin-1 fluorochrome 
conjugated antibodies and the purity of the cells was assessed by flow cytometry. 
 
Next, the mDCs were isolated from the negative fraction using BDCA-1 MicroBeads. 
Cells were washed and re-suspended in 200 µl of MACS buffer with 100 µl FcR 
blocking reagent, 100 µl of CD19 MicroBeads and 100 µl of BDCA-1-biotin per 108 
cells. The CD19 depletion step is required because of a sub-population of B cells that 
express CD1c. The cells and reagents were vortexed to mix thoroughly and incubated 
for 15 minutes at 4 oC. Cells were washed and put on a pre-washed LD column. The 
column was washed through three times with MACS buffer and the CD19 depleted 
effluent was collected. This CD19 depleted fraction was washed and re-suspended in 
400 µl MACS buffer with 100 µl anti-biotin MicroBeads. The cells and reagents were 
vortexed to mix thoroughly and incubated for 15 minutes at 4 oC. After the incubation, 
cells were washed and re-suspended in 500 µl MACS buffer and put onto a pre-washed 
MS column. The column was rinsed through three times with 500 µl of MACS buffer. 
The mDCs were collected by removing the column from the magnetic field and 
plunging with 1 ml MACS buffer and placed on a second MS column for enhanced cell 
purity. Isolated mDCs were cultured in RPMI medium supplemented with 1000 U/ml 
IL-4 (R&D Systems, UK) and 150 ng/ml granulocyte macrophage-colony stimulating 
factor (GM-CSF, Immunex, USA). A sample of mDC was stained with anti-lin-1, 
CD123, CD11c and HLA-DR fluorochrome conjugated antibodies and the purity of the 
cells was assessed by flow cytometry 
  Chapter 2 
 78
 
2.8.5 Isolation of monocytes 
 
Monocytes were isolated from the Percoll interface by plastic adherence. To aid 
adherence of the monocytes, tissue culture flasks previously coated with gelatine were 
used. Flasks were incubated with 2 ml of 2% gelatine (Sigma Aldrich, UK) for 2 hours. 
Excess gelatine was then aspirated and flasks were allowed to dry overnight. The non-
lymphocyte fraction from the Percoll interface was re-suspended in 2 ml of RPMI 
medium and incubated in the flasks for 2 hours to allow the monocytes to adhere. Non-
adherent cells were removed by aspiration and by gently flushing the flask three times 
with 2 ml PBS.  
 
Monocytes were cultured adherently in 3ml RPMI supplemented with 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 35.04 μg/ml L-glutamine (all Invitrogen, UK) 
and 1% autologous, heat inactivated serum. After 24 hours of incubation, a sample of 
monocytes was taken by scraping the flask and flushing the flask with PBS. The sample 
was assessed for purity by staining with anti-CD14 FITC-conjugated antibody and 
analysed by flow cytometry. Cells were at least 98% pure monocytes.  
 
2.9 Generation of monocyte derived macrophages in vitro and maturation of blood 
derived dendritic cells 
 
2.9.1 Generation of macrophages 
 
Macrophages were generated by the differentiation of monocytes. Monocytes were 
isolated as previously described and cultured for 10-12 days to generate macrophages. 
Maturation of monocytes into macrophages was assessed by staining with anti- CD14, 
CD11c, HLA-DR, CD86, and CD1a and analysed using flow cytometry. 
 
If activated macrophages were required, cells were incubated with 200 ng/ml LPS from 
Salmonella minnesota (Sigma Aldrich, UK) for 48 hours. 
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2.9.2 Maturation of dendritic cells 
 
Plasmacytoid dendritic cells were stimulated and matured by culturing freshly isolated 
blood plasmacytoid cells overnight with the addition of 6 μg/ml CpG DNA (InvivoGen, 
UK) to the culture medium. CpG DNA is a TLR9 agonist. It is a synthetic 
oligonucleotide with sequences containing un-methylated CpG, similar to bacterial 
DNA. 
 
Myeloid dendritic cells were stimulated and matured by culturing the freshly isolated 
blood myeloid cells overnight with the addition of 1 μg/ml of CD40 ligand (CD40L, 
R&D systems, UK) and 1 µg/ml of lipopolysaccharide (LPS, Sigma Aldrich, UK) to the 
culture medium. The interaction of CD40L with CD40 on dendritic cells strongly 
enhances dendritic cell functional capacities (Cella et al., 1996). LPS is a major 
component of the outer membrane of Gram-negative bacteria and is a ligand for 
dendritic cell TLR4 (Palsson-McDermott and O'Neill, 2004). 
 
2.10 Transmigration assay 
 
The transmigration assay was carried out using either EA.hy 926 cells or HUVECs as 
specified in the results section. Endothelial cells were either left unstimulated or were 
cultured with 300 or 1000 U/ml IFN- for 72 hours. On the day of endothelial cell 
seeding, Transwell inserts were incubated with 50 l gelatine per well for 30 minutes. 
Endothelial cells were seeded at a density of ~3x105 cells per Transwell insert and left 
overnight to form a confluent monolayer. Endothelial cells were checked for confluence 
prior to the assay by microscopic inspection and were only used if cells were a uniform 
monolayer with a cobblestone appearance. The endothelial cells were washed twice 
with PBS to remove any IFN-. PBMCs from healthy volunteers were separated to 
Percoll pellet cells to remove any monocytes that may block the pores in the Transwell 
insert. In some experiments, purified NK cells were used. Percoll pellet cells or purified 
NK cells were re-suspended at a concentration of 1 x 106 cells/ml and 200 μl of the cell 
suspension was placed in the upper chamber of the Transwell insert. Cells were 
incubated for 6, 12 or 24 hours. As a control, Percoll pellet cells or purified NK cells 
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were cultured alone. Cells were counted in triplicate before and after the migration. A 
sample of cells taken before the migration assay, migrated cells and control cells were 
stained with fluorescence-conjugated antibodies for NK cell surface molecules. This 
enabled the calculation of the percentage migration of NK cells, and the analysis of 
changes in NK cell phenotype or function resulting from migration. 
 
Calculation of the percentage migration 
 
The percentage migration of NK cell subsets was calculated as follows. A sample of 
cells taken before the migration assay and a sample of migrated cells were stained with 
fluorochrome-conjugated antibodies for CD3, CD16 and CD56, and analysed by flow 
cytometry. By gating on CD56bright and CD56dim NK cells separately, the percentage 
of each subset within the NK cell population, before and after migration, could be 
calculated. The number of cells added to each Transwell insert and the number of cells 
in the lower chamber was counted. Percentage migration was calculated using the 
following formula: 
 
% NK cell subset 
post-migration X
Total cell No. 
post-migration 
% NK cell subset 
pre-migration
X Total cell No. pre-
migration
(
(
)
)
X 100 = % migration of NK cell subset
 
 
2.11 Assays to measure cell degranulation, cytokine secretion and proliferation 
  
2.11.1 Degranulation assay 
 
Once activated to kill, NK cells exocytose cytotoxic proteins such as perforin and 
granzymes. This exposes lysosomal-associated membrane protein-1 (LAMP-1 or 
CD107a), which lines the membrane of the cytolytic granules. The expression of 
CD107a can therefore be exploited for use as a marker of degranulation (Alter et al., 
2004).  
 
The effect of migration on the ability of NK cells to degranulate was assessed. To 
measure degranulation, NK cells were stimulated to kill by co-culture with the MHC 
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class I deficient tumour cell line K562, and the expression of CD107a was measured by 
flow cytometry. Migrated cells, and control cells that were cultured in the absence of 
endothelium, were co-cultured with K562 cells. The ratio was optimised to 1 migrated 
or control cell to 1 K562 cell. To measure background degranulation, migrated or 
control cells were also cultured in the absence of K562 cells. Cells were cultured in 
RPMI medium supplemented with 10 μg/ml Brefeldin A and 6 ng/ml Monensin (both 
from Sigma Aldrich, UK). The addition of Brefeldin A to the cell cultures allows better 
detection of intracellular molecules such as CD107a as it blocks protein transport to the 
Golgi complex, a process that would occur following degranulation. Cells were cultured 
in 96 well, V-bottomed plates (VWR, UK) at a final volume of 200 μl per well. A total 
number of 2 x 105 cells were added to each well, with 5 μl of anti-CD107a FITC. Each 
well was mixed thoroughly by repeatedly pipetting and plates were centrifuged at 240 x 
g for 4 seconds to increase cell-cell contact. The incubation time was optimised to 5 
hours, after which the cells were harvested and stained with fluorochrome-conjugated 
antibodies against CD3, CD16 and CD56. NK cell degranulation was measured as the 
percentage of NK cells expressing CD107a as assessed by flow cytometry. 
 
2.11.2 IFN-γ production assay 
 
The effect of migration on the capacity of NK cells to produce IFN-γ was measured 
using a cytokine stimulation assay. Expression of IFN-γ was quantified by intracellular 
staining and flow cytometry. A sample of migrated cells, and a sample of cells that had 
been kept in culture in the absence of endothelium, were cultured with cytokines that 
stimulate NK cells to produce IFN-. Cells were cultured at a concentration of 1 x 106 
cells/ml of RPMI medium supplemented with 10 ng/ml of IL-12, IL-15 and IL-18 (all 
from Peprotech, UK). A volume of 200 μl of cells was added to universal tubes. Cells 
were cultured for 1 hour after which 10 μg/ml of Brefeldin A (Sigma Aldrich, UK) was 
added to the cell cultures, the universal tubes were vortexed to re-suspend cells. Cells 
were then cultured for a further 9 hours. After the cytokine stimulation, cells were 
stained with fluorochrome-conjugated antibodies against CD3, CD16 and CD56. Cells 
were then fixed and permeabilised as previously described and stained for intracellular 
expression of IFN-. The percentage of NK cells expressing IFN- was assessed by flow 
cytometry. 
  Chapter 2 
 82
 
2.11.3 Detection of NK cell proliferation using carboxyfluorescein succinimidyl ester 
staining 
 
To detect NK cell proliferation, cells were labelled with carboxyfluorescein 
succinimidyl ester (CFSE). This fluorescent cell staining dye diffuses freely into the cell 
where intracellular esterases convert the molecule into a membrane impermeable dye. 
With each cell division, the fluorescence intensity decreases by half and this is detected 
by flow cytometry (Lyons, 2000). 
 
CFSE labelling took place in the dark and all the reagents were kept ice cold. Cells were 
washed twice with PBS and then re-suspended in 5 ml of PBS in a 15 ml Falcon tube. 
CFSE (Invitrogen, UK) was diluted to 0.05 μM in PBS and 5 ml of this was added to 
the cells. Cells were incubated for 10 minutes with continuous agitation. The reaction 
was quenched with 5 ml of FCS (Sigma Aldrich, UK) and cells were centrifuged at 240 
x g for 5 minutes at room temperature. Cells were then washed twice in RPMI medium 
and cultured. After the desired time in culture, cells were stained with fluorochrome-
conjugated antibodies against CD3, CD16 and CD56 to allow the analysis of NK cell 
proliferation by flow cytometry.  
 
2.12 Tracking NK cell subsets during migration using carboxyfluorescein 
succinimidyl ester staining 
 
In this protocol, the impermeable nature of CFSE once inside the cell was exploited and 
instead of being used to assess cell proliferation, the dye was used as a cell tracker. In 
particular, the CD56bright and CD56dim NK cell subsets were tracked during migration 
assays. This enabled the analysis of any potential differentiation of one NK cell subset 
to another as a result of migration.  
 
To achieve this, Percoll pellet cells were labelled with fluorochrome-conjugated 
antibodies specific for CD56, CD16, CD3, CD19 and CD20. Cells were then FACS 
sorted (BD FACSAria cell sorting system) into CD56bright CD16- and CD56dim 
CD16+ subsets by technicians at the MRC clinical sciences centre, Hammersmith 
Hospital, London. Half of each NK cell subset was reserved and kept in culture in 
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RPMI medium and half was stained with CFSE as described above. The unlabelled 
CD56bright NK cells were then mixed with the CFSE labelled CD56dim NK cells and 
vice versa. The two cell mixtures were allowed to migrate through two separate 
migration chambers seeded with HUVECs (see the transmigration assay). Cells were 
then stained with fluorochrome-conjugated antibodies for CD3, CD16 and CD56 and 
analysed by flow cytometry. If the CD56bright NK cells had differentiated into the 
CD56dim subset, one would see CFSE positive CD56bright cells in the sample where 
the CD56dim cells had initially been labelled with CFSE. The converse would also be 
true if CD56bright NK cells had differentiated into the CD56dim subset. This method 
not only allowed the tracking of NK cell subsets, but also allow for quantification of 
any cell proliferation that might take place. 
 
2.13 Co-culture experiments 
  
2.13.1 Co-culture of NK cells with macrophages 
 
The effect of trans-endothelial migration on the interaction of NK cells with 
macrophages, in particular macrophage–induced NK cell proliferation and production of 
IFN-, was investigated. NK cells which had been cultured in the absence of 
endothelium, or had previously migrated, were co-cultured with autologous resting or 
stimulated macrophages. A sample of resting and stimulated macrophages, migrated 
NK cells and NK cells cultured in the absence of endothelium, were cultured alone as 
negative controls. To investigate proliferation, NK cells were labelled with CFSE after 
the migration assay and prior to the co-culture. All cells were washed and re-suspended 
in fresh TCM prior to the co-culture assay. Cells were co-cultured at a ratio of 1 NK 
cell: 10 macrophages in 96 well, V-bottomed plates with approximately 1 x 104 NK 
cells and 1 x 105 macrophages per well. Plates were centrifuged at 240 x g for a few 
seconds to increase cell-cell contact. After 72 hours of co-incubation, plates were 
centrifuged at 240 x g for 5 minutes. Cells were then re-suspended in FACS buffer and 
stained with fluorochrome-conjugated antibodies specific for NK cell surface 
molecules. The extent of NK cell proliferation was analysed by flow cytometry. 
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2.13.2 Co-culture of NK cells with dendritic cells 
 
To investigate the effect of trans-endothelial migration on the interaction of NK cells 
with dendritic cells, NK cells were co-cultured with autologous pDCs or mDCs which 
were either immature or mature. NK cells were either untreated or pre-treated by 24 
hours culture with 100 U/ml of IL-2 (R&D systems, UK), and either cultured in the 
absence of endothelium, or had previously migrated through endothelium. A sample of 
immature dendritic cells, mature dendritic cells, migrated NK cells, and NK cells 
cultured in the absence of endothelium were cultured alone as negative controls. All 
cells were washed and re-suspended in fresh TCM prior to the co-culture assay. Cells 
were co-cultured at a ratio of 1 dendritic cell: 5 NK cells in V-bottomed, 96 well plates. 
Approximately 2 x 104 dendritic cells and 1 x 105 NK cells were added to each well and 
the plate was centrifuged for a few seconds at 240 x g to pellet the cells and increase 
cell-cell contact. Co-cultures were incubated for 24 hours after which cells were stained 
with fluorochrome-conjugated antibodies for markers of interest and analysed by flow 
cytometry. 
 
2.14 Statistical Analysis 
 
Statistical analysis of the data was performed using the program GraphPad Prism4 
(GraphPad Software Inc., USA). Paired data was analysed using the Wilcoxon matched 
pairs test. A non-parametric test was used as the distribution of the results was not 
assumed to be Gaussian. P values < 0.05 were regarded as statistically significant. 
Throughout this thesis, the p value is stated if statistical significance was reached. 
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Chapter 3 
 
NK cell migration using the EA.hy 926 endothelial cell line model 
 
3.1 Background and aims 
 
NK cells migrate through vascular endothelium towards pro-inflammatory cytokines 
and accumulate in inflamed tissues. Here they destroy virally infected cells and tumour 
cells, secrete cytokines and interact with other cells of the immune system. Migration 
through the endothelium has been shown to affect many cells types in terms of 
phenotype and functional capacities (Nourshargh and Marelli-Berg, 2005). The 
experiments described in this chapter were aimed at assessing the effect of migration 
through the vascular endothelium on the phenotype and functions of NK cells. 
 
Peripheral blood NK cells comprise approximately 10% CD56bright and 90% 
CD56dim cells (Cooper et al., 2001a). At sites of inflammation this proportion is 
reversed and CD56bright NK cells predominate (Dalbeth and Callan, 2002; Pridgeon et 
al., 2003; Ottaviani et al., 2006). The accumulation of these cells could be due to 
preferential recruitment of the CD56bright subset or local differentiation of CD56dim to 
CD56bright NK cells. The aims of experiments described in this chapter were to 
determine whether CD56bright cells had greater capacity to migrate across endothelium 
and whether CD56 dim cells had the capacity to differentiate into CD56bright cells 
during the process of migration. 
 
In order to address these aims, a model of cell migration across vascular endothelium 
was required. EA.hy 926 endothelial cells are a human cell line that shows 
characteristics of differentiated endothelial cells. These cells are derived from the fusion 
of HUVECs with the continuous human lung carcinoma cell line A549. EA.hy 926 
endothelial cells are, to date, the best characterised macro-vascular endothelial cell line, 
expressing integrins and demonstrating adhesive properties similar to HUVECs (Mutin 
et al., 1997). For these reasons the EA.hy 926 endothelial cells were chosen as suitable 
endothelial cells for the model. 
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EA.hy 926 endothelial cells were grown on transwell inserts with a pore size of 5μm. 
This pore size was selected to prevent the endothelial cells from falling through the 
transwell insert, ensuring that the endothelial cells form a mono-layer rather than a bi-
layer either side of the transwell insert. PBMCs comprise both small lymphocytes and 
larger non-lymphocyte cells. The larger non-lymphocyte cells would block the 5μm 
pores. Therefore a process of eliminating these cells from the PBMCs prior to the 
migration assay was required. This was achieved by Percoll density gradient 
centrifugation, a process that separates PBMCs into a Percoll pellet, consisting of 
lymphocytes, and a Percoll interface, consisting solely of non-lymphocyte cells. Using 
Percoll pellet cells rather than PBMCs has the advantage of enriching for NK cells. The 
transmigration assay does not require a pure population of NK cells as cell counts and 
flow cytometric analysis of the cells before and after migration enables the calculation 
of the absolute number of NK cells.  
 
Percoll pellet cells were harvested and were either allowed to migrate through the 
EA.hy 926 endothelial cell monolayer or kept in culture in the absence of endothelium 
as a control. Migrated cells were harvested from the lower chamber of the transwell 
insert and in some assays cells were also harvested from the upper chamber of the 
transwell insert. Cells from the upper chamber have come into contact with endothelium 
but have not migrated through the endothelium, and provide additional data on the 
effect of contact with endothelial cells on NK cell functions and phenotype. 
Subsequently, cells were either stained with fluorochrome-conjugated antibodies 
specific for molecules of interest, or were subjected to assays that test the functional 
capacities of NK cells. A sample of cell taken before the migration assay was also 
analysed for baseline expression levels of the NK cell markers of interest, and for NK 
cell functional capacities.  
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3.2 Results 
 
3.2.1 Separation of PBMCs into lymphocyte and non-lymphocyte fractions 
 
PBMCs were isolated by Ficoll density gradient centrifugation as previously described. 
Cells were then separated into lymphocyte (Percoll pellet) and non-lymphocyte (Percoll 
interface) fractions using Percoll density gradient centrifugation. To assess the purity of 
the fractions, cells were stained with fluorochrome-conjugated antibodies against CD3, 
CD19, CD20 and CD56 and analysed by flow cytometry. Lymphocytes were identified 
as cells that express either CD3, CD19, CD20 or CD56 and the lymphocyte fractions 
were found to be 91.31 +/- 3.85 % (n = 9) pure. An example is given in Figure 3.1. 
 
 
 
Figure 3.1 Separation of lymphocytes into lymphocyte and non-lymphocyte 
fractions. Lymphocytes were isolated from PBMCs using Percoll density gradient 
centrifugation. The purity of the lymphocyte fraction was assessed by staining with 
fluorochrome-conjugated antibodies against CD3, CD19, CD20 and CD56, and 
analysed by flow cytometry. A dot plot from one representative sample is shown, with 
the quadrant markers set using the fluorescence minus one approach. Percentages of 
NK cells, NKT cells, T and B cells, and non-lymphocyte cells are shown adjacent to the 
corresponding corner of the dot plot, clockwise from the top left respectively. 
 
 
3.2.2 Optimisation of the stimulation of EA.hy 926 endothelial cells 
 
Pro-inflammatory cytokines are released during an inflammatory response. The vascular 
endothelium is stimulated by these cytokines, resulting in the activation of endothelial 
cells and the up-regulation of adhesion molecule expression, facilitating immune cell 
migration towards the site of inflammation. In order to emulate this in vitro, a suitable 
3.73 % 2.82 %
85.30 %8.14 % 
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stimulation for the endothelium was required. The cytokine IFN-γ is abundant in 
inflammation and is commonly used to stimulate endothelium in cell migration assays 
(Berg et al., 2002; Marelli-Berg et al., 2004). 
   
Experiments were performed to optimise the concentration of recombinant human (rh) 
IFN-γ to be used to stimulate the EA.hy 926 endothelial cells. There is disagreement 
within published literature as to the quantity of rhIFN-γ that is required for the 
stimulation of endothelial cells. Some studies have used no stimulation at all (Sancho et 
al., 1999; Lally et al., 2005), whereas other investigators have used concentrations 
ranging from 50-1000 U/ml of rhIFN-γ (Marelli-Berg et al., 2004; Wald et al., 2006). 
Investigators from laboratories within Imperial College advised using between 300-
3000 U/ml of rhIFN-γ. Therefore, as a preliminary experiment, the following quantities 
of rhIFN-γ were tested: 0, 1000, and 3000 U/ml. The percentage of NK cells that 
migrated through the endothelium was measured for each concentration of rhIFN-γ and 
was used to determine the optimum stimulation for EA.hy 926 endothelial cells for use 
in future migration assays.  
 
Microscopic examination revealed that after the 72 hours of culture with or without 
rhIFN-γ, the EA.hy 926 endothelial cells had adopted a star-shaped and elongated 
morphology that is associated with activation. A stimulated endothelium was also 
confirmed by successful lymphocyte migration. As can be seen in Figure 3.2, the 
highest percentage of migration of the CD56bright subsets of NK cells was achieved 
when the endothelial cells were stimulated with 1000 U/ml rhIFN-γ; 56.21%. However, 
the difference between this level of stimulation and no stimulation at all was not 
significant, with percentage migration for CD56bright cells recorded at 45.28%. This 
was not found to be the case for the CD56dim subset; the highest percentage of 
migrating cells was achieved when the endothelial cells were un-stimulated; 29.52%, 
with slightly less cells migrating; 27.25% if the endothelium was stimulated with 1000 
U/ml rhIFN-γ. Surprisingly, the highest stimulation, 3000 U/ml rhIFN-, yielded the 
lowest number of migrating cells, with only 27.80% of CD56bright and 9.65% of 
CD56dim NK cells migrating under these conditions. For this reason, 3000 U/ml of 
rhIFN-γ was not re-tested using lymphocytes from further donors, and was not 
considered for future migration assays.  
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Figure 3.2 Optimisation of the stimulation of EA.hy 926 endothelial cells using 
lymphocytes from one donor. Lymphocytes from one donor were allowed to migrate 
through EA.hy 926 endothelial cell monolayers for 6 hours. EA.hy 926 endothelial cells 
were either cultured in medium alone, or were stimulated for 72 hours prior to seeding 
by the addition of 1000 or 3000 U/ml rhIFN-γ to the culture medium, denoted on the x-
axis by 0, 1000 and 3000. A sample of migrated cells, and cells that were collected 
before the migration assay, were counted and analysed by flow cytometry.  Experiments 
were carried out in duplicate with the average result plotted on the graph. The 
horizontal lines represent the mean percentage migration of cells with the value stated 
on the graph. The percentage of CD56bright (yellow) and CD56dim (blue) NK cells 
that migrated were calculated using the data from flow cytometry and the cell counts.  
 
Further migration assays were performed using endothelium that had not been 
stimulated and endothelium that had been subjected to stimulation with 1000 U/ml 
rhIFN-γ. Cells from a total of 6 donors were tested to compare these two conditions. 
Results showed that pre-stimulation of the endothelium did not enhance CD56bright 
NK cell migration with 41.17% migrating across unstimulated and 40.71% migrating 
across rhIFN-γ stimulated endothelial cells. However, CD56dim NK cells migration 
was enhanced by pre-stimulation of the endothelium with 14.18% migrated across 
unstimulated vs. 21.27% across rhIFN-γ stimulated endothelial cells. Statistical analysis 
comparing unstimulated with rhIFN-γ stimulated endothelium revealed that there was 
no statistical difference between the two conditions in terms of the percentage of either 
subset of NK cells migrating. Although pre-stimulation with rhIFN-γ enhanced 
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CD56dim NK cell migration, the NK cells were clearly able to migrate across 
unstimulated endothelial cells. One could speculate that processing of the EA.hy 926 
endothelial cells in itself resulted in a stress-induced state of activation, and hence the 
observed high number of migrating cells. 
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Figure 3.3 Optimisation of the stimulation of the EA.hy 926 endothelial cells. 
Lymphocytes were allowed to migrate through EA.hy 926 endothelial cell monolayers. 
EA.hy 926 endothelial cells were cultured for 72 hours prior to seeding with either (A) 
culture medium alone or (B) 1000 U/ml rhIFN-γ. A sample of cells before and after 
migration was counted and analysed by flow cytometry. These data allowed the 
calculation of percentage migration of CD56bright and CD56dim NK cells. Each data 
point is from one single donor and represents a mean of 3 experiments performed. 
Horizontal lines represent the mean percentage migration of cells, as stated on the 
graph. Statistical analyses of the relative capacities of CD56bright (orange) and 
CD56dim (blue) NK cells to migrate were carried out using a paired Wilcoxon signed 
rank test, p<0.05 (*) or p<0.01 (**) with the p values stated on the graph (n=6). 
 
Results revealed a consistent, preferential accumulation of the CD56bright subset of NK 
cells post-migration. This was found to be independent of the level of stimulation of the 
EA.hy 926 endothelial cells. Importantly, the observed accumulation of the CD56bright 
subset is similar to that seen in the synovium of inflamed joints of patients with 
rheumatoid arthritis. Taking into consideration the relatively high numbers of migrating 
cells in the absence of stimulation for the endothelium, and the consistency of the trend 
of preferential accumulation of the CD56bright subset of NK cells, it was decided that 
unstimulated endothelium would be used for future migration assays. Furthermore, it 
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has the additional benefit of eliminating the possible contamination of the migration 
assay with any residual rhIFN-γ.  
 
3.2.3 Optimisation of the time course of the NK cell migration assay 
 
Defining a time course for the migration assay was hindered by the lack of previous NK 
cell migration studies, and the broad range of time courses that have been used in the 
few studies that have been done. Perhaps the most comparable protocol to the one used 
in this thesis is provided by Berman and Muller (Berman and Muller, 2000) who 
suggest that a time course of 3.5 to 4 hours is required to obtain a significant and 
measurable number of migrating NK cells (~10%). A study on the effect of CD4 
ligation on the migration of NK cells also used a time course of 4 hours (Bernstein et 
al., 2006). Migration assays using T cells provided some information, with one study 
evaluating the effect of migration on T cells with time courses of 4, 8, 16 and 24 hours 
(Berg et al., 2002). With these studies in mind, 4, 6, 12 and 18 hours were tested as 
possible time courses for the migration assay. 
 
As can be seen in Figure 3.4, the highest number of migrating CD56bright NK cells was 
achieved with a time course of 12 hours; 27.12% (n=5). However, for CD56dim NK 
cells, a longer time course of 18 hours saw the most cells migrating; 12.49% (n=2). The 
shorter time courses of 4 and 6 hours were found to yield half the number of migrating 
CD56bright NK cells; 13.33% (n=3) and 12.88% (n=7) respectively. A longer time 
course of 18 hours saw 22.66% (n=2) of the CD56bright NK cells migrating therefore, 
no further migration of this subset was noted if cells were allowed to migrate for longer 
than 12 hours. However, statistical analysis found that there were no significant 
differences between the different time courses. For the CD56dim subset, a similar 
percentage of cells were found to migrate at 4, 6 and 12 hours with 8.52% (n=3), 7.88% 
(n=7) and 7.75% (n=5) of cells migrating respectively, all of which are lower than the 
yield achieved when cells were allowed to migrate for 18 hours. Again, no statisitically 
significant differences were found between the time courses for the migration of the 
CD56dim subset of NK cells. 
 
Identical to the trend seen in the previous section, the CD56bright subset accumulated 
after migration more than CD56dim NK cells, and this was found to be independent of 
the time course. The CD56bright subset was found to migrate significantly more than 
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the CD56dim subset when cells were allowed to migrate for 6 hours (Figure 3.4 B 
p=0.0313, n=7). 
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Figure 3.4 Optimisation of the time course of the NK cell migration assay 
Lymphocytes were allowed to migrate through unstimulated EA.hy endothelial cell 
monolayers for 4 (n=3), 6 (n=7), 12 (n=5) or 18 hours (n=2) denoted on the graph by 
4hr, 6hr, 12hr and 18hr respectively. Experiments were repeated in triplicate for each 
donor and data represents the mean average of these experiments. A sample of cells 
was taken before and after migration for counting and analysis by flow cytometry to 
enable calculation of the percentage migration of CD56bright and CD56dim NK cells. 
For time courses of 6 and 12 hours, horizontal lines represent the 5th, 25th, median, 75th 
and 95th percentiles. For time courses of 4 and 18 hours, horizontal lines represent the 
minimum, median and maximum values. Median values are stated on the graph. 
Statistical analyses of the relative capacities of CD56bright and CD56dim NK cells to 
migrate were carried out using a paired Wilcoxon signed rank test with values 
considered significant if p< 0.05 represented by *. The p value is  stated on the graph. 
 
Due to the lack of any statistical difference between the different time courses, as well 
as the broad spread of results obtained at 6 hours, the decision was made to undertake 
an experiment using lymphocytes from a single donor and time courses of 6, 12 and 18 
hours. This had the advantage of eliminating donor variation, with the objective of 
clarifying the optimal time course. The percentage of CD56bright NK cells migrating 
was found to be optimal when NK cells were allowed to migrate for 6 hours (6 hours: 
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31.77%, 12 hours: 16.67% 18 hours: 27.33%) For the CD56dim subset however, the 
time course of 18 hours was optimal (6hrs: 8.25%, 12 hours: 5.21% 18 hours: 12.03%) 
(Figure 3.5). No statistical difference was found between the time courses and this is 
likely to be due to the small number of experiments performed (n=3). 
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Figure 3.5 Optimisation of the time course of the NK cell migration assay using 
lymphocytes from one donor. Lymphocytes from one donor were allowed to migrate 
through un-stimulated EA.hy endothelial cell monolayers for 6, 12 or 18 hours. The 
number of cells was counted before and after the migration assay. A sample of cells 
taken before migration, and a sample of migrated cells, was analysed by flow 
cytometry. The percentage migration of CD56bright (orange) and CD56dim (blue) NK 
cells were calculated using these data. Horizontal lines represent the minimum, median 
and maximum values of triplicate experiments with the median stated on the graph. 
 
Regardless of the time course, the trend of CD56bright accumulating more than the 
CD56dim subset post-migration was maintained. With high numbers of migrating cells 
of both NK cell subsets and considering the degradation of endothelium and NK cell 
viability with increasing time in culture, the time course of 6 hours was chosen for 
future migration assays. 
 
3.2.4 The accumulation of CD56bright NK cells post-migration 
 
As discussed in the previous section, migration data has consistently shown that 
CD56bright NK cells accumulate more than the CD56dim subset post-migration. In 
order to confirm this finding, further migration assays using samples from additional 
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donors were carried out. The data in this section is collated from all migration assays 
regardless of the stimulation of endothelium or the time course of the assay.  
 
Figure 3.6 shows an example of flow cytometric analysis of lymphocytes from one donr 
that have been subjected to a migration assay. NK cells have been gated on using the 
gating strategy described in chapter 2.7.3. The figure shows that NK cells before 
migration include 1.82% CD56bright and 95.72% CD56dim cells. Once migrated and 
collected from the lower chamber of the transwell insert, the percentage of CD56bright 
NK cells was found to have risen to 4.00%, whereas the percentage of CD56dim NK 
had dropped to 91.23%. Control NK cells, kept in culture in the absence of 
endothelium, were found to have a similar percentage composition to that of cells before 
migration; CD56bright 1.96% and CD56dim 95.49%. Therefore, one could speculate 
that the processes of contact with the endothelium and/or migration are responsible for 
an accumulation of the CD56bright subset and this cannot be attributed to the culturing 
of NK cells.   
 
 
Figure 3.6 Example dot plots of the accumulation of CD56bright NK cells post-
migration. Lymphocytes were allowed to migrate through un-stimulated EA.hy 926 
95.72 %
1.82 % 4.00 % 
91.23 % 
1.96 % 
95.49 % 
NK cells before migration Migrated NK cells 
Control NK cells
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endothelial cell monolayers for 6 hours or were kept in culture alone as a control. A 
sample of control cells and samples of cells taken before and after migration were 
stained with fluorochrome-conjugated antibodies against CD3, CD16 and CD56 for 
analysis by flow cytometry. CD56bright (R3) and CD56dim (R4) NK cells were gated 
on using the gating strategy described in chapter 2.7.3. The relative percentages of 
CD56bright and CD56dim NK cells are given on the dot plot. Clockwise from the top 
left, dot plots show NK cells before migration, migrated NK cells and control cells 
respectively. 20,000 events shown in each dot plot. 
 
The assay does not emulate the extent of accumulation of CD56bright NK cells seen in-
vivo in the synovial fluid from inflamed joints of patients with rheumatoid arthritis. 
However, for this donor and the majority of other donors, preferential migration of 
CD56bright NK cells compared with the CD56dim NK cells is seen such that the 
frequencies of CD56bright NK cells amongst total NK cells approximately doubles 
following migration. 
 
Multiple experiments confirmed the finding that CD56bright NK cells accumulate more 
than the CD56dim subset post-migration. The scatter plot in Figures 3.7 illustrates the 
individual values, with box and whiskers graphs of the same data shown for consistency 
with the other figures in this thesis. Figure 3.7 depicts experiments that were repeated 
on different donors. Although there was a significant range of values and considerable 
inter-donor variation, statistical analysis confirmed that the percentage migration of 
CD56bright NK cells is significantly more than that of the CD56dim subset (p=0.002, 
n=11).  
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Figure 3.7 The accumulation of CD56bright NK cells post-migration. Lymphocytes 
were allowed to migrate through EA.hy 926 endothelial cell monolayers. These graphs 
include data from migration assays using different quantities of rhIFN-γ for the 
stimulation of the EA.hy 926 endothelial cells, and migrations lasting 6, 12 or 18 hours 
(n=11). A sample of cells before and after migration was counted and analysed by flow 
cytometry. The percentage migration of CD56bright and CD56dim NK cells was 
calculated using these data. A scatter graph (left) shows individual values, with each 
data point representing a mean average of 3 counts for that donor.The horizontal bar 
represents the mean average of this data. A box and whiskers graph (right) is also 
shown for consistency with the other figures in this thesis. In the scatter graph, 
horizontal lines represent the median percentage migration of cells. In the box and 
whiskers graph, from bottom to top, the horizontal lines represent the 5th, 25th, median, 
75th, and 95th percentiles. A statistical analysis was carried out using a paired Wilcoxon 
signed rank test, with p values of less than 0.01 represented by **. The p values are 
stated on the graph. 
 
The experiments do not however clarify the mode of accumulation of CD56bright NK 
cells. It is possible that CD56bright NK cells are preferentially recruited in the 
migration assay. An alternative theory is that CD56dim NK cells differentiate into the 
CD56bright subset after the cells have migrated through the endothelium. The next 
section of this thesis will focus on the design of an experiment to elucidate which of 
these theories explains the favoured accumulation of the CD56bright subset. 
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3.2.5 The accumulation of CD56bright NK cells is due to preferential recruitment 
and not the differentiation of CD56dim to CD56bright NK cells 
 
To identify the mode of accumulation of the CD56bright subset of NK cells post-
migration, a tracking assay was designed. Carboxyfluorescein succinimidyl ester 
(CFSE) is commonly used to measure cell proliferation. This fluorescent dye diffuses 
into cells and is converted into a membrane impermeable dye by intracellular esterases. 
If cells stained with CFSE divide, the level of fluorescence of the daughter cells is half 
that of the parent cell. The impermeable nature of CFSE also allows it to be used as a 
tracking dye. Exploitation of this allowed the tracking of both NK cell subsets through a 
migration assay. Lymphocytes were FACS sorted into CD56bright and CD56dim NK 
cells. Each sample was divided into two, with one half being stained with CFSE and the 
other half being left unstained. The CFSE stained CD56bright cells were mixed with the 
un-stained CD56dim and vice versa.  
 
If the accumulation of CD56bright NK cells post-migration is explained by the 
differentiation of CD56dim NK cells into the CD56bright subset then: 
 
(i) In the CFSE stained CD56bright/un-stained CD56dim sample, un-stained 
CD56bright NK cells would be observed post-migration. 
 
(ii) In the CFSE stained CD56dim/un-stained CD56bright sample, CFSE stained 
CD56bright NK cells would be observed post-migration. 
 
If migration resulted in the differentiation of the CD56bright into CD56dim NK cells 
then: 
 
(i) In the CFSE stained CD56bright/ un-stained CD56dim sample, CFSE stained 
CD56dim would be observed post-migration. 
  
(ii) In the CFSE stained CD56dim/ un-stained CD56bright sample, un-stained CD56dim 
cells would be observed post-migration.  
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The proliferation of any cells would also be observed as incremental decreases in the 
fluorescence of any given cell population.  
 
Results from the experiment are depicted in Figure 3.8. Data relating to the experiment 
where CD56bright NK cells were CFSE stained and mixed with unstained CD56dim 
NK cells are shown in Figure 3.8A and B. The plots confirm homogenous staining of all 
of the CD56bright and none of the CD56dim NK cells prior to the migration assay. 
Following migration, all CD56bright cells were found to be CFSE positive (Figure 3.8 
A) and all CD56dim cells were CFSE negative (Figure 3.8B). The 100% CFSE staining 
of the migrated CD56bright NK cells in Figure 3.8A supports the theory that CD56dim 
do not differentiate into CD56bright NK cells and that the accumulation of CD56bright 
cells post-migration is due to the preferential recruitment of this subset. Although all of 
the CD56dim NK cells were CFSE negative in the migrated sample (Figure 3.8B), it is 
not possible to interpret this result due to the small number of cells. Regarding the 
control sample, 1.61% of CD56dim NK cells were found to be CFSE positive (Figure 
3.8 B), and this raises the possibility that culturing of the CD56bright subset can lead to 
differentiation into CD56dim NK cells. However, this is unlikely as the effect is not 
observed in the migrated sample. It is more likely that a very small proportion of the 
CD56bright NK cells started to undergo apoptosis during the course of the assay; such 
cells are known to down-regulate expression of CD56. 
 
Data relating to the experiment where CD56dim NK cells were stained and mixed with 
unstained CD56bright NK cells are shown in Figure 3.8 C and D and are less easy to 
interpret. The CFSE staining of the CD56dim population was not homogenous, with 
two levels of positive staining intensity and a small proportion of cells (7.26%) that did 
not take up the CFSE. Flow cytometric analysis was carried out immediately after 
CFSE staining so this effect cannot reflect cell division and must reflect the variable 
uptake of tracker dye by the cells. Pre-migration, the CD56bright NK cells were free of 
CFSE as expected. Following migration 40.78% of the migrated CD56dim cells were 
found to be CFSE positive. This is not seen in the control sample, where 100% of the 
CD56dim cells remain CFSE positive. This could reflect (i) a halving of the 
fluorescence intensity of CFSE and hence proliferation of the CD56dim subset as a 
result of migration, (ii) migration-driven differentiation of the CFSE negative 
CD56bright cells into CFSE negative CD56dim cells, (iii) apoptosis of some of the 
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CD56bright cells resulting in down-regulation of CD56. After the assay, 1.63% of 
migrated and 6.25% of control CD56bright NK cells were found to be positive for 
CFSE (Figure 3.8 C). Although these percentages are small, this raises the possibility 
that culturing, but not migration, causes a small number of CD56dim to differentiate 
into CD56bright NK cells. 
 
The results from this second half of the experiment are not consistent with those from 
the first which did not show any significant NK cell differentiation. It is most likely that 
they reflect some death of CD56bright NK cells during the assay and some 
contamination. Results from the first part of this experiment suggest that the 
accumulation of CD56bright NK cells post-migration is due to preferential recruitment 
and not due to differentiation of CD56dim NK cells during or following migration. In 
order for any confident conclusions to be drawn on this subject, repeated experiments 
are required and these experiments are described in section 4.2.3.  
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Figure 3.8 The accumulation of CD56bright NK cells is not due to differentiation 
from the CD56dim subset. Lymphocytes were FACS sorted into CD56bright and 
CD56dim NK cells. Half of each subset was stained with CFSE. Stained cells from one 
subset were mixed with unstained cells from the other subset. The different mixtures of 
NK cells were allowed to migrate through un-stimulated EA.hy 926 endothelial cell 
monolayers for 6 hours or were cultured alone as a control. Control cells, migrated 
cells, and cells pre-migration were stained with fluorochrome-conjugated antibodies 
against CD16 and CD56 and analysed by flow cytometry. NK cell subsets were 
analysed using the gating strategy as described in chapter 2.7.3. CD56bright NK cells 
have been stained with CFSE in A and B, and CD56dim NK cells have been stained 
with CFSE in C and D. Gates have been set on the CD56bright NK cells in A and C and 
on the CD56dim NK cells in B and D. The percentage of CFSE positive cells is given in 
the right corner of each dot plot. 
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3.2.6 The effect of migration on NK cell CD56 mean fluorescence intensity 
 
As previously mentioned, several groups have reported that migration induces changes 
in the functions and phenotypes of immune cells (reviewed by (Berg et al., 2002). In the 
first instance, experiments were performed to assess the effect of migration on the mean 
fluorescence intensity (MFI) of CD56 on both the CD56bright and CD56dim subsets of 
NK cells.  
 
Figure 3.9 depicts histograms of CD56 MFI from one representative experiment. Pre-
migration, the CD56 MFI of CD56bright and CD56dim NK cells were 183.10 and 
46.22 respectively. For both subsets, the CD56 MFI decreased as a result of time spent 
in culture regardless of the presence or absence of endothelium. NK cells from the 
upper chamber of the transwell had lower CD56 MFI than pre-migration with values of 
69.22 and 24.56 for CD56bright and CD56dim NK cells respectively. Migrated NK 
cells also had lower levels of CD56 MFI than pre-migration with values of 63.77 and 
22.03. These samples are comparable to that of control cells which had values of 88.23 
and 17.75 for CD56bright and CD56dim NK respectively, suggesting that contact with 
the endothelium and migration do not have an effect on the CD56 MFI of NK cells.  
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Figure 3.9 Histograms of one representative experiment testing the effect of 
migration on the CD56 MFI of NK cells. The histograms show data from one 
representative experiment. Lymphocytes were allowed to migrate through un-stimulated 
EA.hy 926 endothelial cell monolayers or were cultured alone as a control. A sample of 
cells taken before the migration assay, cells from the upper and lower chambers of the 
transwell insert after the migration assay, and control cells were stained with 
fluorochrome-conjugated antibodies against CD3, CD16 and CD56 for analysis by flow 
cytometry. Gates have been set on the CD56bright NK cell population in the first 
column and the CD56dim NK cell population in the second column. Red histograms 
represent cells cultured alone as a control. Blue histograms are CD56bright and green 
histograms are CD56dim NK cells. Values represent percentage staining above non-
specific fluorescence from un-stained cells (black empty histograms).  
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The migration assay was repeated several times (n=7) using lymphocytes from one 
donor (Figure 3.10). Results from this one donor showed no significant difference 
between the control sample and cells from the upper and lower chambers of the 
transwell insert. A slight trend towards higher CD56 MFI was noted on both subsets of 
NK cells that were harvested from the upper chamber, when compared to all other 
conditions.  
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Figure 3.10 Single donor experiments testing the effect of migration on the CD56 
MFI of NK cells. The graph above depicts several experiments carried out using 
lymphocytes from one healthy donor (n=3 for upper chamber results and n=7 for all 
other results)). Lymphocytes were allowed to migrate for 6 hours through EA.hy 926 
endothelial cell monolayers or were cultured alone as a control. A sample of cells 
collected before migration, from the upper and lower chambers of the transwell insert 
after migration, and control cells were stained with fluorochrome conjugated antibodies 
against CD3, CD16 and CD56 for the analysis of CD56 MFI on CD56bright (yellow) 
and CD56dim (green) NK cells by flow cytometry. Horizontal lines represent the 5th, 
25th, median, 75th, and 95th percentiles from bottom to top, with the exception of the 
post-migration upper chamber samples for which the horizontal lines represent the 
minimum, median and maximum values. 
 
The trend of cells from the upper chamber of the transwell insert having higher CD56 
MFI than cells before migration, migrated cells and control cells was upheld when the 
experiment was repeated using lymphocytes from several donors (n=11, Figure 3.11) 
but this difference was not found to be statistically significant. Within the upper 
CD56dim NK CD56bright NK 
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chamber, cells that had come into contact with the HUVEC monolayers but had not 
migrated through them. However, these  multiple donor experiments, the results from 
which are depicted in Figure 3.11, revealed that migration through HUVEC monolayers 
significantly increases CD56 MFI on the CD56bright subset of NK cells (p=0.0313), 
when results are compared with those of the cultured control sample. 
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Figure 3.11 The effect of migration on the CD56 MFI of NK cells. Lymphocytes 
from several donors were allowed to migrate for 6 hours through EA.hy 926 endothelial 
cell monolayers or were kept in culture alone as a control. A sample of cells collected 
before migration, from the upper and lower chambers of the transwell insert post-
migration, and control cells were stained with fluorochrome conjugated antibodies 
against CD3, CD16 and CD56 for the analysis of CD5 MFI on CD56bright (orange) 
and CD56dim (yellow) NK cells by flow cytometry. Horizontal lines represent the 5th, 
25th, median, 75th, and 95th percentiles from bottom to top. A Wilcoxon signed rank test 
was performed to assess the effect of migration on CD56 MFI in relation to cells 
cultured alone. * = p<0.05, the P value is stated on the graph.  
 
3.2.7 The effect of migration on the activation of NK cells 
  
Previous studies have shown that migration increases the activation of T cells (Sancho 
et al., 1999) and eosinophils (Yamamoto et al., 2000) as measured by the expression 
levels of CD69. This molecule is also an early marker of activation on NK cells (Lanier 
et al., 1988; Gerosa et al., 1992; Borrego et al., 1993; Gerosa et al., 1993; Ziegler et al., 
CD56dim NK CD56bright NK 
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1994). We therefore investigated migration-induced changes in expression levels of 
CD69 on both subsets of NK cells. 
 
The percentages of CD69 positive NK cells in one representative migration assay are 
shown in Figure 3.12. Both CD56bright and CD56dim NK cells expressed minimal 
levels of CD69 before migration (1.47% and 0.98% respectively). Following the assay, 
of the cells from the upper chamber; 6.41% of CD56bright and 76.91% of CD56dim 
NK cells were found to express CD69. Of the migrated cells, 53.34% of the CD56dim 
subset expressed CD69, fewer than cells from the upper chamber. In contrast to the 
CD56dim subset, more than twice as many migrated CD56bright cells expressed CD69 
(13.05%) compared to CD56bright cells from the upper chamber (6.41%). These data 
imply that contact with endothelium is sufficient to activate CD56dim NK cells, and 
migration does not enhance and may actually reduce this effect. However, although 
contact with endothelium does activate CD56bright NK cells, migration appears to 
further increase the activation state of this subset. Control NK cells, which had been 
kept in culture in the absence of endothelium, also expressed CD69 to a greater extent 
than cells before migration (CD56bright: 2.22%, CD56dim: 15.89%). However, the 
frequency of expression of CD69 by cells cultured in the absence of endothelium was 
much less than by cells cultured in the presence of endothelium and so cannot fully 
account for the increased CD69 expression seen on NK cells after the migration assay. 
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Figure 3.12 Example dot plots of the effect of migration on NK cell expression of 
the activation marker CD69. Lymphocytes from one representative donor were 
allowed to migrate for 6 hours through un-stimulated EA.hy 926 endothelial cell 
monolayers, or were kept in culture alone as a control. A sample of cells collected 
before migration, from the upper and lower chambers of the transwell insert after 
migration, and from the control cells, was stained with antibodies against CD3, CD16, 
CD56 and CD69, and analysed by flow cytometry. The percentage of CD56bright (blue 
dots) or CD56dim NK cells (pink dots) expressing CD69 is given in the right corner of 
each dot plot. 
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Figure 3.13 depicts multiple (n=6) experiments using lymphocytes from one donor. 
Results differed slightly from the experiment described above; a mean of only 3.04% of 
CD56bright cells from the upper chamber expressed CD69, which is lower than cells 
analysed before migration (3.92%) and only slightly more than the control sample 
(1.70%). However, migration significantly increased the expression of CD69 on the 
CD56bright subset of NK cells (median of 7.79%, p= 0.0313). Similar to single 
experiment described above, CD56dim NK cells from the upper chamber had the 
highest expression levels of CD69 (25.53%). However, this was not found to be 
significantly different when compared to the control (0.51%), although statistical power 
was very low because of the low number of upper chamber samples analysed (n=2). 
Mean expression of CD69 on migrated CD56dim NK cells was again lower than that 
found on the upper chamber population but remained significantly increased compared 
with the control population (median of 18.98%, n=6, p=0.0313). 
 
C
D
56
br
ig
ht
 p
re
-m
ig
C
D
56
br
ig
ht
 p
os
t-m
ig
 u
pp
er
 
C
D
56
br
ig
ht
 p
os
t-m
ig
 lo
w
er
 
C
D
56
br
ig
ht
 c
on
tro
l
C
D
56
di
m
 p
re
-m
ig
C
D
56
di
m
 p
os
t-m
ig
 u
pp
er
C
D
56
di
m
 p
os
t-m
ig
 lo
w
er
C
D
56
di
m
 c
on
tro
l0
10
20
30
40
50
* p = 0.0313
* p = 0.0313
%
 C
D
69
 e
xp
re
ss
io
n
 
 
Figure 3.13 Single donor experiments investigating the effect of migration on NK 
cell expression of CD69. The graph above depicts several experiments (n=6) carried 
out using lymphocytes obtained from one healthy donor. Cells were allowed to migrate 
through EA.hy 926 endothelial cell monolayers. CD69 expression was analysed using 
flow cytometry. Horizontal lines represent the 5th, 25th, median, 75th, and 95th 
percentiles from bottom to top, with the exception of the post-migration upper chamber 
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samples for which the horizontal lines represent the minimum, median and maximum 
values. A Wilcoxon signed rank test was performed to assess the effect of migration on 
the up-regulation of CD69 expression in relation to NK cells cultured alone. * = P<0.05, 
the P value is stated on the graph. 
 
Multiple experiments using lymphocytes from different donors (n=9) demonstrated a 
similar trend (Figure 3.15). More migrated CD56bright NK cells were found to express 
CD69 (14.08%) than cells from the upper chamber (7.75%) and control cells (2.82%). 
However, none of these differences were found to be statistically significant. Analysis 
of the CD56dim subset again showed that cells from the upper chamber expressed 
CD69 (26.35%) more than migrated (19.35%) or control cells (1.90%). This result was 
not found to be statistically significant, and this is possibly due to the broad range of 
results (inter-quartile range of 5.39- 80.65%). However, the increase in CD69 
expression on CD56dim NK cells resulting from migration was found to be significant 
(p= 0.0078) when compared with the control population. This migration-induced 
increase could be verified by detecting any changes that have occurred in the quantity of 
mRNA coding for CD69 using reverse transcription-polymerase chain reaction (RT-
PCR). 
 
 
  Chapter 3 
 109
C
D
56
br
ig
ht
 p
re
-m
ig
C
D
56
br
ig
ht
 p
os
t-m
ig
 u
pp
er
 
C
D
56
br
ig
ht
 p
os
t-m
ig
 lo
w
er
 
C
D
56
br
ig
ht
 c
on
tro
l
C
D
56
di
m
 p
re
-m
ig
C
D
56
di
m
 p
os
t-m
ig
 u
pp
er
C
D
56
di
m
 p
os
t-m
ig
 lo
w
er
C
D
56
di
m
 c
on
tro
l0
25
50
75
100
** p = 0.0078
%
 C
D
69
 e
xp
re
ss
io
n
 
 
Figure 3.14 The effect of migration on the expression of the activation marker 
CD69 on NK cells. The graph above depicts experiments carried out using lymphocytes 
obtained from several healthy donors (n=9). Cells were allowed to migrate through 
EA.hy 926 endothelial cell monolayers. CD69 expression on CD56bright and CD56dim 
NK cells was analysed using flow cytometry. Horizontal lines represent the 5th, 25th, 
median, 75th, and 95th percentiles from bottom to top. A Wilcoxon signed rank test was 
performed to assess the effect of migration on the up-regulation of CD69 expression in 
relation to NK cells cultured alone. ** = P<0.01, the P value is stated on the graph. 
 
The trends described above were found to be independent of the stimulation of 
endothelium (Figure 3.15). However, the percentages of CD56dim NK cells expressing 
CD69 was much higher when the endothelium was stimulated with 1000 U/ml of 
rhIFN-γ. This effect was seen on cells from the upper chamber (un-stimulated 
endothelium: 26.35%, stimulated endothelium: 81.59%) and also on migrated cells (un-
stimulated endothelium: 19.35%, stimulated endothelium: 36.57%), although the 
difference between stimulated and un-stimulated endothelium was not found to be 
statistically significant. Regarding the CD56bright subset, stimulation of the 
endothelium did not appear to affect the percentage of migrated cells expressing CD69 
(un-stimulated endothelium: 14.08%, stimulated endothelium: 14.23%). However, 
almost twice as many CD56bright NK cells in the upper chamber were found to express 
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CD69 if a stimulated endothelium was used (14.04%) compared to using un-stimulated 
endothelium (7.75%), although this result was not found to be statistically different. 
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Figure 3.15 The effect of stimulation of the endothelium and the migration-induced 
activation of NK cells. Lymphocytes from healthy donors were allowed to migrate for 
6 hours through EA.hy endothelial cell monolayers either (A) un-stimulated (n=9) or 
(B) stimulated with 1000 U/ml rhIFN-γ for 72 hours prior to seeding (n=6). Cells were 
also cultured alone as a control. A sample of cells was taken prior to the migration assay 
to measure baseline CD69 expression. CD69 expression was analysed by flow 
cytometry. Horizontal lines represent the 5th, 25th, median, 75th, and 95th percentiles 
from bottom to top. A Wilcoxon signed rank test was performed to assess the effect of 
migration on the up-regulation of CD69 expression in relation to NK cells cultured 
alone. ** = P<0.01, the P value is stated on the graph. 
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The kinetics of migration-induced expression of CD69 on NK cells was also studied. 
Lymphocytes from one donor were allowed to migrate for time courses of 6, 12 and 18 
hours (Figure 3.16). If cells were allowed to migrate for 6 hours, more CD56bright NK 
cells (8.94%) expressed CD69 than CD56dim NK cells (4.00%). However the 
CD56bright subset had lower CD69 expression levels than CD56dim NK cells when 
cells from this donor were subjected to a migration assay lasting for 12 or 18 hours (12 
hours: 18.42% and 25.16%, 18 hours: 20.55% and 40.89% respectively). As depicted in 
Figure 3.16, the expression of CD69 on both subsets of NK cells increased in proportion 
to the time course of the assay with the highest expression on both subsets seen at 18 
hours. However, there were concerns about the viability of NK cells when a time course 
of 18 hours was used, and for this reason no further experiments using this time course 
were performed.  
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Figure 3.16 Kinetics of migration-induced CD69 expression on CD56bright and 
CD56dim NK cells using lymphocytes from one donor. The graph above depicts an 
experiment carried out using lymphocytes from one donor. Cells were allowed to 
migrate through un-stimulated EA.hy endothelial cell monolayers for 6, 12 or 18 hours 
or were cultured alone for the same time period as a control. A sample of cells taken 
before migration was also analysed for baseline CD69 expression on the NK cell 
subsets. CD69 expression on CD56bright and CD56dim NK cells was assessed by flow 
cytometry. 
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Further migration assays were performed to compare results obtained at 6 and 12 hours 
using cells taken from several different donors (Figure 3.17). Overall, migration for 6 
hours appeared to favour the activation of the CD56dim subset with 15.00% of 
CD56bright cells expressing CD69 versus 27.26% of CD56dim NK cells. However, the 
converse was true when cells were allowed to migrate for 12 hours, with 16.29% of 
CD56bright cells expressing CD69 versus 13.73% of the CD56dim subset of NK cells. 
These results were not found to be significantly different. However, the overall trend of 
exposure to endothelium or migration through endothelium promoting the expression of 
CD69 on NK cells remained the same.  
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Figure 3.17 Kinetics of migration-induced CD69 expression on CD56bright and 
CD56dim NK cells. Lymphocytes from healthy donors were allowed to migrate 
through EA.hy endothelial cell monolayers for (A) 6 hours (n=6) or (B) 12 hours (n=4). 
Cells were also kept in culture alone as a control. A sample of cells taken before 
migration was analysed for baseline CD69 expression on NK cell subsets. CD69 
expression was analysed by flow cytometry. Horizontal lines represent the 5th, 25th, 
median, 75th, and 95th percentiles from bottom to top. 
 
 
3.2.8 The effect of migration on the NK cell receptor CD94/NKG2A 
  
The transmembrane protein NKG2A forms a dimer with CD94. This complex is found 
on NK cells and recognises HLA-E, delivering an inhibitory signal to the cell. The 
CD56bright subset expresses higher levels of the NKG2A/CD94 complex than 
CD56dim NK cells (Cooper et al., 2001a). Engagement of CD94 has been linked with 
the blockade of CD69 induced NK cell cytotoxicity (Borrego et al., 1999). The effect of 
migration on the expression of this inhibitory receptor complex was investigated. In 
keeping with the current knowledge of the expression of CD94/NKG2A on NK cells, 
expression levels of both of the molecules that make up this dimer were found to be 
higher on the CD56bright subset when compared to the CD56dim subset of NK cells 
(Figures 3.18 and 3.19).  
 
As can be seen in Figure 3.18, the expression of CD94 on CD56bright NK cells was 
found to increase by a small amount, both on cells from the upper chamber and 
migrated cells when compared to control cells (upper chamber: 99.41%, migrated: 
98.31%, control 96.46%). This increase was not found to be statitistically significant. 
However, it must be noted that expression levels of CD94 are high on the CD56bright 
subset; therefore there is not much capacity for further increases in the percentage of 
CD56bright NK cells that express this molecule. For the CD56dim subset, no change in 
the expression of CD69 was found on cells from the upper chamber, however a small 
increase on migrated cells was observed when compared to cells before migration, 
although when compared to the control sample, this increase was very marginal and not 
statistically significant (upper chamber: 73.64%, migrated: 80.07%, control: 78.89%). 
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Figure 3.18 Migration and the expression of CD94 on CD56bright and CD56dim 
NK cells. Lymphocytes from one donor were allowed to migrate for 6 hours through 
un-stimulated EA.hy 926 endothelial cell monolayers. Cells were kept in culture alone 
as a control. A sample of cells was taken from the upper and lower chambers of the 
transwell insert post-migration. A sample of cells was also taken before migration for 
the analysis of the baseline expression of CD94. Cells were stained with fluorochrome-
conjugated antibodies against CD56, CD16, CD3 and CD94 and the expression of 
CD94 on CD56bright NK cells (purple) and CD56dim NK cells (green) was assessed by 
flow cytometry. Each condition has two data points; each one representing a single 
experiment performed using lymphocytes from the same donor. Horizontal lines 
represent the median average.  
 
Marginal, and not statistically significant increases in the expression of NKG2A on both 
subsets were observed both on cells from the upper chamber and migrated cells (Figure 
3.19 CD56bright NK cells; upper chamber: 92.46%, migrated: 91.83%, control: 
89.78%. CD56dim NK cells; upper chamber: 37.04%, migrated: 36.68%, control: 
35.73%). Preliminary experiments were not encouraging and it was decided that future 
experiments would not be undertaken. 
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Figure 3.19 Migration and the expression of NKG2A on CD56bright and CD56 NK 
cells. Lymphocytes from one donor were allowed to migrate for 6 hours through un-
stimulated EA.hy 926 endothelial cell monolayers. Cells were kept in culture alone as a 
control. A sample of cells was taken from the upper and lower chambers of the 
transwell insert post-migration. A sample of cells was also taken before migration for 
the analysis of the baseline expression of NKG2A. Cells were stained with 
fluorochrome-conjugated antibodies against CD56, CD16, CD3 and NKG2A and the 
expression of NKG2A on CD56bright NK cells (red) and CD56dim NK cells (blue) was 
assessed by flow cytometry. Each condition has two data points; each one representing 
a single experiment performed using lymphocytes from the same donor. Horizontal 
lines represent the median average. 
CD56dim NK CD56bright NK 
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3.2.9 Migration and the capacity of NK cells to degranulate 
 
As aforementioned, research has established that migration through endothelium alters 
the functional capacities of leukocytes. There is a notable lack of research on the effect 
of migration on the functional capacities of NK cells. Therefore, this study examines the 
effect of migration across EA.hy 926 endothelial cell monolayers on two major 
functions of NK cells, namely killing and cytokine production. Upon engagement with 
target cells, the process of killing involves NK cell degranulation to enable the release 
of cytotoxic proteins such as perforin and granzymes. Degranulation exposes LAMP-1 
proteins (CD107a) which line the membrane of the granules that store cytotoxic 
proteins (Alter et al., 2004).  
 
In this study, the expression of CD107a was exploited for use as a marker of NK cell 
degranulation. To trigger degranulation, NK cells were cultured in the presence of the 
NK cell-specific, MHC class-I deficient tumour cell line cells, K562. As a negative 
control, NK cells were cultured in the absence of K562 and as a positive control, NK 
cells were cultured in the presence of PMA and Ionomycin. Subsequently, cells were 
stained with fluorochrome-conjugated antibodies against CD3, CD16, CD56 and 
CD107a and were analysed by flow cytometry.  
 
A representative example of the dot plots obtained from the flow cytometric analysis of 
this assay are given in Figure 3.20. In the absence of K562, only 1.55% of NK cells 
expressed CD107a. However culturing NK cells with the positive control, Ionomycin 
and PMA, resulted in a high degree of degranulation with 53.03% of cells expressing 
CD107a. NK cell degranulation in response to K562 target cells was successful with 
17.11% of NK cells from this particular donor expressing CD107a. 
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Figure 3.20 Measurement of NK cell degranulation. Percoll Pellet cells from one 
donor were cultured for 5 hours in the presence (+K562) or absence (negative control) 
of K562 target cells, or with PMA and ionomycin (positive control). Cells were stained 
with fluorochrome-conjugated antibodies against CD3, CD56 and CD107a and analysed 
by flow cytometry. The percentage of cells expressing CD107a is given in the right 
corner of each dot plot. 
 
After the successful test experiment, the effect of NK cell migration on the capacity to 
degranulate was investigated. Example dots plots from one donor are shown in Figure 
3.21, and illustrate the effect of migration on the degranulation of NK cells. For the 
CD56bright subset, after culture with K562, the highest expression of CD107a was seen 
on cells sampled before the migration assay (46.24%). The expression of CD107a more 
than halved once CD56bright cells had come in contact with endothelium, with 16.26% 
of cells sampled from the upper chamber of the transwell insert, and 22.25% of 
migrated cells were found to express CD107a. Both of these values are higher than the 
percentage of control cells found to express CD107a (11.57%). This indicates that for 
the CD56bright subset, contact with the endothelium and also migration, may to some 
extent maintain the capacity of this subset of NK cells to degranulate. This pattern was 
not observed for the CD56dim NK cells from this particular donor. Before migration, 
culture with K562 caused only 3.56% of this subset to express CD107a. The 
percentages of CD56dim cells expressing CD107a in response to K562 were as follows; 
upper chamber (7.36%), migrated cells (6.04%), and control cells (6.99%). The similar 
expression levels suggest that neither contact with endothelium or migration has any 
effect on the degranulation of CD56dim NK cells from this particular donor.    
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Figure 3.21 A representative example of the effect of migration on the 
degranulation of NK cells. Percoll Pellet cells from one donor were subjected to a 
migration assay. Samples of cells were collected before migration and after migration 
from the upper lower chambers. A sample of cells was also cultured alone as a control. 
Subsequently, cells from the migration assay were cultured for 5 hours in the presence 
of K562 target cells in a degranulation assay. Cells were then stained with 
fluorochrome-conjugated antibodies against CD3, CD56 and CD107a and were 
analysed by flow cytometry. CD56bright (blue) and CD56dim (pink) NK cell subsets 
were gated on as described in chapter 2.7.3. The percentage of cells expressing CD107a 
is given in the top right of each dot plot. 
 
Figure 3.22 displays data from multiple degranulation assays (n=5) carried out using 
lymphocytes from several donors. Also included are the results from the negative and 
positive controls. As expected, cells cultured in the absence of K562 expressed very 
3.56 % 46.24 % 
7.36 % 16.26 % 
22.25 % 6.04 % 
11.57 % 6.99 % 
CD56bright NK CD56dim NK
Before 
migration 
C
D
56
 A
PC
 
CD107a 
Upper 
chamber 
Lower 
chamber 
Control 
  Chapter 3 
 119
little CD107a. However, when cultured with K562 target cells, more degranulation was 
observed and expression levels were even higher if cells were cultured in the presence 
of the positive control, PMA and Ionomycin. The data in Figure 3.23 are not adjusted 
for negative controls; hence only the trend is described. Adjusted data is given later in 
this section. 
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Figure 3.22 The effect of migration on NK cell degranulation. Graph of 
degranulation assay showing negative and positive controls. Percoll Pellet cells from 
several donors (n=5) were subjected to a migration assay. Samples of cells were 
collected before migration and after migration from the upper and lower chambers of 
the transwell. A sample of cells was also cultured alone as a control. Subsequently, cells 
from the migration assay were cultured for 5 hours in the presence (+K562) or absence 
(-K562) of K562 target cells, or with PMA and Ionomycin (+ PMA & Iono) as a 
positive control. Cells were then stained with fluorochrome-conjugated antibodies 
against CD3, CD56 and CD107a and were analysed by flow cytometry. CD56bright 
(orange) and CD56dim (light green) NK cell subsets were gated on as described in 
chapter 2.7.3. From bottom to top, horizontal lines represent the 5th, 25th, median, 75th 
and 95th percentiles or minimum, median and maximum percentage of cells expressing 
CD107a. 
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Multiple experiments (n=5), with data adjusted for the negative controls of 
degranulation in the absence of K562 cells are depicted in Figure 3.23. Similar to the 
single donor experiment just described, the percentage of CD56dim NK cells expressing 
CD107a in a degranulation assay was not affected by either contact with endothelium 
(8.04%) or migration through endothelium (8.85% vs. control 9.85%). However, the 
percentage of CD56bright NK cells expressing CD107a in a degranulation assay was 
affected by migration but not contact with endothelium. Before migration, 34.01% of 
CD56bright cells expressed CD107a in response to K562, and similar expression levels 
were found on migrated cells (35.26%) but not cells from the upper chamber of the 
transwell insert (18.75%). Both of the pre-migration and migrated CD56bright NK cells 
had higher expression of CD107a than the control sample (26.67%) however, results 
were not found to differ significantly. This suggests that migration does not increase the 
capacity of CD56bright NK cells to degranulate, but may to some degree maintain 
degranulation, which would otherwise degrade as a result of culture. 
 
 
 
Figure 3.23 The effect of migration on NK cell degranulation. Lymphocytes from 
multiple donors were allowed to migrate through EA.hy 926 endothelial cell 
monolayers or were kept in culture alone as a control. Samples of cells were collected 
before migration, from the upper and lower chambers of the transwell insert after 
migration, and from the control samples. Cells from the migration assay were 
subsequently cultured in the presence or absence of K562 target cells in a degranulation 
CD56bright NK CD56dim NK 
pr
e-
m
ig
up
pe
r c
ha
m
be
r
lo
w
er
 c
ha
m
be
r
co
nt
ro
l
pr
e-
m
ig
up
pe
r c
ha
m
be
r
lo
w
er
 c
ha
m
be
r
co
nt
ro
l0
25
50
75
100
%
 C
D
10
7a
+
  Chapter 3 
 122
assay. Cells were then stained with fluorochrome-conjugated antibodies against CD3, 
CD56, CD16 and CD107a and analysed by flow cytometry. CD56bright (light blue) and 
CD56dim (dark blue) NK cells were gated on using the strategy described in chapter 
2.7.3. From bottom to top, with the exception of the upper chamber, horizontal lines 
represent the 5th, 25th, median, 75th and 95th percentiles. For the upper chamber, from 
bottom to top, horizontal lines represent the minimum, medium and maximum values. 
 
3.2.10 Increase in CD56- CD16- cells after the exposure of NK cells to K562 in a 
degranulation assay 
 
Data from the analysis of degranulation assays suggested that, after encounter with 
K562 target cells, there an increase in the percentage of CD56- CD16- cells. Results 
using lymphocytes from one donor showed that in the absence of K562, of the total 
cells in the CD3- cell gate, 41.3% were found to be CD56- CD16-, and this increased to 
49.8% in the presence of K562 (Figure 3.25). Simultaneously, the percentage of 
CD56dim NK cells decreased and the percentage of CD56bright NK cells increased 
(Figure 3.25). The expression of CD107a on CD56-CD16- cells was found to be high 
compared to both NK cell subsets (data not shown). Further investigations were 
performed to elucidate the source of the increased numbers of CD56- CD16- cells. 
 
 
 
 
Figure 3.24 Increase in CD56- CD16- cells after the exposure of NK cells to K562 
in a degranulation assay. Percoll pellet cells were cultured for 5 hours in the presence 
(+K562) or absence (-K562) of K562 target cells. Cells were stained with 
fluorochrome-conjugated antibodies against CD3, CD16 and CD56 and were analysed 
by flow cytometry. NK cells were gated on by selecting the CD3 negative population 
and plotting CD16 and CD56 as shown in the density plots above. The percentages of 
each population are given on the corners of the density plots as follows; top left: 
CD56bright NK, top right and bottom right: CD56dim NK, bottom left: CD56-CD16- 
cells. 
-K562 +K562
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To investigate the possibility that CD56bright or CD56dim NK cells contributed to the 
increase in CD56-CD16- cells after encounter with K562, percoll pellet cells were 
FACS sorted into CD3- CD56bright and CD3- CD56dim NK cells. Each NK cell subset 
was cultured in the presence or absence of K562, stained with CD3, CD56, and CD16 
and analysed by flow cytometry (Figure 3.25). For the FACS sorted CD56bright cells, 
in the absence of K562, 92.9% of cells were found to be true CD56bright NK cells, 
1.2% were CD56dim NK and 5.9% were CD56-CD16- cells. In the presence of K562, 
81.0% were CD56bright, 3% were CD56dim, and 15.9% were CD56-CD16- cells. The 
three-fold increase in CD56- CD16- suggests that CD56bright NK cells contribute to 
the observed increase in CD56- CD16- cells after encounter with K562. There are 
several possible explanations; CD56 expression decreases or CD56 is shed as a 
consequence of exposure to target cells, or the CD56-CD16- population is proliferating 
in response to K562. The latter possibility seems less likely given the time course of the 
assay. 
 
Similar results were obtained with a pure population of CD56dim NK cells. When 
cultured in the absence of K562, 99.3% exhibited the CD56dim phenotype and only 
0.7% were CD56- CD16-. After co-culture with K562, the percentage of cells that were 
of CD56dim phenotype dropped to 97.9% and the CD56-CD16- had increased to 2.0% 
of the total cells. 
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Figure 3.25 Analysis of the origin of CD56-CD16- cells that increase as a result of 
the exposure of NK cells to K562 in a degranulation assay. Percoll pellet cells from 
one donor were FACS sorted into CD56bright and CD56dim NK cells. Cells were 
subsequently cultured for 5 hours in the presence (+K562) or absence (-K562) of K562 
target cells. Cells were then stained with fluorochrome-conjugated antibodies against 
CD3, CD16, and CD56, and were analysed by flow cytometry. The percentages of 
CD56bright NK cells, CD56-CD16- cells, and CD56dim NK cells are given on the 
corners of the density plot from top left anti-clockwise. 
 
3.2.11 Migration and NK cell expression of IFN-γ 
 
An important function of NK cells, in particular the CD56bright subset, is the 
production of IFN-γ. The effect of migration on the capacity of NK cells to produce 
IFN-γ was measured using a cytokine stimulation assay, with measurements made by 
intracellular staining, and analysis by flow cytometry. Briefly, Percoll pellet cells were 
allowed to migrate through EA.hy 926 monolayers or were kept in culture in the 
absence of endothelium as a control. A sample of cells taken before migration, migrated 
cells, and control cells were then cultured in the presence or absence of the cytokines 
IL-12, IL-15 and IL-18, all of which stimulate the production of IFN-γ from NK cells.  
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An example of an experiment performed to show that the cytokine combinations 
stimulated IFN-γ expression by NK cells is shown in Figure 3.26. In this example, only 
0.28% of CD56bright NK cells expressed IFN-γ without cytokine stimulation, but the 
addition of cytokines increased the percentage of cells expressing IFN-γ to 38.19%. For 
the CD56dim subset, only 0.01% of cells were found to express IFN-γ in the absence of 
cytokines and 2.68% in the presence of cytokines.  
 
 
 
Figure 3.26 The induction of IFN-γ expression by NK cells using a cytokine 
stimulation assay. Percoll Pellet cells were subjected to a cytokine stimulation assay 
and were cultured in the presence or absence of 10 ng/ml IL-12, IL-15 and IL-18 for a 
total of 10 hours. After 1 hour, 10 μg/ml of Brefeldin A was added. Subsequently, cells 
were stained with fluorochrome-conjugated antibodies against CD56, CD16 and CD3 
and intracellular staining was carried out for the measurement of IFN-γ expression. 
CD56bright and CD56dim NK cells were gated on using the strategy described in 
chapter 2.7.3. The percentage of CD56bright (blue) and CD56dim (pink) NK cells 
expressing IFN-γ is given in the right corner of the dot plot. 
 
 
When cells from the same donor were applied to a migration assay, analysis of the 
control well showed that culture of the NK cells alone lead to a loss of capacity to 
produce IFN-γ. The process of culturing with the endothelial cells and migration 
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appeared to maintain some of the capacity of the CD56bright subset of NK cells to 
express IFN-γ. This maintenance of functional capacity was not found for the CD56dim 
subset in this individual (Figure 3.27). For the CD56bright subset, the percentage of 
migrated cells expressing IFN-γ (10.10%) was lower than before migration (38.19%) 
but higher than the control sample (4.49%). However, this trend was not seen for the 
CD56dim subset. Before migration, 2.68% of the CD56dim subset expressed IFN-γ. 
Migrated CD56dim NK cells were found to express a very low amount of IFN-γ in 
response to cytokine stimulation (0.28%) and this value was lower than the control 
sample (0.44%). 
 
Figure 3.27 The effect of migration on the capacity of NK cells to express IFN-γ. 
Percoll Pellet cells were allowed to migrate though EA.hy 926 endothelial cell 
monolayers or were kept in culture in the absence of endothelium as a control. A sample 
of cells was also taken before migration. Cells from all 3 conditions were subjected to a 
cytokine stimulation assay and were cultured in the presence or absence of 10 ng/ml IL-
12, IL-15 and IL-18 for a total of 10 hours. After 1 hour, 10 μg/ml of Brefeldin A was 
added. Subsequently, cells were stained with fluorochrome-conjugated antibodies 
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against CD56, CD16 and CD3 and intracellular staining was carried out for the 
measurement of IFN-γ expression. CD56bright and CD56dim NK cells were gated on 
using the strategy described in chapter 2.7.3. The percentage of CD56bright (blue) and 
CD56dim (pink) NK cells expressing IFN-γ is given in the right corner of the dot plot. 
 
This experiment was repeated on 5 different donors and the results are depicted in 
Figure 3.28 which shows the expression levels of IFN-γ on CD56bright (Figure 3.28 A) 
and CD56dim NK cells (Figure 3.28 B), both with and without cytokine stimulation. 
Without cytokine stimulation, the expression of IFN-γ by both CD56bright and 
CD56dim NK cells was minimal with mean average expression levels of 1.53% and 
0.19% before migration, 0.94% and 0.27% after migration, 0.51% and 0.16% on control 
cells respectively. When cultured with cytokines, as expected, the CD56bright subset 
consistently expressed more IFN-γ than the CD56dim subset. Both subsets of NK cells 
expressed the most IFN-γ before migration (CD56bright: 58.23% CD56dim: 4.91%). 
Although less IFN-γ was expressed by both NK subsets after they had migrated through 
endothelium (CD56bright: 25.47%, CD56dim: 4.25%) as compared to before migration, 
migrated cells expressed more IFN-γ than control cells (CD56bright: 9.09%, CD56dim: 
0.28%). Although the differences in IFN-γ expression between migrated and control NK 
cells were not found to be statistically significant, the results do suggest that migration 
may help to maintain some of the capacity of both subsets of NK cells to produce IFN-
γ. 
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Figure 3.28 The effect of migration on the expression of IFN-γ by NK cells. Graph 
of results from the cytokine stimulation assay including negative controls. Percoll 
Pellet cells were allowed to migrate through EA.hy 926 endothelial cell monolayers 
(blue) or were kept in culture in the absence of endothelium as a control (pink). A 
sample of cells was taken before migration (yellow). Cells from all three conditions 
were subjected to a cytokine stimulation assay and were cultured in the presence (+cyt) 
or absence (-cyt) of 10 ng/ml IL-12, IL-15 and IL-18 for a total of 10 hours. After 1 
hour, 10 μg/ml of Brefeldin A was added. Subsequently, cells were stained with 
fluorochrome-conjugated antibodies against CD56, CD16 and CD3 and intracellular 
staining was carried out for the measurement of IFN-γ expression. Cells were then 
analysed by flow cytometry. CD56bright NK cells are shown in A and CD56dim NK 
cells are shown in B. From bottom to top, horizontal lines represent the 5th, 25th, 
median, 75th and 95th percentiles. Results are a mean of 3 experiments carried out for 
each donor (n=5). 
 
The percentages of cells expressing IFN-γ given above are raw data and have not been 
adjusted for the negative control of culture of the cells in the absence of cytokines. Data 
shown in figure 3.29 have been adjusted for the negative controls of cells in the absence 
of cytokines. The figure depicts multiple experiments using lymphocytes from several 
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(n=5) donors. Of the migrated cells, 21.47% of CD56bright and 2.97% of CD56dim NK 
expressed IFN-γ. For the CD56bright subset, migrated cells expressed only slightly 
more IFN-γ than cells analysed before migration (20.55%) and substantially more than 
the control sample (8.56%). The percentage of CD56dim NK cells that express IFN-γ 
after migration (3.92%) is higher than before migration (2.97%) and also higher than the 
control sample (0.24%). However, differences seen did not reach statistical significance. 
 
Figure 3.29 The effect of migration on the expression of IFN-γ by NK cells. The 
graph above depicts experiments carried out using lymphocytes from several donors 
(n=5). Percoll Pellet cells were allowed to migrate though EA.hy 926 endothelial cell 
monolayers or were kept in culture in the absence of endothelium as a control. A sample 
of cells was also taken before migration. Cells from all 3 conditions were subjected to a 
cytokine stimulation assay and were cultured in the presence or absence of 10 ng/ml IL-
12, IL-15 and IL-18  for a total of 10 hours. After 1 hour, 10 μg/ml of Brefeldin A was 
added. Subsequently, cells were stained with fluorochrome-conjugated antibodies 
against CD56, CD16 and CD3 and intracellular staining was carried out for the 
measurement of IFN-γ expression. CD56bright (yellow) and CD56dim (green) NK cells 
were gated on using the strategy described in the chapter 2.7.3. From bottom to top, the 
horizontal lines represent the 5th, 25th, median, 75th and 95th percentile values 
respectively. 
  
 
3.3 Discussion 
 
The objective of the experiments described in this chapter was to design and optimise a 
migration assay that could emulate the in-vivo migration of cells from the periphery to a 
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site of inflammation. The assay could then be used to address the possibility that the 
interaction of NK cells with the endothelium during the process of migration alters the 
phenotype and functional capacities of NK cells. The CD56bright subset of NK cells 
accumulates at sites of inflammation (Pridgeon et al., 2003; Dalbeth et al., 2004; 
Ottaviani et al., 2006). The accumulation of this subset could reflect preferential 
recruitment to the site of inflammation, or the differentiation from CD56dim into 
CD56bright NK cells. Preliminary experiments described in this chapter were also 
carried out to elucidate the mode of this accumulation. 
 
Substantial testing was carried out to optimise the migration assay. A time course of 6 
hours was chosen for the assay as longer time courses did not result in increased 
frequency of migration. At 6 hours, substantial expression of CD69 had occurred on 
migrated NK cells and the viability of both the NK cells and the endothelium was 
maintained. Every effort was made to design an assay without bias, however it must be 
noted that a 6 hour time course favoured the activation of the CD56dim subset of NK 
cells.  
 
Results in this chapter revealed that the CD56bright subset of NK cells accumulate post-
migration significantly more than CD56dim NK cells. Therefore experiments using an 
in vitro system, have successfully emulated previous work showing an enrichment of 
the CD56bright subset of NK cells in inflammatory lesions (Dalbeth et al., 2004). 
Preliminary experiments have suggested that this subset was preferentially recruited and 
the accumulation was not as a result of the differentiation of CD56dim into CD56bright 
NK cells. These experiments could not exclude the possibility that the CD56bright 
subset could differentiate into CD56dim NK cells. If this is found to be true, it would in 
fact support the theory that CD56bright NK cells are preferentially recruited to sites of 
inflammation; more cells would be required post-migration to account for both the 
enrichment of the CD56bright subset, and for some of these cells to differentiate into 
the CD56dim subset.  
 
On the subject of migration-induced NK cell activation; it appears that both contact 
with, and migration through, the endothelium activates both subsets of NK cells. The 
migration-induced up-regulation of CD69 was found to be statistically significant for 
the CD56dim subset of NK cells. CD69 belongs to the family of C-type lectin receptors 
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and is closely related to the NK cell receptor CD94 (Hamann et al., 1993; Ziegler et al., 
1993). Although it is constitutively expressed on some cell types, its expression is 
rapidly induced upon activation of T, B and NK cells. CD69 is a triggering molecule for 
NK cell cytolysis and also acts to co-stimulate the production of cytokines by activated 
NK cells (Moretta et al., 1991; Borrego et al., 1999). As this study has found, migration 
increases NK cell CD69 expression, and is therefore enhancing the activation of these 
cells. In the context of inflammatory lesions, overactive NK cells could contribute to the 
disease pathogenesis.  
 
The accumulation of the CD56bright subset of NK cells also has important pro-
inflammatory consequences. Indeed, previous work has indicated that the CD56bright 
subset in particular intensifies inflammation by engaging in reciprocal activation with 
monocytes. This results in amplified production of the pro-inflammatory cytokines IFN-
γ from the NK cells and TNF-α from monocytes (Dalbeth et al., 2004). Ottaviani et al. 
found that CD56bright NK cells accumulate in psoriatic skin and exacerbate the 
inflammatory plaques (Ottaviani et al., 2006). In fact, similar to the work of Dalbeth et 
al., this group found that 80% of the NK cells in psoriatic plaques are of the CD56bright 
phenotype, which is quite different to peripheral blood where only 10% are of the 
CD56bright subset. These skin infiltrating NK cells release high quantities of IFN-γ, in 
turn strongly inducing keratinocyte activation. Results from this chapter seem to support 
this work. In particular, results emulate the accumulation of CD56bright NK cells seen 
in these studies. Furthermore, the increase in CD69 expression and maintenance of NK 
functional capacities post-migration (Figure 3.24 and 3.30) imply a role for the 
endothelium in the pathogenesis of inflammatory joint disease.   
 
Interesting results emerged from this chapter regarding the degranulation of NK cells. 
The experiments revealed that migration may maintain the capacity of CD56bright NK 
cells to degranulate. Interestingly, CD56bright NK cells consistently expressed higher 
levels of CD107a than CD56dim NK cells. This is surprising as CD107a is a marker of 
degranulation, a process that is commonly thought to occur upon the release of 
cytotoxic proteins, a property generally attributed to the CD56dim subset. Therefore, 
the results from this investigation suggest that CD56bright NK cells also undergo 
degranulation. Thus, the capacity of NK cell cytotoxicity cannot be extrapolated from 
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the results of a CD107a degranulation assay. Alter et al. describe this degranulation 
assay in detail, and noted that CD107a expression correlates with both NK cell cytokine 
secretion and cytotoxicity of target cells (Alter et al., 2004). However, Penack et al. 
observed a close correlation between surface expression of CD107a and NK cell killing, 
indicating that NK cell cytotoxicity can be assessed by this method (Penack et al., 
2005). In support of Penack’s study, Aktas et al. directly correlate the expression of 
CD107a on NK cells with cytotoxic activity (Aktas et al., 2009). The expression of 
CD107a by the CD56bright subset of NK cells was seen in their experiments, but only 
after IL-2 treatment, which is known to increase the cytotoxic capacity of CD56bright 
NK cells to levels comparable to that of CD56dim NK. The findings from both of these 
studies are in disagreement with results from this study, as high levels of CD107a 
expression were observed on CD56bright NK cells that were not pre-treated with IL-2. 
CD56bright NK cells are not well adapted for cytotoxicity; therefore the high 
expression of CD107a is unlikely to reflect cytotoxicity. In agreement with Alter et al. 
perhaps then CD107a should be used as a marker of NK cell functional activity rather 
than simply cytotoxicity. 
 
The increase in the number of CD16-CD56dim/- cells, and the high cytotoxic activity of 
these cells after encounter with target cells in killing assays, has been noted by several 
groups. In a killing assay using K562 target cells, Penack et al. found that this expanded 
CD56dimCD16- population is primarily responsible for the cytotoxic activity against 
these targets (Penack et al., 2005). Unusually, this group found that classical NK cell 
subsets did not degranulate in response to target cell encounter. In addition, this group 
found that unlike other NK cells, the CD56dimCD16- population degranulate in 
response to the myeloid cell line ML2, a target cell generally known to be resistant to 
NK cell killing. However, this study used a one-step CD56 positive selection protocol to 
purify the NK cells, and therefore CD3+ CD56+ cells were not excluded. Perhaps the 
killing of the ML2 cells could have been due to contaminating T cells. This point was 
commented on in a later paper by Zimmer and colleagues (Zimmer et al., 2005) who 
stated that if only CD3- cells were analysed, almost all of the CD56dim CD16- 
population would be absent. Similar to the Penack study, the present study also noted an 
increase in CD56-CD16- cells after exposure of NK cells to K562 target cells. In normal 
killing assays, Percoll pellet cells, which include T cells were used. However, the 
present study used CD3 exclusion by FACS analysis, therefore these cells could not be 
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T cells. To investigate the possibility that NK cells may contribute to the increase in the 
CD56-CD16- cells post-target cell encounter, NK cells were FACS sorted CD3-
CD56bright and CD3-CD56dim NK cells and co-cultured with K562 targets. By using 
cells that had been FACS sorted into the NK cell subsets, T cells were completely 
eliminated, and the possibility that either of the NK cell subsets were contributing to the 
increase in CD56-CD16- cells could be tested. Interestingly, after co-culture with K562 
targets, a concomitant decrease in both subsets of NK cells accompanied the increase in 
CD56-CD16- cells. Co-culture of K562 with pure CD56bright NK cells resulted in a 3 
fold increase in CD56-CD16- cells. However, it must be noted that CD56 expression 
does decrease on NK cells during culture experiments, but not to the degree that can 
account for such an increase in this population. Pure CD56dim NK cells co-cultured 
with K562 targets resulted in an increase in an almost 3-fold increase in CD56-CD16- 
cells. The results from these assays suggest that both subsets of NK cells could 
contribute equally to the increase in CD56-CD16- cells. Similar to the Penack study, 
this study has noted a high expression of CD107a on CD56-CD16- cells after co-culture 
of NK cells with K562 target cells. However, unlike Penack et al., and in keeping with 
the majority of studies, results from the present study have found CD56bright NK cells 
to express high levels of CD107a after co-culture with K562 and is therefore in 
disagreement with the opinion held by Penack et al. that the CD56-CD16- population is 
primarily responsible for the cytotoxic activity against these targets. Grzywacz et al. 
queried the CD56dimCD16- population, and used several methods of NK cell 
purification (Grzywacz et al., 2007). Methods included CD56+ cells MACS selection, 
followed by the exclusion of CD3+ cells through FACS analysis gating. Another 
method used involved CD56+ MACS selection followed by CD3 MACS depletion. 
Methods consistently demonstrated that the majority of CD56dimCD16- cells were 
CD3+ T cells. This group suggest that the slight increase in CD56dimCD16- cells could 
be due to target cell-induced shedding of CD16 from CD56dim NK cells. The method 
of purification of the CD56bright and CD56dim subsets used in the present study 
absolutely excludes the possibility that CD3+ T cells could contribute to the CD56-
CD16- population. However, this does not imply a complete difference of opinion to 
that of Zimmer et al. and Grzywacz et al. The latter study demonstrated that in 
experiments including T cells, 94% of CD56dimCD16- cells were CD3+. The 6% of 
CD56dimCD16- cells that are not T cells is in agreement with the small numbers of this 
population observed in the present study. It is possible that CD56 and CD16 are shed 
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upon target cell encounter and the CD56-CD16- population represents cells that have 
killed their targets.  
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Chapter 4 
 
NK cell migration using the HUVEC migration model 
 
4.1 Background and aims 
 
Inflammation reflects a vascular and immune response to harmful stimulus. For the 
immune cells to get to the site of inflammation, they must first migrate through the 
barrier of the vascular endothelium. The process of migration through vascular 
endothelium is known to have significant effects on the function and phenotype of many 
leukocytes (Reviewed by (Nourshargh and Marelli-Berg, 2005). This subject has been 
extensively studied for the majority of leukocytes, with the exception of the effect of 
migration on the function and phenotype of NK cells.  
 
At sites of inflammation and in several clinical settings, an accumulation of the 
CD56bright subset of NK cells has been noted (Dalbeth and Callan, 2002; Pridgeon et 
al., 2003; Ottaviani et al., 2006). The present study aims to investigate the accumulation 
of the CD56bright subset of NK cells at sites of inflammation and to examine the effect 
of migration on the function and phenotype of NK cells. Thus far, the present study has 
successfully emulated this accumulation using an in vitro model of migration through 
monolayers composed of the EA.hy 926 endothelial cell line. The EA.hy 926 
endothelial cell monolayers were found to be inherently capable of inducing cell 
migration without prior stimulation. With this in mind, the decision was taken not to 
stimulate the EA.hy 926 endothelial cells. The question as to how the CD56bright 
subset of NK cells accumulates was posed in chapter 3, with the possible explanations 
of (i) the differentiation of the CD56dim to the CD56bright subset locally, at the site of 
inflammation or (ii) the preferential recruitment of CD56bright NK cells to the site of 
inflammation. Preliminary evidence described in chapter 3, points towards preferential 
recruitment as the process by which CD56bright NK cells accumulate post-migration. 
The present study has so far shown that migration through EA.hy 926 endothelial cell 
line monolayers enhances NK cell activation and may also maintain the NK cell 
functional capacities including the production of IFN-γ and degranulation.  
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To bring this in vitro model closer to that of the in vivo environment, experiments in this 
chapter were performed using the human primary endothelial cells; HUVECs to create 
the monolayer. The drawback of using human primary endothelial cells for the 
migration model is that the samples of HUVECs will vary between donors, including 
characteristics that are important in migration such as the adhesive properties of the 
endothelium. To avoid this, pooled HUVECs from a minimum of five donors were used 
in all experiments in this thesis. The present chapter examines the effect of migration 
through HUVECs on the activation of NK cells by measuring the early activation 
marker CD69. The present chapter also examines the effect of migration through 
HUVECs on the functional capacities of NK cells, namely IFN-γ production and 
degranulation. As with chapter 3, the present chapter also investigates the accumulation 
of CD56bright NK cells post-migration with the aim to strengthen the evidence that the 
accumulation is due to the preferential recruitment of this subset. Finally, this chapter 
examines the effect of migration on the expression of a comprehensive panel of 
adhesion molecules.  
 
Any migration-induced changes in the expression of adhesion molecules may have 
important consequences on the interaction of NK cells with other immune cells at sites 
of inflammation and also on possible further migration of NK cells to other tissues or 
secondary lymphoid organs. If migration is found to activate NK cells, this could also 
influence the interaction of NK cells with DCs as activated NK cells have been shown 
to stimulate DCs if there is an excess of DCs (Piccioli et al., 2002). This may be 
important in the context of inflammatory joint diseases. In such diseases, non-self 
pathogen molecules are absent; therefore there are no TLR ligands to stimulate the DCs. 
If migration was found to activate NK cells, this could provide an alternative pathway 
of DC maturation. In addition, the interaction of NK cells with DCs has been shown to 
be bi-directional with DCs able to effectively stimulate NK cell proliferation, 
cytotoxicity and IFN-γ production (Fernandez et al., 1999; Gerosa et al., 2002). 
Furthermore, NK: DC interactions have important consequences for the adaptive arm of 
the immune response; mature DCs can facilitate the generation of T cell responses. The 
interaction of activated NK cells with DCs has also been shown to provide a selection 
process for DCs; NK cell-mediated elimination is avoided if the DCs express MHC 
class I, which is acquired during DC maturation. Therefore, only mature DCs that are 
competent to prime T cells survive the NK cell mediated selection process (Ferlazzo et 
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al., 2002; Della Chiesa et al., 2003). Consequently, any migration-induced changes in 
the activation of NK cells could increase the number of mature, competant DCs that are 
present in the inflammatory environment. Another NK cell interaction which is of 
particular relevance to this thesis is the interaction with macrophages in inflammatory 
joint diseases. In inflamed joints, the CD56bright NK cells predominate (Dalbeth and 
Callan, 2002) and have been shown to be able to engage with monocytes in a program 
of reciprocal activation (Dalbeth et al., 2004). By altering the expression of NK cell 
adhesion molecules, migration could potentially affect the adhesion of NK cells to cells 
of the monocyte/macrophage lineage and therefore could augment this interaction.  
 
Finally, this chapter aims to confirm findings on the subject of CD56bright NK cell 
accumulation post-migration and migration-induced activation of NK cells by using 
purified NK cells. By removing other immune cells from the in vitro system, the assay 
differs further from the conditions seen in vivo. However, this allows a more direct 
dissection of the interaction of NK cells with endothelium, and eliminates effects of any 
potential bystander interactions between other lymphocytes and the endothelium. 
 
4.2 Results 
 
4.2.1 Optimisation of the time course of NK cell migration and of the stimulation of 
the HUVECs with rhIFN-. 
 
One of the first steps in leukocyte transmigration is the activation of the endothelium by 
pro-inflammatory cytokines that are released during an inflammatory response 
(Springer, 1994). The resulting up-regulation of adhesion molecules on the endothelium 
facilitates the migration of immune cells towards the site of inflammation. In 
experiments described in chapter 3, no stimulation of the endothelium was required to 
facilitate immune cell migration. However, the migration assays in chapter 3 used 
EA.hy 926 endothelial cell line cells for the production of endothelial cell monolayers. 
The present chapter uses the primary human cells HUVECs instead of the EA.hy 926 
endothelial cell line for the production of endothelial cell monolayers. These two types 
of endothelial cells are both commonly used for migration assays and, although they 
express similar adhesion molecules (Mutin et al., 1997), it is likely these cells will differ 
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in their response to cell culture and cytokine stimulation. For this reason, it was 
important to re-optimise both the stimulation of the endothelial cells and the time course 
for the migration assay using the HUVECs. On the subject of the appropriate cytokine 
to use for the stimulation of the HUVECs, several cytokines and stimulants have been 
used in other studies including TNF-α, IFN-γ, LPS, and IL-1β. Regarding the choice of 
stimulant for the endothelium, for consistency with the previous chapter, rhIFN-γ was 
chosen. In terms of the concentration of rhIFN-γ, a review of the literature suggests that 
both stimulated and unstimulated HUVECs can be used for migration assays (Randolph 
et al., 1998; Brezinschek et al., 1999; Cepinskas et al., 1999; Chen et al., 1999; Sancho 
et al., 1999; Berg et al., 2002; Borthwick et al., 2003). However, most lymphocyte 
migration studies were found to use stimulated HUVECs with a concentration of rhIFN-
γ in the range of 250-300 U/ml (Sancho et al., 1999; Berg et al., 2002). With these 
studies in mind, the effect of no stimulation and 300 U/ml of rhIFN-γ were tested. On 
the subject of the time course for the migration assay, studies of lymphocyte migration 
tend to use longer time courses compared to studies of non-lymphocyte migration, with 
a range of 4-24 hours (Berg et al., 2002; Borthwick et al., 2003). For comparison, non-
lymphocyte migration assays use much shorter time courses of usually no longer than 1-
2 hours (Takahashi et al., 1995; Cepinskas et al., 1999). Taking these studies into 
consideration, it was decided to test the time courses of 12 and 24 hours for the 
migration assay. 
 
The following three conditions were tested: (i) 12 hour time course without stimulation 
for HUVECs (ii) 12 hour time course with 300 U/ml of rhIFN-γ stimulation for the 
HUVECs and (iii) 24 hour time course with 300 U/ml of rhIFN-γ stimulation for the 
HUVECs. Each of the experiments was performed on lymphocytes from one donor to 
enable a comparison and was repeated using lymphocytes from a total of 3 donors. The 
optimum condition was judged by highest percentage of NK cells migrating through the 
endothelium. As can be seen in Figure 4.1, the highest number of NK cells migrating 
was achieved when cells were allowed to migrate for 12 hours with the endothelium 
unstimulated. Under these conditions, 100% of CD56bright and 61.30% of CD56dim 
NK cells were found to migrate. No further migration occurred when the endothelium 
was stimulated with 300 U/ml of rhIFN-γ or when a longer time course for the 
migration assay was used; when the endothelium was stimulated with 300 U/ml of 
rhIFN-γ and the time course was 12 hours, it appeared that 34.93% of CD56bright and 
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8.03% of CD56dim NK cells migrated. A longer time course of 24 hours with the 
endothelium being stimulated with 300 U/ml of rhIFN-γ achieved similar results with 
29.39% of CD56bright and 9.36% of CD56dim NK cells migrating. Although the 
highest number of cells were found to migrate in assays using un-stimulated 
endothelium with a 12 hour time course, a statistical analysis found the number of 
migrating cells to not be statistically different from the other conditions tested. 
 
 
Figure 4.1 Optimisation of the time course of the migration assay and the 
concentration of rhIFN-γ for the stimulation of the HUVECs. Lymphocytes from 3 
donors were allowed to migrate for; (i) 12 hours through unstimulated endothelium 
depicted on the graph as 12 and 0 (ii) 12 hours through endothelium stimulated with 
300 U/ml rhIFN-γ depicted on the graph as 12 and 300 and (iii) 24 hours through 
endothelium stimulated with 300 U/ml rhIFN-γ depicted on the graph as 24 and 300. All 
experiments were carried out in triplicate for each donor and the mean average of these 
results was plotted on the graph. A sample of cells taken before and after the migration 
assay were counted, stained with fluorochrome-conjugated antibodies against CD3, 
CD16 and CD56 and analysed by flow cytometry with each subset gated on using the 
gating strategy described in 2.7.3. The percentage migration was calculated using these 
data. Horizontal lines represent minimum, median and maximum values. 
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Results from these experiments showed that more NK cells migrated when the 
endothelium was left unstimulated. However there is a concern that unstimulated 
endothelium would not reflect the in vivo environment and previous publications in this 
field have tended to favour the stimulation of the endothelium; our preference was 
therefore to use stimulated endothelium if possible. Migration across stimulated 
endothelium was clearly present and the trend for CD56bright NK cells to migrate more 
efficiently than the CD56dim cells seen throughout the previous chapter, was 
demonstrable in these preliminary assays performed using stimulated endothelium. It 
was therefore decided to stimulate the endothelium with 300 U/ml of rhIFN-γ in all 
further migration assays. In the context of the stimulated endothelium, extending the 
time course of the assay did not lead to greater migration. There were a number of 
pragmatic reasons for favouring a 12 hour rather than a 24 hour time course. Firstly, a 
24 hour time course would not allow time for the cells to be immediately used for NK 
cell functional assays, and cells would have to be refrigerated overnight, cryo-preserved 
or cultured for a further 12 hours before further analyses were done. None of these 
options would be ideal as NK cells are particularly sensitive to cell culture and freezing. 
Furthermore, in some assays, NK cells are stained with CFSE before the migration 
assay and this type of staining requires immediate FACS analysis due to the rapid 
degradation of CFSE. A time course of longer than 12 hours would not allow the 
immediate FACS analysis of such experiments. Secondly, as previously mentioned, NK 
cells are particularly sensitive to long term culture, and a 24 hour time course followed 
by NK cell functional assays would result in significant NK cell death.  
 
 
4.2.2 The accumulation of CD56bright NK cells post-migration 
 
The CD56bright subset of NK cells accumulates at sites of inflammation. Experiments 
described in chapter 3 successfully emulated this effect using an in vitro model of cell 
migration through EA.hy 926 endothelial cell line monolayers. Experiments in the 
present chapter aim to confirm these findings using an in vitro model of cell migration 
through HUVEC monolayers. Figure 4.2 shows a representative example of flow 
cytometric data of a migration assay, and depicts the accumulation of the CD56bright 
subset of NK cells post-migration. As can be seen in Figure 4.2 A, before migration of 
the total NK cell pool only 0.97% of cells were found to be CD56bright NK cells and 
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95.77% were CD56dim NK cells. In this particular experiment, as can be seen in Figure 
4.2 B the percentage of CD56 bright NK cells increased to 3.01% after migration, 
whereas 92.18% were of the CD56dim subset. For this particular donor, there are less 
CD56dim NK cells post-migration and a three-fold increase in the CD56bright subset 
post-migration. Furthermore, the control sample depicted in Figure 4.2 C, is similar to 
the sample analysed before migration with 0.99% CD56bright and 95.06% CD56dim 
NK cells, suggesting that migration and not cell culture is the cause of the increase in 
the CD56bright subset of NK cells. The sum of these percentages is not 100%. This is 
because some NK cells fall outside the classical definitions of NK cell subsets which 
are CD56bright CD16- and CD56dim CD16+ and therefore are not included in the 
analysis.  
 
 
NK cells before migration NK cells after migration 
Control NK cells 
A B
C
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Figure 4.2 A representative example of flow cytometric data showing the 
accumulation of the CD56bright subset of NK cells post-migration. Lymphocytes 
were allowed to migrate for 12 hours through HUVEC monolayers that were previously 
stimulated with 300 U/ml of rhIFN-γ. A sample of cells was also kept in culture in the 
absence of HUVECs as a control. A sample of cells was taken before migration (A), 
after migration from the lower chamber of the transwell insert (B) and from the control 
sample (C). Cells were counted and stained with the fluorochrome-conjugated 
antibodies; CD3 PerCP, CD16 PE and CD56 APC for analysis by flow cytometry. NK 
cell subsets were gated using the gating strategy described in 2.7.3. Each FACS dot plot 
depicts 2x105events. 
 
To verify that CD56bright NK cells accumulate post-migration through HUVEC 
monolayers, multiple experiments (n=21) were performed using lymphocytes from 
different donors and the results are depicted in Figure 4.3. Each dot on the scatter plot in 
this figure represents one donor. For each donor, the experiment was performed in 
triplicate and the mean average was plotted on the graph. To enable visualisation of the 
results from each donor, a scatter plots is presented alongside a box and whiskers plot of 
the same data, which is shown for consistency with the other figures in this thesis. 
Results from these assays found the median percentage migration to be 53.40% and 
31.48% for the CD56bright and CD56dim subsets respectively. A statistical analysis of 
these results confirmed that CD56bright NK cells accumulate significantly more than 
the CD56dim subset (p=0.0016) post-migration through HUVEC monolayers. 
Interestingly, and clearly seen in the scatter plots, the data shows that there are two 
discrete groups of individuals. In one group, there is almost 100% migration of the 
CD56bright NK cells, in the other group, the number of migrating CD56bright NK cells 
is lower overall with a greater spread of results. A further analysis comparing the 
phenotype of CD56bright NK cells from individuals whose cells are particularly apt at 
migrating, with CD56bright NK cells from the individuals whose cells migrate more 
moderately could provide interesting results with regard to the expression of adhesion 
molecules and chemokine receptors that are involved in the process of migration. This 
possible difference in the population could reflect a genetic predisposition for 
CD56bright NK cells that are more able to migrate. Alternatively, it could reflect a 
subgroup of people which at the time of sampling were under inflammatory stress and 
hence their CD56bright NK cells were ready to migrate to the site of inflammation, 
perhaps already having increased the expression levels of adhesion molecules compared 
to individuals who at the time of sampling were healthy. 
.  
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Figure 4.3 The accumulation of CD56bright NK cells post-migration through 
HUVEC monolayers. Lymphocytes were allowed to migrate for 12 hours through 
HUVEC monolayers that were previously stimulated with 300 U/ml of rhIFN-γ. A 
sample of cells was also kept in culture in the absence of HUVECs as a control. A 
sample of cells was taken before migration, after migration from the lower chamber of 
the transwell insert and from the control sample. These samples were counted and 
stained with fluorochrome-conjugated antibodies against CD3, CD16 and CD56 for 
analysis by flow cytometry. NK cell subsets were gated using the gating strategy 
described in 2.7.3 and the percentage migration of NK cell subsets was calculated using 
these data. Each dot on the scatter plot (left) represents one donor. For each donor, the 
experiment was performed in triplicate, a mean average was calculated and the result 
was plotted on the graph. The horizontal lines on the scatter plot (left) represent the 
mean average of the results from all of the donors. A box and whiskers graph is 
presented (right) for consistency with the other figures in this thesis. From bottom to 
top, horizontal lines in this graph represent the 5th, 25th, median, 75th and 95th 
percentiles. Statistical analysis of the relative capacities of CD56bright and CD56dim 
NK cells to migrate was carried out using a paired Wilcoxon signed rank test.  p< 0.01 
is represented by ** and the value is stated on the graph (n=21). 
 
4.2.3 The accumulation of CD56bright NK cells is due to preferential recruitment and 
not the differentiation of CD56dim NK cells 
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The accumulation of the CD56bright subset of NK cells post-migration seen in the 
previous chapter can be explained by a number of theories; firstly, the CD56dim subset 
could differentiate into the CD56bright subset post-migration. Secondly, the 
CD56bright NK cells could preferentially proliferate post-migration. Finally, the 
CD56bright subset could be preferentially recruited leading to more of the CD56bright 
subset migrating through the endothelium. These different theories were explored using 
the EA.hy 926 endothelial cell line migration model in chapter 3.2.5. However only one 
donor was tested and the findings were difficult to interpret fully. The data did show 
that, at least for this one donor, migration does not cause CD56dim NK cells to 
differentiate into CD56bright NK cells and that differentiation therefore could not 
explain the observed accumulation post-migration. The experiment in chapter 3.2.5 
could be interpreted to show some differentiation of CD56bright to the CD56dim subset 
as a result of cell culture. However, these results could also be explained by the down 
regulation of CD56 expression on a small proportion of CD56bright NK cells resulting 
from apoptosis during the assay. Experiments in the present chapter use the same 
protocol, utilising CFSE to track purified NK cells migration assays, with the difference 
of replacing the EA.hy 926 endothelial cell line with a HUVEC monolayer, therefore 
bringing the assay closer to that of the in vivo environment.  
 
Briefly, lymphocytes were FACS sorted into a pure population of CD56bright and a 
pure population of CD56dim NK cells. Each sample was divided into two, with one half 
being stained with CFSE and the other half being left unstained. The CFSE stained 
CD56bright cells were mixed with the un-stained CD56dim cells and vice versa. Cells 
were then subjected to a migration assay and analysed by flow cytometry. An example 
of the FACS data from one representative experiment is depicted in Figures 4.4 and 4.5. 
As can be seen in Figure 4.4, NK cells were successfully purified by FACS sorting into 
CD56bright and CD56dim subsets with populations that were at least 98% pure. FACS 
plots in Figure 4.4 A also confirm homogenous staining of all of the CD56dim subset 
and none of the CD56bright subset with CFSE and Figure 4.4 B confirming clean CFSE 
staining in the converse sample. 
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Figure 4.4  FACS sorting and CFSE staining of NK cell subsets for the study of the 
accumulation of the CD56bright subset of NK cells post-migration. Lymphocytes 
were FACS sorted into CD56bright and CD56dim NK cells. The samples were divided 
into two and with one half being stained with CFSE and the other half being left 
unstained. Stained cells from one subset were mixed with unstained cells from the other 
subset. Cells were stained with CD56 APC and analysed by flow cytometry. CD56dim 
NK cells have been stained with CFSE in A and CD56bright NK cells have been stained 
with CFSE in B.  
 
The results from the NK cell tracking experiment will give evidence on the subject of 
the accumulation of the CD56bright subset of NK cells post-migration.  
 
As previously described in chapter 3.2.5; if the accumulation of CD56bright NK cells 
post-migration is explained by the differentiation of CD56dim NK cells into the 
CD56bright subset then: 
 
(i) In the CFSE stained CD56bright/un-stained CD56dim sample, un-stained 
CD56bright NK cells would be observed post-migration. 
 
(ii) In the CFSE stained CD56dim/un-stained CD56bright sample, CFSE stained 
CD56bright NK cells would be observed post-migration. 
 
If migration resulted in the differentiation of the CD56bright into CD56dim NK cells 
then: 
 
(i) In the CFSE stained CD56bright/ un-stained CD56dim sample, CFSE stained 
CD56dim would be observed post-migration. 
CD56dimCFSE 
 
CD56brightCFSE 
A B
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(ii) In the CFSE stained CD56dim/ un-stained CD56bright sample, un-stained CD56dim 
cells would be observed post-migration.  
 
The proliferation of any cells would also be observed as incremental decreases in the 
fluorescence of any given cell population.  
 
The analysis of the results from these experiments proved more difficult in terms of 
quantification than the experiments described in chapter 3.2.5. FACS plots in chapter 
3.2.5 were analysed using quadrants to assess the percentage of CFSE positive or 
negative cells. In these experiments, the levels of CD56 expression of the main 
population of NK cells remained very similar before and after the migration assay. This 
allowed the use of the same quadrant before and after the migration assay, therefore 
eliminating biased. However, the expression of CD56 on NK cells in experiments 
described in the present chapter does not remain the same when comparing cells before 
and after the migration assay. Therefore, the same quadrant cannot be used for the 
analysis of cells before and after the migration assay. However, the pre-migration 
sample is not used as a control, and is only used to check the purity of the FACS sorting 
and the CFSE staining. Consequently, it is not necessary to analyse cells pre-migration 
using the same quadrant as the other samples. Therefore an alternative gating strategy 
was used that enabled the gate to remain consistent between the migrated samples and 
the control sample, and for the percentage of cells expressing CFSE to be analysed. For 
this reason, and for clarity, the figures are segregated into cells before the migration 
assay (Figure 4.4) and cells after the migration assay (Figure 4.5). 
 
Figure 4.5 shows FACS plots of the NK cell tracking experiment using cells from one 
representative donor and depicts the sample of cells in which the CD56dim NK cells 
were stained with CFSE mixed with the unstained CD56bright NK cells. The 
percentage of CFSE positive CD56bright cells were found to be similar when 
comparing the migrated sample with the control sample; 0.55% of CD56bright cells 
from the upper chamber post-migration (cells that had come into contact with 
endothelium but had not migrated, Figure 4.5 A), 0.50% of CD56bright cells from the 
lower chamber post-migration (migrated cells, Figure 4.5 B), and 0.86% of CD56bright 
cells from the control sample (Figure 4.5 C). These results suggest that CD56dim NK 
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cells do not differentiate into CD56bright NK cells as a result of contact with, or 
migration through HUVEC monolayers, and supports the theory that CD56bright NK 
cells are preferentially recruited in migration assays. 
 
 
 
Figure 4.5 The accumulation of CD56bright NK cells post-migration is due to 
preferential recruitment and not the differentiation of CD56dim NK cells. Sample 
with CD56dim NK cells stained with CFSE. Lymphocytes were FACS sorted into 
CD56bright and CD56dim NK cells. The samples were divided into two and with one 
Upper chamber 
post-migration 
Lower chamber 
post-migration 
Control 
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half being stained with CFSE and the other half being left unstained. Stained cells from 
one subset were mixed with unstained cells from the other subset. The different mixtures 
of NK cells were allowed to migrate for 12 hours through HUVEC monolayers that 
were previously stimulated with 300 U/ml of rhIFN-γ. Cells were also kept in culture in 
the absence of endothelium as a control. A sample of cells was taken post-migration 
from both the upper chamber (A) and the lower chamber (B) of the transwell insert. The 
former are cells that have come into contact with endothelium but have not migrated. 
The latter are cells that have migrated. The control cells were also sampled (C) and all 
samples were stained with fluorochrome-conjugated antibodies against CD56 APC for 
analysis by flow cytometry. The above dot plots show the sample in which CD56dim NK 
cells were stained with CFSE mixed with unstained CD56bright NK cells. 
 
Figure 4.6 shows FACS plots of the NK cell tracking experiment using data from the 
same representative donor as shown in Figure 4.4 and 4.5. Figure 4.6 depicts the sample 
of cells in which the CD56bright NK cells were stained with CFSE mixed with 
unstained CD56dim NK cells. In this sample, 1.32% of migrated CD56dim NK cells 
were found to be CFSE positive (Figure 4.6 A), which is slightly higher than cells both 
from the upper chamber post-migration; 0.19% (Figure 4.6 B) and from the control 
sample; 0.26% (Figure 4.6 C). These results suggest that a very small proportion of 
CD56bright NK cells could be differentiating into CD56dim NK cells as a result of 
migration. As aforementioned in chapter 3.2.5, apoptosis-induced decrease in the 
expression of CD56 cannot be excluded as a possible explanation. It is possible that this 
effect is only observed with the migrated sample because the act of migration activates 
the cells and therefore hastens cells death. 
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Figure 4.6 The accumulation of CD56bright NK cells post-migration is due to 
preferential recruitment and not the differentiation of CD56dim NK cells. Sample 
with CD56bright NK cells stained with CFSE. Lymphocytes were FACS sorted into 
CD56bright and CD56dim NK cells. The samples were divided into two and with one 
half being stained with CFSE and the other half being left unstained. Stained cells from 
one subset were mixed with unstained cells from the other subset. The different mixtures 
of NK cells were allowed to migrate for 12 hours through HUVEC monolayers that 
were previously stimulated with 300 U/ml of rhIFN-γ. Cells were also kept in culture in 
the absence of endothelium as a control. A sample of cells was taken post-migration 
from both the upper chamber (A) and the lower chamber (B) of the transwell insert. The 
Upper chamber 
post-migration 
Lower chamber 
post-migration 
Control 
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former are cells that have come into contact with endothelium but have not migrated. 
The latter are cells that have migrated. The control cells were also sampled (C) and all 
samples were stained with APC-conjugated anti-CD56 antibody for analysis by flow 
cytometry. The above dot plots show the sample in which CD56bright NK cells were 
stained with CFSE and mixed with unstained CD56dim NK cells. 
 
The NK cell tracking experiment was repeated for several donors (Figure 4.7, n=4). The 
percentage of NK cells that could possibly be considered to have differentiated from the 
CD56bright to CD56dim subset and from CD56dim to CD56bright NK cells is depicted 
in Figure 4.7 A and B respectively.  
 
 
 
Figure 4.7 The accumulation of CD56bright NK cells post-migration is due to 
preferential recruitment and not differentiation of CD56dim NK cells. Lymphocytes 
were FACS sorted into CD56bright and CD56dim NK cells. The samples were divided 
into two, one half being stained with CFSE and the other half being left unstained. 
Stained cells from one subset were mixed with unstained cells from the other subset. 
Cells were allowed to migrate for 12 hours through HUVEC monolayers that were 
previously stimulated with 300 U/ml of rhIFN-γ. Cells were also kept in culture in the 
absence of endothelium as a control. A sample of cells was taken post-migration from 
U
pp
er
 c
ha
m
be
r
Lo
w
er
 c
ha
m
be
r
C
on
tro
l0
1
2
3
4
5
6
%
 o
f N
K
 c
el
ls
 d
if
fe
re
nt
ia
tin
g
0.625
1.380
0.120
U
pp
er
 c
ha
m
be
r
Lo
w
er
 c
ha
m
be
r
C
on
tro
l0
1
2
3
4
5
6
%
 o
f N
K
 c
el
ls
 d
if
fe
re
nt
ia
tin
g 2.305
3.080
1.735
A.   CD56bright→CD56dim NK B.   CD56dim→CD56bright NK 
  Chapter 4 
 151
both the upper chamber and the lower chamber of the transwell insert. The former are 
cells that have come into contact with endothelium but have not migrated. The latter are 
cells that have migrated. Samples were analysed by flow cytometry, NK cell subsets 
were gated, and the percentage of cells differentiating was calculated as the percentage 
of cells with a change in the expression level of CFSE. The percentage of cells 
differentiating from CD56bright to CD56dim is depicted in A, and the percentage of 
cells differentiating from CD56dim to CD56bright NK cells is depicted in B. Horizontal 
lines represent the 5th, 25th, median, 75th and 95th percentiles from bottom to top with 
median values stated on the graph (n=4). 
 
We cannot conclude that contact with HUVECs and indeed migration may stimulate a 
very small number of NK cells to differentiate into their counter-subset. Slightly more 
CD56bright NK cells appear to ‘differentiate’ into CD56dim than CD56dim into 
CD56bright, although these differences were not statistically significant. Hence, 
‘differentiation’ of CD56dim NK cells cannot explain the observed accumulation of 
CD56bright NK cells post-migration. In fact, in order to compensate for some of the 
CD56bright differentiating into CD56dim, and to also maintain the observed 
accumulation of CD56bright cells post-migration, more CD56bright NK cells must have 
migrated than are recorded in the post-migration lower chamber samples. However, as 
previously mentioned, what appears to be differentiation of the CD56bright to the 
CD56dim subset could in fact reflect a decrease in CD56 expression resulting from 
apoptosis.  
 
4.2.4 The effect of migration through HUVEC monolayers on the CD56 MFI of NK 
cells 
 
NK cells are commonly identified by the lack of expression of CD3 and presence of cell 
surface CD56. CD56 is also called neural cell adhesion molecule or NCAM and normal 
cells that express this molecule include NK cells, subsets of T cells, neural cells, glia 
and skeletal muscle tissues. Although the function of this molecule on immune cells is 
largely unknown, a few studies have demonstrated a role in cell adhesion, with anti-
CD56 antibodies inhibiting NK cell-target cell binding (Nitta et al., 1989). One study 
has suggested a role for CD56 in the communication between NK cells and T cells. This 
group showed that via engagement of CD56 with fibroblast growth factor receptor-1 on 
Jurkat T cells, NK cells were able to co-stimulate TCR-induced IL-2 production by the 
T cells (Kos and Chin, 2002). Other evidence for the function of CD56 has been given 
in studies of the nervous system. Research has shown that CD56 may have a role in 
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neural growth and synaptic plasticity. Indeed, knockout mice lacking CD56 have 
normal NK and T cell functions but have deficient spatial learning (Cremer et al., 1994; 
Becker et al., 1996; Stoenica et al., 2006). In tissue pathology, the expression of CD56 
is used to ascertain tumour types as it is expressed by particular cancers such as small 
cell lung cancer, myelomas, brain tumours, acute myeloid leukaemia and 
neuroblastoma. Indeed, the use of anti-CD56 antibodies as a possible therapy for certain 
cancers has been studied (Jensen and Berthold, 2007). In vitro data from one study 
showed that NK cells can inhibit tumour cell growth when cultured with the cell line 
HuH2,8 and that this effect is directly attributed to the engagement of CD56 (Takasaki 
et al., 2000). In contrast, studies by the Lanier group suggest that CD56 does not play a 
major role in the cytolytic function of NK cells against tumour targets (Lanier et al., 
1991). 
 
Thus at present there is ongoing controversy about the functional importance of CD56 
expression by NK cells. Every experiment in the present study uses CD56 for the 
identification of NK cells. Hence, data on the subject of the effect of migration on 
expression levels of CD56 by NK cells are readily available. 
 
On the subject of the measurement of CD56 in a migration assay, the vast majority of 
classical NK cells express CD56; therefore the number of cells expressing this molecule 
is likely to remain the same in a migration assay. Furthermore, the gating strategy used 
in the present study selects NK cells that are positive for CD56; hence all NK cells in 
the present study are CD56+, therefore there is little point in measuring the percentage 
of cells that express CD56, as we would for other markers of interest. However, 
migration may alter the number of CD56 molecules on a particular cell, therefore as an 
alternative method for assessing migration-induced changes in CD56 expression, the 
MFI of CD56 was measured.  
 
Figure 4.8 depicts histograms of the FACS data obtained from a migration assay using 
lymphocytes from one representative donor. Briefly, lymphocytes were allowed to 
migrate through HUVEC monolayers or were kept in culture in the absence of HUVECs 
as a control. After 12 hours, cells were harvested from both the upper and lower 
chambers of the transwell insert and from the control sample. Cells from the upper 
chamber had come into contact with endothelium but had not migrated whereas cells 
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from the lower chamber had migrated. CD56 MFI on NK cells was assessed by flow 
cytometry. For this particular donor, before migration CD56bright and CD56dim NK 
cells had MFI values of 278.11 and 73.22 respectively. Post-migration, NK cells from 
the upper chamber had higher CD56 MFI than before migration; CD56bright cells were 
found to have a CD56 MFI of 350.56 and for the CD56dim subset this was found to be 
100.07. Migrated CD56bright cells that were harvested from the lower chamber had 
slightly higher CD56 MFI than those of the upper chamber with a value of 368.36, 
whereas for the CD56dim subset, migrated cells had a slightly lower CD56 MFI of 
94.05 compared to cells from the upper chamber. Control samples exhibited CD56 MFI 
values similar to those of cells before migration; 282.77 and 69.41 for CD56bright and 
CD56dim NK cells respectively. In this experiment, contact with HUVECs increased 
the CD56 MFI on both NK cell subsets. Migration increased this value further for the 
CD56bright subset; however, migration seemed to down-regulate this effect by a small 
amount on the CD56dim subset.  
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Figure 4.8 The effect of migration on the CD56 MFI of CD56bright and CD56dim 
NK cells. Histograms show FACS data from one representative experiment. 
Lymphocytes were allowed to migrate for 12 hours through HUVEC monolayers that 
had been previously stimulated with 300 U/ml of rhIFN-γ or lymphocytes were kept in 
culture in the absence of HUVECs as a control. A sample of cells was taken before 
migration, from the upper and lower chambers of the transwell insert post-migration, 
and also from the control sample. Cells from the upper chamber had come into contact 
with HUVECs but had not migrated. Cells from the lower chamber had migrated. 
Samples were stained with fluorochrome-conjugated antibodies against CD3, CD19, 
CD16 and CD56 and analysed by flow cytometry. Gates have been set on the 
CD56bright NK cell population in the first column and the CD56dim NK cell 
population in the second column. Red histograms represent cells cultured alone as a 
CD56bright NK CD56dim NK 
Before 
migration 
Upper 
chamber 
Lower 
chamber 
  Chapter 4 
 155
control. Blue histograms are CD56bright and green histograms are CD56dim NK cells. 
The red filled histograms represent the same subset of NK cells that have been kept in 
absence of endothelium as a control. Values represent percentage staining above non-
specific fluorescence from un-stained cells (black empty histograms).  
 
The experiment was repeated 3 times on one representative donor and the results are 
shown in Figure 4.9. As expected, CD56bright NK cells had higher CD56 MFI than the 
CD56dim subset. For this particular donor, the mean CD56MFI of both subsets of NK 
cells was found to be higher on cells before the migration assay than on cells after the 
assay or in the control sample. Before migration the CD56 MFI was found to be 295.1 
and 80.08 for CD56bright and CD56dim NK cells respectively. Following the 12 hours 
of culture, cells in the control well had lower MFIs of 187.1 and 45.68 for the 
CD56bright and CD56dim NK cells respectively. CD56bright and CD56dim NK cells 
that were harvested from the upper chamber of the transwell insert were found to have 
higher CD56 MFI values than cells within the control sample; 211.4 and 62.57 
respectively. Migrated cells were found to have even higher CD56 MFI; 239.9 and 
76.68 respectively. However, a statistical analysis showed these differences to not be 
statistically significant.  
 
 
Figure 4.9 The effect of migration through HUVEC monolayers on the CD56 MFI 
of NK cells. Multiple experiments carried out using lymphocytes from one 
representative donor. Lymphocytes were allowed to migrate for 12 hours through 
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HUVEC monolayers that had been previously stimulated with 300 U/ml rhIFN-γ or 
lymphocytes were kept in culture in the absence of endothelium as a control. A sample 
of cells was taken before the assay, denoted on the graph as pre-mig, and after the 
migration assay from both the upper and lower chamber of the transwell insert, denoted 
as post-mig upper and post-mig lower respectively. Control cells were also sampled. 
Samples were then stained with fluorochrome-conjugated antibodies for analysis by 
flow cytometry and CD56bright (red) and CD56dim (blue) NK cells were gated on for 
the assessment of CD56 MFI. From bottom to top, horizontal lines represent minimum, 
median and maximum values (n=3). 
 
To enable a stronger conclusion to be drawn on the subject, the effect of migration on 
the CD56 MFI of NK cells was assessed using lymphocytes from a further 19 donors 
and results from these experiments are depicted in Figure 4.10. Before the migration 
assay, the CD56bright subset had a CD56 MFI value of 265.2 which increased to 337.7 
on cells that were harvested from the upper chamber of the transwell insert. These cells 
had come into contact with HUVEC monolayers but had not migrated through the 
monolayers; therefore contact alone appears to facilitate an increase in CD56 MFI. 
Migrated CD56bright NK cells were found to have a CD56 MFI of 308.1, which is 
slightly less than the cells from the upper chamber but slightly more than control cells 
which had a value of 300.6. This suggests that for the CD56bright subset, contact with 
HUVECs increases CD56 MFI and migration down regulates this effect but maintains 
CD56 MFI just above that of the control. CD56dim NK cells exhibited a similar trend to 
the CD56bright subset; before migration the CD56 MFI of CD56dim NK cells was 
found to be 84.75, however, cells from the upper chamber were found to have a higher 
value at 95.39. Migrated CD56dim NK cells were found to have a CD56 MFI of 84.59 
which is almost exactly the same as cells before migration, however this value is above 
that of control cells which had a CD56 MFI of 75.97. Statistical analysis reveals that 
contact with HUVEC monolayers significantly increases CD56 MFI of the CD56dim 
subset of NK cells with a p value of 0.0209 (n=19). 
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Figure 4.10 Multiple experiments testing the effect of migration through HUVEC 
monolayers on the CD56 MFI of NK cell subsets. Lymphocytes were allowed to 
migrate for 12 hours through HUVEC monolayers that had previously been stimulated 
with 300 U/ml of rhIFN-γ or lymphocytes were kept in culture in the absence of 
endothelium as a control. A sample of cells was taken before the assay, denoted on the 
graph as pre-mig, and after the assay from both the upper and lower chambers of the 
transwell insert, denoted as post-mig upper and post-mig lower respectively. Control 
cells were also sampled. Cells were then stained with fluorochrome-conjugated 
antibodies for analysis by flow cytometry and CD56bright (orange) and CD56dim 
(blue) NK cells were gated on for the assessment of CD56 MFI. From bottom to top, 
horizontal lines represent 5th, 25th, median, 75th and 95th percentiles. Statistical analysis 
was performed using a Wilcoxon signed rank test with a P value of less than 0.05 
represented by *. The P value is stated on the graph (n=19). 
 
4.2.5 Migration and NK cell activation. 
  
The early activation marker CD69 was used in chapter 3 to quantify the effect of 
migration through EA.hy 926 endothelial cell line monolayers on the activation of NK 
cells. Findings from chapter 3 revealed that migration activates NK cells, in particular 
the CD56dim subset. The aim of the present chapter was to verify findings from chapter 
3 and bring the migration assay closer to that of the in vivo environment by replacing 
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the endothelial cell line with primary human endothelial cells; HUVECs. Research from 
other groups has shown that migration increases the activation of other immune cells 
and similar to the present study, these groups measured the effect of migration on cell 
activation by quantifying CD69 expression levels (Sancho et al., 1999; Yamamoto et 
al., 2000). However, no research has been done to measure the effect of migration on 
NK cell activation. Hence, experiments in the present chapter were aimed at quantifying 
the effect of migration through HUVEC monolayers on the activation of NK cells by 
measuring expression levels of CD69. 
 
An example of the flow cytometric data obtained from an experiment performed using 
lymphocytes from one donor is depicted in Figure 4.11. In this example 2.20% of 
CD56bright and 2.17% of CD56dim NK cells were found to express CD69 before the 
migration assay. This increased to 30.97% and 12.25% on CD56bright and CD56dim 
cells respectively that had come into contact with HUVECs. Expression levels increased 
further to 40.01% of migrated CD56bright cells expressing CD69. However the further 
increase that seen with the migrated CD56bright was not seen with the CD56dim 
subset; only 5.86% of migrated CD56dim cells were found to express CD69 and this is 
less than cells that had come into contact with endothelium but had not migrated (from 
the upper chamber of the transwell insert). Only 1.81% of CD56bright and 3.95% of 
CD56dim cells in the control sample were found to express CD69. Overall, results from 
this experiment suggest that contact with HUVECs increases the expression of CD69 on 
both subsets of NK cells; however, migration increases expression levels further for the 
CD56bright subset but appears to down regulate the expression of CD69 on the 
CD56dim subset.  
  Chapter 4 
 159
  
 
Figure 4.11 The effect of migration on the expression of the early activation 
antigen CD69 on CD56bright and CD56dim NK cells. Lymphocytes were allowed to 
migrate for 12 hours through HUVEC monolayers that were previously stimulated with 
300 U/ml of rhIFN-γ or lymphocytes were kept in culture in the absence of HUVECs as 
a control. A sample of cells was taken before migration, post-migration from both the 
upper and lower chambers of the transwell insert, and from the control sample. Cells 
from the upper chamber had come into contact with HUVECs but had not migrated. 
Cells from the lower chamber had migrated. Samples were stained with fluorochrome-
CD56bright NK CD56dim NK 
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conjugated antibodies against CD3, CD16, CD56 and CD69 and were analysed by flow 
cytometry. Gates have been set on the CD56bright population in the first column and on 
the CD56dim population in the second column. The percentage of cells expressing 
CD69 is given in the top right corner of the dot plot. 2,500 and 5,000 events are shown 
in dot plots of CD56bright and CD56dim NK cells respectively. 
 
These preliminary results are from only one experiment using lymphocytes from one 
donor. The experiment was repeated three times using lymphocytes from a single donor. 
Data from these experiments are shown in Figure 4.12 and results from these 
experiments showed a slightly different trend compared to the single experiment 
described above, with migration tending to further increase CD69 expression on the 
CD56dim NK cells. As can be seen in Figure 4.12, for both subsets of NK cells, contact 
with HUVECs was found to increase the percentage of CD56bright and CD56dim NK 
cells expressing CD69 from 2.52% and 6.87% before migration to 40.91% and 14.10% 
respectively. Migration through the HUVEC monolayers was found to increase this 
effect further to 53.14% and 20.17% of CD56bright and CD56dim NK cells expressing 
CD69 respectively. Low expression levels of CD69 on cells in the control samples; 
4.06% and 4.09% of CD56bright and CD56dim NK cells expressing CD69 respectively, 
suggests that this effect is not mediated by cell culture but is facilitated by the 
interaction of NK cells with HUVECs. 
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Figure 4.12 Migration and its effect on the expression of CD69 by NK cells. 
Multiple experiments performed using lymphocytes from one donor. Lymphocytes 
from one donor were allowed to migrate for 12 hours through HUVEC monolayers that 
where previously stimulated with 300 U/ml of rhIFN-γ or lymphocytes were cultured in 
the absence of HUVECs as a control. A sample of cells was taken before the migration 
assay, denoted by pre-mig on the graph, after the migration assay from both the upper 
and lower chambers of the transwell insert, denoted by post-mig upper and post-mig 
lower respectively, and from the control sample. Samples were stained with 
fluorochrome-conjugated antibodies and were analysed by flow cytometry. CD56bright 
(orange) and CD56dim (blue) NK cell subsets were gated on using the gating strategy 
described in 2.7.3. Horizontal lines represent the minimum, median and maximum 
values (n=3). 
 
The results described above are from experiments using lymphocytes from only one 
donor, therefore for a clearer and more reliable result, the experiment was repeated for 
several (n=12) donors. As can be seen in Figure 4.13, the trend is maintained; contact 
with HUVECs significantly increases the expression of CD69 with 8.38% and 3.94% of 
CD56bright and CD56dim NK cells from the upper chamber of the transwell insert 
expressing CD69 respectively, when compared to the control sample in which 1.81% 
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and 2.74% of CD56bright and CD56dim NK cells were found to express CD69 
respectively. Migration appears to enhance this effect, with a higher percentage of 
migrated cells expressing CD69; 10.58% of CD56bright and 6.75% of CD56dim NK 
cells, than cells that have come into contact with HUVECs but have not migrated and 
also the control sample. Statistical analysis revealed that both contact with HUVECs 
alone and also migration significantly increases the percentage of CD69+ cells of both 
NK cell subsets when compared to control samples. These results could be further 
verified using RT-PCR techniques to quantitiatively measure mRNA levels in these 
different groups of cells. 
 
 
 
Figure 4.13 The effect of migration through HUVEC monolayers on the expression 
of CD69 by NK cell subsets. Lymphocytes were allowed to migrate for 12 hours 
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through HUVEC monolayers that where previously stimulated with 300 U/ml of rhIFN-
γ or lymphocytes were cultured in the absence of HUVECs as a control. A sample of 
cells was taken before the migration assay, denoted by pre-mig on the graph, after the 
migration assay from both the upper and lower chambers of the transwell insert, 
denoted by post-mig upper and post-mig lower respectively, and from the control 
sample. Cells were then stained with fluorochrome-conjugated antibodies and analysed 
by flow cytometry. CD56bright (orange) and CD56dim (blue) NK cell subsets were 
gated on using the gating strategy described in 2.7.3. From bottom to top, horizontal 
lines represent the 5th, 25th, median, 75th and 95th percentiles. Statistical analysis was 
performed using a Wilcoxon signed rank test, P<0.05=*, P<0.01=** and 
P<0.001=***, the P values are stated on the graph (n=12). 
 
From these results, it can be concluded that contact with HUVECs and to a greater 
extent, migration through HUVEC monolayers, significantly increases the activation of 
both CD56bright and CD56dim NK cells, as quantified by the expression of the early 
activation antigen CD69.  
 
4.2.6 The effect of migration on the expression of adhesion molecules by NK cells 
  
Adhesion molecules have a multitude of functions including the migration of cells to 
sites of inflammation, cell-cell interactions, and homing of immune cells to secondary 
lymphoid organs. The interaction of the endothelium with the immune cells as they pass 
through, en route to the site of inflammation, may alter the expression of adhesion 
molecules. This has implications for the function of the cell once it has arrived at the 
site of inflammation. Other groups have investigated the effect of migration through 
endothelium on adhesion molecule expression; using a HUVEC model of migration 
similar to the one used in the present study, Brezinschek et al. found that T cells acquire 
endothelial cell components during migration, including the adhesion molecules CD31, 
CD49d, CD54 and CD62E (Brezinschek et al., 1999).  Berg and colleagues found that 
along with the up regulation of co-stimulatory receptors, migration also induced the up 
regulation of the adhesion molecules CD11a and CD49d on T cells, and these 
phenotypic changes conferred improved capacity for tissue infiltration by these cells 
(Berg et al., 2002). Furthermore, Grisar et al. noted that the migration of monocytes 
through endothelium increased the expression of the adhesion molecules CD54 and 
CD11a and that the effect was enhanced if the endothelium was activated by pre-
treatment with cytokines (Grisar et al., 2001). The effect of migration on the expression 
of adhesion molecules by NK cells has thus far not been studied. Therefore, 
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experiments in the present chapter aim to quantify the effect of migration through 
HUVEC monolayers on a comprehensive panel of adhesion molecules. Each adhesion 
molecule that was investigated is described in brief and the findings from experiments 
follow this description. The sub-figures in the present chapter have one figure legend to 
prevent repetition, and this is given after the first sub-figure; Figure 4.14 A. Adhesion 
molecules are expressed by the majority of NK cells, therefore MFI of the molecule, 
rather than the percentage of cells expression the molecule, may be a more useful 
interpretation of the effect of migration. Therefore, graphs of the MFI of adhesion 
molecules are depicted and the percentage of cells expressing the molecule is stated in 
the text in brackets adjacent to the data for MFI.  
 
The integrins are involved in the arrest of leukocytes on the endothelium during the 
process of migration. Integrins are arranged in dimers, with one α and one β subunit. 
CD11a is the α subunit and CD18 is the β subunit for αLβ2 (LFA-1), which can interact 
with ICAM-1 and ICAM-2. Migration through both unstimulated and cytokine-
stimulated HUVECs has been shown to increase the expression of CD11a on monocytes 
(Grisar et al., 2001). This group showed that the increase in CD11a expression on 
monocytes post-migration resulted from the interaction with the endothelium and was 
not due to the preferential recruitment of CD11ahigh monocytes. Interestingly, the 
interaction between LFA-1 and ICAM-1 has been shown to be a co-stimulatory 
pathway that is involved in interactions between antigen presenting cells and T cells 
(Zuckerman et al., 1998). Hence, the effect of migration on NK cell expression of 
CD11a could have important consequences regarding further interactions with immune 
cells and also further migration. 
 
Illustrated in Figure 4.14 A, before the migration assay CD56bright and CD56dim NK 
cells were found to have a MFI for CD11a of 98.46 (100%) and 135.3 (98.98%) 
respectively. No marked changes were observed and statistical tests found any 
differences in the expression of CD11a to not be significant. The CD11a MFI was found 
to be 108.6 (98.35%) and 150.5 (99.97%) for CD56bright and CD56dim NK cells 
respectively, after contact with HUVECs (cells from the upper chamber of the transwell 
insert post-migration). On cells that had migrated through the monolayer, CD11a MFI 
was found to be 129.0 (99.97%) and 161.2 (99.67%) respectively, and values recorded 
for control samples were 90.07 (97.59%) and 139.7 (99.97%) respectively.  
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Figure 4.14 Migration-induced adhesion molecule expression by CD56bright and 
CD56dim NK cells. Lymphocytes were allowed to migrate for 12 hours through 
HUVEC monolayers that were previously stimulated with 300 U/ml rhIFN-γ or 
lymphocytes were kept in culture in the absence of HUVECs as a control. A sample of 
cells was taken before migration, denoted by pre-mig on the graph, post-migration from 
both the upper and lower chambers of the transwell insert, denoted by upper and lower 
on the graph, and from the control cells. Cells were then stained with flourochrome-
conjugated antibodies against CD56, CD16, CD3 and against the adhesion molecule of 
interest which in A was CD11a (n=7), CD11b in B (n=4), CD18 in C (n=7), CD29 in D 
(n=4), CD31 in E (n=7), CD44 in F (n=7), CD49d in G (n=7), CD54 in H (n=4) and 
CD62L in I (n=7). Samples were analysed by flow cytometry and CD56bright (yellow) 
and CD56dim (blue) NK cells were gated on using the gating strategy described in 
2.7.3. From bottom to top, horizontal lines represent the 5th, 25th, median, 75th and 95th 
percentiles. For graphs B, D and H n=4 and for all other graphs n=7. For each donor, 
the assay was performed in triplicate and the mean average was plotted on the graph. 
 
As previously mentioned, the integrins consist of one α and one β subunit. The integrin 
αMβ2 , more commonly known as Mac-1, is composed of CD11b, which provides the α 
subunit and CD18, providing the β subunit (Larson and Springer, 1990). Mac-1 is 
expressed by many leukocytes that are involved in innate immunity including NK cells, 
granulocytes and cells of the monocytes/macrophage lineage. This adhesion molecule is 
involved in many functions of innate immune cells including cell migration, 
phagocytosis and cytotoxicity (Solovjov et al., 2005). Mac-1 also mediates the uptake of 
Figure 4.14 A. CD11a 
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complement-coated particles. As with LFA-1, Mac-1 also interacts with ICAM-1 and 
ICAM-2 (Hogg et al., 2002). 
  
Before migration, the MFI of CD11b on the CD56bright subset was 43.88 (99.45%), 
with a value of 41.10 (98.11%) on cells that were cultured with HUVECs but had not 
migrated, and 43.28 (98.99%) on cells that had migrated through the HUVEC 
monolayers. Furthermore, controls samples recorded CD11b MFI of 36.32 (97.31%) on 
CD56 bright NK cells and a statistical analysis showed these differenced to not be 
significant, suggesting that migration does not affect the expression of this adhesion 
molecule on CD56bright NK cells. Regarding the CD56dim subset, before migration 
the CD11b MFI was found to be 62.42 (95.12%), 51.52 (98.77%) after contact with 
HUVECs, and was recorded at 43.25 (97.60%) on cells that had migrated through the 
HUVEC monolayer. Furthermore, control samples recorded a CD11b MFI of 47.30 
(97.03%) on this subset, hence migration does not appear to increase or maintain the 
MFI of CD11b on the CD56dim subset of NK cells. 
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As previously discussed, CD18 is the β subunit in both LFA-1 and Mac-1 and when 
paired with CD11c, forms the integrin αXβ2. As expected, CD18 is involved in cell 
Figure 4.14 B. CD11b 
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adhesion and therefore facilitates cell migration through endothelium and plays an 
important role in inflammation (Wilson et al., 1999). 
 
Before migration the CD56bright subset was found to have a CD18 MFI value of 207.7 
(98.17%). Post-migration, cells that had only come in contact with HUVECs and had 
not migrated had a value of 259.7 (99.86%). However, migrated CD56bright cells were 
found to have a much higher CD18 MFI of 420.3 (99.98%). Although migration 
appears to more than double CD18 MFI of the CD56bright subset of NK cells, this 
difference was not found to be statistically significan when compared to control 
samples, the latter cells were found to have a CD18 MFI of 207.0 (99.72%). Similarly, 
the MFI of CD18 on CD56dim NK cells before migration was found to be 292.7 
(94.99%), 354.5 (99.96%) on cells that had come into contact with HUVECs but had 
not migrated through the monolayers, 383.5 (99.85%) on migrated cells and 331.7 
(99.46%) on cells in the control sample. Again, these differences were not found to be 
statistically significant. These data are depicted in Figure 4.14 C. 
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Another integrin subunit is CD29 which is also known as β1. CD29 can form six dimer 
combinations with α subunits and, like the other integrin subunits, it provides different 
Figure 4.14 C. CD18 
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receptors depending on the combination. For example, when β1 forms a dimer with α3, 
it becomes the receptor for laminin and epiligrin. However, when coupled with α5 it 
provides the receptor for fibronectin. As with the other integrins, CD29 enhances 
lymphocyte binding to endothelium, thereby facilitates lymphocyte migration (Green et 
al., 1998; Brakebusch and Fassler, 2005).  
 
Experiments quantifying the affect of migration on the CD29 MFI of NK cells showed 
that before migration, CD56bright NK cells had a MFI of 119.9 for CD29 (62.73%). 
Cells from the upper chamber post-migration, which had come into contact with 
HUVECs but not migrated through the monolayer, had a CD29 MFI of 124.2 (60.02%) 
and cells that had migrated had a CD29 MFI of 140.7 (61.40%) which is slightly higher, 
but not statistically different to cells from the control sample which were found to have 
a CD29 MFI of 128.0 (61.19%). Regarding the CD56dim subset, MFI values for CD29 
were recorded at 146.6 (58.44%) before migration, 148.3 (55.71%) after contact with 
HUVECs and 165.3 (52.10%) for cells which had migrated. Furthermore, there was 
little difference between the migrated cells and the control cells, which recorded a CD29 
MFI of 164.4 (54.99%). Hence, neither contact with or migration through HUVEC 
monolayers alters the CD29 MFI of CD56dim NK cells. 
 
 
 
Figure 1.14 D. CD29  
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Platelet endothelial cell adhesion molecule (PECAM-1) is also known as CD31, and 
plays an important role in the diapedesis step of migration. It is found concentrated at 
endothelial cell borders and blocking of this molecule allows leukocytes to arrest on 
endothelial cells but prevents them from extending a pseudopod between the endothelial 
cells. Blocking of PECAM-1 reveals the importance of this molecule in cell migration 
as anti-PECAM-1 antibodies inhibits up to 90% of cell migration (Muller, 2003). T cells 
have been shown to acquire CD31 from endothelial cells by membrane transfer during 
the process of migration (Brezinschek et al., 1999). It is therefore plausible that NK 
cells could also obtain CD31 though migration. CD31 binds in a homophillic manner; 
therefore any change in expression levels that may be caused by migration could alter 
the efficiency of further migration of the NK cell. 
 
As can be seen in Figure 4.14 E, before migration the MFI of CD31 on CD56bright and 
CD56dim NK cells was found to be 45.57 (93.86%) and 29.67 (85.54%) respectively. 
NK cells harvested from the upper chamber of the transwell insert after the migration 
assay were found to have a CD31 MFI of 34.25 (72.73%) and 16.41 (37.57%) 
respectively. These cells had come into contact with HUVECs but had not migrated. 
Cell that had migrated through the HUVEC monolayers were found to have CD31 MFI 
values of 64.79 (82.41%) and 20.15 (62.73%) recorded for CD56bright and CD56dim 
NK cells respectively. These expression values were not found to differ statistically 
  Chapter 4 
 170
from the values recorded for the control samples which were 41.00 (54.34%) and 21.71 
(28.46%) for CD56bright and CD56dim NK cells respectively. 
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The adhesion molecule CD44 is implicated not only in lymphocyte migration, but in 
many other processes such as cell-cell interactions, haematopoiesis and lymphocyte 
activation (Haynes et al., 1989; Shimizu et al., 1989). CD44 is the receptor for 
hyaluronic acid but can also interact with collagens and matrix metalloproteinases. NK 
cells express CD44 in its inactive form and require the presence of cytokines such as IL-
2 and IL-15 for its activation. Engagement of CD44 on NK cells is also thought to 
enhance IFN-γ production (Sague et al., 2004) and cytotoxicity (Galandrini et al., 1994). 
Hence, any migration-induced changes in CD44 expression on NK cells may have 
consequences for the interaction of NK cells with other cells at the site of inflammation, 
including cells of the adaptive system via the production of cytokines, potential 
pathogens, and also components of inflamed joints 
 
 
Figure 4.14 E. CD31 
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Before the migration assay the CD44 MFI of CD56bright cells was 369.3 (99.88%) and 
CD56dim cells was 77.68 (94.12%). For both of the NK cell subsets, contact with 
HUVECs increased the CD44 MFI to 553.9 (96.00%) and 107.8 (94.30%) respectively. 
This effect was enhanced on NK cells that successfully migrated with a CD44 MFI of 
572.6 (50.47%) for CD56bright and 172.0 (44.66%) for CD56dim NK cells (Figure 
4.14 F) compared to the control sample; 399.0 (73.26%) and 106.2 (60.61%) for 
CD56bright and CD56dim NK cells respectively. However, these trends did not reach 
significance in statistical tests. 
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Figure 4.14 F. CD44 
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Integrins mediate the firm adhesion of immune cells to vascular endothelium. NK cells 
express 1, 2 and 7 integrins and peripheral blood NK cells abundantly express α4β1 
which is the receptor for VCAM-1 and MadCAM-1. The α4 subunit of this receptor is 
also known as CD49d. The interaction of α4β1 with VCAM-1 has been shown to be 
important for the migration of NK cells across inflamed endothelium (Gismondi et al., 
1991) and MadCAM-1 binding has been shown to facilitate migration across mucosal 
high endothelial venules (Perez-Villar et al., 1996). Any migration-induced changes in 
the expression of CD49d on NK cells could therefore impact on further cell migration 
either into inflamed tissues or to mucosa.  
 
The effect of migration on the expression of CD49d is depicted in Figure 4.14 G. 
Neither contact with HUVEC monolayers or migration through them alters the MFI of 
CD49d on CD56dim NK cells. Before migration this subset had a CD49d MFI of 68.23 
(99.42%), CD56dim cells harvested from the upper chamber that had contact with 
HUVECs but had not migrated were found to have a CD49d MFI of 70.69 (98.57%), 
with migrated and control cells found to have values of 71.44 (99.94%) and 70.80 
(97.19%) respectively. However, migration did appear to alter the CD49d of the 
CD56bright subset; before migration the CD49d MFI of these cells was 94.45 (99.76%) 
and after contact with HUVECs a similar level was recorded at 102.1 (99.35%) and 
migrated cells showed an increase to 127.9 (99.82%) which is above levels recorded for 
the control sample; 70.80 (97.70%). However, a statistical analysis revealed no 
significant differences. 
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As previously mentioned, the integrins mediate firm adhesion of leucocytes to the 
endothelium. One of the ligands for integrins is ICAM-1, also known as CD54, and is 
thought to be one of the most important receptors for firm adhesion (Hogg et al., 2002). 
ICAM-1 is constitutively expressed on lymphocytes, but can be up regulated by 
cytokines and other inflammatory cells (Springer, 1994). More recently, ICAM-1 has 
been implicated in pro inflammatory signal transduction pathways, resulting in the 
recruitment of cells such as macrophages and granulocytes (Etienne-Manneville et al., 
1999). If it were found that migration does change the expression of CD54 on NK cells, 
this could have consequences for the site of inflammation in terms of further 
recruitment of immune cells.  
 
As can be seen in Figure 4.14 H, neither contact with the HUVECs or migration through 
the HUVEC monolayers appeared to have an effect on the CD54 MFI of either subset of 
NK cell and this was confirmed by a statistical analysis of the results. Before migration, 
for the CD56bright subset the CD54 MFI was 59.41 (80.87%). A slight increase to 
66.62 (81.09%) was observed on CD56bright cells that had come in contact with 
HUVECs, and this value was very similar to that found on migrated cells; 64.80 
Figure 4.14 G. CD49d 
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(80.66%) and control cells; 62.57 (83.23%). Regarding the CD56dim subset, before 
migration the CD54 MFI was found to be 31.39 (78.55%), which is remarkably similar 
to cells that had come into contact with HUVECs; 31.36 (74.91%) and control cells; 
31.25 (75.86%). However, for this subset, migrated cells had slightly higher CD54 MFI; 
36.55 (74.01%), than cells from the other conditions. However, this difference failed to 
reach statistical significance when analysed. 
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L-selectin is also known as CD62L and is involved in adhesion of leucocytes to the high 
endothelial venules of peripheral lymph nodes. CD62L is constitutively expressed by 
most circulating lymphocytes. However, the CD56bright subset of NK cells expresses 
CD62L at levels higher than that of all other immune cells giving these cells a selective 
advantage for migration to the lymph nodes (Frey et al., 1998; Patel et al., 2002). 
Therefore, any migration-induced change in the expression of L-selectin has 
implications for the further migration of NK cells to secondary lymphoid organs. 
 
 As expected and in keeping with current knowledge, results from the present study 
showed that irrespective of the conditions, the CD56bright subset express higher levels 
of CD62L than the CD56dim subset of NK cells (Figure 4.14 I). Regarding the effect of 
Figure 4.14 H. CD54 
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migration on the CD62L MFI; before migration 604.2 (98.09%) and 84.37 (33.59%) 
were recorded for CD56bright and CD56dim NK cells respectively. After contact with 
HUVECs CD62L Mfi values were recorded at 487.1 (95.86%) and 59.37 (32.59%) 
respectively. For the CD56bright subset, the MFI of CD62L decreased further to 448.8 
(96.74%) on cells that had migrated through the HUVEC monolayers. However, for the 
CD56dim subset migration increased the CD62L MFI to 95.69 (45.36%). Control cells 
were found to have a CD62L MFI of 422.3 (95.11%) and 79.35 (35.50%) for 
CD56bright and CD56dim NK cells respectively (Figure 4.14 I). A statistical analysis 
revealed that neither the migration-induced decrease seen on the CD56bright NK cells 
nor the increase seen on the CD56dim NK cells were significantly different to the 
control sample values. 
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4.2.7 Migration and NK cell function 
 
NK cells respond to stimuli by killing target cells or by producing cytokines, in 
particular IFN-γ. The two subsets of NK cells have different functional capacities; the 
CD56bright subset is better adapted for the production of cytokines whereas the 
CD56dim subset is better adapted to target cell killing (Cooper et al., 2001a; Poli et al., 
Figure 4.14 I. CD62L 
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2009). Chapter 3 examined the effect of migration through EA.hy 926 endothelial cell 
line monolayers on the capacity of NK cell functional capacity. This chapter aims to 
reproduce those experiments but to bring the migration assay closer to the in vivo 
environment by replacing the endothelial cell line with the primary human endothelial 
cells. This has the advantage of excluding the possibility that observations from 
experiments, in particular the function of NK cell killing of target cells, are due to 
contact with tumour cells rather than the act of migration. Hence, results from the 
present chapter aim to provide further evidence for findings in chapter 3.  
 
To investigate the effect of migration through HUVECs on the expression of IFN-γ by 
NK cells a migration assay was performed followed by a cytokine stimulation assay. 
Briefly, Percoll pellet cells were allowed to migrate for 12 hours through HUVEC 
monolayers or were kept in culture in the absence of HUVECs as a control. A sample of 
cells was taken before migration, after migration from the migrated cells in the lower 
chamber of the transwell insert and also from the control cells. Samples were then 
cultured in the presence or absence of the cytokines IL-12, IL-15 and IL-18 all of which 
are known to stimulate the production of IFN-γ from NK cells. The expression of IFN-γ 
was measured by intracellular cytokine staining and analysed by flow cytometry. 
 
A representative experiment is depicted in Figure 4.15. As expected, the CD56bright 
subset of NK cells was found to produce more IFN-γ in response to cytokine 
stimulation than the CD56dim subset. Without cytokine stimulation, the NK cells 
produced very little IFN-γ; 0.00% 0.50% and 0.37% of CD56bright cells were found to 
express IFN-γ that were sampled before migration, after migration and from the control 
respectively. However, after cytokine stimulation this increased with 18.40%, 32.68% 
and 13.83% of CD56bright cells expressing IFN-γ respectively (Figure 4.15 A). 
Therefore, in this particular experiment, migrated CD56bright cells were found to 
express more IFN-γ than cells before migration and also more than the control cells. 
This suggests that migration could be increasing the capacity of CD56bright NK cells to 
express IFN-γ. Similar to the CD56bright subset, the CD56dim NK cells were found to 
express very little IFN-γ without cytokine stimulation with 0.11%, 0.17% and 0.15% of 
cells before migration, after migration and from the control expressing IFN-γ 
respectively. However, IFN-γ expression was higher on cells that had been cultured in 
the presence of cytokines; 1.34%, 4.55% and 2.25% respectively (Figure 4.15 B). 
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Again, migration appeared to increase the capacity of the CD56dim subset to express 
the cytokine IFN-γ.  
 
- cytokines + cytokines 
Before 
migration 
Migrated 
Control 
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Figure 4.15 The effect of migration on the capacity of NK cells to express IFN-γ. 
Dot plots above depict one representative experiment. Lymphocytes were allowed to 
migrate for 12 hours through HUVEC monolayers that had been previously stimulated 
with 300 U/ml of rhIFN-γ or lymphocytes were kept in culture in the absence of 
HUVECs as a control. Cells were sampled before migration, after migration from the 
lower chamber of the transwell insert and from the control sample. Cells from the lower 
chamber had successfully migrated. Samples were then cultured in the presence (right 
column) or absence (left column) of 10 ng/ml IL-12, IL-15 and IL-18 for a total of 10 
hours. After 1 hour, 10 μg/ml of Brefeldin A was added. Cells were then stained with 
fluorochrome-conjugated antibodies against CD3, CD16, CD56 and IFN-γ for analysis 
by flow cytometry. CD56bright NK cells are gated in A and CD56dim NK cells are 
gated in B. The percentage of IFN-γ+ cells is given on each dot plot. 10,000 events are 
shown on each plot. 
 
The experiment described above was repeated using lymphocytes from several donors 
(n=8). The raw data which has not been adjusted for the negative controls is displayed 
- cytokines + cytokines 
Before 
migration 
Migrated 
Control 
B 
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in Figure 4.16 to show that consistently, cells cultured in the absence of stimulating 
cytokines as a control expressed very low levels of IFN-γ and that cells cultured in the 
presence of stimulating cytokines consistently produced IFN-γ. In the absence of 
cytokines, a median average of 0.085%, 0.57% and 0.11% of CD56bright cells sampled 
before migration, after migration and from the control were found to express IFN-γ 
respectively. Expression levels were found to be higher if the CD56bright cells were 
cultured in the presence of stimulating cytokines; 20.15%, 24.59% and 13.19% 
respectively (Figure 4.16 A). In agreement with results from the example experiment 
described above, migration increases the capacity of this subset to produce IFN-γ. In 
fact, fewer cells in the control sample were found to express IFN-γ than before 
migration, suggesting that culturing CD56bright NK cells decreases the capacity to 
produce IFN-γ and that migration overcomes this and raises the capacity to levels above 
that of non migrated cells that are freshly sampled from peripheral blood. Regarding the 
CD56dim subset, in the absence of cytokines, a median average of 0.15%, 0.14% and 
0.21% of cells that were sampled before migration, after migration and from the control, 
were found to express IFN-γ respectively. However, more cells that were cultured in the 
presence of stimulating cytokines; 2.06%, 3.98% and 1.29% were found to express IFN-
γ respectively. Similar to the CD56bright subset, it appears that culturing CD56dim NK 
cells decreases their capacity to express IFN-γ and that migration overcomes this effect 
and in fact further increases the capacity to above that of cells before migration, the 
latter being cells that are freshly stained from peripheral blood. The adjusted data from 
these experiments is depicted in Figure 4.17. 
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Figure 4.16 The effect of migration on NK cell IFN-γ expression. Detection of IFN-
γ production using a cytokine stimulation assay. Lymphocytes were allowed to 
migrate for 12 hours through HUVEC monolayers that were previously stimulated with 
300 U/ml of rhIFN-γ or were kept in culture in the absence of HUVECs as a control. A 
sample of cells was taken before migration, after migration from the lower chamber of 
the transwell insert and from the control sample, denoted on the graph as pre-
migration, migrated and control respectively. Samples were then cultured for 10 hours 
in the presence or absence of 10 ng/ml of IL-12, IL-15 and IL-18, denoted on the graphs 
by +cyt and –cyt respectively. After 1 hour, 10 μg/ml of Brefeldin A was added to the 
cell cultures. After co-culture with the cytokines, cells were surface stained with 
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fluorochrome-conjugated antibodies against CD3, CD56 and CD16 followed by 
intracellular staining for the detection of IFN-γ by flow cytometry. NK cell subsets were 
gated with results for CD56bright NK cells depicted in A (orange) and CD56dim NK 
cells depicted in B (blue). From bottom to top, horizontal lines represent the 5th, 25th, 
median, 75th and 95th percentiles (n=8). For each donor, the assay was performed in 
triplicate and the mean average is recorded on the graph. 
 
Data were further adjusted for background levels of cytokine expression by subtracting 
these levels from those obtained following cytokine stimulation. These results are 
shown in Figure 4.17 (n=8). The figure demonstrates that migration overcomes the 
decrease in the capacity of NK cells to express IFN-γ that is caused by cell culture and 
increases the capacity to a level that is higher than that of cells sampled before the 
migration assay. Before migration 19.78% of CD56bright cells were found to express 
IFN-γ in response to cytokine stimulation; this increased to 24.34% for cells that had 
migrated through HUVEC monolayers but decreased to 12.29% for cells that were 
cultured in the absence of HUVECs. A median average of 1.89% of CD56dim NK cells 
expressed IFN-γ in response to cytokine stimulation before migration, rising to 3.92% 
of cells that had successfully migrated and decreasing to 1.08% of cells that were 
cultured in the absence of HUVECs (Figure 4.17). A statistical analysis gave a p value 
of 0.0781 for both subsets of NK cells. 
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Figure 4.17 The effect of migration on the expression IFN-γ by CD56bright and 
CD56dim NK cells. Lymphocytes were allowed to migrate for 12 hours through 
HUVEC monolayers that were previously stimulated with 300 U/ml of rhIFN-γ or were 
kept in culture in the absence of HUVECs as a control. A sample of cells was taken 
before migration, after migration from the lower chamber of the transwell insert and 
from the control sample denoted on the graph as pre-migration, migrated and control 
respectively. Samples were cultured for 10 hours in the presence or absence of 10 ng/ml 
of IL-12, IL-15 and IL-18 with the addition of 10 μg/ml of Brefeldin A after 1 hour. 
Cells were then surface stained with fluorochrome-conjugated antibodies against CD3, 
CD56 and CD16 followed by intracellular staining for the detection of IFN-γ by flow 
cytometry. CD56bright (orange) and CD56dim (blue) NK cells were gated using the 
strategy described in 2.7.3. From bottom to top, horizontal lines represent the 5th, 25th, 
median, 75th and 95th percentiles (n=8). For each donor, the assay was performed in 
triplicate and the mean average is recorded on the graph. Data in this graph shows the 
percentage of IFN-γ+ cells which has been adjusted for the negative control by 
subtracting the value obtained when cells were cultured in the absence of cytokines 
from the value obtained when cells were cultured in the presence of cytokines. 
 
The NK cell function of cytotoxicity is more commonly associated with the CD56dim 
subset of NK cells. Contrary to this, results from the killing assays performed in the 
present chapter indicate that the CD56bright subset appear to be more adept at killing. 
However, the killing assays in the present chapter measure killing through the analysis 
of the expression of CD107a after co-culture of NK cells with K562 target cells. As 
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discussed in chapter 3.3, and in keeping with results in the present chapter, this assay is 
perhaps a better measure of NK cell degranulation rather than killing.  
 
The effect of migration on the degranulation of NK cells was assessed by performing a 
migration assay and subsequently co-culturing cells with K562 target cells and 
measuring NK cell expression of CD107a by staining and flow cytometry. For a 
baseline measurement of degranulation, a K562 killing assay was performed on freshly 
isolated cells, also described in the present chapter as cells before migration. For a 
negative control, a K562 killing assay was performed on cells that were cultured in the 
absence of HUVECs.  
 
A representative experiment is depicted in Figure 4.18. For this particular donor, of the 
CD56bright NK cells before migration 3.24% were found to express CD107a in the 
absence of, and 25.90% in the presence of K562, giving a specific degranulation in 
response to the K562 target cells of 22.60%. Of the migrated CD56bright NK cells, only 
0.61% were found to express CD107a in the absence of, compared to 21.48% in the 
presence of K562; therefore 20.07% of cells exhibited specific degranulation in 
response to targets. Regarding control CD56bright NK cells, 3.59% expressed CD107a 
in the absence of, and 16.40% in the presence of K562; therefore 12.81% of CD56bright 
cells from the control sample exhibited specific degranulation (Figure 4.18 A). Results 
from this donor indicate that cell culture causes a decrease in the capacity of 
CD56bright NK cells to degranulate in response to K562 targets. This decrease is 
partially prevented if cells had previously migrated through HUVEC monolayers. 
However, migration does not appear to increase the capacity of CD56bright NK cells to 
degranulate in response to K562 targets above that of cells measured before migration. 
Regarding the CD56dim subset, of the cells that were sampled before migration, 1.22% 
expressed CD107a without target cells present and 7.63% with K562 target cells in the 
culture system. Therefore, 6.41% were found to specifically degranulate in response to 
K562. Very few migrated CD56dim NK cells, 0.32%, that were cultured in the absence 
of targets were found to express CD107a; however, in the presence of target cells, 
13.27% were found to express CD107a, therefore 12.95% of cells had specifically 
degranulated. As regards the control CD56dim NK cells, 0.84% and 8.63% of cells 
were found to express CD107a in the absence and presence of K562 respectively, with a 
specific degranulation calculated at 7.79% (Figure 4.18 B). In this particular 
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experiment, and unlike the findings for the CD56bright subset, cell culture of CD56dim 
NK cells does not appear to decrease the capacity to express CD107a in response to 
targets. Migration of CD56dim NK cells does however appear to increase the 
degranulation capacity of this subset above both control cells and cells sampled before 
the migration assay. 
 
 
 
+K562-K562
Before 
migration 
A 
Migrated 
Control 
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Figure 4.18 The effect of migration through HUVEC monolayers on the capacity 
of NK cells to degranulate in a K562 killing assay. Dot plots above depict one 
representative experiment. Lymphocytes were allowed to migrate for 12 hours through 
HUVEC monolayers or were kept in the absence of HUVECs as a control. A sample of 
cells was taken before migration, after migration and from the control sample. Samples 
were then cultured for 5 hours in the presence (right column, +K562) or absence (left 
column, -K562) of K562 target cells with the addition of anti-CD107a FITC-conjugated 
antibody. Subsequently, cells were stained with fluorochrome-conjugated antibodies 
against CD3, CD16 and CD56 for analysis by flow cytometry. CD56bright NK cells are 
gated in A and CD56dim NK cells are gated in B. The percentage of CD107a+ cells is 
given on each dot plot. 10,000 events are shown on each plot. 
 
The experiment was repeated using samples taken from several donors (n=9) and the 
data, which has not been adjusted for the negative control, is depicted in Figure 4.19. 
Data adjusted for the negative control is shown later on in Figure 4.20. As can be seen 
Before 
migration 
B 
Migrated 
Control 
+K562-K562
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in Figure 4.19, before the migration assay, 2.82% of CD56bright NK cells in the 
absence of, and 28.70% of cells in the presence of K562 targets were found to express 
CD107a. Of the CD56bright cells that had migrated, 5.43% and 27.91% were found to 
express CD107a in the absence and presence of targets respectively. Regarding the 
control sample, slightly more CD56bright cells, 10.74%, were found to express CD107a 
in the absence of targets as compared to cells from other conditions, and 20.32% in the 
presence of K562 target cells (Figure 4.19 A). Results for the CD56dim NK cell subset 
show that before migration 0.52% and 6.67% of cells were found to express CD107a in 
the absence and presence of target cells respectively, whereas 0.46% and 10.63% of 
migrated cells were found to express CD107a respectively. Regarding the control 
CD56dim cells; 1.87% expressed CD107a in the absence of, and 11.13% in the 
presence of K562 target cells (Figure 4.19 B). The finds are further discussed alongside 
the description of Figure 4.20. 
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Figure 4.19 The effect of migration on NK cell degranulation. The detection of NK 
cell degranulation using a K562 killing assay with measurement of CD107a 
expression by flow cytometry. Lymphocytes were allowed to migrate for 12 hours 
through HUVEC monolayers that were previously stimulated with 300 U/ml of rhIFN-γ 
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or were kept in culture in the absence of HUVECs as a control. A sample of cells was 
taken before migration, after migration from the lower chamber of the transwell insert 
and from the control sample, denoted on the graph as pre-migration, migrated and 
control respectively. Subsequently, cells were cultured in the presence or absence of 
K562 target cells denoted by + or – respectively with the addition of anti-CD107a 
FITC-conjugated antibody to the cell cultures. Cells were then stained for the 
expression of CD3, CD56 and CD16 and analysed by flow cytometry. NK cell subsets 
were gated as described in 2.7.3 and the percentage of CD56bright NK cells (orange) 
expressing CD107a is depicted in A with results for CD56dim NK cells (blue) shown in 
B. From bottom to top, horizontal lines represent the 5th, 25th, median, 75th and 95th 
percentiles respectively (n=9). For each donor, the assay was performed in triplicate 
and the mean average is recorded on the graph. 
 
The data from experiments performed to assess the affect of migration on the 
degranulation of NK cells were then adjusted for the negative controls; values obtained 
in the absence of K562 were subtracted from those obtained in the presence of K562, 
and are presented in Figure 4.20. Similar to the findings from the representative 
experiment depicted in Figure 4.18, the median average of nine experiments showed 
that migration of CD56bright NK cells does, to some extent maintain the capacity of 
this subset to express CD107a in response to K562 targets, although it does not increase 
the capacity to above that of cells freshly isolated from peripheral blood, i.e. before 
migration. For this subset, 22.98%, 20.72% and 7.40 of cells before migration, migrated 
cells and control cells respectively, were found to express CD107a in response to targets 
(Figure 4.20). Again, cell culture appears to decrease functional capacity, which is 
partially rescued by migration through HUVEC monolayers. Differing from the single 
experiment shown in Figure 4.18, overall data for the CD56dim subset suggests that 
neither cell culture nor migration alters the capacity of these cells to express CD107a in 
response to K562 targets. In fact, a similar percentage of cells expressed CD107a 
irrespective of the condition; 6.60% before migration, 5.35% after migration and 7.40% 
within the cultured control population (Figure 4.20). If anything, the results suggest that 
migration may actually decrease the capacity of CD56dim NK cells to express CD107a 
in response to K562 target cells although the effect is minimal. 
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Figure 4.20 The effect of migration on the degranulation of CD56bright and 
CD56dim NK cells quantified by a killing assay and the measurement of CD107a 
expression. Lymphocytes were allowed to migrate for 12 hours through HUVEC 
monolayers that were previously stimulated with 300 U/ml of rhIFN-γ or were kept in 
culture in the absence of HUVECs as a control. A sample of cells was taken before 
migration, after migration from the lower chamber of the transwell insert and from the 
control sample denoted on the graph as pre-migration, migrated and control 
respectively. Subsequently, cells were cultured in the presence or absence of K562 
target cells and in the presence of anti-CD107a FITC-conjugated antibody. NK cell 
subsets were gated on as described in 2.7.3 and the percentage of CD56bright NK cells 
(orange) expressing CD107a is depicted in A and CD56dim (blue) in B. From bottom to 
top, horizontal lines represent the 5th, 25th, median, 75th and 95th percentiles 
respectively (n=9). For each donor, the assay was performed in triplicate and the mean 
average is recorded on the graph. The data in this graph are adjusted for the negative 
controls by subtracting the values obtained from cells cultured in the absence of K562 
from the values obtained from cells cultured in the presence of K562 target cells. 
 
 
 
4.2.8 Migration of purified NK cells. Optimisation of NK cell purification 
 
Finally, this chapter aims to confirm findings on the subject of CD56bright NK cells 
accumulation post-migration and migration-induced activation of NK cells by using 
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purified NK cells. By removing other immune cells from the in vitro system, the assay 
detracts further from the conditions seen in vivo. However, this allows a more direct 
dissection of the interaction of NK cells with endothelium, and eliminates any potential 
bystander interactions of other lymphocytes with the endothelium. 
 
To eliminate any potential bystander effect of T cells on the migration assay, and to 
dissect out the interaction of endothelial cells with NK cells alone, the migration assay 
was performed using purified NK cells. Firstly a method of purifying NK cells from 
Percoll pellet cells that achieved a high level and reproducible purity was required. In 
order to achieve this, three NK cell purification methods were tested; 
(i) Positive selection of NK cells using MACS microbeads as described in 2.82. 
Briefly, lymphocytes were labelled with anti-CD3 microbeads and were 
placed on a LD column to deplete T cells. Subsequently, the cells were 
labelled with anti-CD56 microbeads and placed on a MS column to select 
CD56+ NK cells. The CD3 depletion step is required to eliminate any 
CD56+ T cells. 
(ii) Negative selection using Dynal magnetic beads as described in 2.8.1.2. 
Lymphocytes were labelled with anti-CD3 and anti-CD19 Dynal magnetic 
beads, placed onto a Dynal magnet and the eluted NK cell rich fraction was 
collected. 
(iii) Negative selection using MACS microbeads as described in 2.8.1.1. Briefly, 
lymphocytes were labelled with anti-CD3, CD19 and CD20 microbeads, put 
onto a LD column and the eluted NK cell fraction was collected.  
 
The three methods of purification were initially tested using lymphocytes from one 
donor and results from these experiments are shown in Figure 4.21. Before purification 
32.24% of Percoll pellet cells were found to be NK cells (Figure 4.21 A). Positive 
selection using MACS microbeads achieved a NK cell purity of 97.31% (Figure 4.21 
B), Dynal depletion of CD3+ and CD19+ attained a purity of 92.57% (Figure 4.21 C). 
However, the highest purity; 98.91% NK cells was achieved by using negative selection 
by MACS microbeads (Figure 4.21 D).  
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Figure 4.21 Optimisation of the purification of NK cells. NK cells were purified from 
Percoll pellet cells. Cells before purification are depicted in A. 3 methods of NK cell 
purification were tested; MACS positive selection of cells that express CD56 which is 
depicted in B, Dynal depletion of CD3 and CD19 which is depicted in C and MACS 
depletion of CD3 and CD19 which is depicted in D. Cells were then stained with 
antibodies against CD3 and CD19 conjugated to PerCP and CD56 conjugated to APC 
for analysis by flow cytometry. 10,000 events are shown in each dot plot and the 
percentage of CD3-CD19- NK cells that are within the live lymphocyte gate is given on 
each plot. 
 
Results indicate that the optimal method for purifying NK cells is negative selection by 
MACS microbeads. This was followed very closely by the positive selection method. 
However, for the purposes of this thesis it is important that the NK cells remain in their 
A. Before purification 
B. MACS CD56 positive selection 
C. Dynal CD3 and CD19 depletion 
D. MACS CD3 and CD19 depletion 
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most inactive state. By engaging CD56 with the microbeads, it is possible that NK cell 
function or phenotype may be affected with resulting implications for the interaction 
with endothelium. Furthermore, the function of CD56 on NK cells is largely unknown, 
hence the negative selection by MACS microbeads was chosen for further assays. 
 
4.2.9 CD56bright NK cells accumulate post-migration in assays using purified NK 
cells 
 
To assess the accumulation of NK cell subsets post-migration, NK cells were purified as 
described in 4.2.8 and were allowed to migrate for 12 hours through HUVEC 
monolayers or were cultured alone as a negative control. Cells were sampled before 
migration and after the migration assay from both the upper and lower chambers of the 
transwell insert. A representative experiment is shown in Figure 4.22. Given as a 
percentage of the total NK cell population, cells before migration were found to include 
3.91% CD56bright and 79.17% CD56dim cells. In the upper chamber after the 
migration assay, a similar percentage of CD56bright NK cells were found; 4.07% 
compared to cells before migration. However, a slightly higher proportion; 84.37% of 
CD56dim NK cells were found. Migrated cells included 12.93% and 64.70% of 
CD56bright and CD56dim NK cells respectively and control cells were found to include 
4.70% and 80.71% respectively (Figure 4.22). These results show a higher proportion of 
CD56bright and a lower proportion of CD56dim NK cells post-migration. Similar to 
results from experiments using Percoll pellet cells, it appears that CD56bright NK cells 
accumulate post-migration in assays using purified NK cells.  
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Figure 4.22 The accumulation of CD56bright NK cells in a migration assay using 
purified NK cells. NK cells were purified from Percoll pellet cells by MACS depletion 
of CD3+ and CD19+ cells. Purified NK cells were allowed to migrate for 12 hours 
through HUVEC monolayers that were previously stimulated with 300 U/ml of rhIFN-γ 
or purified NK cells were kept in culture in the absence of HUVECs as a control. A 
sample of cells was taken before the migration assay (A), after the migration assay from 
both the upper (B) and lower (C) chambers of the transwell insert, and from the control 
sample (D). Cells from the upper chamber of the transwell insert had come into contact 
with HUVECs but had not migrated whereas cells from the lower chamber had 
migrated. All samples were stained with flourochrome-conjugated antibodies against 
CD56 and CD16 and analysed by flow cytometry. 25,000 cells are depicted in each dot 
plot. CD56bright and CD56dim NK cells are gated as depicted by R4 and R5 
respectively. The percentage of each subset as a portion of the total NK cell population 
is given adjacent to the region marker on each plot. 
 
The experiment was repeated to confirm the preliminary findings described above. Data 
from cell counting and FACS analysis of cells before and after the migration assay 
allowed the calculation of the percentage migration of each of the NK cell subsets. 
These data are shown in Figure 4.23. The CD56bright subset of NK cells consistently 
migrated more than the CD56dim subset; an average percentage migration of 85.83% 
A. Before migration B. Post-migration upper chamber 
C. Post-migration lower chamber D. Control 
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and 28.17% was found for CD56bright and CD56dim NK cell respectively  as shown in 
Figure 4.23, and this difference was found to be statistically significant (p = 0.0002, 
n=13). Similar to the experiments using percoll pellet cells, there appears to be a cluster 
of individuals whose CD56bright NK cells almost all migrate and the other individuals 
have a more broad spread of the percentage of CD56bright NK cells that migrate 
through HUVEC monolayers. As previously described, this could reflect natural genetic 
differences, or NK cells that have been stimulated and have up-regulated adhesion 
molecules, therefore are more apt at migrating, and the latter could be due to infection 
or immune stimulation at the time of sampling these individuals. 
 
 
 
Figure 4.23 The accumulation of CD56bright NK cells post-migration through 
HUVEC monolayers. Lymphocytes were allowed to migrate for 12 hours through 
HUVEC monolayers that were previously stimulated with 300 U/ml of rhIFN-γ. A 
sample of cells before and after migration was counted and analysed by flow cytometry. 
The percentage migration of CD56bright and CD56dim NK cells was calculated using 
these data. A scatter graph (left) shows individual values with a box and whiskers graph 
(right) given for consistency with the other figures in this thesis. In the scatter graph, 
horizontal lines represent the mean percentage migration of cells. In the box and 
whiskers graph, from bottom to top, the horizontal lines represent the 5th, 25th, median, 
75th and 95th percentiles with CD56bright cell depicted in blue and CD56 dim cells in 
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yellow. A statistical analysis was carried out using a paired Wilcoxon signed tank test, 
with p values of less than 0.001 represented by ***. The p value is stated on the graph 
(n=13). For each donor, the assay was performed in triplicate and the mean value was 
plotted on the graph. 
 
4.2.10 Migration and its effect on CD56 MFI of purified NK cells 
 
The functional significance of CD56 expression on NK cells remains unclear. 
Nevertheless, data relating to CD56 expression during cell migration were readily 
available from the experiments and were analysed. A representative experiment 
assessing the effect of migration on the CD56 MFI of NK cells is depicted below in 
Figure 4.24. As expected, all CD56bright NK cells and the majority of CD56dim NK 
cells were found to be positive for the expression of CD56. As can be seen in Figure 
4.24, CD56bright cells before migration had the highest CD56 MFI of 284.57. 
CD56bright cells from the upper chamber of the transwell insert were found to have a 
CD56 MFI of 203.16, and the migrated cells had a lower MFI of 146.25, compared to 
the control sample in which cells had a CD56 MFI of 173.28 (Figure 4.24). This 
experiment suggests that cell culture decreases CD56MFI of CD56bright NK cells. 
However, levels are maintained above that of the control on cells from the upper 
chamber of the transwell but are down regulated to levels less than the control sample 
on migrated cells. Regarding the CD56dim subset, a similar trend was observed; before 
migration CD56 MFI was 66.77, which dropped to 55.18 for cells from the upper 
chamber, 45.86 for migrated cells and 48.32 for control cells (Figure 4.24). Again, 
contact with HUVECs appears to partially maintain CD56 MFI on CD56dim cells, 
although expression is down regulated by migration.  
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Figure 4.24 CD56 MFI of purified NK cells after migration through HUVEC 
monolayers. The histograms above show FACS data from one representative 
experiment. NK cells were purified from Percoll pellet cells by MACS depletion of 
CD3+ and CD19+ cells. Purified NK cells were allowed to migrate for 12 hours 
through HUVEC monolayers that had been previously stimulated with 300 U/ml of 
rhIFN-γ or NK cells were kept in culture in the absence of HUVECs as a control. 
Samples were taken before migration, after migration from both the upper and lower 
chambers of the transwell insert and also from the control sample. Cells from the upper 
chamber had come into contact with HUVECs but had not migrated whereas cells from 
the lower chamber had migrated. Samples were stained with fluorochrome-conjugated 
antibodies against CD3, CD16 and CD56 for analysis by flow cytometry. Gates have 
been set on the CD56bright NK cell population in the first column and the CD56dim NK 
cell population in the second column. Red histograms represent cells cultured alone as 
a control. Blue histograms are CD56bright and green histograms are CD56dim NK 
Lower 
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Upper 
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cells. Values represent percentage staining above non-specific fluorescence from un-
stained cells (black empty histograms). 
 
The experiment was repeated (n=11) using lymphocytes from several donors. For each 
donor the assay was repeated in triplicate and the mean average result was plotted on 
the graph depicted in Figure 4.25. Results were found to be slightly different to those of 
the single donor described above. CD56bright NK cells that were assessed before 
migration had a CD56 MFI of 330.3. CD56bright cells from the upper chamber, cells 
that had migrated and control cells were found to have a CD56 MFI of 234.9, 210.4 and 
185.5 respectively. A statistical analysis revealed no marked differences between the 
conditions. Regarding CD56dim NK cells, the same trend as seen for the CD56bright 
subset was seen; cells before migration, from the upper chamber, migrated cells and 
control cells were found to have CD56 MFI values of 91.05, 64.61, 59.76 and 55.44 
respectively. Again, no significant differences were seen when a statistical analysis was 
carried out. 
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Figure 4.25 The effect of migration on the CD56 MFI of NK cells. Migration assays 
using purified NK cells. NK cells were purified from Percoll pellet cells by MACS 
depletion of CD3+ and CD19+ cells. Purified NK cells were allowed to migrate for 12 
hours through HUVEC monolayers that had been previously stimulated with 300 U/ml 
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of rhIFN-γ or were kept in culture in the absence of HUVECs as a control. A sample of 
cells was taken before migration denoted as pre-mig on the graph, after migration from 
both the upper and lower chambers of the transwell insert denoted by upper and lower 
and from the control sample denoted by control. All samples were stained with 
flourochrome-conjugated antibodies against CD3, CD16 and CD56 for analysis by flow 
cytometry. CD56bright (orange) and CD56dim (blue) NK cells were gated on using the 
gating strategy described in 2.7.3. From bottom to top, horizontal lines represent the 
5th, 25th, median, 75th and 95th percentiles (n=11). 
 
4.2.11 Activation of pure NK cells post-migration 
 
As with experiments performed using Percoll pellet cells, the migration-induced 
activation of purified NK cells was assessed by flow cytometric analysis of expression 
levels of CD69. Results from a representative experiment are depicted in Figure 4.26. 
Before the migration assay, only 1.86% of the CD56bright subset was found to express 
the early activation antigen CD69. Of the CD56bright cells that were harvested after the 
migration assay from the upper chamber of the transwell insert, 17.35% expressed 
CD69. These cells had come into contact with, but had not migrated through the 
HUVEC monolayers. However, fewer migrated cells; 7.11% were found to express 
CD69. Nevertheless, this is higher than the percentage of cells found to express CD69 
in the control sample; 3.23%. Regarding the CD56dim subset, 5.48% of cells before 
migration were found to express CD69. After the assay, 19.32% of cells from the upper 
chamber and 12.76% of cells from the lower chamber were found to express CD69, 
both of which are greater than the 9.03% of control cells which were found to express 
CD69. Results from this one experiment suggest that culturing purified NK cells may 
increase CD69 expression. Expression is increased further by contact with endothelium 
but then decreased after migration. 
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Figure 4.26 Activation of purified NK cells after migration through HUVEC 
monolayers. NK cells from one representative donor were purified from Percoll pellet 
cells by MACS depletion of CD3+ and CD19+ cells. Purified NK cells were then 
allowed to migrate for 12 hours through HUVEC monolayers that were previously 
stimulated with 300 U/ml of rhIFN-γ or NK cells were cultured in the absence of 
HUVECs as a control. A sample of cells was taken before migration, after migration 
from both the upper and lower chambers of the transwell insert and also from the 
control sample. Cells from the upper chamber had come into contact with HUVECs but 
had not migrated, whereas cells from the lower chamber had migrated. All samples 
were stained with fluorochrome-conjugated antibodies against CD3, CD16, CD56 and 
CD69 for analysis by flow cytometry. CD56bright cells are gated on in the left column 
Before 
migration 
Upper 
chamber 
Lower 
chamber 
Control 
CD56bright NK CD56dim NK 
  Chapter 4 
 200
and CD56dim cells are gated on in the right column. The percentage of cells that 
express CD69 is given on each dot plot. 5,000 events are shown on each dot plot.   
 
Multiple experiments gave several interesting results. Firstly, purified CD56dim NK 
cells appear to be activated more than CD56bright NK cells regardless of whether they 
are kept in culture alone or in the presence of HUVECs. Secondly, for the CD56dim 
subset of NK cells, both contact with HUVECs and even more so migration were found 
to significantly up regulate CD69 expression with migration through endothelium 
having the greater effect; the percentage of CD69+ CD56dim NK cells were found to be 
4.43% and 5.51% vs. the control sample; 3.76% with p values of 0.0105 and 0.0245 
respectively (Figure 4.27). Although both contact with and migration through HUVECs 
significantly increased the expression of CD69 on the CD56bright subset, in contrast to 
the CD56bright subset, contact with the HUVECs alone seemed to have a greater effect 
than migration through the HUVECs with 13.37% and 10.15% being CD69+ 
respectively with p values of 0.0002 and 0.0052 respectively (Figure 4.27). A 
comparison of migration assays using Percoll pellet cells with migration assays using 
purified NK cells reveals the same trend for the CD56bright subset i.e. contact with 
HUVECs increases CD69 expression but migration increases CD69 expression further. 
However, for the CD56dim subset the trend was found to be different. In assays using 
Percoll pellet cells, similar to the CD56bright subset, contact with HUVECs increased 
CD69 expression and migration increased this effect further. Conversely, in assays 
using purified NK cells, contact with HUVECs increased CD69 expression but 
migration partially down regulated the activation. Quatitative analysis of the CD69 
mRNA content of these cells using RT-PCR would further confirm these findings, and 
is a technique that would be used in future experiments/  
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Figure 4.27 Migration of purified NK cells and the effect on the expression of 
CD69. NK cells were purified from Percoll pellet cells by MACS depletion of CD3+ 
and CD19+ cells. Purified NK cells were allowed to migrate for 12 hours through 
HUVEC monolayers that had been previously stimulated with 300 U/ml of rhIFN-γ or 
were kept in culture in the absence of HUVECs as a control. A sample of cells was 
taken before migration denoted as pre-mig on the graph, after migration from both the 
upper and lower chambers of the transwell insert denoted by post-mig upper and post-
mig lower and from the control sample denoted by control. All samples were stained 
with flourochrome-conjugated antibodies against CD3, CD16, CD56 and CD69 for 
analysis by flow cytometry. CD56bright (orange) and CD56dim (blue) NK cells were 
gated on using the gating strategy described in 2.7.3. From bottom to top, horizontal 
lines represent the 5th, 25th, median, 75th and 95th percentiles. Statistical analysis was 
performed using a paired Wilcoxon signed rank test, p<0.05 (*), p<0.01 (**) and 
P<0.001=***.  The p values stated on the graph (n=14). 
 
Alongside the differences in the trends of migration-induced CD69 described above, in 
assays performed using Percoll pellet cells, a consistently higher percentage of 
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CD56bright NK cells were found to express CD69 as compared to the CD56dim subset 
and in fact the converse was found to be true of assays using purified NK cells. 
 
4.3 Discussion 
 
The objectives of experiments in the present chapter are to bring the migration assay 
closer to that of the in vivo environment by replacing the EA.hy 926 endothelial cell line 
with primary human cells, HUVECs. Moreover, replacing the cell line has the 
additional benefit of excluding the possibility that NK cell activation is not due to cell 
migration but due to contact with tumour cells. This has particular importance when 
considering NK cells because one of the main functions of NK cells is to react to, and 
eliminate tumour cells, and this response begins with the activation of the NK cell. 
Similar to chapter 3, the experiments in the present chapter investigate the accumulation 
of the CD56bright NK cells in inflammatory lesions and aimed to ascertain the mode of 
this accumulation using the HUVEC migration model. Furthermore, experiments in the 
present chapter intended to confirm findings from chapter 3 in terms of migration-
induced activation, and migration-induced maintenance of the capacity of NK cells to 
degranulate and also to express IFN-γ. This chapter also examined the effect of 
migration through HUVEC monolayers on the phenotype of NK cells, in particular 
adhesion molecules. The present chapter also considered the possibility that other 
lymphocytes may influence the interaction of NK cells with the endothelium. By using 
purified NK cells in the migration assay, the bystander effect of other lymphocytes was 
eliminated.  
 
The accumulation of CD56bright NK cells post-migration was confirmed in migration 
assays using HUVEC monolayers. A statistical analysis of the relative capacities of 
CD56bright and CD56dim NK cells to migrate revealed that CD56bright NK cells 
accumulate significantly more than the CD56dim subset. These findings provide further 
support for results from chapter 3 and show that the in vitro migration assay developed 
in the present study successfully emulates the accumulation of CD56bright NK cells 
that is observed in inflammatory lesions in vivo. The accumulation of these cells can be 
explained by either preferential recruitment of CD56bright NK cells or differentiation of 
the CD56dim to the CD56bright subset post-migration. To address this, a NK cell 
tracking assay was developed in chapter 3, and a preliminary experiment was 
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performed. Data from the experiment in chapter 3 certainly supported the preferential 
recruitment theory however, some of the experiments proved difficult to interpret, and 
the present chapter sheds some light on this subject. The tracking assay was repeated, 
with the modification of replacing the endothelial cell line with HUVECs. Results do 
not support the idea that significant numbers of NK cell subsets differentiate into their 
counter-subset. Furthermore, a higher proportion of CD56bright NK cells were found to 
decrease levels of CD56 expression than the CD56dim subset. Hence this raises the 
possibility that the assay may be underestimating the migration of CD56bright NK cells. 
 
On the subject of migration-induced NK cell activation, in assays using Percoll pellet 
cells, experiments in the present chapter found that migration consistently induced the 
activation of CD56bright NK cells more than the CD56dim subset. Cells after contact 
with HUVECs and were further activated if they migrated through the HUVEC 
monolayers.  
 
Changes in NK cell adhesion molecule expression were also tested and no marked 
differences were found a statistical analysis was performed to compare cells that had 
migrated through HUVEC monolayers and cells from control samples. 
Increased adhesive properties has important implications regarding further cell 
migration and also the interaction of NK cells with other immune cells at the site of 
inflammation, the lack of increase in CD62L expression indicates that migration would 
not promote further trafficking of NK cells to lymph nodes.  
 
The results for the study of the effect of migration on NK cell functional capacity are 
summarised below in Table 4.1. NK cell degranulation results parallel those in chapter 
3. Findings for IFN-γ expression are similar to chapter 3 with the difference that for the 
CD56bright subset, migration through HUVEC monolayers seems to have a greater 
effect than migration through EA.hy 926 endothelial cell line monolayers with 
approximately 4% more cells expressing IFN-γ more than before migration, vs. only 
approximately 1% respectively. 
 
NK cell function CD56bright NK CD56dim NK 
IFN-γ production ↑ ↑ 
  Chapter 4 
 204
Degranulation in response 
to K562 target cells 
 
may be slightly maintained 
by migration through 
HUVEC monolayers 
 
- 
 
Table 4.1 Summary of findings on the effect of migration through HUVEC 
monolayers on the functional capacity of NK cells. Columns from left to right list the 
NK cell functions that were tested, and a depiction of the effect of migration through 
HUVEC monolayers on these functions for CD56bright and CD56dim NK cells 
respectively. Upward pointing arrows indicate an increase and – indicates no change. 
 
As aforementioned, pure NK cell migration assays were performed with the intention of 
eliminating the potential bystander effect of other lymphocytes on the endothelium for 
the reason that T lymphocyte-endothelial cell interactions have been well documented 
in the literature.  For a while it has been known that endothelial cells express both MHC 
class I and class II peptide complexes and can present antigen to T cells. This provides 
the body with an alternative mechanism of immune surveillance for pathogens. In 
return, the activated T cells provide both soluble and contact dependent mechanisms of 
endothelial cell activation (Pober, 1999). For example, in the presence of cytokines, or 
the ligation of CD40 by T cells, endothelial cells up regulate the expression of adhesion 
molecules including; E-selectin, ICAM-1 and VCAM-1, bestowing them with the 
ability to bind to circulating leucocytes (Springer, 1995). This bi-directional interaction 
extends to the maintenance of endothelial cell MHC expression, which is shown to 
decrease in culture systems and can be maintained by treatment of the endothelium with 
T cell derived IFN-γ (Pober et al., 1983). Significant for the present study is the finding 
that memory T cells respond to interaction with endothelial cells by secreting the 
cytokine IL-2 (Ma and Pober, 1998), which is known to activate NK cells. With this 
knowledge in mind, subchapters 4.2.8-4.2.11 in the present study address the possibility 
that other lymphocytes in the Percoll pellet, in particular T cells, could affect the 
interaction of NK cells with endothelium. To do this, the other lymphocytes in the 
Percoll pellet were eliminated and the migration assay was performed using the pure 
NK cell fraction. Similar to experiments performed with all lymphocytes in the Percoll 
pellet present, migration assays performed using purified NK cells confirmed that 
CD56bright NK cells significantly accumulate post-migration compared to the 
CD56dim subset. Hence one can deduce that the accumulation of this subset must be 
due to the interaction with endothelium alone and not due to T cell derived IL-2 induced 
activation and subsequent migration of this particular subset. In keeping with 
  Chapter 4 
 205
experiments using Percoll pellet cells, the CD56 MFI of purified NK cells was, to a 
small extent, maintained by interactions with HUVECs. Furthermore, it appears that, in 
the absence of T cells, the HUVEC monolayers are able to activate NK cells; again 
eliminating the possibility that T cell derived IL-2 is involved. A measurement of 
migration-induced expression of the early activation antigen CD69 shows similar results 
when using purified NK cells compared to using all lymphocytes in the Percoll pellet. 
Identical to the trend seen in experiments with Percoll pellet cells, contact with 
HUVECs increased the percentage of CD56bright cells expressing CD69, and migration 
enhanced this effect with a peak percentage expression found on migrated cells. 
However, the trend for the CD56dim subset differed slightly when assays using purified 
NK cells were compared to assays using all lymphocytes in the Percoll pellet; in assays 
using purified NK cells the peak percentage of cells found to express CD69 was 
observed on cells that had come into contact with HUVECs but had not migrated. 
Moreover, fewer migrated cells were found to express CD69, and although the value 
was above the control sample, it suggests that migration may, to a small degree, down 
regulate some of the CD69 expression caused by contact with HUVECs. Interestingly, 
and converse to experiments performed using Percoll pellet cells, migration was found 
to induced more CD56dim NK cells to express CD69 than the CD56bright subset.  It is 
possible that IL-2, which could have derived from T cell interactions with the 
endothelium, was required for the full effect on CD56bright NK. Therefore perhaps the 
presence of other lymphocytes does not affect the preferential recruitment of 
CD56bright NK cells, but may have an effect on their activation in migration assays. 
 
Results seem to support a role for CD56bright NK cells in inflammation as the 
activation, phenotypic and functional changes induced by migration are more prominent 
for this subset. Importantly, the results in the present chapter provide additional 
evidence for findings in chapter 3, bringing the assay closer to that of the in vivo 
environment and providing reassurance that the reactions of the NK cells are not as a 
result of interaction with a tumour cell line, but rather a result of interaction with 
endothelium. Furthermore, migration assays using purified NK cells verified that the 
accumulation of CD56bright NK cells post-migration is a direct result of the interaction 
of this subset of NK cells with the endothelium. These experiments also showed that 
other lymphocytes, at least in part play a role in activating NK cells during this process, 
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and this was particularly noted for the CD56bright subset which were most affected by 
the lack of T cells in purified NK cell migration assays.  
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Chapter 5 
 
Migration and the interaction of NK cells with macrophage and 
dendritic cells 
 
5.1 Background and aims 
 
Work presented in previous chapters has shown migration through endothelium to have 
some effect on the phenotype of NK cells, their degranulation and IFN-γ production. 
However, the list of known NK cell functions is growing, with recent advances showing 
that NK cells can exhibit complex bi-directional interactions with cells of both the 
innate and adaptive arms of the immune system. Such interactions have consequences 
much further along the chain of an immune reaction than NK cell killing and cytokine 
production, even so far as assisting in the formation of immunological memory. 
Therefore, one can hypothesise that if migration through endothelium is affecting the 
classical functions of NK cells, perhaps it is also altering their more recently described 
interactions with other immune cells. Experiments in the present chapter aim to test this 
hypothesis, with particular focus on the effect of migration on the interaction of NK 
cells with cells of the monocyte/macrophage lineage and DCs.  
 
Communications have been shown to occur between NK cells and cells of the 
monocyte/macrophage lineage. For example, NK cells are stimulated to produce IFN-γ 
and also are recruited to sites of inflammation by MIP-1α which is supplied by 
macrophages (Salazar-Mather et al., 2000; Dalbeth et al., 2004). Reciprocally, the NK 
cell derived IFN-γ activates macrophages (Diefenbach and Raulet, 2002). Furthermore, 
one particular subset of NK cells; the CD56bright subset can drive the differentiation of 
monocytes into TH1 promoting DCs which could potentially exacerbate synovial 
inflammation if the scenario of inflammatory arthritidies is considered (Zhang et al., 
2007). Recently, the Davis group has demonstrated that macrophages can stimulate NK 
cell proliferation, and that NK cells can regulate macrophages that have been stimulated 
with high doses of LPS by killing them, suggesting a new regulatory function for NK 
cells (Nedvetzki et al., 2007).   
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The present study examines the effect of NK cell migration on macrophage-induced 
changes in NK cells. Macrophages were differentiated from monocytes and preparations 
were tested for both purity and successful differentiation. NK cells were allowed to 
migrate through endothelium and then co-cultured with autologous macrophages. 
Following this, the effect of NK cell migration on macrophage-induced proliferation of 
the NK cells was examined using CFSE.  
 
On the subject of NK: DC interactions and of interest to experiments in the present 
study, Della Chiesa et al. have shown that in the presence of CpG DNA, NK cells can 
stimulate pDCs to release IFN-α and this cytokine reciprocally activates NK cells by 
increasing their ability to kill (Della Chiesa et al., 2006). The mechanisms involved in 
NK: DC interactions, in particular during viral infections, were described by Andoniou 
et al. (Andoniou et al., 2005). This group showed that NK cell cytotoxicity is activated 
by CD11b+ DC that have been infected with MCMV, a response which they showed to 
be dependent on NKG2D and IFN-α. This group also showed that such DCs could 
activate the IFN-γ production arm of NK cell responses and that DC-derived IL-18 was 
responsible for this and resulted in better control of viral replication. Another 
documented effect of the co-culture of pDCs with NK cells is the enhanced elimination 
or ‘editing’ of immature mDCs, with the theory that only DCs with the capacity to 
instigate an appropriate T cell response are saved from killing, thereby enhancing the 
efficiency of the adaptive system (Gerosa et al., 2002; Piccioli et al., 2002; Ferlazzo and 
Munz, 2004). The Trinchieri group who were the first to use freshly isolated DCs for 
NK: DC co-culture experiments, found that the reciprocal interaction between NK cells 
and DCs could substantially affected the innate response depending on the microbial 
stimulus (Gerosa et al., 2005). The present chapter investigates the effect of NK cell 
migration on the subsequent interaction with DCs. Freshly isolated autologous pDCs 
and mDCs were used in both immature and mature states. As a first step in these 
experiments, the purity of DC preparations and the induction of maturation were tested. 
Along with successful DC isolation, it was important to be able to replicate the effects 
of NK: DC interactions before adding the complication of the migration assay to the 
experiments. Therefore, preliminary NK:DC co-cultures were carried out and the 
following parameters were measured; the expression of CD69 as an early activation 
marker of NK cells, the expression of TNF-α, IFN-γ, Perforin, Granzyme A by NK cells 
and also DC expression of CD80, CD83, CD86, CD40, CD56 and HLA-DR. 
  Chapter 5 
 
 209
Subsequently, experiments examined the effect of NK cell migration on these NK cell: 
DC cross-talk outputs through the co-culture of DCs with both migrated NK cells and 
NK cells that had been cultured for the same period of time in the absence of 
endothelium as a control.  
 
5.2 Results 
 
5.2.1 Macrophage preparations 
 
Macrophages were obtained by the differentiation of freshly isolated peripheral blood 
monocytes. Initially, monocytes were isolated from the Percoll interface by plastic 
adherence which is described in detail in chapter 2.8.5. Briefly, cells from the Percoll 
interface, which comprise cells of the monocyte/macrophage lineage and dendritic cells, 
were incubated for 2 hours in plastic flasks that were previously coated with 2% gelatin 
(Sigma Aldrich, UK). Subsequently, flasks were washed thoroughly with PBS to 
remove non-adherent cells and the adherent monocytes were cultured for 24 hours in 
media supplemented with 1% autologous serum. After 24 hour in culture, the purity of 
the monocytes was assessed by staining for CD14 and analysis by flow cytometry. 
Monocytes were found to be at least 80% pure. Macrophages were generated by 
culturing these monocytes for 10 days and were found to be consistently 95% pure. The 
difference in the purity of the monocyte compared to the macrophage samples is likely 
to be due to contamination by other cells in the monocyte sample and the inability of 
these cells to survive in culture without the addition of cytokines to the culture medium. 
A representative example in which 80.33% of the monocyte preparation (Figure 5.1 A) 
and 97.93% of macrophage preparation (Figure 5.1 B) were found to be CD14+ is 
shown below. 
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Figure 5.1 Monocyte and macrophage preparations. Monocytes were isolated from 
the Percoll interface by plastic adherence. After 24 hours the purity of the monocytes 
was tested.  To test the purity, cells were stained with anti-CD14 FITC-conjugated 
antibody and analysed by flow cytometry. To generate macrophages, monocytes were 
cultured for a total of 10 days after which the purity was tested. Red filled histograms 
depict monocyte and macrophage preparations in A and B respectively. Values 
represent percentage staining above non-specific fluorescence from unstained cells 
using the fluorescence minus one approach (black empty histograms).  
 
Initially preliminary experiments in the present chapter used unstimulated macrophages 
for NK cell: macrophage interaction experiments. As will be described in the next 
subchapter, results from these preliminary experiments indicated that this interaction 
may have an effect on the proliferation of NK cells. However, the number of 
proliferating NK cells was small and as a result macrophages were stimulated with LPS 
to test the possibility that activated macrophages are required to stimulate NK cell 
proliferation. Indeed, literature suggests that pre-treatment of macrophages with LPS is 
required to stimulate the proliferation of NK cells, and that no significant NK cell 
proliferation is seen if NK cells are co-cultured with untreated macrophages (Nedvetzki 
et al., 2007). To stimulate, macrophages were cultured for 48 hours with the addition of 
200 ng/ml LPS Salmonella minnesota (Sigma Aldrich, UK) to the culture medium.  
 
5.2.2 Migration and the interaction of NK cells with macrophages 
 
To enable the investigation of the interaction of macrophages with autologous migrated 
NK cells, macrophages were generated and, after 9 days in culture, the same donor was 
bled and NK cells were purified by MACS depletion of CD3 and CD19 from Percoll 
pellet cells. The NK cells were either allowed to migrate through HUVEC monolayers 
A B 
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or were kept in culture for the same period of time as a control. Migrated and control 
NK cells were then labelled with CFSE to allow the measurement of NK cell 
proliferation and NK cells were co-cultured with or without the autologous 
macrophages for 48 hours. Subsequently, cells were labelled with fluorescent-
conjugated antibodies against NK cell markers and were analysed by flow cytometry. 
Proliferation was measured as the percentage of NK cells that were found to be CFSElow 
and the effect of NK cell migration was judged by comparing values for migrated NK 
cells with control NK cells. An example experiment is depicted in Figure 5.2. In this 
particular example, 0.00% of control CD56bright NK cells were found to proliferate in 
the absence of, and a very small number; 0.20%, were found to proliferate in the 
presence of macrophages. Slightly more of the migrated CD56bright NK cells were 
found to proliferate; 1.27% cultured in the absence of and 5.32% in the presence of 
macrophages, suggesting that macrophages can induce a small amount of NK cell 
proliferation and also that migration may augment this effect. Observations of the other 
NK cell subset; CD56dim NK cells showed that of the control cells 1.60% proliferated 
in the absence of and 2.23% proliferated in the presence of macrophages. Interestingly, 
1.56% of migrated CD56dim cells cultured in the absence of macrophages were found 
to proliferate. This is similar to the control NK cells, suggesting that, at least in this 
experiment, migration does not affect the proliferation of CD56dim NK cells. However, 
in the presence of macrophages, migrated CD56dim NK cells were found to proliferate 
the most with 8.43% proliferating, when compared to all other samples. This could 
indicate that migration may have an effect on macrophage-induced proliferation but not 
basal proliferation of CD56dim NK cells (all results are shown in Figure 5.2). 
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Figure 5.2 NK cell migration and macrophage-induced proliferation of NK cells. 
Purified NK cells from one representative donor were allowed to migrate through 
HUVEC monolayers or were kept in culture in the absence of HUVECs as a control. 
Migrated and control NK cells were then stained with CFSE and subsequently co-
cultured with or without LPS treated autologous macrophages for 48 hours. Cells were 
then stained with CD56 APC and CD16 PE antibodies for the analysis of NK cell 
CD56bright NK cells CD56dim NK cells 
Migrated NK cells 
alone  
Migrated NK cells + 
macrophages 
Control NK cells 
alone 
Control NK cells + 
macrophages 
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proliferation by flow cytometry. CD56bright NK cells are gated on in the left column 
and CD56dim NK cells are gated on in the right column. As close to 20,000 events are 
shown in each dot plot as possible. The percentage of CFSElow cells is given on each dot 
plot. 
 
Multiple experiments (n=4) showed the percentage of proliferating NK cells to be very 
low in the absence of macrophages; 0.77% of migrated and 0.00% of control 
CD56bright NK cells (Figure 5.3 A) and 1.29% of migrated and 0.32% of control 
CD56dim NK cells (Figure 5.3 B). The migrated NK cells tended to proliferate more 
than the control NK cells although no statistical difference was found. The addition of 
LPS treated macrophages to the co-culture was found to increase the number of 
proliferating NK cells of both subsets, and migrated NK cells were found to proliferate 
more than control cells; a mean of 1.23% of migrated CD56bright and 6.55% of 
migrated CD56dim NK cells vs. 0.10% of control CD56bright and 1.50% of control 
CD56dim NK cells proliferated in these experiments (Figure 5.3). Interestingly, it 
appeared that CD56dim NK cells had a higher proliferative capacity, regardless of the 
conditions, compared to the CD56bright subset of NK cells.  
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Figure 5.3 The effect of migration on macrophage-induced NK cell proliferation. 
CFSE labelled NK cells that had previously migrated through HUVEC monolayers, 
denoted as migrated on the graph, or had been kept in culture in the absence of 
HUVECs as a control, denoted as control on the graph, were co-cultured for 48 hours 
in the presence (+) or absence (-) of LPS stimulated autologous macrophages. 
Subsequently, cells were labelled with fluorescence-conjugated antibodies against NK 
cell markers and were analysed by flow cytometry to assess NK cell proliferation. 
CD56bright NK cells are gated on in A and CD56dim NK cells in B. Horizontal lines 
represent the 5th, 25th, median, 75th and 95th percentiles (n= 4). 
 
5.2.3 Isolation of blood pDC and mDC  
All experiments in the present chapter used freshly isolated blood DCs. Briefly, PBMCs 
were isolated from buffy coats by Ficoll density gradient centrifugation. Subsequently, 
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the PBMCs were separated by Percoll density gradient centrifugation into a Percoll 
pellet, consisting of lymphocytes, and a Percoll interface, consisting of non-lymphocyte 
cells. The Percoll interface was further separated using MACS magnetic microbeads 
into the blood DC populations using anti-BDCA-1 microbeads for the isolation of mDC 
and anti-BDCA-4 microbeads for the isolation of pDC as previously described in 
chapter 2.8.4. The purity of the DC subpopulations were analysed by flow cytometry 
and samples were found to be at least 80% pure. An example of the phenotypes for the 
mDC and pDC obtained is given below in Figure 5.4 A and B respectively.  
 
 
 
Figure 5.4 Phenotype of purified mDC and pDC. DCs were freshly isolated from 
peripheral blood using Percoll and subsequently with BDCA-1 and BDCA-4 MACS 
magnetic microbeads for mDC (A) and pDC (B) subpopulations respectively. Cells 
were then labelled with anti-lin-1 (CD3, CD14, CD16, CD19, CD20, and CD56) FITC, 
HLA-DR PerCP, CD123 PE and CD11c APC antibodies for the analysis of cell purity 
by flow cytometry. R1 is the live lymphocyte gate which is based on cell granularity 
(side scatter, SSC-Height) and cell size (forward scatter, FSC-Height). The percentage 
of cells expressing a particular marker is given in the corresponding quadrant of each 
dot plot. 
 
 
A. mDC 
B. pDC 
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5.2.4 Induction of DC maturation 
 
In order to examine the interaction of NK cells with DCs, it was important to use DCs 
in a mature state. In normal physiology, DC maturation occurs subsequent to the 
acquisition of antigen and DCs respond by up regulating the co-stimulatory molecules 
CD80, CD86 and CD40 (Caux et al., 1994), the activation marker CD83 and the antigen 
presenting molecules MHC class I and II (Banchereau et al., 2000). To achieve this in 
vitro, DCs were cultured with TLR ligands according to their subtype; pDCs were 
cultured in the presence of CpG DNA which is a ligand for TLR9, and mDCs were 
cultured in the presence of LPS which is a ligand for TLR4. DCs are very sensitive to 
cell culture, therefore it was necessary to culture the cells in the presence of the 
following essential survival factors; IL-3 for pDCs (Bauer et al., 2001), and IL-4 and 
GM-CSF for mDCs (Sallusto and Lanzavecchia, 1994; Kadowaki et al., 2001), which 
would extend the lifespan of cultured DCs from 24 to 72 hours, allowing time for 
NK:DC co-culture experiments to be performed (Ito et al., 2001).  
 
Graphs showing mDC up-regulation of markers of maturation following treatment with 
LPS are shown below in Figure 5.5. Of the immature mDCs that were not treated with 
LPS, 2.98% were CD83+. Following treatment with LPS, the number of cells 
expressing this molecule increased to 13.71%. CD86 expression also increased from 
17.68% of immature cells to 28.36% of LPS treated cells being CD86+. A small 
increase in the number of mDCs expressing CD80 due to treatment with LPS was 
noted; from 1.12% to 3.04% of cells being CD80+. Likewise, there was also a small 
increase in CD40 expression from 1.64% to 5.60%. Overall, HLA-DR expression did 
increase after mDCs were treated with LPS. However, in some samples, no increase and 
in one sample a decrease in the number of cells expressing this molecule was seen. This 
raises doubts as to the effectiveness of the maturation in these experiments, as a increase 
in HLA-DR expression in particular, is thought of as a definitive marker of this process. 
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Figure 5.5 Phenotype of immature and LPS treated mDC. mDC were isolated from 
the Percoll interface of a buffy coat using MACS magnetic microbeads. mDC were then 
cultured overnight in the presence of IL-4 and GM-CSF and in the absence  or presence  
of LPS denoted immature and LPS treated respectively. mDCs were then stained with 
anti- CD83 FITC, CD86 FITC, CD80 PE, HLA-DR PerCP and CD40 APC conjugated 
antibody for analysis by flow cytometry shown in A, B, C, D and E respectively. In B, D 
and E, from bottom to top, horizontal lines represent the 5th, 25th, median, 75th and 95th 
percentiles (n=4). In A and C, from bottom to top horizontal lines represent the 
minimum, median and maximum values (n=3). 
 
Maturation of pDCs with the TLR9 ligand, CpG DNA, and the associated change in 
expression levels of the markers, is depicted below in Figure 5.6. Low expression of 
CD83 was seen on immature pDCs with only 2.17% being CD83+. The expression of 
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this molecule moderately increased to 7.73% being CD83+ after co-culture with CpG 
DNA. Immature pDCs were found to moderately express CD86; 26.10% CD86+, which 
increased to 47.04% after treatment with CpG DNA. A small increase in the number of 
pDCs expressing CD80 was noted, from 0.61% of immature pDC, to 4.60% of CpG 
DNA treated pDCs being CD80+. Similarly, CD40 expression was low on immature 
pDCs with only 2.08% being CD40+, and this increased to 6.37% being CD40+ after 
treatment with CpG DNA. The maturation of pDCs in these experiments may have been 
more successful that the maturation of mDCs; all samples of pDCs showed an increase 
in HLA-DR expression after treatment with CpG DNA from a mean of 68.56% to 
85.88%. 
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Figure 5.6 Phenotype of immature and CpG DNA treated pDC. pDC were isolated 
from the Percoll interface of a buffy coat using MACS magnetic microbeads. pDC were 
cultured overnight in the presence of IL-3 and in the absence or presence of CpG DNA 
denoted on the graph as immature and CpG treated respectively. pDC were then 
stained with anti-CD83 FITC, CD86 FITC, CD80 PE, HLA-DR PerCP and CD40 APC 
antibodies for analysis by flow cytometry shown in A, B, C, D and E respectively. From 
bottom to top, horizontal lines represent the minimum, mean and maximum values 
respectively (n=2). 
 
The analysis of DC co-stimulatory molecules and activation markers demonstrated that 
the methodology of maturation of both mDC and pDC was in part successful. 
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5.2.5 NK: DC interactions preliminary experiments 
 
Studying the effect of migration on NK: DC interactions is a complex in vitro 
experiment, and it was thought to be sensible to ensure that NK: DC co-cultures could 
be carried out successfully before adding NK cell migration to the already quite intricate 
assay. Results from one preliminary co-culture experiment were in agreement with 
current literature, confirming that NK cells are activated by both immature, and 
particularly by mature DCs as shown in Figure 5.7; 27.27% CD56bright NK cells that 
cultured alone were found to be CD69+ with a MFI of 13.93 vs. 37.88% with a MFI of 
21.46 when co-cultured with immature pDC, 43.03% MFI 24.66 with CpG DNA treated 
pDC, 28.99% MFI 14.37 with immature mDC and 51.57% MFI 19.57 with LPS treated 
mDC (Figure 5.7). Regarding the CD56dim subset, 36.90% of this subset cultured in the 
absence of DCs was found to be CD69+ with a MFI of 16.13 vs. 54.34% with a MFI of 
24.00 when co-cultured with immature pDC, 71.82% MFI 32.10 with CpG DNA treated 
pDC, 49.35% MFI 18.79 with immature mDC and 65.25% MFI 26.31 with LPS treated 
mDC (Figure 5.7).  
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Figure 5.7 Activation of NK cells by mDC and pDC. NK cells and DCs were purified 
from the Percoll pellet and Percoll interface of a Buffy coat respectively using MACS 
magnetic microbeads. Cells were co-cultured for 24 hours at a ratio of 1 DC: 5 NK 
cells or were cultured alone as a control. DCs were either immature or were treated 
with CpG DNA or LPS for pDC and mDC respectively. Subsequent to the co-culture, 
cells were stained with fluorochrome-conjugated antibodies against CD69, CD16 and 
CD56 to enable flow cytometric analysis of CD69 expression by NK cell subsets. 
CD56bright NK cells are depicted in the column on the left and CD56dim NK cells on 
the right. The percentage of NK cells that express CD69 is shown in A and CD69 MFI 
is shown in B. Results are single samples from a single donor. 
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Only the NK cell marker CD69 was able to be measured in pDC: NK co-culture 
experiments due to the low number of pDCs that can be isolated from peripheral blood 
and the requirement for a minimum number of cells required for flow cytometric 
analysis. The decision to only measure CD69 and not IFN-γ, TNF-α, Perforin and 
Granzyme A was made because, in order to measure these intracellular molecules, 
intracellular rather than surface staining would be performed and this requires more 
washing steps resulting in loss of cells making flow cytometric analysis more difficult. 
 
Regarding the DC mediated induction of the expression of cytokines by NK cells, small 
but incremental increases in both the percentage of NK cells expressing IFN-γ and the 
MFI of this molecule were observed; 0.12% of CD56bright NK cells were IFN-γ+ with 
a MFI of 5.11 when cultured alone, 0.52% MFI 5.87 when these cells were cultured 
with immature mDC and 0.68% MFI 6.29 with mDC that had been previously treated 
with LPS (Figure 5.8). A similar trend was observed for the CD56dim subset of NK 
cells; 0.03% of this subset that were cultured in the absence of mDC were found to be 
IFN-γ+ with a MFI of 3.64 increasing to 0.06% MFI 4.58 when cultured with immature 
mDC and 0.09% MFI 4.84 with LPS treated mDC (Figure 5.8). However, levels of IFN-
γ expression seen in these experiments were very low making results difficult to 
interpret. 
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Figure 5.8 Induction of NK cell IFN-γ expression by mDC. NK cells and mDCs were 
purified from the Percoll pellet and Percoll interface of a Buffy coat respectively using 
MACS magnetic microbeads. Cells were co-cultured for 24 hours at a ratio of 1 mDC: 
5 NK cells or were cultured alone as a control. mDC were either immature or were 
treated with LPS. Subsequent to the co-culture, cells were stained with flourochrome-
conjugated antibodies against IFN-γ, CD56 and CD16 to enable the analysis of NK cell 
IFN-γ expression by flow cytometry. CD56bright NK cells are gated on in the left 
column and CD56dim in the right column. The percentage of IFN-γ+ cells is shown in A 
and IFN-γ MFI is shown in B. Results are single samples from a single donor. 
 
TNF-α expression by NK cells was very low, difficult to measure and almost 
undetectable in some experiments and therefore these results should be treated with 
caution. Nevertheless, the percentage of TNF-α+ NK cells were found to be negligible 
if NK cells were cultured alone; 0.00% for CD56bright and 0.01% MFI 3.53 for 
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CD56dim NK cells, and also negligible if cultured with immature mDC; 0.00% for 
CD56bright and 0.03% MFI 4.43 for CD56dim NK cells. However, in the presence of 
LPS treated mDC, a detectable number of NK cells were found to express this cytokine; 
0.66% MFI 6.11 for CD56bright and 0.77% MFI 4.79 for CD56dim NK cells (Figure 
5.9). 
 
 
 
Figure 5.9 mDC induction of TNF-α expression by NK cells. NK cells and mDCs 
were purified from the Percoll pellet and Percoll interface of a Buffy coat respectively 
using MACS magnetic microbeads. Cells were co-cultured for 24 hours at a ratio of 1 
mDC: 5 NK cells or were cultured alone as a control. mDC were either immature or 
were treated with LPS. Subsequent to the co-culture, cells were stained with 
N
K
 a
lo
ne
N
K
 +
 m
D
C
N
K
 +
 m
D
C
 L
PS
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
%
 T
N
F-
+
CD56bright NK CD56dim NK 
N
K
 a
lo
ne
N
K
 +
 m
D
C
N
K
 +
 m
D
C
 L
PS
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
%
 T
N
F-
+
A
N
K
 a
lo
ne
N
K
 +
 m
D
C
N
K
 +
 m
D
C
 L
PS
0
1
2
3
4
5
6
7
TN
F-
 M
FI
 B 
N
K
 a
lo
ne
N
K
 +
 m
D
C
N
K
 +
 m
D
C
 L
PS
0
2
4
6
TN
F-
 M
FI
  Chapter 5 
 
 225
flourochrome-conjugated antibodies against TNF-α, CD56 and CD16 to enable the 
analysis of NK cell TNF-α expression by flow cytometry. CD56bright NK cells are 
gated on in the left column and CD56dim in the right column. The percentage of TFN-
α+ cells is shown in A and TNF-α MFI is shown in B. Results are single samples from a 
single donor. 
 
High expression levels of the cytotoxic molecule Granzyme A were observed in these 
preliminary experiments and, as expected, the CD56dim subset, which is more adapted 
to killing, were found to express more of this molecule compared to CD56bright NK 
cells. Co-culture of NK cells with mDCs increased the number of Granzyme A+ 
CD56bright NK cells from 61.92% MFI 40.53 recorded for CD56bright NK cells 
cultured in the absence of mDC to 69.56% MFI 53.85 in the presence of immature mDC 
and 77.03% MFI 49.65 in the presence of LPS treated mDC (Figure 5.10). However, the 
number of Granzyme A+ CD56dim NK cells remained relatively stable regardless of 
the addition of mDC to the co-culture or the maturation status of these mDC; 98.14% 
Granzyme A+ MFI 62.92 recorded for CD56dim NK cells that were cultured alone, 
98.21% MFI 73.64 with immature mDC and 96.05% MFI 62.22 with LPS treated mDC 
(Figure 5.10). 
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Figure 5.10 NK cell Granzyme A expression after co-culture of NK cells with 
mDC. NK cells and mDCs were purified from the Percoll pellet and Percoll interface of 
a Buffy coat respectively using MACS magnetic microbeads. Cells were co-cultured for 
24 hours at a ratio of 1 mDC: 5 NK cells or were cultured alone as a control. mDC 
were either immature or were treated with LPS. Subsequent to the co-culture, cells were 
stained with flourochrome-conjugated antibodies against Granzyme A, CD56 and 
CD16 to enable the analysis of NK cell Granzyme A expression by flow cytometry. 
CD56bright NK cells are gated on in the left column and CD56dim in the right column. 
The percentages of Granzyme A+ cells are shown in A, and the Granzyme A MFI is 
shown in B. Results are single samples from a single donor. 
 
Experiments measuring the induction of NK cell perforin expression by mDCs gave a 
different pattern of results. The number of Perforin+ cells and the Perforin MFI of 
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83.98% MFI 240.49 when cultured with immature mDC and 78.81% MFI 198.33 when 
cultured with mDC previously treated with LPS (Figure 5.11). However, the CD56dim 
NK cell subset showed a different trend; a relatively high percentage of NK cells 
cultured in the absence of mDC; 98.04% were perforin+ with a MFI of 300.36. This 
decreased to 67.61% Perforin+ MFI 179.10 in the presence of immature mDC. 
However, a higher percentage of CD56dim NK cells were perforin+; 90.79% with a 
MFI recorded at 290.16 when cultured with LPS treated mDC (Figure 5.11). 
 
 
Figure 5.11 Perforin expression by NK cells following co-culture with mDC. NK 
cells and mDCs were purified from the Percoll pellet and Percoll interface of a Buffy 
coat respectively using MACS magnetic microbeads. Cells were co-cultured for 24 
hours at a ratio of 1 mDC: 5 NK cells or were cultured alone as a control. mDC were 
either immature or were treated with LPS. Subsequent to the co-culture, cells were 
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stained with flourochrome-conjugated antibodies against Perforin, CD56 and CD16 to 
enable the analysis of NK cell Perforin expression by flow cytometry. CD56bright NK 
cells are gated on in the left column and CD56dim in the right column. The percentage 
of Perforin+ cells is shown in A and Perforin MFI is shown in B. Results are single 
samples from a single donor. 
 
The reciprocal effect of the co-culture of NK cells with DCs was also examined with 
measurements of DC activation markers and co-receptors being made. Figure 5.12 
depicts the results obtained for pDCs. In the absence of NK cells, the percentage of 
pDCs found to express CD83 was 7.17% MFI 21.83 and this increased to 12.12% 
CD83+ MFI 14.96 after maturation with CpG DNA. The presence of NK cells 
decreased the expression of this marker to 2.40% MFI 11.37 for immature pDCs and to 
1.59% MFI 8.48 for CpG DNA treated pDCs (Figure 5.12 A).  
 
Figure 5.12 Expression of DC co-receptors and activation markers following co-
culture of pDC with NK cells. NK cells and pDCs were purified from the Percoll 
pellet and Percoll interface of a Buffy coat respectively using MACS magnetic 
microbeads. Cells were co-cultured for 24 hours at a ratio of 1 pDC: 5 NK cells or 
were cultured alone as a control. pDC were either immature or were treated with CpG 
DNA. Subsequent to the co-culture, cells were stained with flourochrome-conjugated 
antibodies against CD83, CD80, HLA-DR, CD56, CD86 and CD40, depicted in A-F 
respectively for analysis by flow cytometry. For each marker of interest, the percentage 
of cells found to be positive for that particular marker is shown in (i) and the MFI in 
(ii). Results are single samples from a single donor. 
 
A very small number of immature and CpG DNA treated pDCs were found to be 
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MFI 19.25 and 5.14% MFI 17.81 respectively if the pDCs were co-cultured with NK 
cells (Figure 5.12 B). 
 
pDC HLA-DR expression was found to be quite low on immature pDC; 6.78% were 
HLA-DR+ MFI 102.73. However, expression of this molecule increased once the pDCs 
were cultured in the presence of CpG DNA this rose to 61.21% being HLA-DR+ MFI 
187.61. Slightly more pDCs expressed HLA-DR in the presence of NK cells; 64.62% 
MFI 255.62 for immature pDCs co-cultured with NK cells and 64.00% MFI 230.48 for 
CpG DNA treated pDCs co-cultured with NK cells (Figure 5.12 C). 
 
CD56 expression increased after pDC CpG DNA maturation from 28.16% MFI 115.63 
to 38.79% MFI 79.19. However, co-culture with NK cells appeared not to increase the 
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expression of this marker on either immature pDCs; 27.45%, MFI 21.81 or on CpG 
DNA treated pDCs; 30.01%, MFI 18.22 (Figure 5.12 D). 
 
 
However, the presence of NK cells did slightly increase pDC expression of CD86. In 
the absence of NK cells 1.56% MFI 14.73 and 2.29% MFI 22.71 of immature and CpG 
DNA treated pDCs were found to be CD86+ respectively, increasing to 3.61% MFI 
21.30 and 3.41%, MFI 18.61 for immature and CpG DNA treated pDCs that were 
cultured in the presence of NK cells respectively (Figure 5.12 E). 
 
 
pDC CD40 expression increased a little from 3.48% CD40+ MFI 18.51 to 5.00% 
CD40+ MFI 12.53 as a result of maturation with CpG DNA. Co-culture with NK cells 
boosted CD40 expression to 9.54% MFI 40.23 and 7.45% MFI 31.95 for immature and 
CpG DNA treated pDC respectively (Figure 5.12 F). 
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An identical analysis was performed for mDCs. Immature mDCs were found to express 
small amounts of CD83. LPS maturation increased the percentage of CD83+ cells and 
the MFI of this molecule from 4.65% CD83+ MFI 15.91 to 5.65% MFI 26.37. The 
addition of NK cells to the culture system further increased CD83 expression to 7.74%, 
MFI 21.32 for immature mDC and 11.61%, MFI 27.82 for LPS treated mDC (Figure 
5.13 A). 
 
Figure 5.13 Expression of DC co-receptors and activation markers following co-
culture of mDC with NK cells. NK cells and mDCs were purified from the Percoll 
pellet and Percoll interface of a Buffy coat respectively using MACS magnetic 
microbeads. Cells were co-cultured for 24 hours at a ratio of 1 mDC: 5 NK cells or 
were cultured alone as a control. mDC were either immature or were treated with LPS. 
Subsequent to the co-culture, cells were stained with flourochrome-conjugated 
antibodies against CD83, CD80, HLA-DR, CD56, CD86 and CD40, depicted in A-F 
respectively, for analysis by flow cytometry. For each marker of interest, the percentage 
m
D
C
 a
lo
ne
m
D
C
 L
PS
 a
lo
ne
m
D
C
 +
 N
K
m
D
C
 L
PS
 +
 N
K
0
5
10
15
%
 C
D
83
+
m
D
C
 a
lo
ne
m
D
C
 L
PS
 a
lo
ne
m
D
C
 +
 N
K
m
D
C
 L
PS
 +
 N
K
0
10
20
30
C
D
83
 M
FI
A (i) (ii) 
pD
C
 a
lo
ne
pD
C
 C
pG
 a
lo
ne
pD
C
 +
 N
K
pD
C
 C
pG
 +
 N
K
0
2
4
6
8
10
%
C
D
40
+
F (i) (ii) 
pD
C
 a
lo
ne
pD
C
 C
pG
 a
lo
ne
pD
C
 +
 N
K
pD
C
 C
pG
 +
 N
K
0
10
20
30
40
50
C
D
40
 M
FI
  Chapter 5 
 
 232
of cells found to be positive for that particular marker is shown in (i) and the MFI in 
(ii). Results are single samples from a single donor. 
 
Similarly, only 1.29% of immature mDCs were found to express CD80 with a MFI of 
21.01. Upon LPS maturation 6.20% were found to express CD80 with a MFI of 38.11. 
Co-culture with NK cells appeared to decrease the percentage of CD80+ cells to 0.99% 
MFI 33.11 of immature mDC and 0.09% MFI 48.67 for LPS treated mDC (Figure 5.13 
B).  
 
HLA-DR expression increased upon maturation from 91.50% MFI 436.11 to 94.34% 
MFI 561.77 after culture with LPS. Furthermore, NK cells up-regulated the expression 
of this molecule to 100% being HLA-DR+ MFI 690.96 for immature mDC and 100% 
HLA-DR+ MFI 774.86 for LPS treated mDC (Figure 5.13 C). 
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The expression of CD56 by mDC appeared to drop very slightly upon maturation from 
4.80% CD56+ with a MFI of 31.95 to 3.27% MFI 19.25. The addition of NK cells to 
the culture system increased the number of CD56+ immature and treated mDCs to 
6.44% MFI 30.28 and 9.00% MFI 26.58 respectively (Figure 5.13 D). 
 
Regarding the expression of CD86; LPS maturation of mDCs slightly increased 
expression from 4.25% MFI 57.31 to 6.27% MFI 74.86. NK cells augmented this effect; 
10.26% of immature mDC cultured with NK cells were CD86+ MFI 68.68 and 12.24% 
MFI 84.77 of LPS treated mDC were found to be CD86+ (Figure 5.13 E). 
 
 
Finally, CD40 expression increased from 8.40% MFI 37.49 to 56.27%, MFI 49.11 after 
LPS maturation. However co-culture with NK cells had almost no effect with 9.17% 
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MFI 60.84 of immature mDC and 52.20% MFI 66.45 being CD40+ if cultured in the 
presence of NK cells (Figure 5.13 F). 
 
 
 
5.2.6 mDC interactions with migrated NK cells 
 
Preliminary experiments detailed above have shown that the co-culture of mDCs with 
NK cells results in some small alterations in the phenotypic profile of both cell types. A 
small increase in mDC expression of CD83 and CD86 was noted, an increase in NK cell 
CD69 expression with a slight decrease in Perforin and increase in Granzyme A 
expression seen for the CD56bright subset. The experiments in the present subchapter 
test the hypothesis that migration may alter the effects of NK cell cross-talk with DCs 
with regard to their phenotypes. To enable this, NK cells were isolated and were either 
allowed to migrate through HUVEC monolayers or were cultured alone as a control. 
Meanwhile, mDCs were cultured in the presence or absence of LPS. Subsequently, NK 
cells and mDCs were co-cultured and examined for the expression of markers of 
interest, comparing read-outs of migrated NK cells co-cultured with mDCs to control 
NK cells co-cultured with mDCs. 
 
An example experiment of NK cell activation resulting from their interaction with DCs 
is shown in Figure 5.14 and suggests that the absence or presence of immature or LPS 
treated mDCs had little effect on NK cell expression of CD69: the percentage of 
CD56bright NK cells found to be CD69+ were 6.35%, 5.68% and 7.20% and the 
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percentage of migrated cells found to be CD69+ 11.85%, 8.05% and 9.65% when cells 
were co-cultured without mDCs, with immature mDCs and with LPS treated mDCs 
respectively (Figure 5.14). Regarding the CD56dim subset; the activation state of the 
control CD56dim NK cells increased from 7.59% of cells being CD69+ to 11.30% if 
cells were co-cultured with immature mDC and to 16.70% of cells being CD69+ if co-
cultured with LPS treated mDC. However, this was not found to be the case for 
migrated CD56dim NK cells; 19.84% of migrated NK cells cultured in the absence of 
mDCs were found to be CD69+, in the presence of immature mDCs, 16.77% of cells 
were CD69+. With LPS treated mDCs, 22.88% were CD69+ (Figure 5.14). Results 
from this experiment suggest that migration does not augment the DC-induced NK cell 
activation. Furthermore, contrary to the preliminary experiments, the addition of mDCs 
did not increase CD56bright NK cell CD69 expression. Further experiments are 
described below, and allow more definitive comments to be made. 
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Figure 5.14 NK cell activation following migration through HUVEC monolayers 
and subsequent co-culture with mDCs. NK cells and mDCs were purified from the 
Percoll pellet and Percoll interface of a Buffy coat respectively using MACS magnetic 
microbeads. NK cells were either allowed to migrate through HUVEC monolayers or 
were cultured alone as a control. mDC were cultured in the absence or presence of 
LPS. Subsequently, migrated and non-migrated NK cells were co-cultured in the 
presence or absence of immature or LPS treated mDC for 24 hours at a ratio of 1 mDC: 
5 NK cells. Cells were then stained with CD16 PE, CD56 APC and CD69 FITC-
conjugated antibodies for the analysis of NK cell activation by flow cytometry. 
CD56bright and CD56dim NK cells were gated on in the left and right columns 
respectively and the percentage of cells expressing CD69 is given in the top right 
quadrant of each dot plot.  
 
Multiple experiments (n=4) revealed similar results to the preliminary experiment 
described above; control CD56bright NK cells retained similar levels of activation 
regardless of the absence or presence of mDCs. Cultured alone, 3.92% of these cells 
were found to be CD69+, 3.55% expressed CD69 in the presence of immature mDCs 
and 3.72% in the presence of LPS treated mDC. Similarly, migrated CD56bright NK 
cells showed no change in activation when comparing cells cultured with mDCs to 
those cultured without; in the absence of mDC 5.56% of migrated CD56bright NK cells 
were CD69+, 3.44% in the presence of immature mDC and 5.11% in the presence of 
LPS treated mDC (Figure 5.15 A). Furthermore, CD56dim NK cells were only 
moderately activated by mDC. The percentage of CD69+ cells were as follows; 7.59% 
of control CD56dim NK cells in the absence of mDC, 13.06% with mDC and 16.15% 
with LPS treated mDC. Regarding migrated CD56dim NK cells; 17.42% were CD69+ 
in the absence of mDC, 15.53% in the presence of mDC and 19.00% with LPS treated 
mDC (Figure 5.15 B). If NK cells were pre-treated with IL-2, for both subsets, the 
presence of mDC actually decreased the activation state of NK cells, particularly if 
mDCs had been exposed to LPS, and this was found to be independent of whether NK 
cells had migrated previously through endothelium (Figure 5.15). Results suggest that 
NK cell migration does not augment the interaction of NK cells with mDCs. 
 
  Chapter 5 
 
 238
 
Figure 5.15 The effect of migration on CD69 expression by NK cells following co-
culture with mDCs. NK cells and mDCs were purified from the Percoll pellet and the 
Percoll interface of a Buffy coat using MACS magnetic microbeads. NK cells were 
allowed to migrate through HUVEC monolayers or were kept in culture in the absence 
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of HUVECs as a control. Migrated and non-migrated NK cells were co-cultured for 24 
hours at a ratio of 1 mDC: 5 NK cells with mDC that were either immature or were 
treated with LPS or were cultured alone as a control. Subsequently, cells were stained 
with flourochrome-conjugated antibodies against CD69, CD56, and CD16 for the 
analysis of NK cell activation by flow cytometry. In one experiment, NK cells were pre-
activated with rhIL-2 denoted on the graph as +IL-2. CD56bright (red) and CD56dim 
(blue) NK cells were gated on in graph A and B respectively. From bottom to top, the 
horizontal lines represent minimum, median and maximum values respectively. 
 
Preliminary experiments found that mDCs potentially have a small effect on NK cell 
expression of cytokines and this section investigates the possibility that prior migration 
of the NK cells may alter the mDC induction of NK cell cytokine expression. The 
presence of mDC, even mDC that had been treated with LPS, appeared to have no affect 
on the expression of IFN-γ by migrated CD56bright NK cells; 0.81% of migrated 
CD56bright cells cultured alone were found to express IFN-γ however, if cultured in the 
presence of mDCs, the percentage of IFN-γ+ cells remained low at 0.48% with 
immature mDCs and 0.85% with LPS treated mDCs (Figure 5.16 A). Of the control 
CD56bright NK cells that were cultured in the absence of mDCs 1.48% were IFN-γ+ 
and this number increased slightly to 2.27% and to 3.31% if cells were cultured in the 
presence of immature and LPS treated mDC respectively (Figure 5.16 A). The presence 
of mDCs had no effect on migrated CD56bright NK cells but did have a small effect on 
control NK cells indicating, if anything, that migration may hinder CD56bright NK cell 
cross-talk with mDC. However, if NK cells were pre-treated with IL-2, the presence of 
mDCs proportionately decreased NK cell IFN-γ expression regardless of whether the 
NK cells had previously migrated or not (Figure 5.16 A). Conversely, the presence of 
mDCs enhanced migrated CD56dim NK cell IFN-γ expression; 3.22% of these cells 
were IFN-γ+ if cultured alone but in the presence of mDC 4.56% were IFN-γ+ and 
10.88% were IFN-γ+ in the presence of LPS treated mDC (Figure 5.16 B). Also in 
contrast to findings for CD56bright NK cells, the expression of IFN-γ by control 
CD56dim NK cells appeared to be unaffected or possibly reduced by the presence of 
mDC in these experiments; when cultured alone, 5.16% were IFN-γ+ whereas in the 
presence of immature mDC and LPS treated mDC only 3.23% and 2.41% were found to 
be IFN-γ+ (Figure 5.16 B). This could be interpreted as migration augmenting the mDC 
induced CD56dim NK cell IFN-γ expression. Opposite consequences are seen for the 
two subsets of NK cells with the presence of mDC reducing the IFN-γ expression of 
migrated CD56bright and increasing the expression of this molecule on migrated 
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CD56dim NK cells. However, these results are extremely preliminary with no 
significant differences found when making statistical comparisons between any of the 
conditions. 
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Figure 5.16 The effect of migration on IFN-γ expression by NK cells following co-
culture with mDCs. NK cells and mDCs were purified from the Percoll pellet and the 
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Percoll interface of a Buffy coat using MACS magnetic microbeads. NK cells were 
allowed to migrate through HUVEC monolayers or were kept in culture in the absence 
of HUVECs as a control. Migrated and non-migrated NK cells were co-cultured for 24 
hours at a ratio of 1 mDC: 5 NK cells with mDC that were either immature or were 
treated with LPS or were cultured alone as a control. Subsequently, cells were stained 
with flourochrome-conjugated antibodies against IFN-γ, CD56, and CD16 for the 
analysis of IFN-γ expression by flow cytometry. In one experiment, NK cells were pre-
activated with rhIL-2 denoted on the graph as +IL-2. CD56bright (orange and green) 
and CD56dim (blue and dark blue) NK cells were gated on in graph A and B 
respectively. From bottom to top, the horizontal lines represent minimum, median and 
maximum values respectively. 
 
Reciprocally, NK cells can alter the functions and phenotypes of DCs and the 
hypothesis that migration of NK cells could affect this was also assessed. The presence 
of NK cells whether migrated or not, appeared to decrease the expression of CD83 on 
immature mDCs from 6.39% being CD83+ with a MFI recorded at 18.00 to 3.27% MFI 
9.41 and 3.69% MFI 10.21 in the presence of migrated and control NK cells 
respectively. Similarly, 10.85% of LPS treated mDCs cultured alone were found to be 
CD83+ with a MFI of 26.5, higher than 9.07% MFI 12.01 and 7.57% MFI 12.53 for 
cells that were cultured in the presence of migrated and control NK cells respectively 
(Figure 5.17 A). It seems that the presence of NK cells in these experiments, regardless 
of whether they have previously migrated through endothelium or not, decrease CD83 
expression by mDCs. This is not consistent with preliminary experiments where CD83 
expression was increased by the presence of NK cells. In addition, no difference was 
observed when comparing migrated with control NK cells in their ability to induce the 
expression of mDC CD83. 
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Figure 5.17 Reciprocal effect of migrated NK cells on the phenotype of mDCs. NK 
cells and mDCs were purified from the Percoll pellet and the Percoll interface of a 
Buffy coat using MACS magnetic microbeads. NK cells were allowed to migrate 
through HUVEC monolayers or were kept in culture in the absence of HUVECs as a 
control. Migrated and control NK cells were co-cultured with mDCs for 24 hours at a 
ratio of 1 mDC: 5 NK cells with mDC that were either immature or were treated with 
LPS or were cultured alone as a control. Subsequently, cells were stained with 
flourochrome-conjugated antibodies against CD83 (A), CD86 (B), CD40 (C), CD56 
(D), HLA-DR (E) and CD80 (F) for analysis by flow cytometry. For each marker of 
interest, the percentage of cells found to be positive for that particular marker is shown 
in (i) and the MFI in (ii). From bottom to top, the horizontal lines represent minimum, 
median and maximum values respectively (n=3).  
 
Furthermore, the percentage of CD86+ cells were found to be 18.19% MFI 19.49, 
20.37% MFI 16.01 and 18.83% MFI 21.28 for immature mDC and 26.09% MFI 27.58, 
24.35% MFI 19.34 and 28.44% MFI 23.26 for LPS treated mDC that were cultured 
alone, in the presence of migrated and in the presence of control NK cells respectively 
(Figure 5.17 B). These experiments suggest that NK cells do not affect mDC CD86 
expression which is in contrast to the increase seen in the preliminary experiment and 
prior migration of NK cells does not appear to affect this output of NK: mDC cross-talk. 
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mDC expression levels of CD40 increased if cultured with NK cells; in the absence of 
NK cells, 3.21% of immature mDC were CD40+ with a MFI of 2.89 rising to 24.00% 
MFI 12.20 and 23.83% MFI 11.85 in the presence of migrated and control NK cells 
respectively. Additionally, CD40 expression by LPS treated mDC was increased from 
7.33% being CD40+ with a MFI of 9.77 to 27.13% MFI 12.95 and 23.83% MFI 20.08 if 
cells were co-cultured with migrated and control NK cells respectively (Figure 5.17 C). 
The migration of NK cells through endothelium does not however appear to alter the 
NK cell-induced up-regulation of this molecule on immature NK cells. However, results 
indicate that NK cells migration may affect NK cell-induction of expression of CD40 by 
LPS treated mDC. These results are inconsistent with preliminary experiments which 
found that NK cells have no effect on mDC CD40 expression. 
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In these experiments, the presence of NK cells appeared to suppress CD56 expression 
by immature mDCs; when cultured alone, 10.33% of immature mDCs were CD56+ 
with a MFI of 16.64 which reduced to 7.04% MFI 10.76 and to 8.74% MFI 12.96 if 
cells were co-cultured with migrated and control NK cells respectively. The opposite 
was found to be true for LPS treated mDC; 4.79% MFI 16.54 was recorded for cells 
cultured alone, with higher expression levels of 9.69% MFI 12.59 and 13.62% MFI 
15.52 for cells cultured in the presence of migrated and control NK cells respectively 
(Figure 5.17 D). These results suggest that NK cells may boost CD56 expression on 
LPS treated mDCs but prior migration of the NK cells through endothelium has no 
effect. 
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The co-culture of NK cells with mDCs resulted in a minimal decrease in mDC HLA-
DR expression; 89.63% of immature mDC were found to be HLA-DR+ with a MFI of 
769.8 if they were cultured alone. However, the addition of NK cells to the culture 
system resulted in a decrease to 87.22% MFI 345.1 and to 82.10% MFI 274.8 in the 
presence of migrated and control NK cells. LPS treated mDCs were affected in a similar 
way; when cultured alone, 97.87% of these cells are HLA-DR+ with a MFI of 867.5 
which is down-regulated to 87.76% being HLA-DR+ MFI 343.7 and to 83.60% MFI 
269.6 if cells are co-cultured with migrated and control NK cells respectively (Figure 
5.17 E). These results are again contradictory to those in preliminary experiments 
although neither were found to be significant.  
 
m
D
C
m
D
C
 L
PS
m
ig
 N
K
 +
 m
D
C
co
nt
ro
l N
K
 +
 m
D
C
m
ig
 N
K
 +
 m
D
C
 L
PS
co
nt
ro
l N
K
 +
 m
D
C
 L
PS
0
10
20
30
%
C
D
56
+
m
D
C
st
im
 m
D
C
m
D
C
 +
 m
ig
 N
K
m
D
C
 +
 c
on
tro
l N
K
m
D
C
 L
PS
 +
 m
ig
 N
K
m
D
C
 L
PS
 +
 c
on
tro
l N
K
0
5
10
15
20
C
D
56
 M
FI
D (i) (ii) 
  Chapter 5 
 
 247
 
 
The expression of CD80 by immature mDC was found to be down-regulated by the 
presence of NK cells from 1.77% being CD80+ with a MFI of 13.98 for immature mDC 
cultured alone to 0.42% MFI 11.02 and 0.81% MFI 11.31 in the presence of migrated 
and control NK cells respectively. Results for LPS treated mDC differed from this; 
1.59% were CD80+ MFI 19.28 if cultured alone, 1.54% CD80+ MFI 18.61 and 0.99% 
MFI 18.17 were recorded for mDCs that were cultured in the presence of migrated and 
control NK cells respectively (Figure 5.17 F). The differences are very small however, 
results from these experiments suggest a down-regulating effect of NK cells and this 
agrees with the trend from preliminary experiments. In addition, prior migration of the 
NK cells does not affect the CD80 expression of mDCs. 
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5.2.7 pDC interactions with migrated NK cells 
 
The cross-talk between pDCs and NK cells was examined in the preliminary experiment 
described in subchapter 5.2.5 and it was found that NK cells are activated by the 
presence of pDCs. Reciprocally, NK cells were shown to alter pDC expression of co-
stimulatory molecules and activation markers including decreasing CD83 expression 
and increasing CD80, CD86, CD40 and slightly augmenting HLA-DR expression. In 
the present chapter, experiments aimed to take these findings further and investigate the 
effect of NK cell migration on this cross-talk. Two experiments were performed to 
analyse the effect of NK cell migration on pDC-induced NK cell activation. NK cells 
were allowed to migrate through HUVEC monolayers or were kept in culture in the 
absence of endothelium as a control. Subsequently, NK cells were co-cultured with 
pDCs or were cultured alone. The moderate to high levels of NK cell activation usually 
seen post-migration was found to be reduced after the further 24 hours that these cells 
were kept in culture during the co-culture experiments. Hence a low percentage of 
CD69+ cells,  particularly for the CD56bright subset, was observed in the migrated and 
control NK cell samples; cultured alone, only 2.41% of  migrated and 2.70% of control 
CD56bright NK cells were CD69+ and 11.47% of migrated and 7.19% of control 
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CD56dim NK cells were found to be CD69+. In most instances, the co-culture of NK 
cells with pDCs resulted in almost no change in the expression of CD69; in the presence 
of pDCs 2.55% of migrated CD56bright NK cells were CD69+ vs. 2.41% in the absence 
of pDC. Regarding the CD56dim subset, 11.04% were CD69+ in the presence of pDCs 
vs. 11.47% in their absence. Similarly, of the control NK cells 1.33% of CD56bright in 
the presence of, and 2.70% in the absence of, pDCs were found to express CD69 and 
7.19% of CD56dim NK cells in the presence of vs. 7.19% in the absence of pDCs were 
found to be CD69+. Results stated in the text are the mean average of the two 
experiments shown in Figure 5.18. Although the mean average of these data are 
representative for the majority of these results, there is one exception; the mean average 
of results for the control CD56dim NK cells gives the impression that the presence of 
pDCs has no effect on CD69 expression. However, in one experiment, the presence of 
pDCs decreases and in the other experiment the presence of pDCs increases CD69 
expression. Overall, data from these NK: pDC experiments suggest that contrary to 
current research, the co-culture of NK cells with pDCs regardless of the migration status 
of the NK cells does not activate NK cells. The discrepancy between these results and 
the literature and preliminary experiments is likely due to the additional 24 hours cells 
spend in these co-culture experiments diminishing the ability of the NK cells to be 
activated. 
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Figure 5.18 Migration and pDC-induced activation of NK cells. NK cells and pDCs 
were purified from the Percoll pellet and Percoll interface of a Buffy coat using MACS 
magnetic microbeads. NK cells were allowed to migrate through HUVEC monolayers 
or were kept in culture in the absence of HUVECs as a control. Migrated and control 
NK cells were co-cultured with pDCs at a ratio of 1 mDC: 5 NK cells or migrated and 
control NK cells were cultured alone as a control for the NK:DC part of the experiment. 
Subsequently, cells were stained with anti-CD69 FITC, CD16 PE and CD56 APC-
conjugated antibodies for the analysis of CD69 expression by flow cytometry. 
CD56bright NK cells are gated on in A and CD56dim NK cells are gated on in B. The 
horizontal marker is the mean of 2 experiments. 
 
The effect of NK cell migration on NK cell: pDC cross-talk and alterations in pDC co-
receptor and activation marker expression was also investigated. Some changes in the 
expression of pDC markers of interest were observed. However, results were difficult to 
interpret due to the low number of cells. 
 
Expression of the DC maturation marker CD83 by pDCs was found to be higher on 
immature pDCs compared to LPS treated pDCs; 7.75% CD83+ MFI 17.59 vs. 5.96% 
CD83+ MFI 11.98 respectively, an unexpected result as this molecule is normally up-
regulated upon maturation (Figure 5.19 A). This result suggests that the maturation of 
the pDCs with CpG DNA in this experiment was unsuccessful. Nevertheless, the 
expression levels of CD83 decreased if pDCs were co-cultured with NK cells compared 
to pDCs cultured in the absence of NK cells; 7.75%, MFI 17.59 compared to 0.98%, 
MFI 6.18 and 0.51%, MFI 5.51 for immature pDCs alone, with migrated NK cells and 
with control NK cells respectively. For pDCs incubated with CpG DNA that were 
cultured in the absence of NK cells; 5.96% MFI 11.98 were CD83+ compared to 4.29% 
MFI 10.44 and 0.42% MFI 5.93 for cells cultured in the presence of migrated NK cells 
and in the presence of control NK cells respectively (Figure 5.19 A). The decrease in 
CD83 expression is consistent with findings from the preliminary experiments. 
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Figure 5.19 Reciprocal effect of migrated NK cells on the phenotype of pDCs. NK 
cells and pDCs were purified from the Percoll pellet and Percoll interface of a Buffy 
coat using MACS magnetic microbeads. NK cells were allowed to migrate through 
HUVEC monolayers or were kept in culture in the absence of HUVECs as a control. 
Migrated and control NK cells were co-cultured with pDCs at a ratio of 1 mDC: 5 NK 
cells or migrated and control NK cells were cultured alone as a control for the NK:DC 
part of the experiment. Subsequently, cells were either unstained for the particular 
marker of interest as a control, or were stained with anti-CD83 in A, CD80 in B, HLA-
DR in C, CD86 in D, CD56 in E and CD40 antibody  in F for the analysis of the 
expression of these markers by flow cytometry. The first row shows immature pDCs and 
the second row shoes pDCs that have been treated with CpG DNA. Depicted in columns 
from left to right are unstained pDCs that were cultured alone, stained pDCs that were 
cultured alone, pDCs co-cultured with migrated NK cells and pDCs co-cultured with 
control NK cells with the MFI of the marker of interest given on each histogram.  
 
The co-stimulatory molecule CD80 was found to be expressed by immature pDC, but 
similar to CD83, once the pDC were incubated with CpG DNA, surprisingly no up-
regulation of this molecule was observed confirming that the maturation process was 
not successful. Regarding immature pDCs that were cultured alone, 0.37% were found 
to be CD80+ with a MFI of 9.88. If the pDCs were treated with CpG DNA, comparable 
expression levels were observed with 0.46% being CD80+ MFI 9.22. Immature pDC 
expression of CD80 decreased to levels lower than cells cultured alone if the cells were 
co-cultured with migrated or with control NK cells; 0.01%, MFI 4.07 and 0.00%, MFI 
3.16 respectively. However, slightly more of pDCs that were incubated with CpG DNA 
were found to be CD80+ if cultured with migrated NK cells; 1.43%, MFI 9.98 
Unstained 
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pDC  
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compared to those cultured with control NK cells; 0.03%, MFI 2.46 (Figure 5.19 B). 
These results are contrary to preliminary experiments which showed an increase as a 
result of co-culture with NK cells. 
 
 
 
Results for NK cell-induced expression of HLA-DR by immature pDC were found to be 
consistent with the preliminary findings described in subchapter 5.2.5. When cultured 
alone, 78.24% of immature pDC were found to be HLA-DR+ with a MFI of 64.14 
rising to 87.37% MFI 113.04 in the presence of migrated NK cells and 90.79% MFI 
130.67 in the presence of control NK cells (Figure 5.19 C). Although the presence of 
NK cells increased the expression of this molecule, both migrated and control NK cells 
induced a similar expression level, suggesting that prior migration does not affect NK 
cell up-regulation of HLA-DR. Results for pDCs incubated with CpG DNA were very 
inconsistent; 63.43% of cells cultured alone were found to be HLA-DR+ with a MFI 
read-out of 22.46 compared to 8.00%, MFI 12.09 and 96.13%, MFI 160.11 for CpG 
DNA treated pDCs co-cultured with migrated and control NK cells respectively (Figure 
5.19 C). The poor and inconsistent read-outs observed for CPG DNA treated pDCs are 
likely due to the low number of cells, making these results difficult to interpret. 
However, the results for immature pDCs are consistent with the rise in HLA-DR 
expression observed in the preliminary experiments. 
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Another co-stimulatory molecule; CD86 was not up-regulated on pDCs following 
incubation with CpG DNA, again suggesting that the maturation process in this 
experiment was unsuccessful. However, the presence of NK cells, regardless of whether 
NK cells had previously migrated through endothelium or not, appeared to decrease 
expression levels of this molecule on pDCs from 28.67% MFI 25.40 for immature pDCs 
cultured alone to 4.34% MFI 13.01 when co-cultured with migrated NK cells and 
3.33% MFI 12.26 when co-cultured with control NK cells (Figure 5.19 D). A similar 
trend was observed for CpG incubated pDCs; 28.67% CD86+ MFI 24.44 was recorded 
for CpG DNA treated pDCs cultured alone compared to 6.38% MFI 12.28 for pDCs 
with migrated NK cells and 2.44% MFI 10.50 for pDCs cultured with control NK cells 
(Figure 5.19 D). These results are in contrast to preliminary experiments that showed a 
small increase in CD86 expression after co-culture with NK cells. 
C Unstained Alone + Migrated NK + Control NK 
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A population of CD56+ HLA-DR+ cells sharing other properties with classical CD56- 
DCs has been recently described (Burt et al., 2008). Investigation of this potential 
subset of DCs showed that these cells could be derived in vitro by the differentiation of 
monocytes using IFN-α, resulting in functional CD56+ DCs (Papewalis et al., 2008) 
that can promote TH1 T cell responses (Gruenbacher et al., 2009). Hence the possibility 
that NK cells, and particularly NK cells that have previously migrated through 
endothelium, may up-regulate the expression of CD56 on blood pDCs was investigated. 
pDCs were found to express CD56; expression of this molecule was dampened by the 
presence of NK cells. When cultured alone, the percentage of CD56+ immature pDCs 
was found to be 5.94% MFI 15.13 compared to 1.82% MFI 3.59 and 0.77% MFI 3.71 
for pDCs co-cultured with migrated and control NK cells respectively (Figure 5.19 E). 
CpG DNA pre-treated pDCs cultured alone were found to have expression levels of 
CD56 similar to immature pDCs; 3.70% were CD56+ with a MFI of 15.35. Similarly, 
expression levels decreased with the addition of NK cells to the culture system to 1.75% 
MFI 13.58 and 0.51% MFI 2.85 with migrated and control NK cells respectively 
(Figure 5.19 E). Again, this is inconsistent with preliminary experiments which found 
the expression of CD56 by pDCs to be unaffected by the presence of NK cells. 
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pDC expression of CD40 appeared to be unaffected by the presence of migrated NK 
cells and decreased slightly in the presence of control NK cells. Alone, 6.48% of 
immature pDCs were CD40+ with a MFI of 10.71 vs. 2.06% MFI 10.09 with migrated 
and 4.77% MFI 7.36 with control NK cells. However for CpG incubated pDCs, the 
presence of migrated NK cells increased the expression of CD40 above levels for cells 
cultured alone and also for those cultured with control NK cells; 5.22% MFI 11.00 for 
cells cultured alone, 10.00% MFI 7.05 for pDCs with migrated NK and 5.96% MFI 7.11 
with control NK cells (Figure 5.19 F). This is not consistent with preliminary 
experiments that showed a small increase of CD40 expression in the presence of NK 
cells. 
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Due to the low numbers of pDCs that can be isolated from blood, it was difficult to 
examine several markers of interest in one experiment by flow cytometry. Solutions to 
this problem include flow cytometry using more than 4 colours, which would allow the 
analysis of more markers of interest from a smaller number of cells. Another solution 
would be to perform multiple experiments, each analysing only a few markers of 
interest, therefore a larger quantity of cells could be used and better flow cytometric 
data obtained.  
 
5.3 Discussion 
 
To enable the investigation of the effect of NK cell migration on the interaction of NK 
cells with cells of the monocyte/macrophage lineage, pure populations of both cell types 
were required. Work in the present chapter demonstrated successful preparation of 
macrophage populations, achieving a purity of above 95%. Furthermore, in agreement 
with Nedvetski et al. (Nedvetzki et al., 2007), pre-treatment of macrophages with 200 
ng/ml LPS Salmonella Minnesota was a necessary pre-requisite for the successful 
induction of NK cell proliferation by these cells. Some interesting results came from 
NK: macrophage co-culture experiments. Firstly, it appeared that to a small degree, 
migration alone increased the proliferative capacity of CD56bright but not CD56dim 
NK cells. However, when cultured in the presence of macrophages, a higher percentage 
of both NK cell subsets had proliferated compared to cells cultured in the absence of 
Unstained Alone + Migrated NK + Control NK F 
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macrophages. Interestingly, in the presence of macrophages, the highest percentage of 
proliferating cells was recorded for the CD56dim subset. Results suggest that migration 
increases the basal proliferation of CD56bright NK cells and also increases the 
macrophage-induced proliferation of both CD56bright and in particular, CD56dim NK 
cells. In the context of inflammation, the observed macrophage-induced proliferation of 
CD56bright NK cells adds to the reciprocal activation story, as these cells respond by 
activating macrophages via the production of IFN-γ. However, although the higher 
proliferation of the more cytotoxic CD56dim NK cells may not have as direct 
consequences for macrophages, this NK cell subset would of course play a major role in 
killing any pathogen in the context of inflammation due to an infection, and also in DC 
editing. Potential mechanisms for the macrophage-induced enhancement of NK cell 
proliferation include the secretion of IL-15 by macrophages (Dalbeth et al., 2004, 
Nedvetzki et al., 2007) and NK cell-NKG2D recognition of stress inducible ligands on 
macophages (Nedvetzki et al., 2010). The contribution of these potential mechanisms 
could be analysed by the segregation of macrophages from the NK cells in the co-
culture experiments using a micro-pore membrane which would allow the transfer of 
soluble molecules between the cells but prevent direct cell contact. This would enable 
an analysis of the contribution of IL-15 or soluble NKG2D ligands. The contribution of 
an individual factor, for example IL-15, could be further analysed using antibody 
blocking experiments in which saturating quantities of anti-IL-15 antibody could be 
added to the culture medium in a migrated NK cell: macrophage co-culture experiment. 
The blocking antibody would eliminate the IL-15 from the NK cell: macrophage cross-
talk and allow a quantitative analysis of its contribution by measuring NK cell 
proliferation, using the FACS based assay described above, and by comparing cell 
cultures with and without the blocking antibody. 
 
Regarding NK: DC interactions, the preliminary experiments in the present chapter 
show successful in vitro DC maturation. However, in migration studies of NK: pDC 
cross-talk, the maturation of pDC was found to be unsuccessful with almost no increase 
in the expression of co-stimulatory molecules, a phenotypic change that confirms a 
mature pDC phenotype. Thus, results from NK: CpG DNA treated pDC experiments 
remain inconclusive and further experiments are required to firstly test the quality of 
CpG DNA used and then to re-test the parameters measured in these experiments. 
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Preliminary experiments with the aim of achieving read-outs from NK: mDC co-
cultures corroborate with current research (Gerosa et al., 2005) and findings suggesting 
that immature and in particular mature mDCs are able to activate NK cells, shown by an 
increase in CD69 expression levels. These preliminary experiments also found that NK 
cells can up-regulate mDC expression of CD83, CD86 and to a small degree, HLA-DR. 
However, experiments studying the effect on NK cell migration on this cross-talk gave 
some conflicting results. The migration studies found mDCs to have no effect on NK 
cell activation and to down-regulate mDC expression of CD83, HLA-DR and CD80 but 
up-regulate CD40. Overall, the presence of NK cells in the migration study experiments 
appeared to be suppressing rather than activating the mDCs which is in contrast to many 
studies which have shown NK cells to mediate DC maturation (Coudert et al., 2002; 
Piccioli et al., 2002; Mocikat et al., 2003; Adam et al., 2005). These inconsistencies are 
likely due to the technical difficulties of the longer term culture of NK cells in the 
experiments that firstly require a NK cell migration assay followed by a NK: DC co-
culture. Perhaps these assays are longer than cells can function properly for. Very few 
parameters were affected by the prior migration of NK cells, with the exception of a 
possible protective effect on mDC HLA-DR expression and a possible increase of 
CD40 expression on LPS treated mDC but the changes are very small and with no 
statistical difference found between them. 
 
Preliminary pDC: NK cell co-culture experiments were consistent with current literature 
(Gerosa et al., 2005) and found pDCs to be able to activate NK cells as measured by 
expression of the early activation antigen CD69. Due to the lack of cells, CD69 was the 
only NK cell parameter measured in NK: pDC co-culture experiments. Regarding the 
reciprocal activation of pDCs, the expression levels of CD80, CD40, CD86, and to a 
small degree HLA-DR was found to increase when cells were co-cultured with NK 
cells. However, CD83 expression dropped under these conditions and CD56 expression 
remained unchanged. These results imply that NK cells can mediate DC maturation. 
Research undertaken by Piccioli and colleagues supports these findings and the authors 
suggest that this interaction plays an important role in anti-tumour immunity where non-
self molecules, which are the classical stimulants for DC maturation, are lacking 
(Piccioli et al., 2002).  However, the potential for NK cells to stimulate and induce 
maturation of DCs in the absence of non-self molecules could be disadvantageous in 
auto-immunity, particularly when considering the subsequent T cell interaction with 
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mature DCs. Migration studies gave some contrasting results to preliminary 
experiments; the co-culture of pDCs with NK cells in these experiments suggested that 
pDCs can not activate NK cells, regardless of the migration status of the NK cells. It is 
likely that this discrepancy can be explained by the extra 24 hours in culture 
diminishing the ability of NK cells to be activated by pDCs. This theory is supported by 
the observations in these experiments that even migrated NK cells cultured in the 
absence of pDCs have low CD69 expression, which is opposite to migration assays 
described in chapters 3 and 4 where migrated NK cells express moderate to high levels 
of CD69. Discrepancies between migration studies and preliminary experiments were 
found regarding pDC expression of CD86, CD40 and CD80 which were found to be 
decreased by the presence of NK cells in migration studies but increased in preliminary 
experiments. However, results from migration studies showed a NK cell-induced 
increase in HLA-DR and decrease in CD83 which is consistent with the preliminary 
experiments. Regarding the effect of migration on NK: pDC cross-talk, a possible 
maintenance of some pDC expression of CD56 and CD86 which could be attributed to 
the presence of migrated NK cells was noted. However, since results from migration 
studies were so inconsistent with preliminary experiments it is impossible to interpret 
the results from migrated NK cell: pDC cross-talk outputs with confidence. 
 
No statistical differences were found between expression levels of molecules on either 
NK cells or DCs when cultured together compared to cells cultured alone. However, 
only a small number of experiments were performed and additional NK: DC co-cultures 
need to be performed in future experiments to gain a clearer picture. Results in this 
chapter suggest that migration does not augment NK: DC cross-talk. However, since 
many inconsistencies were seen between preliminary experiments and migration 
studies, these results are inconclusive. The sensitivity of NK cells to long term culture 
perhaps make these questions too difficult to answer in the context of in vitro assays and 
further experimentation with a different experimental design would help to ascertain the 
effect of NK cell migration on NK: DC cross-talk. 
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Chapter 6 
 
Phenotypic characterisation of an unconventional CD56- CD16+ 
subset of NK cells 
 
 
6.1 Background and aims 
 
An unconventional and highly dysfunctional novel subset of NK cells has been noted in 
several pathological conditions. Mavilio and colleagues have published several studies 
characterising this novel NK cell subset, with a particular interest in their involvement 
in HIV-1 disease progression. During the course of this disease, the cross-talk between 
NK cells and DCs is known to become aberrant. This results in incomplete DC 
maturation and a lack of DC editing, the latter process would normally select the most 
appropriate DCs to establish the adaptive response, and faults in both processes result in 
a deficient T cell response (Fauci et al., 2005). Mavilio et al. found these abnormalities 
to be particularly pronounced in a subset of NK cells which were CD56- CD16+, and 
these cells were expanded in patients with high viral replication but rare in healthy 
donors or patients whose viraemia has been suppressed by Anti Retroviral Therapy 
(ART) (Mavilio et al., 2003; Alter et al., 2005; Mavilio et al., 2006). Due to the high 
frequency of these abnormal NK cells, their low expression of NKp30 and TRAIL, and 
the finding that NKp30+ KIR- NKG2Adim NK cells are responsible for DC maturation 
(Vitale et al., 2005), the authors suggest that the CD56- CD16+ NK cells are responsible 
for the incomplete maturation of DCs observed in HIV-1 infection (Mavilio et al., 
2006). Characterised as having high expression levels of inhibitory NK cell receptors, 
low natural cytotoxicity receptors with the exception of NKG2D, and being poorly 
cytotoxic with little or no cytokine production, these cells have been shown to occur at a 
frequency of 7% of the total NK cell compartment in healthy donors and 28% in HIV-1 
viraemic patients (Mavilio et al., 2005). Another study noted an enormous expansion of 
CD56- CD16+ 2B4+ NK cells in a patient with Ocular Myasthenia Gravis, constituting 
up to 86% of the total lymphocyte population. Phenotypic analysis of this NK cell 
subset revealed, similar to the Mavilio study, low expression of NKp30 with 34% being 
NKp30+ vs. 78% in healthy donors and these cells were also found to express negligible 
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levels of NKp46. Functionally, these cells were found to be poorly cytotoxic but had a 
high proliferative capacity resulting from 2B4/CD48 interactions. This patient went into 
remission after immuno-suppression, and treatment was accompanied by a decrease in 
the cell count of these CD56- CD16+ 2B4+ NK cells (Nguyen et al., 2006). Similarly, 
Fujita and colleagues reported that a patient diagnosed with the autoimmune disease 
primary Sjögren’s Syndrome had a high CD56- CD16+ cell count with 2520 cells/ μl 
vs. 100 cells/ μl typically found in healthy donors, and that these cells were suppressed 
after treatment with non-steroidal anti-inflammatory drugs in combination with high 
dose steroid therapy (Fujita et al., 2007). Furthermore, a sharp increase in the number of 
CD56- CD16+ NK cells was seen in patients with HIV-1 and Hepatitis C co-infection 
despite successful ART therapy (Gonzalez et al., 2009). An explanation as to why 
results from this study differ to the experiments of Mavilio et al. could be either a high 
number of these cells resulting from Hepatitis C, which is supported by the observation 
that the number of CD56- CD16+ NK cells was found to parallel Hepatitis C viral load 
or that the high number of these cells results from HIV infection with failure to suppress 
this by ART due to the simultaneous infection with Hepatitis C. Interestingly, in this 
study the number of CD56- CD16+ cells before treatment correlated with clinical 
outcomes. To date, no study has fully characterised the phenotype of this 
unconventional CD56- CD16+ NK cell subset. By means of 6 colour flow cytometry, 
experiments in the present chapter aim to give a comprehensive phenotypic profile of 
these cells using samples from healthy volunteers. Briefly, lymphocytes were freshly 
isolated from peripheral blood and stained with fluorochrome-conjugated antibodies 
against NK cell markers for analysis by flow cytometry. Work carried out by Hikari 
Osaki is also documented in the present chapter to provide a more complete picture of 
this potential novel CD56- CD16+ subset of NK cells. 
 
6.2 Results 
 
6.2.1 Defining the CD56- CD16+ subset of NK cells 
 
Defining what is and what isn’t an NK cell can be difficult. Previous studies have 
referred to the CD56- CD16+ cells as a subset of NK cells. However, CD56 expression, 
along with the lack of expression of CD3 and CD19 or CD20 are commonly used to 
identify NK cells. Furthermore, the only marker that is exclusively expressed by NK 
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cells is NKp46, although not all NK cells posses this surface molecule. As shown in the 
subsequent subchapter, the CD56- CD16+ cells by definition do not express CD56 and 
also the majority do not express NKp46, therefore can they be classified as true NK 
cells? Analysis by flow cytometry finds this CD56- CD16+ population to be within the 
lymphocyte gate, therefore eliminating DCs and cells of the monocyte/macrophage 
lineage as potential candidates, to lack CD3, CD19 and CD20 expression, therefore 
eliminating T and B cells, and to express high levels of CD16. From these observations, 
one can understand how researchers have identified these cells as NK cells. However, 
cells are not defined by phenotype alone but also by function and hence functional 
analysis of these CD56- CD16+ cells is required. The dot plot results from flow 
cytometric analysis of PBMCs depicted in Figure 7.1 shows how these CD56- CD16+ 
cells are gated and defined in the work presented in this chapter. Cells within the live 
lymphocyte gate were selected and any CD3, CD19 or CD20 cells were excluded by 
negative gating. The markers most commonly used to define NK cell subsets; CD16 and 
CD56 were plotted and subsets were gated as defined by CD56+ CD16- for the 
CD56bright subset, CD56+ CD16+ for the CD56dim subset and CD56- CD16+ for the 
novel NK cell subset as depicted in Figure 7.1 by green, blue and red circles 
respectively. 
 
Figure 6.1 Gating of NK cell subsets and CD56- CD16+ cells. PBMCs were isolated 
from whole blood and stained with antibodies against CD3, CD19, and CD20 
conjugated to PerCP, CD56 conjugated to APC and CD16 conjugated to PE. Cells were 
selected on the basis of lack of CD3, CD19 and CD20 expression and CD16 was plotted 
against CD56 for visualisation of the NK cell subsets CD56bright, CD56dim and CD56- 
CD16+ encircled in green, blue and red respectively. 100,000 events shown. 
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6.2.2 Phenotyping of CD56- CD16+ NK cells using four colour flow cytometry. 
 
Extensive phenotyping of the CD56- CD16+ population of NK cells, described in the 
present sub-chapter, was carried out by Hikari Osaki using 4 colour flow cytometry and 
is included to give a more detailed picture of this subset. Table 6.1 summarises the 
results comparing the CD56- CD16+ NK cells to the more conventional CD56bright 
and CD56dim NK cell subsets. In summary, CD56-CD16+ NK cells did not express 
IFN-γ but did express intermediate levels of Granzyme A and Perforin, suggesting that 
like the CD56dim subset, these cells have some cytotoxic activity. Furthermore, these 
cells had similar expression levels of NKG2D, NKG2C, NKG2A, NKp30, NKp44 and 
NKp46 and 2B4 to that of CD56dim NK cells. Analogous to CD56dim NK cells, CD27 
expression was absent from CD56- CD16+ cells which is in contrast to CD56bright NK 
cells, some of which do express this molecule. Thus far, the phenotype of CD56- 
CD16+ NK cells is comparable to CD56dim NK cells. However, some differences were 
noted including lower CD94 expression than both CD56bright and CD56dim NK cells, 
different KIR expression to the conventional NK cells; KIRs are not expressed by 
CD56bright but are expressed at high levels by CD56dim NK cells whereas the number 
of KIR+ CD56- CD16+ cells was found to be intermediate. In contrast to NK cells, the 
CD56- CD16+ population were found to express high levels of the co-stimulatory 
molecules CD85 and CD86.  
 
 CD56bright CD56dim CD56- 
CD16+ 
IFN-γ + - - 
Granzyme A + + + + + +  
Perforin + + + + + + 
2B4 + + + + 
NKG2D + + + + 
KG2C + + + 
NKG2A + + + + + 
NKp46 + + + + 
NKp44 + + - - 
NKp30 + + + 
CD85 - - + + 
CD27 + + - - 
CD86 - - + + 
CD94 + + + + + + 
KIR - + + + 
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Table 6.1 Summary of the phenotypic analysis of CD56- CD16+ NK cells. The table 
depicts a summary of the results from 4-colour flow cytometric analysis by Hikari 
Osaki. Markers of interest are listed in the first column and expression levels are 
depicted as – if cells did not express the marker, +, + + and + + + if cells were found to 
express low, intermediate or high levels of the marker respectively. CD56bright NK 
cells are shown in the second column, CD56dim in the third and CD56- CD16+ cells in 
the fourth column. Results represent averages of at least 9 experiments. 
 
Overall, the CD56- CD16+ population appears to have a phenotype more similar to the 
CD56dim than the CD56bright subset of NK cells. However, the expression of co-
stimulatory molecules raises the possibility that these cells could have antigen 
presenting properties and this point is addressed later in the chapter. 
 
6.2.3 Phenotyping of CD56- CD16+ NK cells using 6 colour flow cytometry 
 
Further phenotyping of the CD56- CD16+ subset using 6 colour flow cytometry 
allowed the investigation of the co-expression of markers of interest including the co-
stimulatory molecules CD85 and CD86 and the class II molecule and DC marker HLA-
DR with NK cell markers. Mean results from 3 donors are shown in Figure 6.1.  
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Figure 6.2      Summary of CD56- CD16+ NK cell phenotyping using 6 colour flow 
cytometry. PBMCs were isolated from healthy volunteers (n=3) and were stained with 
fluorescence-conjugated antibodies against markers of interest for analysis by 6 colour 
flow cytometry using a BD LSR II flow cytometer. Unlike the rest of the results in this 
thesis, data was analysed using FACS DIVA software. Horizontal lines represent mean 
and maximum results. Results for the CD56bright, CD56dim and CD56-CD16+ cells 
are shown in the top, middle and lower rows respectively. 
 
The majority of CD56- CD16+ cells were HLA-DR+ and most of these HLA-DR+ cells 
co-expressed the co-stimulatory molecules CD85 and CD86. This is quite a different 
phenotype to the classical NK cells subsets as less than 3% of CD56dim NK and less 
than 15% of CD56bright NK cells express any one of these three molecules. The 
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definitive NK cell marker, NKp46 was found to be expressed by the majority of the 
classical NK cell subsets; 91.60% of CD56bright and 76.7% of CD56dim compared to 
21.85% of the CD56- CD16+ population. Very few of the CD56-CD16+ cells co-
expressed NKp46 with HLA-DR, CD85 or CD86. However, the CD56-CD16+ cells did 
show co-expression of NKp46 with KIR and Granzyme A. The results suggest that 
there are broadly two subsets of CD56-CD16+ cells; one of which has a similar 
phenotype to conventional CD56dim NK cells with the expression of NKp46, 
Granzyme A and  KIR and the second of which is dissimilar with expression of CD85 
and CD86. Whilst the majority of the HLA-DR+ CD56-CD16+ cells belong to this 
latter CD85+ CD86+ subset, we did note a small population of HLA-DR+ cells with the 
NKp46+, Granzyme A+ and KIR+ phenotype.  
 
Although the CD56- CD16+ population fall within the live lymphocyte gate, the 
possibility that cells of the monocyte/macrophage lineage could be within this gate 
needed to be addressed. To test this, cells were stained with FITC-conjugated anti-
CD14 antibody in addition to markers that would enable the identification of NK cells. 
The dot plot in Figure 6.2 depicts the results from the flow cytometric analysis. All live 
PBMCs were gated on and were plotted with CD14 against CD56. CD56bright NK cells 
are shown in pink, CD56dim in orange, and CD56- CD16+ cells in blue with all other 
cells depicted in green (Figure 6.2). The classical NK cell subsets appear to express the 
lowest levels of CD14 with the CD56- CD16+ cells being segregated into two 
subpopulations, one with CD14 expression levels similar to the classical NK cells and 
one with intermediate CD14 expression levels which is lower than cells of the 
monocyte/macrophage lineage (Figure 6.2). These results agree with the theory that 
CD56- CD16+ cells are of two types; we hypothesise that the CD85+ CD86+ subset of 
CD56- CD16+ cells would be the cells showing evidence of CD14 expression.  
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Figure 6.3 Flow cytometric analysis comparing CD14 expression on all PBMCs 
with CD56bright and CD56dim NK cells and the CD56- CD16+ subset. PBMCs 
from one healthy volunteer were isolated by Ficoll density centrifugation and were 
stained with CD56 APC-conjugated and CD14 FITC-conjugated antibody for analysis 
by flow cytometry. All PBMCs were gated on and CD%6bright NK cells are shown in 
pink, CD56dim NK cells in orange and CD56- CD16+ cells in blue. All other PBMCs 
are depicted in green.  
 
6.3 Discussion 
 
An interesting and possibly novel subset of NK cells has been described with studies 
predominantly related to clinical pathology. The present chapter provides a detailed 
phenotypic profile of these cells and results have shown that it is probable these cells 
fall into two groups; one group similar to CD56dim NK cell with the difference of 
negative expression of CD56, and a second group that share traits of NK cells with DCs. 
Cells that share the features of NK cells and DCs have been recently and extensively 
reported. Indeed, interferon-producing killer dendritic cells or ‘IKDCs’ have been 
described as both NK cells with antigen presenting properties (GeurtsvanKessel et al., 
2009) and DCs that can acquire cytotoxic capacity (Larmonier et al., ; Chaperot et al., 
2006; Hardy et al., 2007; Stary et al., 2007) and it is possible that the CD56- CD16+ 
cells that we have studied fall into one or the other of these descriptions. Possibly the 
most closely related to the CD56- CD16+ cells reported in the present chapter are the 
mDC subpopulation reported by Schmitz et al. to be CD16+ mM-DC8+ with the ability 
to induce tumour directed antibody dependent cell mediated cytotoxicity (Schmitz et al., 
2002). Indeed, the lack of CD56 expression by these cells would be consistent with a 
hypothesis that these cells are DCs with functional and phenotypic features of NK cells. 
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However, results in the present chapter could also be interpreted as the cells being NK 
cells with DC-like markers and this alternate view is supported by the observations of 
Hanna et al. that NK cells co-cultured with influenza-infected target cells up-regulate 
CD86 and HLA-DR expression (Hanna et al., 2004), both of which are expressed at 
high levels by the CD56- CD16+ cells. Furthering this discussion, a small expansion of 
CD56- cells after NK cell functional assays was noted in experiments in the present 
thesis, perhaps representing NK cells that have been ‘spent’. Therefore another 
hypothesis emerges; CD56- CD16+ cells are NK cells that have become activated, 
hence the high expression of HLA-DR and co-stimulatory molecules and decreased 
CD56 expression after fulfilling their function. In the context of other studies on CD56- 
CD16+ cells, this does introduce the possibility that the high numbers of these cells seen 
in pathological settings could reflect NK cells that have carried out their function rather 
than cells which are responsible for the disease pathology.  
 
The large numbers of cells seen in the clinical studies, which are detailed in the 
introduction to this chapter, cannot be accounted for by an increase in conventional DCs 
or NK cells and therefore these studies do point towards CD56- CD16+ cells as being a 
novel subset worthy of further investigation. Notably, it is likely that NK cell 
researchers incidentally have considerable data that could be accessed by re-gating 
FACS plots using a CD56-CD16+ gate. Further examination of the phenotype of CD56- 
CD16+ cells, including measurements of the markers typically used to identify DCs; 
CD123 and CD11c and other DC markers such as MHC class I and the co-stimulatory 
molecule CD80 would also provide an insight as to the true definition of these cells. 
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Chapter 7 
 
Conclusions and future work 
 
Interactions between immune cells and vascular endothelial cells occur as they pass 
from the blood stream, through the vessel wall to the site of inflammation. This cross-
talk interaction is now known to be complex, with important implications regarding the 
numbers and types of cell that reach the inflammatory focus. Immune cell migration 
occurs under both physiological and pathological conditions. Usually the former reflects 
immune surveillance by T cells and the latter the body’s response to trauma or infection. 
Knowledge of the effect of interactions with endothelial cells during physiological 
lymphocyte trafficking is very sparse. However, a bank of knowledge regarding 
migration under pathological conditions is growing, with the majority of migrated T 
cells exhibiting a more pro-inflammatory phenotype (reviewed by (Nourshargh and 
Marelli-Berg, 2005). Migrated cells contribute to protection in diseases and infections 
which resolve, but in conditions of non-resolving inflammation, the question remains as 
to whether these migrated cells are providing protection, or contributing to the 
pathology. One such disease of non-resolving inflammation is rheumatoid arthritis. 
Samples of synovial fluid from patients with rheumatoid arthritis show an abnormal 
accumulation of the CD56bright subset of NK cells (Dalbeth and Callan, 2002; 
Pridgeon et al., 2003; Dalbeth et al., 2004). These CD56bright NK cells have also been 
found at other sites of inflammation, including in pleural and peritoneal fluid in patients 
with pneumonia or peritonitis (Dalbeth et al., 2004). 
 
The work presented in this thesis determines the method of the accumulation of the 
CD56bright subset of NK cells which is seen at sites of inflammation. This thesis also 
examines the effect of the interaction of NK cells with the endothelium by measuring 
NK cell activation, phenotype, functional capacities and interactions with DCs and cells 
of the monocyte/macrophage lineage.  
 
Initial experiments presented in chapter 3 set up an in vitro model of cell migration 
using the EA.hy 926 endothelial cell line. A preliminary experiment using this model 
suggested that the accumulation of the CD56bright subset of NK cells is due to 
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preferential recruitment and not local differentiation from the CD56dim subset. A 
similar method of accumulation has been shown by Pitzalis and colleagues for CD4+ 
CD45RO+ T cells in a model of inflammation using suction induced blisters, and 
similar to findings in the present study, this group also ruled out in situ proliferation or a 
conversion from another phenotype (Pitzalis et al., 1991). Experiments in this thesis 
found the accumulation of CD56bright NK cells post-migration to be significantly 
higher than CD56dim NK cells, but experiments did not emulate the very high numbers 
seen in vivo where 90% of the NK cell pool are CD56bright (Dalbeth and Callan, 2002). 
One possible explanation for this is the lack of pro-inflammatory cells and factors in the 
in vitro assay which could contribute to the grater quantity of recruitment of 
CD56bright NK cells seen in vivo. Thus further experiments are required to examine the 
relative contribution of the endothelium compared to the contribution made by cells and 
cytokines that would be found at sites of inflammation. Perhaps this information would 
give an insight into the most effective target for anti-inflammatory therapies that exploit 
the process of cell migration. Experiments in Chapter 4 used HUVECs rather than 
EA.hy 926 endothelial cells to bring the assay closer to the in vivo environment. These 
experiments confirmed that CD56bright NK cells are preferentially recruited and 
investigated this further by analysing the quantity of differentiation from one NK cell 
subset to the other. Differentiation between the NK cell subsets was not convincingly 
demonstrated, although we could not rule out the possibility that some might 
differentiate into CD56dim NK cells. If anything, this would imply that the number of 
CD56bright NK cells migrating in the experiments was underestimated. The possibility 
that CD56bright NK cells do differentiate into CD56dim NK cells is a theory which has 
been supported in a number of studies (Nagler et al., 1989; Mrozek et al., 1996; 
Caligiuri, 2008). Regarding the results of our studies, we suggest that rather than 
phenotype conversion, any change in the number of NK cells of a particular subset is 
likely to reflect a decrease in CD56 expression. It is possible that this results from the 
longer term cell culture of NK cells in these experiments. 
 
Overall, both contact with endothelium and migration through endothelium activated 
NK cells. The different experimental systems; in Chapter 3 a tumour cell line was used 
to create the endothelium, whereas in Chapter 4 primary cells were used, gave different 
results regarding which subset was activated the most. The CD56dim subset was 
activated more than the CD56bright in experiments in Chapter 3. This may be because 
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CD56dim NK cells are more adapted for cytotoxicity, and the EA.hy 926 endothelial 
cell line cells were acting as MHC class I deficient tumour targets. Furthermore, the 
CD56dim NK cells that had come into contact with endothelium, but had not migrated 
through it, were found to be more activated than migrated cells, supporting the 
possibility that the CD56dim NK cells were indeed preferentially activated to kill the 
tumour cells. This raises questions of the maintenance of endothelium integrity through 
the assay. However, the endothelium always looked intact when microscopically 
examined after the assay. Nonetheless, for this reason, assays using EA.hy 926 
endothelial cell lines would benefit from a quantitative measure of endothelium 
integrity. The converse was found to be true in experiments using primary cells 
(Chapter 4); CD56bright NK cells were activated more than the CD56dim subset. 
Activation of the NK cells in these assays provided reassurance that the results in 
Chapter 3 was not solely due to a reaction to the MHC class I deficient endothelial cell 
tumour cell line, but due to interactions with the endothelium. Other phenotypic and 
functional changes resulting from interactions with the endothelium, including 
maintenance of the capacity of NK cells to degranulate and to produce IFN-γ, and an 
overall increase in adhesion molecule expression, have implications for non-resolving 
inflammation. The interactions with the endothelium appear to be arming the NK cells 
with a better ability to contribute to inflammation, and possibly for further migration. 
Consequences of this could be exacerbation of the disease through protraction of the 
inappropriate inflammation. 
 
Work in Chapter 5 investigated the effect of migration through endothelium on the 
interaction of NK cells with both cells of the monocyte/macrophage lineage and also 
DCs. Some interesting results emerged from the NK: Macrophage co-culture 
experiments: overall, the CD56dim NK cell subset appeared to have a higher 
proliferative capacity. Although this result is preliminary, and did not reach statistical 
significance in our study, this is a novel difference between the NK cell subsets 
regarding their functional capacity. Furthermore, in the presence of macrophages NK 
cells that had migrated through endothelium tended to proliferate more than NK cells 
cultured in the absence of endothelium, indicating that migration could enhance this 
interaction. Additional experiments are however, required to improve statistics and to 
confirm such findings. NK:DC co-culture experiments were more difficult to interpret. 
Preliminary experiments generally agreed with current literature with NK cells 
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becoming activated and DCs showing a more mature phenotype (Andoniou et al., 2005; 
Gerosa et al., 2005; Della Chiesa et al., 2006). However, further experiments, which 
introduced migration through endothelium as a variable, were inconsistent with the 
preliminary experiments; no NK activation and a decrease or no change in expression 
levels of some DC maturation markers was recorded, regardless of weather the NK cells 
had migrated through endothelium. The inconsistencies between the preliminary 
experiments and migration studies may result from the extended time that NK cells 
were kept in culture in the latter experiments, as this can have an adverse effect on their 
activation and functional competency. Successful long term culture of NK cells has 
been achieved by very few groups and although the cells in the present study were alive 
in these longer assays, whether their behaviour is comparable to cells in vivo is 
questionable. A solution to this would be to design experiments which are initially in 
vivo and then in vitro. One possibility is to purify NK cells from inflammatory fluid; 
these cells would have already migrated from the periphery to the site of inflammation. 
Subsequently, these cells could be co-cultured in vitro with either blood or fluid-derived 
DCs and macrophages. This would substantially reduce the time NK cells spend in 
culture, thereby giving the NK cells more chance of having full functional competency, 
and would obviate the need for HUVECs. This would be a great advantage particularly 
as endothelium from different body compartments is known to be heterogeneous, with 
the potential to also have heterogeneous effects on migrating cells. HUVECs are from 
umbilical cord, and the type of endothelium the cells will cross in vivo will depend on 
the anatomical region of the inflammation (Belloni et al., 1992; Garlanda and Dejana, 
1997; Ribatti et al., 2002; Lang et al., 2003). Furthermore, migration did not appear to 
have any effect on NK:DC cross-talk, but this result should be dismissed due to the lack 
of consistency between NK:DC cross-talk read-outs from shorter and longer term in 
vitro assays. Further experimentation, using an experimental system as described above, 
is necessary to determine if migration through endothelium affects the cross-talk 
between NK cells and DCs. 
 
The final chapter in this thesis comprehensively analysed the phenotype of a potentially 
new subset of NK cells, described in several studies as being highly dysfunctional and 
capable of contributing to disease pathology (Mavilio et al., 2003; Alter et al., 2005; 
Mavilio et al., 2006; Nguyen et al., 2006; Fujita et al., 2007; Gonzalez et al., 2009). The 
present study provides a much more in depth comparison of the traditional NK cell 
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subsets with this CD56- CD16+ population than previous studies and has found this 
subset to comprise of two cell types; one with a phenotype very similar to the CD56dim 
subset of NK cells, and another that shares many traits with DCs. One theory that would 
cover both of these subgroups of CD56- CD16+ cells is that they represent ‘spent’ NK 
cells which have carried out their function and have lost CD56 expression. A second 
theory is that the smaller, DC-like subgroup is a hybrid NK-DC cell, dubbed in other 
research papers as interferon-producing killer dendritic cells or ‘IKDCs’ (Larmonier et 
al., ; Chaperot et al., 2006; Shortman and Villadangos, 2006; Hardy et al., 2007; Stary et 
al., 2007; GeurtsvanKessel et al., 2009). This population now requires further analysis 
through functional assays to determine the potential importance of these cells in vivo. 
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